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PREFACE 
 
The stability of our genome is granted by a complex array of DNA repair systems that 
counteract DNA damage. DNA damage and DNA repair are necessarily linked to oncology, as the 
vast majority of genomic mutations originate from unrepaired or aberrantly repaired DNA lesions. 
Genome instability is an initiating factor during tumorigenesis, but plays also a fundamental role 
during tumor progression, because certain tumors can become reliant on a subset of DNA repair 
pathways to thrive. Interestingly, in the current clinical practice almost every therapeutic approach to 
cancer induces DNA damage. The study of DNA repair pathways is therefore crucial to understand 
the tumor response to conventional anti-cancer therapy and to develop novel approaches that exploit 
DNA repair pathway weaknesses in tumor cells. 
This thesis work will focus on one particular DNA repair pathway (namely, the base excision 
repair – BER) that, in the last decade, has emerged as novel and appealing target for anti-cancer 
therapy. One of the components of BER that might be suitable for drug development is the 
apurinic/apyrimidinic endonuclease 1 (APE1), an enzyme that is critical to the pathway. APE1, in 
fact, is the major abasic endonuclease in mammalian cells, but it also regulates gene expression 
through redox-dependent and independent modulation of transcription. Currently, many laboratories 
are focusing on the development of specific APE1 inhibitors targeting the many functions of the 
protein: these molecules are very promising candidates for anti-cancer therapy, both as single agents 
and as adjuvants in combination therapy. However, the main limitation in translating these inhibitors 
from bench top to bedside is represented by the fact that APE1 is ubiquitously expressed, and 
systemic inhibition of this essential protein would likely have deleterious consequences. 
A proteomic study carried out in the laboratory that hosted me during my PhD project 
revealed that the APE1 interactome is far more diverse than expected; among the proteins interacting 
with APE1, in fact, there are factors involved in the ribosome biogenesis and in different RNA 
processing steps. APE1, moreover, was unexpectedly found to accumulate within nucleoli through the 
interaction with the phosphoprotein nucleophosmin (NPM1), thus suggesting a putative role for 
APE1 during ribosome biogenesis. These studies are rather pioneering, as in this decade the scientific 
community is strongly reconsidering the view of the nucleolus as a mere ribosome factory. A novel 
concept of the nucleolus as a stress sensor is emerging, and a growing number of studies are revealing 
the presence of DNA repair factors among the proteins populating this organelle. Yet, their precise 
function still represents a question mark. 
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During my PhD studies I contributed to the thorough characterization of the APE1/NPM1 
interaction, revealing its relevance to cancer. We discovered that this protein-protein association 
controls the APE1 catalytic activity during BER and, importantly, we observed that an aberrant 
APE1/NPM1 interaction occurring in a subset of acute myeloid leukemia (AML) patients sensitizes 
cells to DNA-damaging agents. Crucially, impairment of the APE1/NPM1 interaction hinders cancer 
cell proliferation. Therefore, we believe that targeting this molecular association might prove 
efficacious in treating cancers that overexpress both APE1 and NPM1, because these tumors might 
rely on an increased APE1/NPM1 interaction for survival and proliferation. 
The characterization of the APE1/NPM1 interaction revealed a substantial gap into our 
knowledge of the NPM1 biology. Many evidences in literature point to a function of this 
multifunctional protein during the DNA damage response (DDR); nevertheless our knowledge 
concerning the exact role(s) of NPM1 in this context is still scanty. The discovery of the APE1/NPM1 
association represented the first relevant hint to a possible direct role for NPM1 in the BER pathway. 
As it will become clear in this thesis, however, working on the sole APE1/NPM1 interaction was like 
scratching the tip of an iceberg. 
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ABSTRACT 
 
The base excision DNA repair pathway (BER) is an essential cellular process that deals with 
small lesions originating from oxidation and alkylation of DNA, which occurs spontaneously, as a 
result of the intracellular metabolism, or after exposure to genotoxins (e.g. anti-tumor drugs). 
Unfortunately, dysregulation of BER enzymes is observed in some tumors and can foster cancer cells 
survival upon DNA damage caused by chemo- and radio-therapy. Recent findings highlighted an 
unexpected complexity of BER. Apparently unrelated protein components are now listed as novel 
modulators of the pathway; in addition, the individuation of BER factors within nucleoli opens 
questions on potential roles for BER proteins beyond DNA repair. 
The interaction between the apurinic/apyrimidinic endonuclease 1 (APE1) and 
nucleophosmin (NPM1) is a perfect example of the BER complexity. As the main AP-endonuclease 
in mammalians, APE1 is central to BER; yet, through the association with NPM1, APE1 accumulates 
within nucleoli in tumor cells. Here it possibly takes part to RNA processing, a function that is 
somehow unrelated to the canonical APE1 role in BER. Furthermore, the APE1/NPM1 interaction 
modulates both the BER and the nucleolar roles of APE1, being essential for the proliferation of 
cancer cells. On the other hand, despite the growing body of evidence linking NPM1 and the DNA 
damage response, it is not clear whether NPM1 could play a direct role in the modulation of the 
overall BER. 
My PhD project was aimed at the thorough characterization of the APE1/NPM1 association 
and of the general role of NPM1 in BER. A first part of this thesis will describe the development of 
small molecules able to disrupt the APE1/NPM1 interaction in tumor cells as novel tools for 
investigation and for translational purposes. The second part of this work will focus on the 
characterization of NPM1 as modulator of the BER. This thesis work led to the individuation of low 
molecular weight compounds targeting the APE1/NPM1 interaction and displaying anti-tumor 
properties. In addition, I demonstrate here for the first time the implication of NPM1 as multi-level 
modulator of the BER pathway, providing new insights into the role of BER proteins within nucleoli. 
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INTRODUCTION 
 
1. The endless knot: DNA damage and DNA repair systems 
The genetic information required to build a functional organism is carved on an intrinsically 
unstable substrate called DNA. The chemical nature of the DNA makes this molecule a powerful 
system to carry information; yet the very same composition of nucleic acids renders our genes 
susceptible to alterations. Byproducts of cellular metabolism, chemotherapeutic drugs, UV-radiation 
continuously expose our genome to life-threatening mutations. Consequently, in order to grant the 
integrity of DNA, cells have evolved an array of DNA repair systems. This chapter will introduce the 
concept of DNA damage, briefly reviewing our current knowledge of the complex network of 
pathways that are commonly referred to as “DNA repair systems”. 
 
1.1. Seek and destroy: from DNA lesions to repair systems 
The cellular environment is constantly targeted by DNA-damaging threats; endogenous (e.g. 
reactive oxygen species – ROS1) as well as exogenous (e.g. ionizing radiation – IR) stimuli are 
common sources of DNA lesions [1]. The magnitude of the issue is nicely exemplified by a crude 
estimate of 10
5
 DNA-damaging events per day in a single human cell; this implies that DNA repair 
systems must work at the striking rate of roughly 10
16
-10
18
 repair events per day in an adult human 
organism [2]. Unrestricted accumulation of DNA lesions can induce mutagenesis (base substitutions, 
insertions, deletions and chromosomal rearrangements), contributing to cell death, cancer, 
neurodegeneration and aging. For this reason our cells possess several DNA repair systems; each of 
them operates on a particular subtype of DNA lesion, often with overlaps in the damage selectivity 
[3]. The spectrum of possible DNA lesions is wide: at a first glimpse DNA damage can be broadly 
categorized into (i) single nucleobases modifications (e.g. oxidation, alkylation, generation of abasic 
(AP) sites), (ii) damage to the phosphate backbone (i.e. single and double-strand breaks) and (iii) 
inter/intra-strand crosslinks [2]. Fig. 1 schematically lists the main DNA repair pathways, along with 
the type of lesion that is usually dealt with by each pathway. 
 
                                                          
1
 A list of the abbreviations has been placed at the end of the thesis, for clarity. 
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Fig. 1 – Schematic representation of the major DNA repair pathways in eukaryotic cells. Repair 
pathways or crucial enzymes are reported at the top, while the respective lesion is indicated at the 
bottom. APTX: aprataxin; BER: base excision repair; DSBR: double-strand break repair; HR: 
homologous recombination; MGMT: O
6
-methylguanine-DNA methyltransferase; MMR: mismatch 
repair; NER: nucleotide excision repair; NHEJ: nonhomologous end joining; PNKP: polynucleotide 
kinase 3’-phosphatase; SSBR: single-strand break repair; TDP1: tyrosyl-DNA phosphodiesterase 1; G-
Me
: O
6
-methylguanine; TˆT: thymine dimer; I: inosine; U: uracil; Go: 8-oxoguanine. Source: [3]. 
 
The DNA repair systems acting in eukaryotic cells are usually organized into multi-step 
pathways, where groups of enzymes work in serial manner in order to resolve specific target lesions. 
Indeed, while prokaryotes and lower eukaryotes display several direct reversal enzymes, the only 
lesions directly reverted in mammals are O
6
-alkylguanine adducts. This kind of damage, mainly 
introduced by endogenous and exogenous methylating agents (e.g. S-adenosylmethionine [1] and N-
methylnitrosourea [4], respectively), is generally removed by a single suicide enzyme, namely 
MGMT [5]. Complex photo-adducts and other helix-distorting lesions are usually produced by 
environmental mutagens (e.g. UV irradiation, benzopyrene) by reactions with endogenous products of 
lipid peroxidation (e.g. malendialdehyde) or by certain chemotherapeutic drugs (e.g. cisplatin). The 
nucleotide excision repair (NER) pathway deals with such bulky lesions, removing a patch of DNA 
spanning several nucleotides around the site of damage and replacing it with undamaged nucleotides 
[6]. Bases mismatches and insertion-deletion loops are generally removed by the mismatch repair 
system (MMR); this pathway is in charge for the detection and elimination of replication errors, as 
well as of deleterious repair intermediates arising from the homologous recombination (HR) repair 
[7]. Single nucleotide lesions constitute a subtle modification of the DNA sequence that seldom leads 
to significant distortion in the double-helix structure. Bases modifications occur very frequently in 
eukaryotic cells, as mitochondrial respiration can foster the production of ROS, leading to nucleotides 
oxidation. Typical examples of nucleobase lesions are oxidation derivatives (e.g. 7,8-dihydro-8-
oxoguanine – 8-oxo-dG) or alkylation byproducts (e.g. 3-methyladenine); the latter being mainly 
introduced by chemotherapeutic alkylating agents (e.g. temozolomide). The base excision repair 
(BER) pathway is the DNA repair system that detects these small lesions and removes the damaged 
nucleotide(s). This particular DNA repair pathway is central to this thesis and will be described in 
great detail in the next chapter. DNA strand breaks are very toxic and mutagenic lesions which can 
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induce chromosomal rearrangements. It has been calculated that a single double-strand break (DSB) 
is sufficient to arrest the cell cycle of a eukaryotic cell [8]. In order to cope with such cytotoxic 
lesions our cells have two DSB repair systems, namely the nonhomologous end joining (NHEJ) and 
the HR pathways. The two enzymatic systems are preferentially used in distinct cell cycle phases (i.e. 
HR prevails over NHEJ during the S and G2 phases); with NHEJ being the major DSBs repair system 
in higher eukaryotes [3]. 
Notably, each DNA damaging agent induces a widespread spectrum of lesions, and this is 
particularly evident for anti-cancer agents. Cisplatin, for instance, generates DNA adducts, interstrand 
crosslinks (ICLs) and oxidative-stress [9, 10]. It is therefore clear that a single DNA repair pathway 
cannot cope with a DNA damaging challenge as an isolated entity. Accordingly, several evidences 
point to the existence of diverse cross-talks between DNA repair pathways. BER, just to name one, is 
tightly and dynamically connected to the single-strand break repair (SSBR) pathway, as single-strand 
breaks (SSBs) are repair intermediates generated during the BER process itself [11]. In addition, also 
the NER and the MMR pathways have recently been suggested to share connection points with the 
BER, especially when DNA lesions are very heterogeneous, as in the case of cisplatin [10-13] or 5-
fluorouracil [14]. 
In conclusion, the description of DNA repair pathways as static arrays of sequential 
operations is nowadays outdated. Rather, DNA repair pathways must be regarded as dynamic systems 
that co-operate and sometimes compete to repair DNA with extreme plasticity, adapting to the 
existing damage load and characteristics. 
 
1.2. The DNA damage response 
As our knowledge of DNA repair pathways deepened, the definition of “DNA repair system” 
itself evolved. Currently it seems more appropriate to name “DNA damage response” (DDR) the 
complex signaling network that is responsible for the maintenance of the genome stability. The 
current concept of DDR is centered onto DNA checkpoints as key entities that monitor DNA integrity 
throughout the cell cycle, working together with canonical DNA repair pathways. DNA checkpoints 
are therefore not responsible for DNA damage sensing per se (this is a task carried out by DNA repair 
pathways), their role is rather to grant an appropriate response to any kind of insult the cell genome 
might take. The typical behavior of a coordinated DDR involves: halting the cell cycle to allow 
adequate time to repair DNA or to trigger apoptosis; preventing the generation of secondary lesions, 
by directing the primary lesion to the most appropriate repair pathway and by boosting that pathway; 
modifying transcription [5]. 
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The DDR works at least at five levels (Fig. 2): sensors recognize DNA lesions and chromatin 
abnormalities. Usually, the detection of the lesion is directly carried out by DNA repair proteins. 
Proximal transducer kinases, such as the ataxia telangiectasia mutated (ATM) and the ataxia 
telangiectasia and Rad3 related (ATR), mediate the very first DNA damage signaling event. Distal 
transducer kinases (e.g. Chk1 and Chk2) are then responsible for the amplification of the signaling 
cascade. The importance of phosphorylation at this stage of the DDR is highlighted by the finding 
that DNA damage elicits over 900 distinct phosphorylation events, involving more than 700 
substrates [15]. Mediators determine both the temporal and the spatial progression of the DDR by 
coordination of the phosphorylation events, whereas effectors determine the outcome of the DDR. A 
typical example of effector molecule is the p53 tumor suppressor, the stabilization of which is 
quantitatively linked to the DNA damage load and may lead to cell cycle arrest, apoptosis or 
senescence [16, 17]. 
 
 
Fig. 2 – Schematic description of the canonical DNA damage response. Genomic instability 
induced either by direct DNA damage (here represented by a DSB) or by replicative stress is detected 
by specific sensors (e.g. the Mre11-Rad50-Nbs1 or “MRN complex”, or the Rad9-Rad1-Hus1 or “911 
complex”) and immediately transduced to proximal kinases (i.e. ATM, ATR). Mediators determine the 
spatial and temporal activation of the DDR through coordination of the phosphorylation cascade to the 
distal transducers (i.e. Chk1, Chk2). Effectors govern the final outcome of the response through direct 
and indirect modulation of the cell cycle engines. Adapted from [18]. 
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It is worth mentioning that in the last decades the nucleolus has emerged as novel and 
unusual site where the DDR might originate. In particular, it appears that some kinds of cell stress, 
DNA damage in particular, are sensed through this organelle, leading to p53 stabilization [19-21]. 
This topic is central to this thesis and it will be thoroughly discussed in a dedicate paragraph (2.4 
“Nucleoli and BER. The ribosome factory revisited”). 
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2. Base excision repair. A pathway for sneaky lesions 
As mentioned in the first chapter, the BER pathway canonically deals with small non-bulky 
lesions that do not induce major distortion in the double-helix structure. Examples of such lesions are 
oxidized or alkylated DNA nucleobases, but also deamination products, such as uracil or inosine [3]. 
The importance of this pathway is underlined by the fact that DNA damage resolved by BER is very 
common in our cells; current estimates suggest that there are more than 100 kinds of oxidative base 
modifications, potentially arising as the result of ROS attack ([22] and references therein). In 
addition, the occurrence of abnormal nucleobases can be highly mutagenic, as some lesions do not 
block the DNA polymerase, which can incorporate the wrong nucleotide. This can lead, for instance, 
to transversion mutations in the case of 8-oxo-dG:A mispairings [23, 24]. Other modified bases (e.g. 
thymine glycol), conversely, directly hinder the progression of DNA or RNA polymerase, triggering 
apoptotic responses ([3] and Fig. 3). 
 
 
Fig. 3 – Frequency and mutagenic potential of some common bases and sugar lesions. The graph 
depicts the chemical composition of a subset of canonical BER substrates. The mutagenic potential 
refers to the likelihood of inaccurate duplication or bypass over the lesion; as a general rule, with few 
exceptions, the greater the blocking potential, the lower the mutagenic capacity. Source: [25]. 
 
The following paragraphs will give an overview of the BER pathway, with particular 
emphasis on the coordination of this complex DNA repair system. The current implication of BER 
enzymes in tumorigenesis and therapy resistance, as well as the possibility to target BER enzymes for 
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anti-cancer therapy, will be briefly outlined. This section will end with a short glimpse on our current 
knowledge of the non-canonical roles of the BER proteins, providing some preliminary consideration 
concerning the still puzzling presence of BER enzymes within nucleoli. 
 
2.1. Exploring the BER pathway 
The BER pathway is an essential DNA repair system in higher eukaryotes; accordingly, 
homozygous knockout of the core BER factors (apurinic/apyrimidinic endonuclease 1 – APE1, DNA 
polymerase – Pol, X-ray repair cross-complementing 1 – XRCC1, DNA ligase I – LigI and DNA 
ligase III – LigIII) results in embryonic or early post-natal lethality [3]. Enzymatic and non-enzymatic 
components of the pathway co-operate in a sequential manner following five major steps: (i) 
recognition and excision of the damaged base, (ii) incision of the resulting AP site to generate a nick 
on the DNA backbone, (iii) processing of the DNA ends surrounding the nick, (iv) filling of the 
nucleotide gap and (v) sealing of the nick ([3, 26] and Fig. 4). 
 
 
Fig. 4 – The BER pathway: importance of its modulation to avoid the formation of aborted 
intermediates. Schematic representation of the BER-mediated DNA repair. Each stage involves the 
intervention of one or more proteins (indicated by ellipses and boxes). The canonical separation of the 
pathway in two sub-pathways (short and long patch BER) is depicted. Note that in the absence of 
proper coordination of the BER, each enzymatic step can generate an aborted intermediate that, in turn, 
can lead to different deleterious consequences. Adapted from [11, 27]. 
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As already mentioned, BER copes with small and non-bulky damaged bases; therefore, in 
order to detect such “sneaky” lesions, cells possess a pool of specialized enzymes called DNA 
glycosylases. These proteins are thought to scan the DNA helix, recognizing and excising the 
damaged base in a lesion-specific manner. DNA glycosylases can be categorized into monofunctional 
or bifunctional, depending on their mechanism of action. While monofunctional DNA glycosylases 
(e.g. the uracil-DNA glycosylase – UNG) simply cleave the C1’-N-glycosidic bond, generating an 
AP-site, bifunctional enzymes have an associated -lyase activity (e.g. the 8-oxoguanine DNA 
glycosylase – OGG1) that, in addition to the elimination of the damaged base, cleaves the DNA 
backbone leaving a 3’-,-unsaturated aldehyde blocking moiety. An additional family of DNA 
glycosylases (represented by the human NEIL1 and NEIL2 enzymes) is also able to operate a ,-
elimination reaction, leaving a 3’-phosphate-blocked nick on the DNA backbone [28]. Higher 
eukaryotes display a vast array of DNA glycosylases (at least 11 in human [28]), with significant 
redundancy in their damage selectivity. Accordingly, single knockout of many enzymes of this class 
is not lethal per se, even if accumulation of unrepaired DNA lesions occurs [29, 30]. 
The base excision step generally leaves behind an AP-site that is immediately recognized and 
processed by an AP-endonuclease, which cleaves 5’ to the baseless site, nicking the DNA backbone 
and generating a 3’-OH and a 5’-dRP (deoxyribonucleotide-phosphate) moiety. In metazoans the 
major AP-endonuclease activity is ascribed to APE1, a multifunctional enzyme that will be described 
in great detail in the following chapter of this thesis. APE1 incision is usually sufficient to generate 
the DNA ends suitable for the conclusion of the repair process; further oxidation of the DNA termini, 
base-excision operated by bifunctional glycosylases, or complex repair intermediates, however, 
require the intervention of other end-processing enzymes such as aprataxin (APTX), the 
polynucleotide kinase 3’-phosphatase (PNKP) or the tyrosyl-DNA phosphodiesterase 1 (TDP1). The 
dRP-lyase activity of Pol and minor APE1 activities (see below) may also contribute to the “end-
cleaning” process. These end-tailoring enzymes convert the SSB to a single-nucleotide gap that can 
be efficiently filled in and re-ligated [26, 28, 31-34]. 
After the end-processing step, the repair process can take two different sub-pathways. 
Typically, BER proceeds via the short-patch (SP) pathway, engaging Pol to replace the missing 
nucleotide, followed by the XRCC1-LigIII complex which is responsible for the ligation of the nick 
[35]. Under some circumstances, such as the presence of a 5’-moiety that is refractory to the Pol 
lyase activity, low ligation efficiency, or during the S phase of the cell cycle (i.e. when replication-
associated proteins are more abundant), BER can be completed through a strand displacement-
dependent gap filling process called long-patch (LP) pathway [3, 36]. LP-BER relies on replicating 
polymerases such as DNA polymerase  and ,in a complex with the sliding clamp PCNA 
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(proliferating cell nuclear antigen); Pol is able to carry out a strand displacement-dependent gap 
filling as well, but only after stimulation by specific protein-protein interactions [37]. During LP-BER 
a stretch of 2-12 nucleotides generated during the synthesis process is removed by the flap 
endonuclease FEN1 and subsequent intervention of the PCNA-associated LigI seals the nick [37, 38]. 
As mentioned in the first chapter, the BER is not an isolated process, but it shares protein 
components with at least two sub-pathways, namely SSBR and nucleotide incision repair (NIR) [27]. 
SSBs are generated by a plethora of cues, including ROS, ionizing radiation, radiomimetic drugs and 
topoisomerase I inhibitors, but are also unavoidable intermediates generated during BER processing. 
The SSBR pathway initiates through recruitment of the poly(ADP-ribose) polymerase PARP1, which 
recognizes exposed SSBs and modulates the repair process through enzymatic ADP-ribosylation of 
protein substrates. Interestingly, many BER proteins (e.g. XRCC1, Pol) interact with PARP1 ([37] 
and Fig. 5). Moreover, PARP1 has been shown to enhance the BER processing of uracil and AP-sites 
overall [39], highlighting the tight connection between BER and SSBR. More recently, Ischenko and 
Saparbaev individuated a glycosylase-independent branch of the BER that specifically deals with a 
subset of base lesions (e.g. 5-hydroxy-2’-deoxycytidine, uracil). The so called NIR pathway requires 
intervention of APE1 as entry-point enzyme, through a direct incision step at the damaged base [40-
42]. Although very interesting, the physiological impact of the NIR pathway is still undergoing 
investigation, as within the intracellular milieu the presence of specific DNA glycosylases would 
likely render the NIR process poorly efficient. 
 
2.2. Coordination of BER. The power is nothing without control 
The concept of BER as a streamline process in which isolated enzymes carry out sequential 
reactions independently of one another is well outdated. The current view of BER is that of a dynamic 
intertwining of different enzymes and auxiliary proteins that operate in a highly orchestrated manner. 
Temporal and spatial coordination of BER (and, in general, of any DNA repair pathway) is essential 
for at least two reasons: 
i. Imbalance in the BER components has been linked to genetic instability. In particular, 
overexpression of several core elements of the pathway is a hallmark of cancer progression 
and resistance to therapy [43-46]. These observations are possibly explained by the fact that 
increased expression of a single BER factor results in competition or excessive enzymatic 
activity, which is not buffered by sufficient amounts of the other proteins in the pathway. 
This has been formally shown, for instance, for APE1 [47], N-alkyladenine DNA glycosylase 
(AAG) [48] and Pol [49, 50] 
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ii. Abortive intermediates of the pathway display intrinsic cytotoxicity. As introduced in the 
previous paragraph, in the absence of coordination the BER pathway may expose toxic 
reaction products to the cellular environment. Paradoxically, unprotected intermediates (e.g. 
SSBs) are much more toxic than the initial damaged bases (Fig. 4 and [51]). Therefore, the 
fine synchronization of the pathway is possibly the result of an evolutionary tradeoff between 
the rapid repair of mutagenic lesions and the potential hazard of deleterious intermediates that 
such repair generates. 
Several models have been proposed in order to explain the mechanisms that have evolved to 
optimize the repair efficiency of the BER pathway. A first hypothesis dates back to 2000, when 
Wilson and Kunkel presented the so called “passing the baton” model for the BER coordination [11]. 
This model was based on the evidence that many BER factors are tightly associated by means of 
direct protein-protein interaction, or through DNA-protein interaction. Wilson and Kunkel suggested 
that the reaction substrate is channeled from the DNA glycosylase to the DNA ligase without any 
interruption that would expose toxic intermediates [11]. This model is supported by the evidence that 
many BER proteins interact with each other, displaying increased affinity for the reaction product of 
the upstream enzyme, rather than for their own substrate. A subsequent model proposed by Allinson 
and colleagues suggested that reaction rates of enzymatic activities within the pathway are 
concurrently tuned in order to achieve the required synchronization [39]. This model, for instance, 
postulates that the DNA glycosylases turnover rate and PARP1 contribute to the coordination of the 
repair process. According to this model, each kind of lesion affects differently the downstream 
pathway, which flexibly optimizes the repair rates with oscillations as great as one order of magnitude 
in terms of repair capacity [39]. 
A model that was somehow opposing the “passing the baton” paradigm postulated the 
existence of pre-formed complexes of BER factors (BERosomes) that process the DNA lesion as 
separate units [52, 53]. This concept was further elaborated to a “unified model”, which separated the 
whole BER process into three functional processes (lesion recognition, strand scission/gap tailoring 
and DNA synthesis/ligation) each carried out by one or more transient multi-protein complexes and 
coordinated by scaffold proteins and post-translational modifications (PTMs) [27]. 
Despite the apparent divergence among the models that have been put forward to explain the 
complexity of BER, each of them probably describes different aspects of a unique and highly 
dynamic process. It is currently clear that the fine modulation of the BER pathway is achieved 
through a complex network of more or less stable protein-protein interactions and PTMs. 
Phosphorylation, acetylation, methylation, SUMOylation, as well as ubiquitination of almost every 
BER component have been suggested to play a role in the modulation of the pathway [27, 37, 54]. 
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Moreover, direct as well as DNA-mediated interactions among BER enzymes and non-enzymatic 
scaffolds (e.g. XRCC1, PCNA) coordinate catalytic activities and dictate the selection of the sub-
pathway appropriate for each situation ([27, 37] and Fig. 5). 
An emerging concept is the role of non-canonical proteins as BER modulators. Several 
proteins apparently unrelated to the pathway have recently been discovered as novel unexpected 
coordinators of the BER [19]. p53, for instance has been implicated in the modulation of both APE1 
and Pol [37], whereas our laboratory discovered nucleophosmin (NPM1) as a new modulator of the 
APE1 enzymatic activity (see below). Additional modulation of the BER pathway is also achieved 
through evolutionarily acquired disordered extensions of some BER components, as will be discussed 
later. 
 
 
Fig. 5 – The complexity of the BER protein-protein interaction network. Canonical BER proteins 
are highlighted. Proteins detected within the same complex are connected by solid lines. Dashed lines 
connect proteins that do not share a complex, but that functionally influence each other. Stimulatory 
(closed arrows), inhibitory (open arrows) or stimulatory/inhibitory (closed arrows with a rectangle) 
effects are indicated. Lines without arrows indicate interaction in the absence of known effect. Source: 
[37]. 
 
BER enzymes are generally abundant proteins endowed with a relatively long half-life. Given 
the highly dynamic environment that every organism faces, it is clear that the amount of BER proteins 
must constantly oscillate and adjust to the steady-state DNA damage load. It is currently accepted that 
the enzymes engaged in the repair process are stabilized, while excessive components not involved in 
DNA repair are targeted for proteasomal degradation. The recent identification of several factors 
belonging to the ubiquitin-proteasome system as modulators of the BER stability shed new light on 
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the quick regulation of the BER dynamics ([28, 54, 55] and references therein). The turnover of Pol, 
for instance, is the result of a balance between mono- or poly-ubiquitination reactions (mediated by 
the Mcl-1 ubiquitin ligase E3 – Mule and CHIP, respectively) and de-ubiquitination activities (carried 
out by the ubiquitin specific protease USP47) [56-58]. Interestingly, Mule activity is modulated 
through direct binding to the p14 alternative reading frame (p14
Arf
) tumor suppressor [55], a DNA 
damage-responsive factor ([59-62] and Fig. 6) that is involved in the cellular protection against DNA 
damage and oncogenic activation. The mechanisms controlling p14
Arf
 activation are only beginning to 
be elucidated, and it has been proposed that, under stress conditions, this protein is able to trigger a 
cell cycle delay through the stabilization of p53. This process is likely mediated by concurrent 
inhibition of the E3-ligases Mule and of the mouse double minute homolog 2 (Mdm2) which, under 
basal condition, target p53 for proteasomal degradation [63]. The p14
Arf
/Mule axis, therefore, appears 
an interesting connection point between DNA damage sensing and the modulation of the BER protein 
amount; the fine mechanisms controlling these fluctuations, however, still need thorough explanation. 
 
 
Fig. 6 – Modulation of the BER protein stability through the p14Arf/Mule axis. Schematic 
representation of the pathway that regulates the steady-state levels of the core BER components (i.e. 
Pol, XRCC1 and LigIII). BER proteins not engaged in DNA repair are constantly targeted for 
proteasomal degradation through Mule-mediated mono-ubiquitination and CHIP-mediated poly-
ubiquitination. Upon DNA damage sensing, activation of the p14
Arf
 tumor suppressor inhibits Mule, 
thus allowing quick stabilization of the BER proteins required to repair the lesion. Adapted from [28]. 
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2.3. BER as a target for anti-cancer therapy 
Very few diseases have been directly associated with defects in the BER pathway, perhaps as 
a consequence of the already mentioned importance of the core BER components for life. Among the 
few enzymes that have been linked to disease it is worth mentioning the glycosylases MUTYH and 
UNG, associated with cancer predisposition and immunological disorders, respectively [3]. Several 
investigators are pursuing the hypothesis that subtle variations among individuals, rather than overt 
inactivation of the BER capacity, are associated with disease occurrence, likely in an environmental 
exposure-dependent manner [64, 65]. 
A crucial feature of many cancer types is the overexpression of BER proteins, which 
frequently leads to the onset of chemo- and radio-resistance ([5] and references therein). 
Overexpression of APE1, for instance, has been reported to confer resistance to several 
chemotherapeutics (e.g. cisplatin, bleomycin) [66, 67] as well as to ionizing radiation [45]. In addition 
to these “macroscopic” expression phenotypes, more subtle variations, such as polymorphisms have 
been suggested to affect predisposition to tumor development. Polymorphic variants of APE1, 
XRCC1, OGG1 and Pol, for instance, have been shown to affect DNA repair capacity, increasing 
susceptibility to cancer and negatively impacting on the overall survival [5, 68, 69]. 
Despite the presence of conflicting reports, it is possible to conclude that polymorphic 
variants, as well as expression patterns of BER proteins, might be important prognostic and predictive 
indicators in cancer. Several preclinical studies, moreover, have shown that downregulation of BER 
components sensitizes cells to different chemotherapeutics. For these reasons it has been suggested 
that the BER pathway might prove an effective druggable target to induce chemo-sensitization in 
specific tumor subtypes [30, 70]. Several laboratories are currently working in order to develop 
inhibitors of the core enzymes of the pathway (i.e. APE1, Pol and FEN1) that display features 
suitable for translational applications [70]. 
 
2.4. Nucleoli and BER. The ribosome factory revisited 
Before the turn of the century the nucleolus was merely considered the “ribosome factory” of 
the cell; strikingly, proteomics analyses of the nucleolar proteome revealed that these organelles 
contain a plethora of proteins that are not directly related to the classical ribosome processing 
machinery [71-74]. Among these were identified several DNA repair factors (e.g. LigIII, BRCA1, the 
Ku70/80 antigens, XRCC1), although their precise function in nucleoli was (and still is) poorly 
understood (reviewed in [19]). Nowadays, the presence of DNA repair proteins within nucleoli is well 
established ([19] and references therein). Several BER enzymes have been found to accumulate in 
these subnuclear compartments and their nucleolar localization has usually been linked to functions 
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that are uncoupled from their canonical role in the BER pathway. A paradigmatic example is given by 
APE1, which accumulates within nucleoli through the interaction with NPM1 and ribosomal RNA 
(rRNA). The nucleolar fraction of APE1 has been suggested to play a role in the RNA quality control 
processes [75] although the detailed molecular mechanisms of this non-canonical APE1 activity still 
remain elusive (the reader is referred to the next chapter for further details). Very recently, also the 
single-strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1) was shown to localize 
within nucleoli and to take part to the rRNA processing steps [76]. 
An emerging aspect in the biology of the nucleolus is the function of this organelle as a 
sensor for cell stress [21]. Extensive analyses documented a broad rewiring of the nucleolar proteome 
upon DNA damage; DNA repair proteins, in particular, relocalize from nucleoli under stress 
conditions (see for example [77-79], while the topic has been recently reviewed in [19]. The observed 
reorganization of the nucleolar proteome, fascinatingly, appears to be highly specific and selective, 
depending on the DNA damaging stimulus and ranging widely terms of both order of magnitude and 
proteins involved [20, 80]. 
Two key questions are still in need of answer: what is the function of nucleolar DNA repair 
proteins? Is there any functional relevance for the observed relocalization of nucleolar DNA repair 
proteins upon DNA damage? This thesis will try to address these open points, with a particular 
emphasis on BER enzymes. 
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3. Planet of the APE1(s)  
APE1 is a key enzyme in the BER pathway and in mammalian cells. Almost every DNA 
lesion processed through the BER generates a repair intermediate that eventually requires the 
intervention of this protein. APE1, moreover, interacts with several BER components, both upstream 
and downstream in the pathway, acting as a fundamental coordinator for the entire DNA repair 
process [81]. 
APE1 is an abundant protein, ubiquitously expressed in every tissue [82]; the first reports on 
the protein date back to the nineties, when APE1was independently discovered as the main abasic 
endonuclease in cells and as a protein able to activate through a redox-dependent mechanism the 
transcription factor AP-1 [83-85]. Thereafter APE1 was named APE1/Ref-1 (i.e. 
apurinic/apyrimidinic endonuclease 1/Redox effector factor 1) and regarded as a multifunctional 
protein, acting both as a central BER component and as a co-transcriptional modulator. 
As many other core BER enzymes, the protein is essential for cell viability and embryo 
development [86], whereas haploinsufficiency for APE1 has been shown to render mice 
hypersensitive to oxidative stress and enhance spontaneous mutagenesis [87, 88]. Being APE1 a vital 
protein, no APE1-deficient cellular models are available to date, making in vivo studies challenging. 
Therefore, it is still a matter of debate which protein function (i.e. DNA repair, redox, or both) is 
required for cell survival. This chapter will thoroughly describe the functions of the protein, with 
particular emphasis on its overlooked and phylogenetically young N-terminal domain. The recent 
discovery of novel non-canonical roles of APE1 will be discussed, especially in relation with its 
unexpected nucleolar residence and its interaction with NPM1. The chapter will then summarize our 
knowledge about the modulation of APE1, eventually describing the current efforts aimed at the 
pharmacological targeting of APE1 in pathology. 
 
3.1. Protein structure and function 
APE1 is a relatively small protein encompassing 318 amino acids. X-ray diffraction analyses 
revealed a monomeric /-sandwich globular fold that is structurally related to the E. coli 
exonuclease III (ExoIII) [89]. The protein also presents an unstructured N-terminal extension (first 48 
amino acids) which represents a phylogenetically young addition to the protein [90-92]. APE1 can 
conventionally be separated into two functionally independent, but structurally overlapping domains. 
The C-terminal globular region of the protein (residues 61-318) is mainly devoted to the enzymatic 
activity and nucleic acid binding function, whereas the N-terminal portion (residues 1-127) is mainly 
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committed to the redox-dependent activity towards different transcription factors ([82, 93] and Fig. 
7). 
 
 
Fig. 7 – Schematic overview of the structural and functional organization of the APE1 protein. 
The APE1 tripartite functional arrangement is reported, along with the main activities ascribed to each 
domain. The lower part of the figure highlights the main residues known or predicted to undergo 
PTMs. Black bars at the N-terminus represent the bipartite nuclear localization signal. Adapted from 
[94-96]. 
 
The endonuclease function of APE1 on abasic DNA accounts for the vast majority of the total 
AP-site incision activity in a whole cell extract [83, 84]. The protein’s C-terminal domain is highly 
conserved and shares extensive similarity with the E. coli homolog ExoIII [89]; this globular domain 
catalyzes the Mg
2+
-dependent cleavage of the phosphodiester bond 5’ to the AP-site, leaving a 3’-OH 
and a 5’-dRP group flanking the DNA nick. The enzymatic mechanism has been extensively analyzed 
and the fundamental amino-acids involved in the catalysis have been described by multiple 
mutagenesis studies [89, 92, 97, 98]. Beside the canonical activity on AP-site-containing DNA, APE1 
has been reported to possess also additional functions such as 3’-phosphatase, 3’-5’ exonuclease, 3’-
phosphodiesterase, and RNaseH activity [97, 99, 100]. Most of these supplementary activities are 
very weak in vitro and likely contribute to very specific DNA end-tailoring events in vivo. The 3’-
phosphodiesterase activity, for example, has been proposed to take part to the removal of fragmented 
sugar moieties at DNA strand breaks induced by bleomycin [101, 102]. The AP-site incision activity 
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and the additional APE1 functions likely share critical amino acids within the C-terminal domain, 
with few, reaction-specific, exceptions [103-105]. 
Recent and surprising findings revealed that APE1 exerts endonuclease activity also on RNA 
([106] and references therein). The APE1-mediated cleavage of abasic RNA was observed 
concurrently with the unexpected nucleolar accumulation of the protein and was suggested to play a 
role in the rRNA processing mechanisms [75, 107, 108]. Accordingly, siRNA-mediated depletion of 
APE1 in HeLa cells resulted in an accumulation of oxidized RNA species and impairment of protein 
synthesis and cell growth [75]. In parallel studies APE1 was identified in rat liver polysomes as the 
endonuclease responsible for the cleavage of the c-myc mRNA, thus suggesting that the APE1 RNA-
endonuclease activity might control the stability of selected target RNAs [108]. Additional mRNAs 
were also demonstrated to be target of APE1, the in vivo relevance of this overlooked APE1 function, 
however, remains to be elucidated [109]. 
APE1 is the only known DNA repair protein endowed with an associated redox function [110]. 
Since the first report identifying APE1 as the protein able to stimulate the DNA binding activity of 
AP-1 in a redox-dependent manner [85], several laboratories detected a long list of ubiquitous and 
tissue-specific transcription factors that are co-activated by APE1. Among these, there are factors 
relevant to cancer development and growth (e.g. nuclear factor-B – NF-B, HIF-1, Egr-1, p53) 
suggesting that pharmacological targeting of the APE1 redox activity might be an interesting 
approach to anti-tumor treatment (refer to the paragraph 3.3 “APE1 and pathology”) [110]. The 
mechanism underlying the APE1-mediated activation of so many structurally unrelated transcription 
factors is still poorly understood [110, 111]. The C65 residue has been implicated in catalysis, with 
C93 and/or C99 likely working as resolving cysteines during the reaction mechanism [110]. C65 is 
however solvent-inaccessible and a catalytic mechanism involving the partial unfolding of APE1 has 
been proposed [112, 113]. Curiously, the redox domain of APE1 appears to be a phylogenic gain of 
function of the protein, as the zebrafish ortholog (zAPE1) lacks any detectable redox activity. 
Substitution of the residue corresponding to C65 in zAPE1, however, completely restores the redox 
function of the mutant, further pointing to C65 as critical residue for this accessory APE1 activity 
[111]. APE1 has been suggested to modulate transcription factors with two distinct mechanisms; p53, 
for instance, undergoes both redox-dependent and redox-independent modulation by APE1. While the 
first mechanism enhances p53 DNA-binding activity through reduction of the transcription factor 
[114], the redox-independent action of APE1 promotes p53 tetramerization [115]. 
In addition to its canonical activities (i.e. DNA repair and redox), APE1 has been 
demonstrated to directly modulate the transcriptional rate of diverse genes. In particular, APE1 was 
initially discovered as a component of a protein complex binding to the negative calcium response 
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elements (nCaRE) on the parathyroid hormone gene promoter [116] and subsequently suggested to 
play a role in the modulation of the renin gene [117]. It has been proposed that the presence of nCaRE 
sequences upstream the APE1 gene contributes to a negative feedback-like modulation of the APE1 
expression [118]; this hypothesis, however, has not been thoroughly investigated. As nCaRE 
sequences are present in many other genes, it is conceivable that the binding of APE1 to these 
sequences might play a role in the transcriptional modulation of several cellular components. This is 
indeed the case for the SIRT1 deacetylase, which transcription is induced upon oxidative stress by an 
nCaRE-binding complex containing APE1 itself [119, 120]. 
 
3.2. The N-terminal domain: an overlooked molecular device for APE1 
Only very recently the N-terminal extension of APE1 roused the interest of the scientific 
community. This domain has long been barely considered in the structural analyses of the protein as 
its intrinsic lack of ordered structure impairs its ability to crystallize ([90] and references therein). 
Intrinsically disordered regions in DNA repair proteins are only now emerging as important 
regulation points of many aspects of the BER pathway, and several studies highlighted the recent 
phylogenic acquisition of disordered domains in different BER proteins [52, 90, 91]. 
The N-terminal region of APE1 (amino acids 1 to 48) has been shown to modulate diverse 
aspects of the biology of the protein, including its roles in abasic DNA/RNA cleavage (through 
regulation of the catalytic activity and the nucleic acids binding), its function as a transcriptional 
modulator, and its protein-protein interaction network. In particular, it is clear that the N-terminal 
extension of APE1 is required for its stable binding to several protein partners, including XRCC1, 
Pol and NPM1 [75, 121, 122]. This protein region, moreover, is absolutely necessary for the 
discrimination of structural elements in undamaged nucleic acids, a feature that APE1 likely exploits 
during the nCaRE-mediated transcriptional modulation and to detect AP-sites [90, 119]. During part 
of my PhD project I systematically investigated the APE1 binding capacity toward undamaged 
nucleic acids, highlighting that secondary structures (e.g. double-stranded regions interrupted by 
single-stranded local distortions) strongly enhance the APE1 affinity for DNA/RNA [90]. These 
findings deepen our comprehension of the APE1-mediated transcriptional modulation through nCaRE 
sequences binding [119]. Moreover, our observations support a two-step mechanism explaining APE1 
detection of DNA damage: a first, low-affinity, quasi-processive scanning [123] is carried out by the 
unstructured N-terminal region of APE1, which recognizes a local distortion (or an AP-site); the 
interaction is then stabilized by an higher-affinity binding event that is carried out by the whole 
globular domain of APE1 [90]. 
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The phylogenic acquisition of critical lysine residues conferred additional flexibility to the 
APE1 N-terminal domain, as confirmed by both structural and biophysical studies [90, 124]. The 
presence of additional basic residues, in a very plastic structural context, suggest that APE1 could 
exploit its N-terminal extension as a sort of “tail”, which can be easily adapted to bind very different 
interacting partners. Moreover, as observed for other BER components, the intrinsically disordered N-
terminal region also includes residues target of PTMs and a bipartite nuclear localization signal ([125] 
and Fig. 7). APE1 is modulated by means of different PTMs (reviewed in [82, 126, 127]), most of 
which occur indeed within the N-terminal domain. Examples include ubiquitination [128, 129], 
acetylation and proteolysis [130-132]. Among the PTMs on this domain, acetylation at K6 and 7 has 
been demonstrated to modulate APE1 transactivation activity [133], while we showed that acetylation 
at K27, 31, 32 and 35 is important for the tuning of different activities of APE1. In particular, the 
charge status of these residues affects the nucleolar accumulation of the protein, its ability to interact 
with NPM1 and the catalytic activity on abasic DNA, possibly through the modulation of product 
release [90, 91, 124]. Very recently, we also demonstrated that acetylation at the K27-35 lysine 
cluster affects the acetylation status of the K6/7 residues, in a cross-talk involving the SIRT1 
deacetylase [124]. Furthermore, during my PhD project I analyzed the APE1 K35 acetylation pattern 
in triple negative breast cancer specimens, highlighting a profound dysregulation of the APE1 PTMs 
status in tumor tissue [134] (Fig. 8). 
 
 
Fig. 8 – Schematic summary of the multiple regulatory functions exerted by the disordered N-
terminal domain of APE1. The ribbon representation of APE1 (grey) bound to abasic DNA (blue) 
was obtained from the RCSB Protein Data Bank (1DEW) and edited using the SPDBV software 
(version 4.01). The 42 N-terminal amino acids, absent in the original structure, were manually inserted; 
side-chains of the critical lysine residues 27, 31, 32, 35 are highlighted (red). Adapted from [19]. 
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In summary, the N-terminal extension of APE1 represents a novel molecular device that the 
protein acquired during phylogenesis. The evolutionary pressure exerted by an increasingly complex 
environment endowed APE1 with new residues which modulate the protein in many different ways 
(e.g. regulating APE1 activities, subcellular localization, interacting partners, PTMs). Due to its 
diverse effect on APE1, and based on the involvement of APE1 PTMs pattern in cancer, the N-
terminal domain could be considered as a novel and interesting target to pharmacologically modulate 
different functions of the protein. 
 
3.3. APE1 and pathology 
The general importance of APE1 to the cell is conceivable, due to the multiplicity of cellular 
activities exerted by the protein. In accordance with its pivotal role, defects in APE1 activity and 
expression have been connected to cancer and neurodegeneration [135]. 
As already elucidated in the paragraph 2.3 (“BER as a target for anti-cancer therapy”) 
alterations in the whole BER pathway and dysregulation of APE1, in particular, have been linked to 
cancer onset and progression. APE1 expression in human tumors shows a complex and heterogeneous 
pattern, being predominantly nuclear, with cytoplasmic and nuclear-cytoplasmic staining as well [82]. 
The endoribonuclease activity of APE1, its role in the mitochondrial BER, as well as its redox 
activity on newly synthesized transcription factors might in part explain its cytoplasmic localization 
[82, 105]. Alterations in the APE1 localization pattern have been observed in several tumors ([105] 
and references therein). Interestingly, an increased cytoplasmic localization of the protein has been 
linked to more aggressive cancer phenotypes and correlates with lower tumor differentiation, 
increased angiogenesis and lymph node status [46, 136]. Elevated APE1 expression levels, moreover, 
have been linked to tumor resistance to radiation- and platinum-based therapies [45, 67]. Taken 
together, these observations suggest that APE1 may have substantial prognostic significance in 
tumors. 
Given the strong association existing between APE1 and cancer, pharmacological targeting of 
APE1 has been proposed as an appealing approach to improve the current anti-tumor therapy. 
Depletion or downregulation of APE1, in fact, has been show to induce apoptosis [137], cell growth 
defects [138] and sensitization to several DNA-damaging agents [105, 139]; whereas the redox 
activity of APE1 influences different mechanisms that are linked to cancer survival (e.g. growth, 
metastasis, angiogenesis, microenvironment) [110]. In the last decade a considerable effort has been 
made in order to develop small molecule inhibitors specifically targeting a single enzymatic activity 
of APE1 [110, 140]. To date, (2E)-3-[5-(2,3-dimethoxy-6-methyl 1,4-benzoquinoyl)]-2-nonyl-2-
propenoic acid (E3330, APX3330) and few improved analogs are the most potent compounds 
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targeting the redox function of APE1 [141-144]. Potential applications for these inhibitors range from 
adjuvant to anti-tumor therapy to ophthalmological hyper-vascularization diseases [110]. Just to give 
an example, impairment of the APE1-mediated redox activation of AP-1, could have a profound 
effect on tumor resistance to cisplatin, as AP-1 has been suggested to induce the expression of DNA 
repair factors involved in the removal of cisplatin adducts [145]. Very recently, the specificity of 
action of E3330 has been the subject of a lively debate, as it appears that at high concentration the 
compound affects also the endonuclease activity of APE1 [112, 113, 146]. 
Parallel investigations by different groups have led to the design of potent small-molecule 
inhibitors of the APE1 endonuclease function. Optimized screening campaigns and structure-activity 
relationship studies have identified several structurally unrelated compounds with inhibitory activity 
in the single-digit micromolar range ([105, 140, 147-150] and references therein). Use of these 
inhibitors on cell lines potentiates the cytotoxicity of alkylating agents (e.g. methyl methanesulfonate 
– MMS, temozolomide), leading to an accumulation of AP-sites in treated cells. A couple of 
compounds (i.e. N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-
yl)acetamide – compound #3 and N-(3-(benzo[d]thiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-
yl)acetamide – compound #52), moreover, have been preliminarily tested in vivo and showed 
properties amenable for further pharmacological development [148]. At present, methoxyamine (MX) 
is the only APE1 inhibitor actively pursued in clinical trials for the management of advanced tumors 
[151]. The molecule, however, is formally to be considered an indirect BER inhibitor, as it forms 
covalent AP-site adducts that are refractory to APE1 cleavage [152]. 
Additional improvement and characterization of the existing APE1 inhibitors is warranted, as 
they will definitely reveal useful tools to depict the relative contribution of each APE1 activity to the 
cellular response to environmental stimuli. While valuable for in vitro studies, however, it is not clear 
whether unrestricted systemic inhibition of the APE1 functions could achieve specificity of action 
towards tumor cells. For this reason, my PhD project focused on the development and 
characterization of a new class of APE1 inhibitors targeting its protein-protein interaction network, 
and, in particular, the APE1/NPM1 molecular association. 
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4. NPM1: a diverse protein 
Nucleophosmin (B23, numatrin, NO38, here referred to as NPM1) is a multifunctional 
phosphoprotein originally identified as a mitogen-induced factor in B lymphocytes [153]. The NPM1 
gene encodes for three splicing variants (B23.1, B23.2 and B23.3), that differ in their length and 
subcellular localization [154]. NPM1 (B23.1) is by far the best characterized isoform and in this 
thesis I will focus on this protein variant which, as previously explained, was identified as an 
interacting partner of APE1. 
NPM1 is an essential protein that has been associated with several cellular functions, as well 
as to cancer onset and progression. From this standpoint, however, the overall picture of the role of 
NPM1 is still very blurred, as the protein has been described both as a proto-oncogene and as a tumor 
suppressor. Interestingly, the literature offers numerous hints pointing to a possible involvement of 
NPM1 in the DDR; nonetheless, our knowledge on the subject is still very poor. 
This chapter will detail what is currently known about NPM1 functions, with particular 
emphasis on the still debated role of this protein in cancer. An entire section of this chapter (4.3 
“NPM1, a novel player in the DNA damage response?”) will focus on our current comprehension of 
NPM1 role(s) during the DDR, as this will be a central topic to this thesis. 
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4.1. Protein structure and function 
NPM1 is synthesized as a 37 kDa polypeptide that can assemble into higher order oligomers. 
The NPM1 monomer shows a modular structure encompassing 294 amino acids and folds into two 
structurally independent domains (Fig. 9): 
 
 
Fig. 9 – Schematic representation of the NPM1 primary structure. NPM1 contains two main 
structured regions (the N-terminal hydrophobic and the C-terminal DNA/RNA binding domains) that 
are separated by basic and acidic clusters. The subcellular localization of the protein is dynamically 
modulated by one nuclear export signal, a bipartite nuclear localization signal and a nucleolar 
localization signal. Source: [155]. 
 
The N-terminal part of the protein (amino acids 1-122) constitutes a highly conserved -
barrel core domain that is shared among the nucleoplasmin family of molecular chaperones; this 
region is responsible for the oligomerization of NPM1 [156-158]. Five monomers assemble into a 
ring-shaped oligomer; two pentamers, then, join head-to-head forming high molecular weight 
multimers [156, 157]. The N-terminal core is also responsible for several protein-protein interactions 
involving NPM1 (e.g. with p14
Arf
 or APE1) [75, 159]. Mutual interactions between p53, Mdm2 and 
p14
Arf
 are critical for the modulation of cell proliferation and apoptosis; NPM1 likely plays a key 
function in mediating the cross-talk among these factors. For instance, NPM1 regulates p53 levels 
and activity through direct interaction [160] and through competition with p14
Arf
 for Mdm2 binding 
[161, 162]. On the other hand, NPM1 appears to be the focal link between nucleolar integrity and p53 
activation. Although the functional significance of the NPM1/p14
Arf
 interaction is still matter of 
debate, it is clear that the protein-protein association contributes to the stabilization of both 
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molecules. Whether the NPM1-mediated p14
Arf
 sequestration within nucleoli has any functional 
significance is less understood [163]. It is however evident is that, upon triggering of nucleolar stress, 
redistribution of NPM1 to the nucleoplasm and ATM-induced dissociation from p14
Arf
 are two crucial 
events leading to p53 stabilization [163, 164]. 
The C-terminal domain of NPM1 (amino acids 244-294) has been the subject of several 
structural studies, being the protein region most frequently mutated in acute myeloid leukemia (AML 
– see the next paragraph). This protein domain folds into a three-helix bundle that accounts for the 
nucleic acid binding activity of NPM1 [154, 165, 166]. The structural integrity of the NPM1 C-
terminal region is tightly linked to the nucleolar localization of NPM1; it has been proposed that the 
high affinity of NPM1 for ribosomal particles and for G-quadruplex DNA structures is responsible for 
the nucleolar residence of the protein [154, 165, 167]. 
Analysis of the NPM1 primary sequence highlighted the presence of several targeting motifs 
that allow continuous shuttling of the protein from nucleoli to the cytoplasm (Fig. 9 and [168]). This 
feature, along with the high affinity of NPM1 for rRNA particles, and the reported involvement in the 
28S rRNA maturation [169], strongly suggest a role for the protein in the ribosome processing. 
NPM1, in fact, has been proposed to provide the export signals and the chaperoning capabilities (see 
below) necessary for the transcription, maturation and transport of the ribosomal particles [170, 171]. 
There is no record of a comprehensive crystal structure of the full-length protein, so far. 
Nuclear magnetic resonance and circular dichroism analyses, however, shed insight into the dynamic 
organization of the unstructured regions containing one basic and two acidic stretches (Fig. 9) and 
linking the NPM1 N- and C-terminal domains [154, 172, 173]. These intrinsically disordered regions 
are important regulatory domains and acceptors of PTMs that modulate the NPM1 oligomerization 
status and its binding to RNA and G-quadruplex structures [154, 167, 173, 174]. 
The structural characteristics of NPM1 make this protein a paradigm to study protein folding 
dynamics. Recent analyses performed in collaboration with Dr. Marasco (University of Naples) 
allowed us to unveil the remarkable thermal and chemical stability of the NPM1 core domain. 
Notably, we showed that the folding of the C-terminal domain is stabilized by the presence of the 
surrounding disordered regions and by the N-terminal core. This suggests that future structural studies 
on NPM1 must take into account potential stabilizing effects given by the whole protein fold [172]. 
Different studies, moreover, demonstrated that NPM1 exerts chaperone-like activity on a variety of 
substrates, protecting specific target proteins from aggregation and denaturation in vitro [175]. The 
acidic portions of the protein appear necessary for the molecular chaperone activity of NPM1, 
especially on histones. NPM1, in fact, has been shown to assists the proper deposition of histones on 
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chromatin in vivo, thus modulating cellular processes such as transcription and, likely, DNA repair 
[176-180].  
 
4.2. NPM1 and cancer: oncogene or tumor suppressor? 
NPM1 role in cancer is multifaceted: the protein is known to suppress the early stages of 
tumorigenesis, while promoting cell growth in transformed cells. Moreover, tissue- and context-
specific alterations characterize different aspects of NPM1 involvement in cancer [155]. Solid tumors, 
for instance, are often characterized by overexpression of NPM1, while hematological malignancies 
frequently bear mutations and chromosomal rearrangement involving the NPM1 gene. These 
rearrangements have been reported to generate fusion proteins (e.g. NPM1-ALK, NPM1-MLF1, 
NPM1-RAR) that can sustain cell growth in acute promyelocytic leukemia, anaplastic large cell 
lymphoma and AML (reviewed in [163, 171]). The occurrence of NPM1 alterations in about one third 
of adult AML patients, moreover, results in the concerted loss of one or two tryptophan residues that 
act as nucleolar targeting signals, along with the generation of an additional nuclear export signal and 
consequent delocalization of the protein to the cytoplasm (referred to as NPM1c+ mutation) [163]. 
The NPM1c+ mutation is considered a tumor initiating lesion in NPM1c+ AMLs [181, 182] and it is 
thought to promote transformation through overexpression of c-myc [183] and relocalization and/or 
inactivation of different interacting partners with tumor-suppressive function, such as p14
Arf
 [184], 
Miz1 [185] and Fbw7 [183]. NPM1c+ might also act as a dominant negative form, providing a 
dimerization interface and altering the subcellular localization of the wild-type protein, encoded by 
the non-mutated NPM1 allele [163]. Interestingly, the NPM1c+ mutation identifies a prognostically 
favorable subgroup in AML (when present in the absence of mutations at the FLT3-IDT locus), 
showing higher relapse-free survival rates than AML with normal NPM1 [163]; a possible molecular 
explanation for the better response to therapy in NPM1c+ AML patient was recently suggested by our 
group. We demonstrated that NPM1c+ expression induces a cytoplasmic relocalization of APE1 in 
AML cells. The nuclear deprivation of APE1 and the consequent BER deficiency are likely to render 
AML cells more susceptible to genotoxins [186]. 
NPM1 levels generally correlate with proliferation; accordingly, overexpression of NPM1 is 
considered a prognostic marker of recurrence and progression in solid tumors [171, 187, 188]. The 
correlation between increased NPM1 levels and cancer has usually been linked to NPM1 roles in 
ribosome biogenesis [171], but the interaction of NPM1 with Mdm2, p53 and p14
Arf
 might explain its 
involvement in the modulation of tumor cell proliferation. For instance, the elevated NPM1 levels 
observed in cancer may be oncogenic through negative regulation of the p14
Arf
 anti-oncogenic 
functions [62]. NPM1, moreover, has been shown to cooperate with oncogenes in inducing cellular 
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transformation in mouse embryonic fibroblasts (MEFs) [189, 190]. Most of the conclusions drawn so 
far, however, result from experimental data from cell cultures; the lack of suitable mouse models of 
tumorigenesis renders our understanding of the in vivo NPM1 contribution to carcinogenesis 
controversial [171]. 
In conclusion, NPM1 could be considered as a tumor suppressor, in that loss of protein 
function (for instance, through impairment of physiological intracellular localization, or protein-
protein interaction ability) may lead to selective pressure toward loss of p53 function and onset of 
tumorigenesis [63]. On the other hand, when considering the pro-proliferative role of NPM1 and the 
cross-activation of diverse pathway after fusion with different protein partners, one might envision 
NPM1 more as a proto-oncogene. For a comprehensive description of the duality of NPM1 in cancer 
the reader is referred to [155]. 
 
4.3. NPM1, a novel player in the DNA damage response? 
Extensive work has been carried out in order to establish a link between NPM1 and the DDR; 
a clear picture of the exact function of NPM1 in this context, however, is still lacking. Perhaps one of 
the first evidences linking NPM1 and the maintenance of genome stability was the discovery that 
NPM1 associates with centrosomes during the G1 phase of the cell cycle, acting as a licensing factor. 
This function of NPM1 is controlled by cyclin E/Cdk2-dependent phosphorylation and prevents 
centrosome duplication prior to cell division [191, 192]. In accordance with these data, NPM1 
knockout (KO) in mice leads to unrestricted centrosome duplication and overall genomic instability 
[193]. Studies performed on NPM1 KO mice revealed that NPM1 is essential for embryonic 
development and that NPM1 haploinsufficiency accelerates oncogenesis [193]. Loss of NPM1 
function in MEFs results in stabilization of p53 and increased susceptibility to oncogenic 
transformation, with parallel accumulation of DDR markers (i.e. -H2AX and phospho-ATM) [194]. 
These observations are consistent with several reports showing that DNA damage induces the 
expression and/or the nucleoplasmic relocalization of NPM1 [21, 161, 195-198]. More recently, 
NPM1 was shown to undergo phosphorylation-mediated relocalization to sites of DSBs upon IR. 
Moreover, pharmacological interference with NPM1 translocation to DNA lesions prolongs DNA 
damage persistence [199, 200]. In summary, there are many hints that point to a role for NPM1 
during the DDR; in particular, it appears clear that NPM1 function(s) are linked to the cell capacity to 
deal with DNA strand breaks. 
Very recently, our laboratory proposed a possible involvement of NPM1 as novel modulator 
of the BER pathway. Specifically, we demonstrated that NPM1 modulates the AP-site incision 
activity of APE1 [91, 186]. Accordingly, NPM1-deficient MEFs display an increased sensitivity to 
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genotoxins that elicit a BER response (e.g. MMS, oxidizing agents, and bleomycin) [186]. These data 
suggest that NPM1 may play an important role in the modulation of the early BER steps, although no 
information is available on the effect of NPM1 on the overall BER capacity. This thesis work is 
aimed at filling this gap, investigating the connection between NPM1 and the BER.  
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5. The APE1/NPM1 interaction in pathology  
In the last few years we demonstrated that the interaction between APE1 and NPM1 affects 
multiple aspects of the APE1 biology. Vice versa, the impact of this interaction on NPM1 functions, 
if any, is still unknown. The characterization of the APE1/NPM1 association in different tumor cell 
lines highlighted the pivotal role played by this molecular interaction in cancer cells. Existing 
evidences suggest that the APE1/NPM1 interaction could be considered a novel and interesting target 
for cancer therapy. Based on available data it is possible to summarize the effects of NPM1 on APE1 
as follows: 
 NPM1 positively modulates the endonuclease function of APE1 on DNA, but decreases its 
activity on AP-site-containing RNA. The result of this balance affects both cell growth and 
DNA repair capacity in response to genotoxins [75, 91, 186]. 
 NPM1 promotes the accumulation of a fraction of APE1 within nucleoli, where it possibly 
functions as rRNA processing enzyme [75]. Accordingly, interfering with the nucleolar 
localization of APE1 strongly impairs tumor cell growth [124]. 
These observations led us to propose a model explaining the APE1/NPM1 cross-talk in tumor 
cells, both under basal conditions and after genotoxic stress (Fig. 10). 
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Fig. 10 – Proposed dynamic modulation of APE1 through interaction with NPM1, intracellular 
compartmentalization and PTMs. APE1 is mainly localized in the cell nucleoplasm; PTMs on the N-
terminal domain (i.e. acetylation and ubiquitination) fine-tune the protein amount and activity, 
homeostatically maintaining genome stability. A fraction of the non-acetylated protein accumulates 
within nucleoli through the association with NPM1. Here, APE1 is possibly stored and exerts rRNA 
processing-related functions. Genotoxic stress may shift the equilibrium toward the acetylated form of 
APE1, which has lower affinity for RNA and NPM1, thus promoting its release from nucleoli and 
increasing its nucleoplasmic BER activity. Source: [91]. 
 
PTMs on the N-terminal region play a critical role in modulating the APE1 dynamics, as the 
charge status of this protein domain modulates the catalytic function of APE1 [91, 124], its nucleic 
acid binding activity [90] and its association with NPM1 (and, consequently, its nucleolar 
accumulation) [124]. Whether APE1 is retained within nucleoli to boost the nucleoplasmic DNA 
repair capacity upon release, or to maintain cellular proliferation through control of the ribosome 
processing, still remains unanswered. 
Recent studies performed in our laboratory unveiled the potential implication of an aberrant 
APE1/NPM1 interaction in cancer onset and development. For the first time, we observed the 
occurrence of an abnormal APE1/NPM1 interaction in the cytoplasm of AML cells carrying the 
NPM1c+ mutation. The expression of the NPM1c+ form was associated with significant nuclear 
depletion of APE1, with increased sensitivity to genotoxins [186]. These observations lay the 
molecular basis to understand the good prognostic feature of NPM1c+ AMLs. As mentioned in the 
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previous chapters, both APE1 and NPM1 overexpression is a negative prognostic feature in solid 
tumors (e.g. ovarian and hepatocellular cancer). In collaboration with the Azienda Ospedaliera 
Universitaria of Udine we recently carried out a retrospective study on a cohort of 73 ovarian serous 
cancer specimens, and found that the expression profiles of APE1 and NPM1 were positively 
correlated in this carcinoma, with higher APE1/NPM1 expression in more aggressive tumors [188]. 
An increased APE1/NPM1 interaction was also associated with poor differentiation and augmented 
resistance to MMS in hepatic carcinoma cell lines (unpublished observations). These evidences 
suggest that an elevated APE1/NPM1 interaction might increase tumor aggressiveness and resistance 
to therapy. A comprehensive model emerging from the study of APE1, NPM1, and from the 
characterization of their interaction, is summarized in Fig. 11. 
 
 
Fig. 11 – Schematic synopsis of the relative contribution of APE1 and NPM1 during 
tumorigenesis. A. Conditions of NPM1 haploinsufficiency and/or NPM1c+ expression characterize 
hematological malignancies. This situation can lead to BER dysregulation due to aberrant cytoplasmic 
APE1/NPM1 interaction, with intrinsic genomic instability caused by impaired APE1 and NPM1 
function. Transformation is favored on this background and can be triggered by NPM1c+ expression 
itself. B. In solid tumors, the presence of elevated amounts of wild-type APE1 and NPM1 may 
facilitate oncogenic transformation by allowing DDR checkpoint evasion and by sustaining growth 
even under persistent DNA damage (e.g. during therapy). Source: [186]. 
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The apparent involvement of the APE1/NPM1 interaction in cancer development and growth 
suggest that this protein-protein interaction might be a sensible target for anti-tumor therapy. 
Accordingly, we demonstrated that interfering with the APE1/NPM1 interaction HeLa cells abolishes 
APE1 accumulation in nucleoli and strongly impairs cell proliferation [124]. These observations 
highlight the translational relevance that novel compounds targeting the APE1/NPM1 association 
may have. As previously mentioned, APE1 is a ubiquitous protein and systemic administration of 
APE1 inhibitors of either the redox or the endonuclease activity may not be a suitable approach to 
cancer. Targeting the APE1/NPM1 interaction might be an interesting alternative approach to cancer 
treatment, as tumor cell that express higher level of both APE1 and NPM1 might be more sensitive to 
the inhibition of the interaction. 
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AIMS 
 
The information gathered during the last fifteen years strongly suggest that both APE1 and 
NPM1 play an important role during cancer onset and progression; the presence of high levels of 
these proteins, moreover, is frequently a negative prognostic indicator and affects the response to 
anti-tumor therapy. The primary task of my PhD project was the development and characterization of 
novel low molecular weight compounds targeting the APE1/NPM1 interaction for translational 
purposes. The experiments that were carried out in this context led to a profound characterization of 
the functional relevance of the APE1/NPM1 association. These very same experiments, however, 
revealed that our knowledge on basic aspects of NPM1 and BER biology is still scanty. In particular, 
during my PhD project I realized that at least two fundamental questions did not find explanation in 
the existing literature: 
1. Which is the involvement of NPM1 in the DDR? In particular, is there any link between 
NPM1 and the BER pathway beyond the control of the APE1 activity? 
2. What is the purpose of the BER protein localization within nucleoli? Is the nucleolus merely 
a storage site, or is there a rationale behind the nucleolar accumulation of DNA repair 
factors? 
In order to address these questions I systematically analyzed the BER pathway upon 
depletion of NPM1; moreover, by studying the effect of genotoxins known to induce a relocalization 
of NPM1 from nucleoli, I explored the consequences of nucleolar stress on the BER process. 
Due to the limited amount of space, many of the data concerning the characterization of the 
APE1/NPM1 interaction, which have already been published, have been included in the introductory 
part of this thesis. The following chapter will describe the work undertaken during the last part of my 
PhD project which is, so far, submitted for publication. For the sake of clarity, this thesis has been 
divided into two sections. The first part (“Targeting the APE1/NPM1 interaction”) focuses on the 
work carried out in order to develop and characterize small molecules targeting the APE1/NPM1 
association. I describe the high-throughput screening developed in collaboration with the NIH 
Chemical Genomics Center (NCGC – Bethesda (MD), USA) and the efforts made in order to narrow 
the number of hits to three compounds that are able to disrupt the APE1/NPM1 in living cells, 
displaying interesting anti-tumor properties. The second part of the thesis (“Investigating the role(s) 
of NPM1 during the DDR”), instead, aims to clarify the role of NPM1 in the DDR, with particular 
emphasis on its involvement in BER. The experiments performed to pursue this second task also put 
forward a first tentative explanation for the role of BER proteins within nucleoli in tumor cells. 
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RESULTS 
 
The data reported in this chapter are the subject of two articles recently submitted for 
publication: 
 Poletto M. et al., “Inhibitors of the APE1/NPM1 interaction that display anti-tumor 
properties” (Mol Carcinogenesis, under revision) 
 Poletto M. et al., “Nucleophosmin modulates stability, activity and nucleolar accumulation 
of base excision repair proteins” (Mol Biol Cell, under revision) 
 
1. Targeting the APE1/NPM1 interaction 
As elucidated in the introductive chapter, targeting the BER pathway, and in particular APE1, 
is a promising approach to cancer treatment. Aberrant sub-cellular localization, PTM pattern and 
expression levels of APE1 have been linked to tumor development and resistance to traditional 
therapeutic regimens. The interaction with NPM1, moreover, regulates several aspects of the APE1 
biology, ranging from the nucleolar accumulation of APE1 to its AP-site incision activity on DNA 
and RNA. 
The NPM1c+ AML model of aberrant APE1/NPM1 interaction shows that this molecular 
association is relevant in determining the tumor response to therapy [186]. Moreover, the impairment 
of the APE1/NPM1 interaction in tumor cell models strongly affects cell proliferation, suggesting that 
a functional molecular association between APE1 and NPM1 is pivotal for tumor cell growth and 
response to genotoxins [124]. These evidences imply that interfering with the APE1/NPM1 
interaction might prove a relevant strategy to target tumor cell proliferation and/or their sensitivity to 
DNA damaging agents. In addition, targeting the APE1 interactome, rather than its enzymatic 
activities, might reveal more specific toward those cells which display increased APE1 and NPM1 
expression levels. The recent observation of a positive correlation between the expression levels of 
APE1 and NPM1 in ovarian cancer specimens strongly supports this line of research [188]. 
 
1.1. An AlphaScreen®-based high-throughput screening for the identification of 
low molecular weight disruptors of the APE1/NPM1 interaction  
In collaboration with the NIH Chemical Genomics Center (NCGC – Bethesda (MD), USA), 
we set up a quantitative high-throughput luminescence-based screening to detect small molecules able 
to interfere with the APE1/NPM1 interaction. The assay exploits the AlphaScreen
®
 technology (the 
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principle of which is explained in Fig. 12A) using full-length recombinant GST-tagged APE1 and 
His(6)-tagged NPM1. 
 
 
Fig. 12 – A high-throughput screening assay to detect APE1/NPM1 interaction inhibitors. A. 
Principle of the AlphaScreen
®
 assay. The APE1/NPM1 interaction is detected, in solution, when a 
donor and an acceptor bead are brought in close proximity by the molecular association between GST-
APE1 and His(6)-NPM1. Upon excitation at 680 nm, the glutathione-coated donor beads release singlet 
oxygen (
1
O2), which is rapidly quenched by the aqueous milieu. If a Ni
2+
-coated acceptor bead is 
within a range of 200 nm, the transfer culminates in light production at 520-620 nm. B. Schematic 
representation of the Z’ score as measured throughout the screening; a stable score above 0.65 
confirmed the high quality of the assay. C. Graphic overview of the dose-dependent activity for a 
subset of positive hits from the screening. The graph reports the concentration-dependent loss of 
APE1/NPM1 interaction signal for the indicated compounds, relative to the vehicle-treated samples. 
Molecules here reported are the ones further characterized in downstream assays. 
 
Milligram amounts of recombinant proteins were expressed and purified to near homogeneity 
as described in the “Experimental Methods” section. The optimization of the assay was carried out by 
the NCGC team, which downscaled the reaction volume in order to increase the throughput of the 
assay, while minimizing reagent consumption. A pilot set of commercially available small molecule 
libraries (≈12,700 compounds in total) were screened at seven-concentration dilution series (3.7 nM 
to 57 M) with an excellent Z’ score (>0.65) that was maintained throughout the screening (Fig. 
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12B). Positive compounds were rescreened for confirmation and false positives were eliminated 
through a counterscreen assay measuring the AlphaScreen
®
 signal in presence of a GST-His(6) 
conjugate which served as recognition moiety bridging both the donor and the acceptor beads. The 
screening led to the identification of 58 top hits that were selected on the basis of their dose-response 
curves, also manually removing molecules that were likely false positives (e.g. molecules with 
reactive groups, which could lead to modifications of the target proteins) (Fig. 12C). The screening 
assay also gave us some information on the potency of each compound, which was represented by an 
associated AC50 (Supplementary Table 1). 
 
1.2. Selection of molecules able to impair the APE1/NPM1 interaction in living 
cells 
Positive hits from the primary screening were subjected to a panel of orthogonal cell-based 
secondary validation assays. HeLa cells were used as a model to preliminarily test the cytotoxicity 
and the solubility of each compound in the culture medium. Individual toxicity of the molecules was 
tested through the MTS viability assay over a wide range of concentrations (0.1 – 100 M) and time 
points (4 – 24 hours); whereas compound solubility was evaluated by assessing particle deposition 
through a phase contrast microscope. These information were exploited in the subsequent assays to 
reduce the likelihood of confounding effects. 
The interaction with NPM1 is known to modulate the subcellular localization of APE1 [124, 
186]; therefore, I decided to screen the molecules for their ability to induce a relocalization of APE1 
upon cell treatment. HeLa cells were treated with test compounds in at least two different conditions 
(i.e. time and concentration) that affected cell viability less than 50% (as estimated through previous 
MTS assays) and the subcellular localization of APE1 was assessed through immuno-fluorescence. 
Treatment with a subset of the compounds affected differently the APE1 subcellular localization 
(Supplementary Table 1): while cell stimulation with some molecules (e.g. ZM 241385, troglitazone, 
ketoconazole) led to a reduction in the nucleolar accumulation of APE1, treatment with some others 
(e.g. fiduxosin, SB 206553, spiclomazine) elicited a relocalization of the protein to the cytoplasm 
(Fig. 13). 
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Fig. 13 – Immuno-fluorescence-based secondary screening on the putative APE1/NPM1 
inhibitors. Representative immuno-fluorescence panels showing the APE1 relocalization induced in 
HeLa cells by some hits from the primary screening. Left panel – The increased cytoplasmic staining 
for APE1 induced by treatment with SB 206553 is visible on the cytoplasmic focal plane and using a 
quantitative color look-up table rendering (Q LUT). Right panel – Absence of APE1 nucleolar 
accumulation upon cell treatment with ZM 241385. Bars: 8 m. 
 
The molecules that induced a relocalization of APE1 were selected for further validation 
through a Proximity Ligation Assay (PLA). This assay couples the immuno-recognition of two targets 
(i.e. APE1 and NPM1) in fixed cells and a PCR-based amplification of the interaction signal, 
allowing the detection and quantitation of transient, as well as stable interactions, that appear as bright 
spots detectable through confocal microscopy [186, 201, 202]. The primary AlphaScreen
®
 assay was 
carried out with N-terminally tagged proteins; in order to exclude any artifact arising from the 
presence of an N-terminal tag, I exploited an already available HeLa cell line stably expressing a C-
terminally FLAG-tagged version of APE1 [124]. The presence of the tag, in this case, was functional 
to the PLA assay and was already shown not to interfere with the APE1/NPM1 association [186]. 
HeLa cells were incubated with the putative APE1/NPM1 inhibitors under conditions that induced a 
relocalization of APE1 and fixed immediately upon treatment. The extent of residual APE1/NPM1 
interaction was thereby quantified through PLA (Fig. 14). 
 
RESULTS 
40 
 
TESI DI DOTTORATO DI POLETTO MATTIA DISCUSSA PRESSO L’UNIVERSITÁ DI UDINE 
 
Fig. 14 – PLA validation of small molecules targeting the APE1/NPM1 interaction in living cells. 
HeLa cells were treated with the indicated APE1/NPM1 inhibitor and immediately fixed; PLA 
reactions were carried out and scored as described in the “Experimental Methods” section. A. 
Representative confocal micrographs showing a typical PLA result. The anti-FLAG staining (green) 
highlights APE1 and was used to individuate nuclei; the PLA signal is visible as red dots. In the 
control reaction the anti-NPM1 antibody was omitted. Fiduxosin-treated cells show a reduction in the 
PLA signal. Bars: 8 m. B. The extent of APE1/NPM1 association upon treatment with a subset of 
inhibitors was measured through PLA, and the effect of the inhibitors on such interaction is reported as 
a boxplot graph. Left panel – Boxplot representation reporting the median cytoplasm-to-nucleus ratios 
of the amount of PLA interaction spots scored in HeLa cells upon treatment with the indicated 
APE1/NPM1 inhibitors. Right panel – The median number of interaction spots scored in vehicle-
treated cells was used as reference and arbitrarily set to 1.0; the relative extent of APE1/NPM1 
association upon inhibition of the interaction was calculated by scoring the PLA signals in the 
inhibitor-treated cells. Cell challenge with the indicated molecules determines a statistically significant 
reduction in the extent of cellular APE1/NPM1 interaction. Black marks represent the median value of 
the analyzed population; the red line indicates the median of the vehicle-treated cells, for easier 
identification of differences. The amount and the localization of the APE1/NPM1 interaction signals 
were assessed as described in the “Experimental Methods” section. N≥35, NS: not statistically 
significant, *: p<0.05, **: p<0.01, ***: p<0.001.  
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The secondary PLA-based validation screening led to the identification of eight compounds 
(i.e. FSCPX, troglitazone, SB 206553, ZM 241385, rotenone, spiclomazine, fiduxosin and 
myoseverin B) effectively able to interfere with the APE1/NPM1 interaction in living cells. In 
accordance with the preliminary immuno-fluorescence observations (Fig. 13 and Supplementary 
Table 1), a subset of compounds that induced a relocalization of APE1 to the cytoplasm was able to 
relocalize also part of the interaction spots to the cytoplasm (e.g. spiclomazine, fiduxosin). Other 
molecules, instead, did not show any variation in the distribution of the PLA signal, despite the 
observed relocalization of APE1 (e.g. SB 206553). At this point I decided to further restrict the panel 
of molecules under investigation excluding rotenone, a well-known respiratory chain poison and 
myoseverin B, a microtubule-binding molecule [203], because more likely to display off target 
effects. 
 
1.3. Characterization of the molecular target of the top hits compounds 
In order to understand whether the small molecules had preferential effect through APE1 or 
NPM1, I pursued two parallel strategies. On one side, I tested the effect of the APE1/NPM1 inhibitors 
on the APE1 redox activity in living cells; moreover, in collaboration with Dr. Daniela Marasco 
(University of Naples), the in vitro binding characteristics of the small molecules towards 
recombinant purified APE1 and NPM1 were investigated. 
The effect of the APE1/NPM1 inhibitors on the APE1 redox function was assessed by 
exploiting a cell model developed by Cesaratto et al. [204]. Briefly, JHH6 hepatocellular carcinoma 
cells were transfected with a plasmid bearing a luciferase reporter which transcription is driven by an 
interleukin-8 (IL-8) promoter containing NF-B binding sites. Cells were then challenged with tumor 
necrosis factor- (TNF-), which triggers the NF-B-dependent IL-8 transcription through a 
mechanism involving the APE1 redox-mediated activation of NF-B itself [204]. Any APE1/NPM1 
inhibitor influencing the TNF--induced reporter transcription, therefore, could be inferred to affect 
the APE1 redox function. 
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Fig. 15 – Evaluation of the effect of the APE1/NPM1 inhibitors on the APE1 redox function. 
Histogram showing the fold of reporter induction upon JHH6 cells stimulation with the indicated 
APE1/NPM1 inhibitors (10 M) and subsequent challenge with TNF-. E3330 (100 M) was used as 
positive control for APE1 inhibition. Note that some inhibitors do not display any significant effect, 
while others efficiently impair the TNF--mediated reporter activation. The overall effect on the basal 
promoter activity is negligible. The histogram reports the mean ± SD from at least three independent 
experiments. *: p<0.05, **: p<0.01. 
 
As described in Fig. 15, cell treatment with the APE1/NPM1 inhibitors had different effects 
on the APE1 redox activity. While some inhibitors (i.e. FSCPX, ZM 241385 and SB 206553) did not 
display any major effect on the TNF--induced reporter activation, others (i.e. troglitazone, 
fiduxosin, spiclomazine) efficiently blunted the NF-B-mediated response, suggesting an inhibitory 
effect of these molecules on the APE1 redox function. Notably, troglitazone showed an inhibitory 
activity comparable to that of E3330 (a well characterized APE1 redox inhibitor used as positive 
control), even at tenfold lower concentration. These observations suggest that APE1, rather than 
NPM1, is the preferred binding partner for at least a subset of the APE1/NPM1 inhibitors. 
In vitro binding assays carried out at the University of Naples were confirmative of these 
data. Purified recombinant APE1 or NPM1 were immobilized on a surface plasmon resonance (SPR) 
chip and each small molecule was tested for its protein binding activity. Although SPR experiments 
were limited by the poor solubility of the compounds in the aqueous running buffer, it is clear that the 
affinity of the APE1/NPM1 inhibitors is higher for APE1 than for NPM1 (Fig. 16). 
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Fig. 16 – SPR binding experiments with the APE1/NPM1 inhibitors on recombinant purified 
APE1 and NPM1. Each protein was immobilized with similar efficiency on a SPR chip and the 
candidate small molecules were used as analytes. The histogram reports the protein-compound 
interaction efficiency for the indicated APE1/NPM1 inhibitors at two different concentrations. The 
affinity is expressed as maximal binding response adjusted for the compound molecular weight of each 
molecule. Note the good dose-response for APE1 and the poor binding towards NPM1 displayed by all 
the molecules. E3330 was used as positive control for APE1 binding. 
 
Altogether, these observations suggest that the APE1/NPM1 inhibitors analyzed display 
diverse effects toward the APE1 redox function. Moreover, during the inhibition mechanism, the 
preferential binding partner is APE1, rather than NPM1. 
 
1.4. Selected APE1/NPM1 inhibitors sensitize tumor cells to genotoxins and display 
anti-proliferative activity 
In order to investigate the potential anti-tumor properties of the APE1/NPM1 inhibitors I 
assessed whether some of the molecules were able to sensitize tumor cells to different kinds of 
genotoxins. MMS, the radiomimetic drug bleomycin, and the PARP inhibitor PJ34 were chosen as 
genotoxic stimuli able to elicit a BER response [101, 205, 206]. 
As shown in Fig. 17 (panels A and B) cell exposure to either SB 206553 or spiclomazine 
sensitized HeLa cells (cervical cancer) to MMS-induced cell death. Combination of MMS with 
fiduxosin, ZM 241385 or FSCPX did not have any effect sensitizing effect (not shown). Furthermore, 
the interaction between SB 206553 and MMS was synergistic, as assessed through the combination 
index analysis [207]. 
RESULTS 
44 
 
TESI DI DOTTORATO DI POLETTO MATTIA DISCUSSA PRESSO L’UNIVERSITÁ DI UDINE 
 
Fig. 17 – SB 206553, fiduxosin and spiclomazine differentially sensitize cells to MMS, bleomycin 
and PJ34. A-B. HeLa cells were pre-treated for 8 hours with 10 M SB 206553 (A) or spiclomazine 
(B) and then challenged with the indicated amounts of MMS in presence of unchanged APE1/NPM1 
inhibitor concentration for further 8 hours. Cell viability was evaluated by using the MTS assay. C. 
HeLa cells were co-treated for 1 hour with 10 M spiclomazine in presence of increasing amounts of 
bleomycin. Immediately upon treatment, medium was replaced and cell viability was assessed through 
colony formation assay. D. HeLa cells were co-incubated for 1 hour with bleomycin and either 
fiduxosin or SB 206553. Cell viability was evaluated 48 hours later through cell counting. E. MCF-7 
cells were co-incubated for 48 hours with PJ34 and either fiduxosin or SB 206553. F. SF-767 cells 
were co-treated for 48 hours with 10 M fiduxosin in presence of the indicated amounts of PJ34. In 
panels E and F cell viability was assessed by using the MTS assay. The histograms report the mean ± 
SD from at least three independent experiments. *: p<0.05, **: p<0.01. 
 
In a similar manner, a sensitizing activity of fiduxosin, spiclomazine and SB 206553 was 
observed when coupling these APE1/NPM1 inhibitors with bleomycin (Fig. 17, panels C and D). 
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Also in the case of the spiclomazine/bleomycin combination, the combination index analysis 
suggested the presence of a moderate synergism between these drugs. In addition, the cytotoxicity 
induced by the PARP inhibitor PJ34 was enhanced by SB 206553 and fiduxosin in both the 
glioblastoma-derived SF-767 cell line and the breast-cancer derived MCF-7 cell line (Fig. 17, panels 
E and F). 
In summary, selected APE1/NPM1 inhibitors display interesting cell sensitizing effects when 
combined with DNA damaging drugs that trigger the BER activation. In order to investigate whether 
the molecules displayed any anti-proliferative activity as single agents, I measured the proliferation of 
HeLa cells upon acute or chronic exposure to the APE1/NPM1 inhibitors. Notably, cell treatment 
with fiduxosin and spiclomazine resulted in a dose-dependent impairment of the cell growth rate, both 
after short-term (24-72 hours) and long-term (10 days) treatment. SB 206553 had no significant effect 
on cellular proliferation (Fig. 18). 
 
 
Fig. 18 – Fiduxosin and spiclomazine show anti-proliferative activity as single agents. A. HeLa 
cells were treated with vehicle (DMSO) or the indicated APE1/NPM1 inhibitor for 24, 48 or 72 hours. 
Cell proliferation was determined by cell counting in at least three independent experiments and is 
reported as representative growth curve from technical duplicates. *: p<0.05. B-C. HeLa cells were 
seeded at low density and allowed to form colonies for 10 days in presence of increasing 
concentrations of the indicated inhibitors. Survival is expressed as percentage of visible colonies 
assuming the vehicle-treated cells as a reference. Fiduxosin and spiclomazine (B), but not SB 206553 
(C) display a dose-dependent anti-proliferative activity. The histograms report the mean ± SD from at 
least three independent experiments. 
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1.5. Investigating the mechanisms of action of the APE1/NPM1 inhibitors 
The primary screening and the orthogonal validation assays narrowed the number of 
molecules under investigation to three interesting compounds (i.e. spiclomazine, SB 206553 and 
fiduxosin). Based on my data, these molecules are able to disrupt the APE1/NPM1 association in 
living cells and display interesting anti-tumor features, both as single-agents and in combination with 
different genotoxins (Table 1) 
 
 
Table 1 – Characteristics of the positive hits from the secondary validation assays. For each molecule the 
table reports structure, effects on the APE1 redox function (where “++”, “+” and “-” denote the strength of the 
phenotype as strong, mild or absent, respectively), presence/absence of sensitizing effect in combination with 
MMS, bleomycin or PJ-34, and presence of anti-proliferative activity. NA: not available. 
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The sensitization and anti-proliferative effects suggest that an inhibition of the APE1/NPM1 
interaction may impair the function of at least one of the two interacting partners. In order to address 
this issue, I investigated the ribosome biogenesis dynamics and the DNA damage accumulation in 
treated HeLa cells, as biological processes that could be potentially affected by an impairment of the 
APE1/NPM1 association (see also the paragraph 2.4 “APE1 is involved in the ribosome biogenesis 
process”). 
I first assessed whether cell treatment with the APE1/NPM1 inhibitors induced any variation 
in the expression levels of the target proteins. None of the molecules tested led to downregulation of 
APE1 or NPM1 (Fig. 19A); moreover, NPM1 maintained its nucleolar localization over a 72 hours 
treatment with either spiclomazine or fiduxosin (Fig. 19B). Thus, it is possible to conclude that the 
inhibitory effect of fiduxosin, spiclomazine and SB 206553 on the APE1/NPM1 interaction was not 
provoked by a downregulation of the target proteins. Furthermore, at cytostatic spiclomazine and 
fiduxosin dosage, HeLa cells did not show any major nucleolar stress (as demonstrated by the 
integrity of nucleolar structures). 
 
 
Fig. 19 – The APE1/NPM1 inhibitors do not induce modifications of APE1 or NPM1 expression, 
or nucleolar stress. A. HeLa cells were treated with the indicated molecules (10 M for 16 hours) and 
the levels of APE1 and NPM1 were assessed through Western blotting on whole cell extracts (20 g). 
Cell treatment under conditions leading to the disruption of the APE1/NPM1 association does not lead 
to modifications in the APE1 or NPM1 expression pattern. Tubulin was used as loading control. B. 
Representative immuno-fluorescence on HeLa cells treated with either spiclomazine or fiduxosin (20 
M) for the indicated time points. Staining with an anti-NPM1 antibody (red) shows the intactness of 
nucleolar structures. Nuclei were counterstained with TO-PRO-3, bars 16 m. 
RESULTS 
48 
 
TESI DI DOTTORATO DI POLETTO MATTIA DISCUSSA PRESSO L’UNIVERSITÁ DI UDINE 
In accordance with the absence of nucleolar disassembly upon fiduxosin or spiclomazine 
treatment, the ribosome processing profile of HeLa cells treated with the APE1/NPM1 inhibitors did 
not show any obvious alteration (Fig. 20). This indicates that the disruption of the APE1/NPM1 
interaction was not associated with an impairment of the ribosome biogenesis and that other 
mechanisms might be responsible for the observed alteration of the cell proliferation rate. 
 
 
Fig. 20 – Treatment with the APE1/NPM1 inhibitors does not lead to ribosome maturation 
defects. HeLa cells were treated for the indicated time points with either fiduxosin or spiclomazine (20 
M). Cells underwent metabolic labeling and rRNA maturation kinetics was assessed as described in 
the “Experimental Methods” section. Major processing intermediates and ribosomal subunits are 
indicated on the right-hand side. The proteasome inhibitor MG132 (50 M, 2 hours) was introduced as 
positive control [197] and, accordingly, leads to impairment in the late processing steps of rRNA 
maturation. Neither fiduxosin nor spiclomazine induce rRNA biogenesis defects. V: vehicle (DMSO). 
 
I then tested whether cell treatment with the APE1/NPM1 targeting compounds led to DNA 
damage accumulation. Assessment of the AP-site content in genomic DNA indicated that HeLa cell 
treatment with spiclomazine or SB 206553 did not lead to any significant accumulation of abasic 
sites. Fiduxosin, conversely, induced a small increase in AP-sites; albeit statistically significant, the 
accumulation of damage was not comparable to that obtained using the known BER-eliciting 
compound MMS (Fig. 21A). Comet assays performed on HeLa cells confirmed that the APE1/NPM1 
inhibitors did not induce any DNA damage accumulation even at higher dosage (Fig. 21B). These 
observations are consistent with the absence of effects of the small molecules on the APE1 AP-site 
incision activity measured in vitro using HeLa whole cell extracts (Fig. 21C). 
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Fig. 21 – The APE1/NPM1 inhibitors do not induce any major accumulation of DNA damage in 
HeLa cells. A. HeLa cells were treated with fiduxosin or spiclomazine (10 M, 48 hours), SB 206553 
(20 M, 16 hours), or MMS (250 M, 16 hours) as positive control. AP-site accumulation in genomic 
DNA was measured as described in the “Experimental Methods” section. The histogram reports the 
mean ± SD from three measurements. *: p<0.01. B. Comet assay performed on HeLa cells treated with 
fiduxosin or spiclomazine (30 M, 16 hours), SB 206553 (100 M, 16 hours), or H2O2 (200 M, 10 
minutes) as positive control. The boxplot reports the median tail moment (black marks) for the 
analyzed cell population. N≥100. **: p<0.001. C. Representative AP-site incision activity 
measurement on HeLa whole cell extracts (50 ng) pre-incubated with either vehicle (DMSO) or 
fiduxosin (5 M). The APE1/NPM1 inhibitor shows no significant effect on the APE1 endonuclease 
function. The graph reports the mean ± SD from three independent assays. 
 
Taken together, these data show that a subset of bioactive compounds, screened for their 
ability to impair the APE1/NPM1 interaction, display interesting anti-tumor properties (i.e. cell 
sensitization to genotoxins and anti-proliferative activity). The mechanism of action of the selected 
APE1/NPM1 inhibitors is, at present, poorly understood, as treated cells do not show any impairment 
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in the ribosome maturation process or evident accumulation of DNA damage. This suggests that the 
anti-proliferative and sensitizing effects are not related to a major disruption of the BER function of 
APE1 or of the NPM1 activity in ribosome processing. 
The interesting anti-cancer properties of the APE1/NPM1 inhibitors certainly deserve further 
characterization; additional studies aimed at the improvement of these molecules and at the 
comprehension of their mechanism of action are therefore warranted. 
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2. Investigating the role(s) of NPM1 during the DDR 
Despite the valuable insights emerging from the study of NPM1 KO models, the mechanisms 
underlying NPM1 function during the DDR are still poorly understood. It appears clear that NPM1 
expression confers protection not only upon exogenous loads of DNA damage, but also under steady-
state conditions. Our recent work suggested that NPM1 might be a novel modulator of the BER 
pathway, positively regulating the AP-site incision activity of APE1, possibly through mechanisms 
involving both protein-protein and protein-nucleic acids interaction [186]. Yet, the precise 
involvement of NPM1 during the overall BER processing remains unclear. Moreover, the DNA 
damage-induced relocalization of NPM1 from nucleoli, suggests a possible involvement of the 
protein during the DDR. It is not known, however, if NPM1 translocation has any impact on the BER 
capacity. 
 
2.1. NPM1 depletion leads to BER protein upregulation 
Earlier observations from our laboratory revealed the presence of higher APE1 protein 
amounts in NPM1/p53 double KO MEFs (hereafter referred to as NPM1
-/-
) when compared to the 
isogenic single p53 KO control MEF cells (NPM1
+/+
) [186]. In order to understand whether NPM1 
could be further involved in the modulation of the BER pathway downstream APE1, I compared the 
protein and transcript expression profile of representative BER components in NPM1
+/+
 and NPM1
-/-
 
cells. Western blotting analyses on MEF whole cell extracts revealed that BER protein levels were 
largely upregulated as a consequence of NPM1 depletion (Fig. 22, panels A and B). The increased 
BER protein expression, however, was not paralleled by a significantly augmented transcription rate 
of BER genes (Fig. 22C), suggesting that NPM1 effect is mediated post-transcriptionally. In this 
analysis Pol was a notable exception, being upregulated both at the transcript and at the protein 
level. 
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Fig. 22 – NPM1 depletion leads to BER protein upregulation. A. Representative Western blotting 
analysis on NPM1
+/+
 and NPM1
-/-
 MEF whole cell extracts (60 g) showing increased BER protein 
amounts in the absence of NPM1. Proteins probed are indicated on the right hand-side, tubulin was 
used as loading control. B. Histogram reporting the average protein expression fold change in NPM1
-/-
 
cells, as measured through densitometric quantification of the Western blotting signals. C. Histogram 
showing the transcript fold change in NPM1
-/-
 cells, as measured through Real-time PCR. Bars indicate 
the mean ± SD from at least three independent replicates. *: p<0.05, **: p<0.01, Polcs: DNA 
polymerase  catalytic subunit. 
 
In order to rule out any confounding artifact, which may be caused by the intrinsic genetic 
instability exhibited by the NPM1
-/-
 cells [194], I transiently depleted NPM1 in NPM1
+/+
 cells and 
assessed the BER protein levels upon siRNA transfection. In accordance with my previous 
observations, siRNA-mediated knockdown of NPM1 recapitulated the BER expression phenotype for 
many of the proteins tested (Fig. 23). 
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Fig. 23 – Transient downregulation of NPM1 induces BER protein stabilization in MEFs. 
Representative Western blotting analysis on NPM
+/+
 whole cell extracts (50 g) showing the increment 
of BER protein levels upon siRNA-mediated depletion of NPM1 (siNPM1). Proteins probed are 
indicated on the right hand-side, tubulin was used as loading control. The average protein expression 
fold change ± SD from at least three independent replicates is reported on the right hand-side. siScr: 
scrambled control siRNA. 
 
Complete NPM1 KO requires p53 depletion in order to prevent triggering of apoptosis [194]; 
the link between NPM1 expression and BER protein stability was therefore further validated in 
human tumor cell lines bearing either active or inactive wild type p53 (i.e. HepG2 and HeLa, 
respectively). The experiments confirmed that NPM1 downregulation leads to an increased 
stabilization of BER proteins also in human cell lines, with variations in the degree of expression, 
likely reflecting cell-type specific differences (Fig. 24). The discrepancies observed in fold-induction 
when comparing the siRNA-mediated knockdown (Fig. 23 and Fig. 24) and the complete NPM1 KO 
(Fig. 22) are probably related to the residual amount of NPM1 (about 20%) upon depletion (see for 
instance FEN1, PCNA or LigI). Nonetheless, these data imply that NPM1 is a novel modulator of the 
BER protein stability. 
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Fig. 24 – Downregulation of NPM1 induces BER protein stabilization in human cell lines bearing 
different p53 status. A. Representative Western blotting analyses on HeLa and HepG2 whole cell 
extracts (50 g) upon treatment with scrambled (siScr) or NPM1-specific (siNPM1) siRNAs. Proteins 
probed are indicated on the right hand-side, tubulin was used as loading control. B. Histogram 
reporting average protein expression fold change in siNPM1-treated cells; signal from siScr-
transfected cells was taken as reference. Bars indicate the mean ± SD from at least three independent 
replicates. ¥: not statistically significant (p>0.05). 
 
2.2. NPM1 regulates BER protein localization and dynamics during nucleolar 
stress 
NPM1 is considered a hub factor as it mediates the nucleolar retention of different proteins 
[19, 208], including p14
Arf
 [162] and APE1 [75], at least in transformed cells. Given the BER 
dysregulation observed in NPM1
-/-
 MEFs I checked whether NPM1 expression affected the 
subcellular localization of a subset of BER components. Strikingly, while in NPM1
+/+
 cells a fraction 
of LigI, DNA polymerase  catalytic subunit (Polcs), FEN1 and APE1 revealed a nucleolar 
accumulation, the lack of NPM1 resulted in an impaired retention of these BER factors within 
nucleoli (Fig. 25A). 
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Fig. 25 – NPM1 promotes nucleolar accumulation of BER proteins. Representative immuno-
fluorescence micrographs showing the differential subcellular localization of BER factors in NPM1
+/+
 
and NPM1
-/-
 cells. A. Each protein analyzed shows nucleolar accumulation in NPM1
+/+
 MEFs only 
(white arrowheads). Nuclei were counter-stained with TO-PRO-3. B. Fibrillarin shows the typical 
nucleolar staining pattern (green), whereas BER proteins (red) co-localize with fibrillarin only in 
NPM1-proficient cells (yellow). The BER protein analyzed in each experiment is indicated on the left-
hand side. Bars: 16 m. 
 
RESULTS 
56 
 
TESI DI DOTTORATO DI POLETTO MATTIA DISCUSSA PRESSO L’UNIVERSITÁ DI UDINE 
Importantly, failure of BER proteins to accumulate within nucleoli was not determined by 
abnormalities in the nucleolar architecture of NPM1
-/-
 cells, as already reported [162, 194] and 
confirmed by the ordinary nucleolar fibrillarin staining (Fig. 25B). The relevance of NPM1 
expression for the correct nucleolar accumulation of BER proteins was confirmed by reconstitution 
experiments in NPM1
-/-
 MEFs: these cells were transfected with a plasmid expressing a human 
FLAG-tagged NPM1 and restoration of nucleolar localization was observed for a subset of BER 
components (Fig. 26A and [186]). 
 
 
Fig. 26 – NPM1 co-purifies with BER protein complexes and is required for the nucleolar 
accumulation of a subset of BER components. A. NPM1
-/-
 MEFs were transfected with either an 
empty vector (mock) or with a FLAG-tagged human NPM1-expressing plasmid (pNPM1). The 
representative immuno-fluorescence micrographs show the nucleolar accumulation of BER factors 
(red) only in NPM1-expressing cells (green). Nuclei were counter-stained with TO-PRO-3, bars 16 
m. B. HeLa cells were transfected with either an empty vector (mock) or FLAG-tagged NPM1 
(NPM1) and immuno-precipitation was carried out with an anti-FLAG antibody. The immuno-purified 
material was subsequently subjected to Western blotting analyses, revealing an enrichment for several 
BER components. The antibodies used are indicated on the right-hand side. 
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In addition, co-immuno-precipitation experiments performed in HeLa cells confirmed that, 
under basal conditions, NPM1 can be co-purified with proteins belonging to the BER pathway (Fig. 
26B). These data further suggest that NPM1 is essential for the accumulation of BER components 
within nucleoli. 
Several studies verified that DNA damage induces reorganization of the nucleolar proteome, 
with a prevalent outflow from nucleoli (reviewed in [19]). NPM1 has been described as the main 
p14
Arf
 interacting protein [209, 210] and the DNA damage-induced relocalization of both NPM1 and 
p14
Arf
 is well documented [21, 59, 62, 197]. The redistribution of these proteins from nucleoli to the 
nucleoplasm is believed to boost the p53-mediated response [63]. I reasoned that if NPM1 was 
required for nucleolar accumulation of BER proteins, then a DNA damaging cue able to displace 
NPM1 from nucleoli would affect the localization of BER enzymes as well. Canonical BER-eliciting 
genotoxins (e.g. MMS, H2O2) did not affect the localization of NPM1 or APE1 (data not shown); 
conversely, as already reported [59, 211, 212], cell treatment with the DNA damaging agents cisplatin 
and daunorubicin, or the RNA polymerase I (Pol I) inhibitor actinomycin D led to a massive 
relocalization of NPM1 and p14
Arf
 to the nucleoplasm. In accordance with the role of NPM1 in 
promoting the nucleolar accumulation of BER proteins, cell treatment with these compounds resulted 
in a complete nucleolar depletion of LigI, FEN1 and APE1 (Fig. 27 and not shown). 
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Fig. 27 – Cisplatin and daunorubicin induce a subcellular relocalization of NPM1, p14Arf and 
BER enzymes. HeLa cells were treated with cisplatin (100 M, 6 hours, A) or daunorubicin (1 M, 2 
hours, B), fixed and stained with the indicated antibodies. Representative immuno-fluorescence panels 
show the nucleoplasmic relocalization of NPM1 and p14
Arf
; the concomitant depletion of LigI, FEN1 
and APE1 from nucleoli is highlighted by white arrowheads. Nuclei were counter-stained with TO-
PRO-3, bars 16 m. 
 
Taken together, these observations suggest that, in immortalized cells, NPM1 is responsible 
for the nucleolar accumulation of a subset of BER components; upon specific DNA damage or Pol I 
inhibition, NPM1, p14
Arf
 and BER enzymes are released from nucleoli and relocalize to the 
nucleoplasm. 
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2.3. Active redistribution of APE1 from nucleoli protects cells from cisplatin 
Cisplatin treatment has been shown to induce APE1 expression in a lung cancer cell line; 
whereas depletion of APE1 sensitized the same cells to cisplatin-induced apoptosis [67]. Our and 
others’ laboratories, moreover, observed interesting interrelations between cell sensitivity to cisplatin 
and BER capacity ([9, 13] and unpublished results). Given the observed link between BER protein 
localization and cisplatin, I decided to investigate thoroughly the functional significance of the BER 
protein nucleolar accumulation and cell response to cisplatin. 
It is worth highlighting that, upon cisplatin treatment, the relocalization of p14
Arf
 and BER 
proteins takes place in the absence of complete nucleolar breakdown, as still a moderate amount of 
NPM1 is retained within nucleoli (Fig. 27A, Fig. 28B). Under these conditions, however, nucleolar 
stress occurs in a measurable manner, as suggested by the formation of fibrillarin caps ([197] and Fig. 
28A) and by the interruption of nucleolar transcription ([197] and Fig. 28C). 
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Fig. 28 – Cisplatin triggers nucleolar stress, which is followed by NPM1 relocalization. HeLa cells 
were treated with cisplatin (100 M) and the effects on nucleolar function were monitored at different 
time points. A. Representative immuno-fluorescence showing the onset of nucleolar stress 2 hours 
after cisplatin addition, as evidenced by the appearance of perinucleolar fibrillarin caps (insets). Nuclei 
were counter-stained with TO-PRO-3, bars 1 m. B. Representative immuno-staining for NPM1 
reveals the nucleoplasmic translocation between 2 and 4 hours after cisplatin addition. Note that a 
significant amount of NPM1 still populates nucleoli after 6 hours. Bars 8 m. C. Representative 
fluorouridine (FUrd) incorporation assay shows the absence of transcriptional activity within nucleoli 
one hour after cisplatin treatment. White arrowheads highlight the selective incorporation of FUrd in 
nucleolar compartments. Bars 4 m. D. Graphical overview summarizing the timing of cisplatin 
effects. Impairment of nucleolar transcription occurs within 1 hour after cisplatin addition. Fibrillarin 
caps appear after 2 hours, when NPM1 starts to relocalize to the nucloeplasm. The amount of 
redistributed NPM1 was measured by analyzing the immuno-fluorescence presented in panel B 
through quantification of the mean nucleoplasmic NPM1 signal in randomly chosen cells (N≥20). 
 
To exclude that the redistribution of BER proteins is merely a passive consequence of 
nucleolar disassembly, I analyzed the behavior of APE1, as representative enzyme of the pathway. 
Live cell imaging experiments exploiting an APE1-Dendra2 fusion construct [124, 213] revealed that 
APE1 and NPM1 relocalization are uncoupled, as the first protein reduces its nucleolar accumulation 
between 5 and 6 hours after cisplatin challenge (Fig. 29), whereas NPM1 redistribution to the 
nucleoplasm is already visible 2 hours after cell exposure to cisplatin (Fig. 28). As already observed 
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previously [124, 213] and confirmed by live cell imaging studies, the complete nucleolar emptying of 
APE1 induced by cisplatin (Fig. 27) is an artifact arising during the permeabilization procedures 
required for the immuno-fluorescence. In living cells, in fact, cisplatin is more likely to impair the 
nucleolar accumulation capacity of APE1 and other BER enzymes, rather than completely abolishing 
their nucleolar localization. 
 
 
Fig. 29 – Cisplatin impairs the nucleolar accumulation capability of APE1 in a time-dependent 
manner. Live cell imaging analysis on HeLa cells transfected with the APE1-Dendra2 construct and 
treated with cisplatin show the time-dependent depletion of the protein from nucleoli (white 
arrowheads). The transition occurs between 5 and 6 hours after cisplatin addition. Bars 8 m. 
 
APE1 redistribution from nucleoli was further explored using two recently described 
acetylation mutants. APE1
K4pleA
, where the lysine residues K27, K31, K32 and K35 are converted to 
alanine, generating a mutant protein endowed with higher AP-endonuclease activity that does not 
interact with NPM1, accumulates less efficiently within nucleoli and strongly impairs cell 
proliferation. In the second mutant (APE1
K4pleR
) the same lysine residues are mutated to arginine, 
resulting in a protein refractory to acetylation, but not affecting its nucleolar accumulation, the cell 
growth rate or its ability to interact with NPM1 [124]. Remarkably, while cisplatin induced a 
relocalization of APE1
WT
 from nucleoli, the APE1
K4pleR
 mutant was incapable of such redistribution 
(Fig. 30A). Live cell imaging experiments confirmed the peculiar behavior of the APE1
KpleR
 mutant, 
showing a delayed redistribution of the protein in comparison with the wild type form. Importantly, 
expression of either APE1 mutant did not affect the cisplatin-induced relocalization of NPM1 (not 
shown), thus confirming that this phenomenon is directly linked to the APE1 mutation. These 
experiments indicate that, in addition to NPM1, other factors (e.g. rRNA) contribute to the nucleolar 
accumulation of APE1. Moreover, these evidences confirm that during cisplatin-induced nucleolar 
stress APE1 does not freely relocalize to the nucleoplasm as a consequence of nucleolar disassembly, 
nor the protein is simply towed to the nucleoplasm by NPM1. Some kind of PTM involving lysine 
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residues within the N-terminal domain of APE1 (e.g. acetylation [124] or ubiquitination [128, 129]) is 
seemingly required for its redistribution. 
 
 
Fig. 30 – The redistribution of APE1 from nucleoli affects cell sensitivity to cisplatin. A. 
Representative immuno-fluorescence analysis on HeLa cells stably expressing FLAG-tagged APE1
WT
, 
APE1
K4pleA
 or APE1
K4pleR
 and treated with cisplatin (100 M, 6 hours). The treatment induces a 
relocalization of the APE1
WT
 form, but not of the APE1
K4pleR
 mutant (white arrowheads). The 
APE1
K4pleA
 form shows a nucleolar-excluded staining which is not affected by cisplatin. Nuclei were 
counter-stained with TO-PRO-3, bars 16 m. B. MTS viability assay on HeLa cells stably expressing 
different APE1 forms upon depletion of the endogenous APE1 protein and challenged with increasing 
cisplatin concentrations for 24 hours. The APE1
K4pleA
 clone shows a resistant phenotype, while the 
APE1
K4pleR
 clone displays hypersensitivity. The histogram reports the mean viability ± SD from at least 
three independent replicates.  *: p<0.05, **: p<0.01. C. Western blotting analysis on APE1-
reconstituted HeLa cell clones showing the residual amount of endogenous APE1 (endo) and the 
comparable expression of the mutant, FLAG-tagged form (ecto). Tubulin was used as loading control. 
 
In addition, viability assays showed that the ability of APE1 to redistribute from nucleoli 
affects cellular response to cisplatin. I exploited a previously characterized HeLa cell model that, 
through a doxycycline-dependent inducible expression of specific shRNAs, allows me to replace the 
endogenous form of APE1 with ectopically expressed siRNA-resistant wild-type or mutant forms 
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[124, 138]. As shown in Fig. 30, the APE1
K4pleR
-expressing clone was hypersensitive to cisplatin 
treatment, indicating that the APE1 capacity to shuttle from nucleoli plays a critical role in dictating 
cisplatin cytotoxicity. Furthermore, the expression of the APE1
KpleA
 form was protective at lower 
doses of cisplatin (Fig. 30). Since inhibition of the APE1 catalytic activity in the APE1
K4pleA
-
expressing clone did not affect its resistance to cisplatin (Fig. 31), the observed protective effect 
might be ascribed to the lower proliferative capacity of these cells [124]. 
 
 
Fig. 31 – Inhibition of the APE1 catalytic activity in the APE1K4pleA-expressing cells does not 
affect cell sensitivity to cisplatin. HeLa cells stably expressing the APE1
KpleA
 form were incubated 
with increasing cisplating concentrations for 24 hours, in presence of either methoxyamine (MX, 10 
mM, A) or compound #3 (3.5 M, B), to block the APE1 catalytic activity. MMS (24 hours) was used 
as positive control, to demonstrate the sensitizing activity of the APE1 inhibitors at the dosage tested. 
The histograms report the mean ± SD of three independent replicates. *: p<0.05, **: p<0.01. 
 
In conclusion, these experiments point to an active role of APE1 redistribution (and possibly 
that of other BER proteins) upon cisplatin-induced nucleolar stress. The relocalization of APE1, in 
fact, does not appear to be a passive phenomenon, but rather a modulation involving PTMs of specific 
lysine residues seems to be required. Moreover, it is clear that interfering with cisplatin-induced BER 
protein relocalization has a major impact on cell response to this genotoxin. 
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2.4. APE1 is involved in the ribosome biogenesis process 
The effect observed on the BER protein localization upon cisplatin, along with the concurrent 
impairment in the nucleolar transcription, point to a major role for the BER components in the 
maintenance of the ribosome biogenesis. 
In order to gain further insights into the role of nucleolar BER enzymes, using again APE1 as 
a representative enzyme of the pathway I assessed the influence of APE1 depletion on the early 
ribosome biogenesis process. I transiently depleted cells of APE1 and measured the rRNA 
transcription rate through two complementary assays. First, I assessed the nucleolar incorporation of 
fluorouridine (FUrd), a fluorinated UTP analogue, into nascent rRNA transcripts [214, 215]. Notably, 
the depletion of APE1 resulted in a strong impairment in the nucleolar FUrd uptake (Fig. 32A, Fig. 
32B). This observation was corroborated by metabolic [
32
P]-orthophosphate labeling experiments, 
which confirmed the reduced synthesis rate of the 47S rRNA precursor in APE1-depleted cells (Fig. 
32A, Fig. 32C). Altogether, these data demonstrate that the expression of APE1 is crucial for an 
efficient transcription of ribosomal genes.  
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Fig. 32 – Depletion of APE1 leads to nucleolar impairment. A. Representative Western blotting 
analysis on HeLa cells treated with either a scrambled siRNA (siScr) or an APE1-specific siRNA 
(siAPE1) shows the efficiency of APE1 knockdown. Tubulin was used as loading control. B. 
Fluorouridine (FUrd) labeling of siScr- and siAPE1-treated HeLa cells. Left panel – representative 
immuno-fluorescence showing the preferential accumulation of FUrd within transcriptionally active 
nucleoli only in APE1-proficient cells (white arrowheads). Bars correspond to 8 m. Right panel – 
histogram reporting the average FUrd nucleolar incorporation efficiency in siScr and siAPE1 cells. 
Values reported express the average amount of FUrd-positive cells ± SD from at least three 
independent experiments. C. [
32
P]-phosphate metabolic labeling of nascent rRNA transcripts in HeLa 
cells treated with siScr, siAPE1 or actinomycin D (as positive control) reveals the nucleolar 
impairment in APE1-depleted cells. Cells were transfected with siRNAs and 48 hours later pulsed for 1 
hour with [
32
P]-orthophosphate, as described in the “Experimental Methods” section. Left panel – total 
RNA was extracted and the amount of labeled rRNA precursors was measured through 
autoradiography. Ethidium bromide staining was used as loading control. Right panel – histogram 
reporting the average [
32
P]-phosphate incorporation into the 47S precursor in siScr and siAPE1 cells. 
Values reported express the mean incorporation ± SD from at least three independent experiments. 
siScr was used as reference sample. *: p<0.01, **: p<0.001. 
RESULTS 
66 
 
TESI DI DOTTORATO DI POLETTO MATTIA DISCUSSA PRESSO L’UNIVERSITÁ DI UDINE 
I then checked whether the APE1 endonuclease activity of the protein might be involved in 
the modulation of the ribosome biogenesis process. To this aim I exploited the inhibitor “compound 
#3”, which specifically targets the endonuclease activity of the protein [148], and I assessed the 
triggering of nucleolar stress phenotypes in HeLa cells. The onset of nucleolar stress upon APE1 
inhibition was highlighted by the appearance of nucleolar fibrillarin caps (Fig. 33A); in addition, 
FUrd incorporation analyses revealed a reduction of the nucleolar activity in HeLa cells treated with 
compound #3 (Fig. 33B). Metabolic [
32
P]-orthophosphate labeling, however, did not reveal any major 
impairment in the 47S precursor transcription, upon APE1 inhibition (Fig. 33C). Interestingly, on the 
other hand, I measured a reduced processing of mature rRNA species (Fig. 33, panels C and D). 
These data indicate that the APE1 endonuclease activity might be important for the correct processing 
of rRNA transcripts, rather than being involved in the transcription of the early 47S rRNA precursor. 
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Fig. 33 – Inhibition of the APE1 endonuclease activity impairs ribosome biogenesis. HeLa cells 
were treated with compound #3 (1.75 M, 24 hours) and nucleolar stress, rRNA transcription and 
processing were analyzed. A. Representative immuno-fluorescence panels and insets show the 
formation of fibrillarin caps upon inhibition of the APE1 endonuclease activity. Bars correspond to 1 
m, nuclei were counterstained with TO-PRO-3. B. Representative immuno-fluorescence showing the 
incorporation of fluorouridine (FUrd) within transcriptionally active nucleoli only in vehicle-treated 
cells (white arrowheads). Bars correspond to 8 m. C. [32P]-phosphate metabolic labeling of nascent 
rRNA transcripts does not show any significant impairment in the transcription of the 47S precursor, 
but reveals impairment in the processing of rRNA species following APE1 inhibition. Top panel –the 
amount of labeled rRNA precursors was measured through autoradiography, as described in the 
“Experimental Methods” section. Ethidium bromide staining was used as loading control. Bottom 
panel – histogram reporting the average [32P]-phosphate incorporation into the 47S and 41S precursors 
in vehicle- or compound #3-treated cells. Values reported express the mean incorporation ± SD from 
three independent replicates. Vehicle-treated cells were used as reference sample, *: p<0.05. D. 
Analysis of the rRNA processing kinetics in HeLa cells upon [
32
P]-phosphate metabolic labeling. The 
analysis was carried out as in panel C; after the [
32
P]-orthophosphate pulse, cells were chased for the 
indicated time and intermediate rRNA species were analyzed on an agarose gel. The assay reveals a 
profound impairment in the rRNA processing kinetics upon inhibition of APE1. 
 
These experiments, coupled with previous evidences [75], strongly suggest that the 
accumulation of APE1 and, possibly, of other BER enzymes within the nucleolus play an active role 
in the maintenance of the correct nucleolar function of the cell. 
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2.5. NPM1-mediated BER modulation is dependent on the activation of the 
p14
Arf
/Mule axis 
The experiments performed so far allowed me to demonstrate that NPM1 is a novel player in 
the BER pathway. NPM1 acts by promoting BER protein retention in nucleoli (Fig. 25); depletion of 
NPM1, moreover, stabilizes several BER components in a post-translational manner (Fig. 22, Fig. 23 
and Fig. 24). In order to explain the mechanisms underlying this last observation, I investigated the 
interrelation between NPM1 and the p14
Arf
/Mule axis, which has already been implicated in the 
modulation of BER protein stability [55]. 
NPM1 is known to regulate both the stability and the nucleolar accumulation of p14
Arf
. This 
was demonstrated by monitoring the endogenous mouse p19
Arf
 ortholog in p53 KO MEFs [194] or 
through transfection of ectopic p14
Arf
 in human tumor cell lines [162]. Consistently with these 
reports, NPM1 depletion in HeLa cells decreased the stability of p14
Arf
 (Fig. 34A) and induced a 
nucleoplasmic translocation of the residual protein (Fig. 34B). 
 
 
Fig. 34 – p14Arf is unstable and undergoes nucleoplasmic relocalization upon NPM1 depletion. 
HeLa cells were transfected with either scrambled (siScr) or NPM1-specific (siNPM1) siRNAs and 
subjected to Western blotting and immuno-fluorescence analyses. A. Representative Western blotting 
on HeLa whole cell extracts (50 g) highlights the decreased stability of p14Arf after NPM1 
downregulation. Tubulin was used as loading control. B. Representative immuno-fluorescence analysis 
on siNPM1-treated HeLa cells shows the nucleoplasmic redistribution of the residual p14
Arf
. Note that 
the immuno-fluorescence images were acquired at constant microscope settings, and therefore the 
p14
Arf
 staining is saturated to allow for visualization of the downregulated p14
Arf
 protein in siNPM1-
trated cells. Nuclei were counter-stained with TO-PRO-3, bars 16 m. 
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The p14
Arf
 tumor suppressor has been reporter to inhibit the E3-ligase activity of Mule upon 
genotoxic stress [216]. I hypothesized that the chronic nucleoplasmic localization of p14
Arf
, observed 
in NPM-depleted cells, could trigger the stabilization of BER proteins through constitutive inhibition 
of Mule. In agreement with this hypothesis, simultaneous depletion of either NPM1 and p14
Arf
, or 
NPM1 and Mule, efficiently suppressed the upregulation of BER components observed when 
depleting NPM1 only (Fig. 35). 
 
 
Fig. 35 – Interfering with the p14Arf/Mule axis bluntens the BER stabilization effect obtained 
upon NPM1 depletion. HeLa cells were transiently depleted of NPM1, p14
Arf
 and Mule through 
specific siRNAs, as indicated. The expression levels of a subset of BER proteins was then assessed 
through Western blotting on whole cell extracts (50 g) (A). B. Histogram reporting the quantitative 
protein expression fold change for siNPM1, siNPM1+sip14
Arf
 and siNPM1+siMule relative to control 
siRNAs (scrambled, sip14
Arf
 or siMule, respectively). The histogram shows the mean ± SD from at 
least three independent experiments. The statistical analysis was performed by comparing NPM1-
depleted cells with their control counterparts (i.e. sScr, sip14
Arf
 and siMule, respectively). *: p<0.05, 
**: p<0.01. 
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The contribution of p14
Arf
 to the NPM1-mediated control of the BER protein stability was 
further highlighted by knockdown studies on cell lines lacking detectable p14
Arf
 (i.e. U2OS and SK-
BR-3). In these cell lines the upregulation of BER components following depletion of NPM1 was 
partially abolished or reduced in order of magnitude (Fig. 36). A notable exception was represented 
by Pol, but this phenotype might reflect a p14Arf-independent regulation of the protein at the 
transcriptional level, as suggested by the previous Real-time PCR analysis (Fig. 22). 
 
 
Fig. 36 – NPM1-mediated BER protein stabilization is partially impaired in cell lines lacking 
detectable p14
Arf
. U2OS (A) or SK-BR-3 (B) cells were treated with either scrambled (siScr) or 
NPM1-specific (siNPM1) siRNAs and BER protein expression levels were assessed in whole cell 
exctracts (50 g) using the indicated antibodies (right-hand side). The fold of protein induction upon 
NPM1 depletion is indicated for each protein analyzed. HeLa whole cell extract was used as positive 
control for p14
Arf
 expression, while tubulin was used as loading control. 
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Additional immuno-fluorescence studies on NPM1-, p14
Arf
- or Mule-depleted cells revealed a 
cross-modulation existing between these three factors, which dictates their subcellular localization. 
As previously demonstrated (Fig. 34), nucleolar localization of p14
Arf
 was promoted by NPM1, and, 
to a lesser extent, by Mule expression. NPM1 nucleoplasmic accumulation was increased when 
knocking down either p14
Arf
 or Mule, indicating that both proteins partially regulate NPM1 nucleolar 
retention. NPM1 down-regulation, moreover, resulted in the depletion of the nucleolar Mule pool, 
suggesting that Mule subcellular trafficking is, in turn, modulated by NPM1 (Fig. 37). 
  
 
Fig. 37 – The subcellular localization of p14Arf, Mule and NPM1 is modulated by an intricate 
cross-talk. Representative immuno-fluorescence experiments on HeLa cells treated with scrambled, 
p14
Arf
-, NPM1- or Mule-targeting siRNAs (siScr, sip14
Arf
, siNPM1 and siMule, respectively). Cells 
were probed with the antibodies indicated in the upper part of the figure. Note the increased p14
Arf
 
nucleoplasmic localization upon NPM1 and Mule knockdown, the nucleolar depletion of Mule in 
NPM1-depleted cells, and the increased nucleoplasmic staining for NPM1 in p14
Arf
- and Mule-
depleted cells. Nuclei were counter-stained with TO-PRO-3, bars 16 m. 
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2.6. BER capacity is positively modulated by NPM1 
Despite the higher BER protein content, NPM1
-/-
 MEFs have previously been shown to 
display increased susceptibility to BER-eliciting genotoxins [186]. We recently linked the augmented 
sensitivity to MMS, bleomycin and oxidizing agents to an impaired AP-site incision activity in 
NPM1
-/-
 cell extracts [186]. Prompted by the observation that NPM1 depletion leads to a broad 
upregulation of the BER components, here I tested whether the enzymatic steps of the BER process 
downstream APE1 incision may be affected by NPM1 depletion. To this aim, I compared in vitro 
gap-filling, nick-ligation and flap-incision activities at equal amounts of NPM1
+/+
 and NPM1
-/-
 whole 
cell extracts (Fig. 38). 
 
 
Fig. 38 – Comparison between NPM1+/+ and NPM1-/- whole cell extracts show proficiency in gap-
filling, but no significant difference in nick-ligation or flap-incision activities upon depletion of 
NPM1. BER enzymatic activities were meaured by using  standard in vitro radioisotope-based assays, 
as indicated in the “Experimental Methods” section; equal amounts of MEF whole cell exctracts were 
compared in each reaction. BER activities were monitored in time-course reactions and, for every time 
point, the percentage of substrate (S) to product (P) conversion was calculated. Graphs on the right-
hand side report the mean conversion ± SD from at least three independent replicates. For each BER 
activity a representative autoradiogram is reported, along with a Western blotting showing the different 
protein content among NPM1
+/+
 and NPM1
-/-
 cells. *: p<0.05, **: p<0.01. 
As expected, the higher Pol content was paralleled by a small, yet significant increased 
proficiency in gap-filling in NPM1
-/-
 MEFs. Strikingly, despite the higher amount of LigIII and 
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FEN1, both the nick-ligation and the flap-incision activities in NPM1
+/+
 and NPM1
-/-
 cell extracts did 
not differ significantly (Fig. 38). The same repair activity results were obtained using whole cell 
extracts prepared by different methods (i.e. detergent vs. hypotonic extraction), suggesting that my 
measurements were not affected by differential protein extraction efficiency among the two cell lines 
(not shown). 
In order to compare the BER enzymatic activities at equal protein content, I carried out the in 
vitro BER assays after precise normalization of the Pol, LigIII and FEN1 levels in NPM1+/+ and 
NPM1
-/-
 whole cell extracts. This experimental setup highlighted a major impairment in each BER 
enzymatic step in the absence of NPM1, thus suggesting that NPM1 is a previously uncharacterized 
positive modulator of the BER process (Fig. 39). 
 
 
Fig. 39 – In vitro BER assays on NPM1+/+ and NPM1-/- whole cell extracts at equal Pol, LigIII 
and FEN1 content highlight the profound impairment in each BER step after depletion of 
NPM1. BER enzymatic activities were meaured as indicated in Fig. 38; MEF whole cell exctracts 
concentration was adjusted to compare equal protein amounts in each reaction. Graphs on the right-
hand side report the mean percentage of substrate (S) to product (P) conversion ± SD from at least 
three independent replicates. For each BER activity a representative autoradiogram is reported, along 
with a Western blotting showing the comparable protein content in NPM1
+/+
 and NPM1
-/-
 extracts. *: 
p<0.05, **:p<0.001. 
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Despite the remarkable BER impairment in the absence of NPM1, under experimental 
conditions reflecting the protein expression pattern in living cells (i.e. without adjustment in whole 
cell extract amounts), I did not observe significant variations in the BER capacity (Fig. 38). 
Nonetheless, previous studies highlighted an increased sensitivity of NPM1
-/-
 cells to BER-eliciting 
agents [186], along with the appearance of DDR markers in NPM1 KO embryos [194], as alluded to 
earlier. This indicates that the in vitro biochemical assays here reported do not entirely recapitulate 
the in vivo BER dynamics. To address this issue I developed a reporter-based assay suitable for the 
assessment of the overall BER capacity in living cells. A luciferase reporter-containing plasmid was 
heat-depurinated and transfected into living NPM1
+/+
 or NPM1
-/-
 MEFs and the luciferase activity was 
used as a direct measure of BER-mediated repair. As demonstrated by digestion with recombinant 
APE1, this treatment mainly generated AP-sites and SSBs with no detectable DSBs (Fig. 40B); thus, 
the plasmid obtained after heat-induced depurination is a substrate suitable to measure the overall 
cellular BER capacity, without confounding contributions from other DNA repair pathways. 
Using this reporter-based assay I confirmed that, despite the increased BER protein 
expression, NPM1
-/-
 cells have an impaired BER response (Fig. 40A), therefore explaining the 
augmented sensitivity to genotoxins. Consistently, NPM1 depletion in NPM1
+/+
 MEFs recapitulated 
the NPM1
-/-
 phenotype (Fig. 40 A and C); whereas reconstitution of NPM1-/- cells with recombinant 
human NPM1 rescued the BER deficiency (Fig. 40 A and C). Altogether, these results indicate that 
NPM1 is a novel positive modulator of the BER pathway both in vitro and in vivo. 
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Fig. 40 – NPM1 depletion impairs the BER capacity in vivo. A. Reporter-based BER assays 
performed after transfection of a heat-depurinated luciferase plasmid reveal that NPM1
-/-
 cells have an 
impaired repair capacity (left bars). siRNA-mediated depletion of NPM1 in NPM1
+/+
 MEFs confirms 
this finding (middle bars); while transfection of human NPM1 in the NPM1
-/-
 background rescues BER 
capacity (right bars). The histogram reports the mean luciferase activity (relative to that of intact 
DNA) ± SD from at least three independent replicates. *: p<0.01. B. Agarose gel analysis on the heat-
depurinated reporter plasmid shows the formation of a small amount of spontaneously nicked DNA 
after depurination. Digestion of the damaged plasmid with recombinant APE1 results in the conversion 
of the plasmid into nicked and linear DNA, thus confirming the presence of AP-sites. A NdeI-
linearized plasmid was used as marker to determine the migration of the linear vector. ND: not 
digested. C. Representative Western blotting analysis on MEF whole cell extracts from the experiment 
reported in panel A and showing the siRNA-mediated depletion of NPM1 (siNPM1) in NPM1
+/+
 cells 
and the reconstitution of NPM1
-/-
 cells (pNPM1). 
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2.7. Depletion of NPM1 does not significantly impair NHEJ- or HR-mediated DNA 
repair 
As pointed out earlier, several evidences link NPM1 to DNA strand break-repair pathways 
[199, 200]. In the previous chapter I thoroughly analyzed the involvement of NPM1 in the BER-
mediated DNA repair: the overall BER dysregulation in NPM1-depleted cells clearly explains the 
increased sensitivity of NPM1
-/-
 cells to MMS, oxidizing agents, bleomycin and ionizing radiation 
([186] and not shown). Some of the genotoxins used in previous studies, however, may also generate 
DSBs that are not directly targeted by the BER pathway. Therefore, in order to understand whether 
NPM1 has any significant relevance in the clearance of DNA strand breaks, I carried out a broad 
analysis to compare the DSB-repair capacity in NPM1
+/+
 and NPM1
-/-
 cells. 
Western blotting analyses on NPM1-deficient MEFs revealed major variations in the 
expression levels of a small set of NHEJ components, with increased expression of the Ku70 antigen 
and of DNA ligase IV (LigIV), and reduction in the DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs) amount (Fig. 41). Expression studies on a representative subset of HR factors, 
moreover, showed a significant upregulation of Rad51 in NPM1
-/-
 cells (Fig. 41). 
 
 
Fig. 41 – NPM1-depleted cells show upregulation of a subset of DSB-repair proteins. A. 
Representative Western blotting analysis on NPM1
+/+
 and NPM1
-/-
 MEFs whole cell extracts (60 g) 
shows the variation in NHEJ and HR protein amounts in the absence of NPM1. Antibodies used are 
indicated on the right hand-side, tubulin was used as loading control. B. Histogram reporting the 
average protein expression fold change in NPM1
-/-
 cells, as measured through densitometric 
quantification of the Western blotting signals. Bars indicate the mean ± SD from at least three 
independent replicates. *: p<0.05, **: p<0.01. 
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As already shown for the BER pathway, variation in DSB-repair protein levels may reflect a 
dysregulation in the DSB repair capacity of NPM1-deficient cells. In order to compare the NHEJ 
capacity of NPM1
+/+
 and NPM1
-/-
 MEFs, I carried out in vitro end-joining (EJ) assays using linear 
DNA substrates ad hoc generated through restriction of a plasmid DNA substrate. The in vitro EJ 
assays demonstrated that the ligation activity in whole cell extracts from NPM1
-/-
 cells was 
significantly higher than NPM1
+/+
 extracts toward DNA ends with cohesive overhangs (Fig. 42A). 
The ligation efficiency of blunt-ends did not show significant differences even if a trend toward 
higher activity of NPM1
-/-
 lysates was still present (Fig. 42A). 
 
 
Fig. 42 – In vitro end-joining assays reveal a slight proficiency of NPM1-/- whole cell extracts. A. 
EJ assay on a linear DNA substrate with cohesive overhangs generated through restriction of a 
pmirGLO plasmid with the ApaI endonuclease. A representative gel shows the time-dependent 
conversion of the substrate (S) to oligomeric products (P1 and P2). The ApaI recognition sequence is 
also reported. B. EJ assay on a linear DNA substrate with blunt-ends generated through restriction of a 
pmirGLO plasmid with the EcoRV endonuclease. A representative gel shows the time-dependent 
conversion of the substrate (S) to a dimeric product (P). The EcoRV recognition sequence is reported 
below. The histograms (right-hand side) show the average percentage of substrate conversion ± SD 
from three independent experiments. *: p<0.05, M: DNA ladder. 
 
Similar results were obtained using different enzymes, suggesting that the observed behavior 
is not linked to any sequence preference in the substrate. 
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I then assessed the in vivo DSB repair capacity of NPM1
+/+
 and NPM1
-/-
 cells exploiting a 
dual luciferase-containing pmirGLO plasmid. A single DSB was introduced within the vector by 
means of restriction endonucleases; the restriction site was carefully selected in order to repress the 
transcription of one selected reporter gene. MEF cells were subsequently transfected with the linear 
plasmid and the luciferase activity was measured to assess the EJ activity. Using different restriction 
enzymes I probed different biases in the DSB repair, such as the EJ activity on cohesive vs. blunt 
ends, or the overall vs. precise EJ capacity (Fig. 43). 
 
 
Fig. 43 – In vivo end-joining assays highlights the higher activity of NPM1-/- cells toward cohesive 
DNA ends. A. Schematic overview of the plasmid used in the assay with the restriction sites exploited 
to generate the substrate. The restriction endonucleases used are listed in the lower part of the panel, 
along with the characteristics of the substrate generated. KpnI-mediated restriction did not affect the 
activity of any reporter gene and was used to obtain a linear DNA substrate to be used as reference. 
PflMI was used to induce a DSB separating the SV40 promoter from the reporter gene and therefore 
allowing to monitor the overall EJ efficiency (as extensive editing at the DNA damage site is much 
more sustainable in a non coding region). luc2: firefly luciferase reporter; hRluc-neo fusion: 
humanized Renilla luciferase-neomycin resistance reporter cassette. B. In vivo EJ assay on control wild 
type (WT), LigIV
-/-
 and DNA-PKcs
-/-
 HCT116 cell lines highlights the assay performance and 
dependency on the presence of LigIV and, partially, on DNA-PKcs in the case of cohesive ends. The 
histogram reports the average repair efficiency ± SD from three technical replicates. *:p<0.05. C. In 
vivo EJ assay on NPM1
+/+
 and NPM1
-/-
 MEFs shows the proficiency of NPM1-depleted cells during 
cohesive end repair. The histogram reports the average repair efficiency ± SD from three independent 
replicates. **:p<0.01. 
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The in vivo EJ assays results were in accordance with the in vitro data (Fig. 42), highlighting 
a significantly increased EJ capacity for NPM1
-/-
 cells over cohesive overhangs, regardless of the 
repair specificity (Fig. 43). These assays do not point to any significant difference in the EJ activity 
over blunt ended substrates. Reasonably, these data suggest that the presence of higher amounts of 
Ku70 and LigIV slightly improves the DNA EJ capacity of NPM1-deficient cell extracts. 
Differently from other mammalian cells, the EJ capacity of MEFs is extremely low (compare 
the ligation efficiency in MEFs and human cell lines in Fig. 43) and the preferred DSB-repair 
pathway appears to be HR [217]. Therefore, in order to assess the HR-dependent DNA repair in 
NPM1-depleted MEFs, I challenged cells with the etoposide or bleomycin and measured the 
formation of Rad51 foci (Fig. 44). Being Rad51 a major component of the HR pathway involved in 
the homology search and pairing during the repair process, the dynamics of Rad51 foci clearance over 
the time allowed me to estimate the HR-dependent DSB repair. 
 
 
Fig. 44 – The HR pathway is not impaired in NPM1-/- cells. NPM1+/+ and NPM1-/- MEFs were 
treated with etoposide (100 M, 30 minutes) and Rad51 foci-positive cells were scored immediately 
(0) or after the indicated release time points. The histogram shows the mean percentage of Rad51-
positive cells ± SD from three independent experiments. Unt: untreated; *: p<0.05. 
 
The assessment of Rad51 foci formation showed a slightly increased susceptibility of NPM1
-
/-
 cells to etoposide (Fig. 44) and bleomycin (not shown), but similar DNA damage clearance kinetics. 
Consequently, despite the higher Rad51 expression levels in NPM1-depleted cells, it is possible to 
conclude that the HR pathway is not substantially affected by the absence of NPM1. These data are in 
agreement with comet assay analyses that did not reveal significant differences between NPM1
+/+
 and 
NPM1
-/-
 cells neither in the basal DNA damage content nor in the bleomycin-induced strand breaks 
repair (not shown). 
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DISCUSSION 
 
The work described in this thesis broadens our comprehension of the BER mechanisms, 
presenting, on one side, the characterization of novel molecular entities targeting the interaction 
between a BER component and a non-canonical BER modulator. On the other hand, I carried out a 
wide analysis on the possible involvement of NPM1 in the DNA damage response, showing how a 
protein apparently unrelated to DNA repair may affect substantially the DDR. 
The first part of this work led to the characterization of low molecular weight compounds 
targeting the APE1/NPM1 interaction. To the best of my knowledge, this is the first attempt to target 
the BER pathway through impairment of its protein-protein interaction network. The pilot-scale 
strategy set up during this project will be a useful starting point for the development of APE1/NPM1 
inhibitors with increased potency and specificity. These molecules will likely provide novel 
translational tools and could be exploited to thoroughly characterize the biological relevance of the 
APE1/NPM1 association in the tumor biology. 
A parallel and comprehensive analysis of the role(s) of NPM1 in the DDR revealed a tight 
link connecting NPM1 and the BER pathway. Analyses on the BER protein expression, localization 
and activity demonstrated that NPM1 is clearly a novel player in the BER response to DNA damage. 
The significance and the full implications of these findings, however, still remains to be elucidated, as 
it appears clear that canonical BER-eliciting stimuli are not able to induce NPM1 and BER protein 
relocalization. On the other hand, the observation of a link between cell response to cisplatin and 
NPM1/BER protein redistribution might open novel perspectives for a thorough comprehension of 
tumor resistance, explaining the involvement of the BER pathway in the scavenging of cisplatin-
induced DNA damage. 
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1. The APE1/NPM1 interaction as a promising target for anti-
tumor therapy 
This thesis describes, for the first time, a pilot-scale screening aimed at the identification of 
low molecular weight compounds targeting the APE1/NPM1 association. In collaboration with the 
NCGC, we exploited the AlphaScreen
®
 technology using full-length recombinant proteins and 
screened commercially available small molecule libraries in order to obtain putative disruptors of the 
APE1/NPM1 interaction. The hits from the screening underwent further prioritization through 
secondary cell-based orthogonal assays, and I obtained a set of compounds effectively able to 
interfere with the APE1/NPM1 association in living cells. The data available so far do not allow me 
to exclude the presence of in vivo off-target effects of the top-hit molecules, which are already known 
bioactive drugs. Through my proof of concept approach, however, I successfully demonstrated that 
the disruption of the APE1/NPM1 interaction can be achieved via structurally unrelated compounds 
under conditions of limited acute cytotoxicity, leading to interesting anti-tumor phenotypes. The 
APE1/NPM1 inhibitors, in fact, potentiate the cytotoxicity of clinically relevant genotoxins and show 
anti-proliferative activity as single agents in tumor cells of different histological origin (Fig. 17 and 
Fig. 18). 
The mechanism of action of the APE1/NPM1 inhibitors has not been entirely characterized; 
however, as the protein-protein interaction is reported to involve the N-terminal domain of both 
proteins [75, 91], it is reasonable to speculate that the compounds might target the APE1 unstructured 
region or the NPM1 oligomerization domain. The change in the APE1 subcellular localization 
observed upon treatment with the compounds, indeed, suggests that the molecules might target the N-
terminal domain of APE1, which is responsible for the nuclear accumulation of the protein [125] as 
well as for the interaction with NPM1 and rRNA [75, 90, 91]. SPR experiments (Fig. 16), and the 
negative effect of some molecules towards the APE1 redox activity (Fig. 15), would support a 
preference of the compounds for APE1 binding. 
Curiously, among the screening hits was identified troglitazone, a PPAR agonist with anti-
diabetic properties, which was withdrawn from the market for its hepatotoxicity [218]. Troglitazone 
has previously been suggested to exert anti-inflammatory action through inhibition of the NF-B 
pathway [219] and various reports have described interesting anti-tumor properties of the molecule 
[220, 221]. These observations might well be explained by the finding that troglitazone is a very 
potent inhibitor of the APE1/NF-B axis (Fig. 15). A positive interaction between bleomycin and the 
antipsychotic phenothiazine trifluoperazine was also previously reported [222]; the APE1/NPM1 
inhibitor spiclomazine is a member of the phenothiazine class of drugs and, consistently, I measure a 
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synergic effect between bleomycin and spiclomazine (Fig. 17). Albeit trifluoperazine has been 
suggested to impair the NHEJ process [222], an involvement of APE1 [101] or of the APE1/NPM1 
interaction in the elimination of bleomycin-induced DNA damage could also explain the observed 
effects.  
The sensitization effects measured when disrupting the APE1/NPM1 interaction in 
combination with MMS, bleomycin and PJ34 (Fig. 17) are not easily explained, as the endonuclease 
activity of APE1 is not directly impaired, in vitro, by the inhibitors (Fig. 21). Some of the molecules, 
however, induce relocalization of APE1 to the cytoplasm (Fig. 13 and Supplementary Table 1). It is 
therefore tempting to speculate that the sensitization observed toward genotoxins is driven by an 
impairment of the nuclear BER capacity, as already shown for NPM1c+ AML cells [186]. The 
measured effects might also reflect a possible role for the APE1/NPM1 association in the scavenging 
of DNA strand-breaks, as the genotoxins used in this study are likely to lead to the accumulation of 
SSBs and DSBs, in particular during the DNA replication process. Accordingly, NPM1 has been 
reported to associate with PARP1 and PARP2 [223], although the functional relevance of this 
interaction for DNA repair is still evanescent. Moreover, inhibition of the APE1 endonuclease activity 
was demonstrated to induce synthetic lethality in a DSB-repair deficient background [224]. It is 
conceivable, on the other hand, that non-canonical APE1 activities (e.g. RNA binding/cleavage, 
exonuclease, or RNaseH [95]) are involved in the response to the DNA damaging agents used in my 
experiments. Design of more selective APE1/NPM1 interaction inhibitors, therefore, will be useful to 
specifically characterize the relevance of this protein-protein interaction in vivo. 
In conclusion, in the first part of this thesis I show that known bioactive molecules selected 
for their ability to displace the APE1/NPM1 association are endowed with previously uncharacterized 
anti-tumor properties. Potential targets of these inhibitors might be tumors that show upregulation of 
both APE1 and NPM1 levels and that might possibly rely on an increased APE1/NPM1 interaction 
for resistance and/or proliferation. As proposed in the introductory section, ovarian cancer, as well as 
hepatocarcinoma, might reveal sensible targets for the APE1/NPM1 inhibitors. Understanding the 
specificity of action of these molecules in vivo is clearly needed at this point. The improvement of 
these compounds, however, will lead to the development of new useful tools for the biological 
investigation of the APE1/NPM1 interaction under physiological and pathological conditions. 
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2. NPM1 is a novel player in the BER 
The data presented in this thesis demonstrate that NPM1 is a novel multilevel modulator of 
the BER pathway. Previous work showed that NPM1 positively modulates the expression, the activity 
and the nucleolar accumulation of APE1 [186], but nothing was known about the relationship 
between NPM1 and the remainder of the BER pathway. My results suggest that NPM1 operates on 
the BER acting, at least at three different levels: 
1) NPM1 affects the stability of BER proteins. Here I demonstrate that the lack of or 
reduced NPM1 expression results in the stabilization of several BER components (Figs. 22-24). The 
mechanisms underlying the BER protein upregulation still deserves further investigation; it appears 
clear, however, that BER stabilization following NPM1 depletion partially requires the functionality 
of the p14
Arf
/Mule axis (Figs. 35 and 36). It is useful to underline that some of the expression changes 
that I observe are quantitatively small and may be indirect, in that increased expression of one BER 
protein may up-regulate another pathway component. The overall dysregulation of the protein 
expression levels, however, might play a significant role in reducing the coordination of the BER 
process, therefore affecting the repair capacity. 
2) NPM1 promotes the nucleolar accumulation of a subset of BER components. The 
nucleolar localization of many DNA repair proteins is well established [19, 20] and several BER 
factors (including SMUG1 [76], aprataxin [225], APE1 [75, 186], FEN1 [77], PARP1/2 [223]) have 
been implicated in nucleolar functions that are possibly unrelated to their “canonical” DNA repair 
activity. Therefore, the novel discovery of the BER/replicative enzymes LigI and Polcs within 
nucleoli was not unexpected. To the best of my knowledge, however, the prominent role of NPM1 in 
maintaining the nucleolar BER pool was never reported previously, if not for APE1 [75, 186] and 
PARP1/2 [223]. 
3) NPM1 positively modulates the cellular BER capacity. It has previously been shown by 
our group that NPM1 affects the APE1 endonuclease activity through direct protein-protein 
association [75, 91, 186]. In this thesis I demonstrate that NPM1 expression affects virtually each 
enzymatic step downstream the APE1 intervention in the BER process (Figs. 38 and 39). In addition, 
in vivo BER assays point to a significant dysregulation of the BER pathway dynamics upon NPM1 
depletion (Fig. 40). A possible interpretation of these data could take into account the already 
documented chaperone activity of NPM1 [176]; by means of protein-protein or nucleic acid-protein 
contacts NPM1 could act as activator of the overall BER process. Nonetheless, attempts to restore the 
BER activity in NPM1
-/-
 cell extracts using recombinant NPM1 in vitro were unsuccessful (not 
shown). Thus suggesting that PTMs either of, or induced by, NPM1 may be required for BER 
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modulation. Further studies aimed at elucidating the mechanisms underlying the NPM1-mediated 
BER activation are clearly needed at this point. Nevertheless, the BER impairment measured in vivo 
likely reflects a profound role for NPM1 in stimulating BER capacity. Additional analyses aimed at 
the elucidation of the NPM1 role in the DNA DSB-repair systems did not highlight any major effect 
of NPM1 depletion in the NHEJ and in the HR pathways (Figs. 42-44). Given the well-established 
responsiveness of NPM1 to UV-induced DNA damage [59, 195, 226] it would be probably worth to 
extend this analysis to other DNA repair pathways such as the NER. 
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3. BER and the nucleolus: speculations and perspectives on a 
brand new world 
A peculiar aspect of my observations is the widespread relocalization of BER proteins from 
nucleoli upon DNA damage or after inhibition of Pol I-mediated transcription (Fig. 27). A point that 
still deserves extensive investigation is the effective role of BER components within nucleoli. It could 
be argued that nucleoli may act as mere storage depots for DNA repair proteins; under this 
assumption, my data would point to the BER protein redistribution as a means of increasing the 
nucleoplasmic DNA repair capacity. A possible contribution of the BER process to the direct 
elimination of the DNA damage induced by cisplatin was already suggested [10, 12], while 
daunorubicin, actinomycin D, and cisplatin itself have been reported to promote the accumulation of 
oxidative stress and strand-break markers [227-229]. Thus, the involvement of BER in the repair of 
DNA damage induced by these agents appears reasonable. There might be, however, some arguments 
against this hypothesis: first of all, the lack of any support of this model for canonical BER-eliciting 
compounds. Alkylating and oxidizing agents, in fact, have never been reported to induce NPM1 or 
BER protein translocation from nucleoli, nor have I been able to observe clear relocalization 
phenomena upon treatment with MMS or H2O2. In addition, crude estimates on nucleoli 
biochemically isolated from HeLa cells revealed that the BER protein content in these organelles is 
very low (ranging between 0.5% and 9%, depending on the protein, personal observations). A 
relocalization involving such a tiny amount of protein is unlikely to increase significantly the overall 
nucleoplasmic repair capacity. If we observe the problem from another perspective, however, the 
stress onset triggers a dramatic drop in the BER protein content within nucleoli, suggesting that the 
nucleolar BER capacity might be severely affected under these circumstances. As a matter of fact, 
nucleolar BER factors have been suggested to play a role in the rRNA quality control processes: the 
enzymatic activity of the SMUG1 glycosylase has been implicated in the rRNA quality check 
mechanisms [76], while nucleolar FEN1 was proposed to play a role in cell survival [77]. We showed 
that interfering with the nucleolar accumulation of APE1 results in growth defects [124], whereas 
depletion of APE1 leads to the accumulation of damaged rRNA species [75]. These phenotypes, 
however, were not accompanied by any obvious effect on the ribosome biogenesis, possibly reflecting 
a role for APE1 in the rRNA quality control process, rather than in rRNA synthesis [75]. The 
protracted (5-10 days) down-regulation of APE1 in those pioneering experiments, however, could 
have possibly triggered selection mechanisms that masked the early effects of APE1 depletion on the 
ribosome biogenesis. The short-term (48 h) depletion experiments presented in this thesis highlight a 
crucial role for APE1 in the early steps of the ribosome biogenesis process (Fig. 32). In this process, 
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the ribonuclease activity of the protein might be crucial for the elimination of damaged rRNA species; 
this observation, which deserves further investigation, would support the accumulation of oxidized 
rRNA species previously measured upon APE1 knockdown [75]. In addition, my data suggest that 
APE1’s ability to redistribute from nucleoli also affects the cellular response to cisplatin (Fig. 30). 
Thus, it is conceivable that the relocalization of the BER proteins that I observe upon stimuli known 
to affect the cell cycle (e.g. cisplatin, daunorubicin, actinomycin D), but not to activate a canonical 
BER-mediated DNA repair, might contribute to the arrest of cell proliferation trough impairment of 
the rRNA synthesis. This hypothesis, which demands further investigation, would imply a leading 
role of nucleolar BER proteins in controlling cell proliferation. 
As already pointed out, cisplatin is a widely used chemotherapeutic agent that generates a 
broad spectrum of lesions on DNA (and possibly RNA); platinum-based compounds are particularly 
used in combined chemo-radiation strategies. Intrinsic or acquired platinum resistance, however, is a 
major clinical problem, since alternative agents that circumvent cancer resistance do not currently 
exist [30]. It is commonly accepted that cisplatin-related adducts are eliminated by the NER pathway, 
nonetheless, recent findings suggest that BER might be at least partially involved in the removal of 
DNA lesions induced by crosslinking agents [10]. In addition, BER intervention on cisplatin-DNA 
adducts may significantly delay the removal of these lesions, competing with the NER pathway for 
the access to DNA [9]. An alternative explanation for the phenomena I observed takes into account a 
BER contribution to both the DNA repair and the nucleolar function. The presence of BER proteins 
within nucleoli might be necessary for rDNA/rRNA maintenance under unstressed conditions, 
ensuring correct transcription of the ribosomal genes and accurate processing of the rRNA. The 
reorganization of the nucleolar proteome observed upon cisplatin treatment might allow a cell cycle 
arrest through depletion of BER components from nucleoli, concurrently allowing NER factors to 
take over the repair of rDNA free of competing proteins. Interestingly, the importance of nucleolar 
BER proteins for cisplatin resistance is in accordance with a very recent report showing that 5-
fluorouracil-induced rRNA biogenesis defects are dependent on DNA repair protein expression [14]. 
An additional link between BER protein relocalization and cell cycle arrest triggered by 
nucleolar stress is the p14
Arf
 tumor suppressor. Under basal conditions, at least in cancer cells, the 
majority of p41
Arf
 is associated with NPM1 in an inactive, nucleolar state [162, 209]. p41
Arf
 is an 
established DNA damage sensor [59, 60, 230]: in tumor cells DNA damage promotes a transient 
subnuclear redistribution of p41
Arf
 to the nucleoplasm, where it can boost the p53 response through 
interaction with at least two E3-ubiquitin ligases, namely Mdm2 [62, 63] and Mule [216]. My results 
strongly support the notion of the nucleolus as a stress sensor upstream p53. There are still conflicting 
reports concerning the effect of NPM1 on p53 activation following DNA damage. While elevated 
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levels of NPM1 following UV irradiation have been shown to suppress p53-mediated growth arrest, 
other reports point to a positive function of NPM1 on p53. These apparently contradictory 
observations suggest that NPM1 levels, together with the p41
Arf
 and p53 status of the cell, have to be 
taken into account [63]. The observation that NPM1 downregulation triggers p41
Arf
 redistribution, as 
happens under conditions of nucleolar stress, suggest that NPM1 act as a major sensing mechanism 
for the nucleolus. 
Based on my findings, the dynamics following a nucleolar stress response and involving 
NPM1, p14
Arf
 and the BER pathway are compatible with the speculative model depicted in Fig. 45: 
 
 
Fig. 45 – A model for BER modulation during nucleolar stress. A. Under unstressed conditions 
NPM1 localizes within nucleoli, promoting the accumulation of a subset of BER enzymes, along with 
the p14
Arf 
tumor suppressor and a sub-population of Mule. Basal BER capacity is maintained through 
constitutive Mule activity, while cell cycle progression is ensured by p53 destabilization and 
degradation. In this scenario, BER factors exert also nucleolus-specific functions that grant cellular 
proliferation. B. Upon triggering of nucleolar stress, relocalization of NPM1 p14
Arf
 and BER 
components occurs. This may lead to cell cycle delay through p14
Arf
-mediated inhibition of Mule and 
MDM2 and consequent p53 stabilization. Cell cycle arrest is also enforced by BER protein 
redistribution from nucleoli. Simultaneously, BER capacity can be increased through NPM1-mediated 
stabilization of BER proteins and enhancement of enzymatic activity. 
 
Under basal conditions NPM1 may function as a nucleolar gatekeeper, retaining a small 
subpopulation of BER proteins within nucleoli, along with the p14
Arf
 tumor suppressor. The 
nucleoplasmic BER capacity is homeostatically maintained through constitutive degradation of BER 
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factors exceeding the physiological threshold [54]. This mechanism limits the accumulation of DNA 
repair proteins, thus granting a steady state DNA repair level. The triggering of nucleolar stress leads 
to NPM1 release to the nucleoplasm, along with p14
Arf
 and BER proteins. It is likely that this event 
fosters a p53-dependent cell cycle arrest that follows the p53 stabilization induced by NPM1- and 
p14
Arf
-mediated sequestration of Mdm2 [160, 161, 231, 232]. The exit of BER proteins from nucleoli 
might contribute to the arrest of cell proliferation through impairment of the normal rRNA biogenesis 
process. Concurrently, p14
Arf
 may help to increase the BER protein stability through inhibition of the 
Mule E3-ligase activity. 
The signaling cascade following nucleolar stress should grant a cell cycle delay sufficient to 
carry out DNA repair; concurrently the NPM1-mediated activation of BER enzymes in the 
nucleoplasm could promote faster elimination of the DNA damage. The possible involvement of 
NPM1 in the modulation of other DSB-repair pathways is suggested by my experiments and by 
previous work [194, 199, 200], moreover, earlier observations highlighted how the rewiring of the 
nucleolar proteome upon DNA damage involves several DNA repair proteins belonging to different 
DNA repair pathways (reviewed in [19]). Therefore, the speculative model depicted in Fig. 45 might 
be also applicable to other DNA repair pathways, together with the BER. 
It is worth pointing out that the proposed model may be important for tumor cells that are 
characterized by a nucleolar accumulation of p14
Arf
. It has been suggested, in fact, that the 
localization of p14
Arf
 in primary cells might not entirely recapitulate what observed in transformed 
cell models [60]. Nonetheless, the data presented in this thesis link for the first time the NPM1/p14
Arf
 
network and BER, providing a plausible explanation for the observed relocalization of DNA repair 
proteins from nucleoli upon nucleolar stress. Further comprehension of the precise functional 
significance of DNA repair protein within the nucleolus under basal conditions, however, deserves 
more extensive investigation. 
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EXPERIMENTAL METHODS 
 
1. Recombinant protein expression and purification 
For large scale production of recombinant proteins in E. coli I made use of a Bio-Flo110 
(NewBrunswick) fermentor. GST-APE1 was expressed using a pGEX-3X vector, while His(6)-NPM1 
was expressed using a pET-15b [75, 91]. Purification of recombinant proteins was carried out 
essentially as described previously [75, 91], using an ÄKTA Purifier FPLC system (GE Healthcare) 
equipped with GSTrap
TM
 FF and HisTrap
TM
 HP chromatographic columns. Extensive dialysis was 
carried out to remove any trace of elution buffer and the quality of the purification was checked by 
Coomassie-stained SDS-PAGE. 
 
2. AlphaScreen
®
-based high-throughput screening assay 
The entire AlphaScreen
®
-based screening was optimized and carried out at the NIH Chemical 
Genomics Center (NCGC – Bethesda (MD), USA). Protein-protein interaction assessment for GST-
APE1 and His(6)Tag-NPM1 was carried out in 1,536-well plates screening the following libraries 
(number of compounds is indicated in parentheses): FDA Pharmaceutical Collections (2,816), 
MicroSource Spectrum collection (1,408), Tocris/TimTec (1,395), and bioactive compounds from 
Sigma Aldrich LOPAC1280 (1,280), FDA-Tocris-KU-DP (1,376), Prestwick (1,120), BU-GP-
BioMol (1,302), Kinacore (2,037) and NCGC chemistry analogues. Briefly, 3 µl of GST-APE1 (125 
nM final) was dispensed by BioRAPTR (Beckman Coulter) flying reagent dispenser, followed by 
addition of 23 nl of DMSO solution of compound library members achieved by a Kalypsys pintool 
[233]; after compound addition, 1 µl of His(6)Tag-NPM1 (200 nM final) was dispensed and the assay 
plates were incubated for 20 minutes at room temperature. For detection, 1 µl of 20 g/ml 
Glutathione donor/Ni
2+
 chelate acceptor AlphaScreen
®
 bead mix was added. Plates were briefly 
centrifuged and incubated for 20 minutes at room temperature. The AlphaScreen
®
 
chemiluminescence signal was measured with an EnVision multilabel plate reader (PerkinElmer) 
equipped with a 1,536 Plate HTS AlphaScreen
®
 aperture (80 ms excitation time, 240 ms 
measurement time). The signal was compared with that of DMSO-containing samples. Assay buffer 
consisted of 20 mM potassium phosphate pH 7.0, 50 mM NaCI, 5 mM MgCI2, 0.01% Tween-20 and 
2 mM DTT. 
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3. Cell culture and siRNA transfection 
p53
-/-
 (NPM1
+/+
) and p53
-/-
/NPM1
-/-
 (NPM1
-/-
) MEFs [194], HeLa, MCF-7, SF-767, HepG2, 
U2OS, and SK-BR-3 cells were grown in DMEM (GE Healthcare), JHH6 cells were cultured in 
William’s Medium (Sigma) and HCT116 were cultured in McCoy's 5A Medium (Invitrogen). All 
media were supplemented with 10% fetal bovine serum (GE Healthcare), 100 U/ml penicillin, and 
100 μg/ml streptomycin sulphate. HeLa cells reconstituted with mutant APE1 forms were grown as 
already indicated elsewhere [124]. 
For siRNA experiments 1 x 10
5
 cells were seeded onto 6-well plates and transfected 24 hours 
later with 50 pmol of either a scrambled control siRNA or the target-specific siRNA by using the 
Oligofectamine
TM
 Reagent (Invitrogen) as per manufacturer’s indications. Mouse and human NPM1 
siRNAs were from Thermo Scientific (ON-TARGETplus SMARTpool), p14
Arf
 and Mule siRNAs 
were already described [58], while the oligonuclotide sequence used for APE1 was 5’-
UACUCCAGUCGUACCAGACCU-3’. Cells were harvested 48 or 72 hours after transfection. 
Transient transfection procedures were carried out using the Lipofectamine
®
2000 Reagent 
(Invitrogen) as already described [186]. 
 
4. Chemical reagents and viability assays 
Screening compounds were dissolved in DMSO as 10 mM stocks. MMS was from Sigma-
Aldrich, bleomycin sulphate was from Santa Cruz Biotechnology and PJ34 (PARP Inhibitor VIII) 
was from Merck. Daunorubicin was from Bosche Scientific LLC, cisplatin was purchased from 
Sigma and freshly resuspended in dimethylformamide before every use. 
Cell viability was assessed through the MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay (CellTiter 96
®
 AQueous 
One Solution Cell Proliferation Assay – Promega) as per manufacturer’s instructions. Briefly, 4-6 x 
10
3
 cells were seeded in 96-well plates and treated 24 hours later with the indicated compound; cell 
viability was measured at the indicated time points. Bleomycin cytotoxicity and cell proliferation 
were evaluated through cell counting experiments. In short, 3.2 x 10
4
 cells were seeded into 12-well 
plates; 24 hours later cells were treated as indicated, medium was replaced and viability measured 48 
hours later by a Trypan Blue exclusion assay or using a coulter counter (Beckman). For colony 
formation assays 2 x 10
2
 HeLa cells were plated onto 6-well plates; 24 hours later cells were exposed 
to the selected compound(s) and cells were allowed to grow until formation of visible colonies (9-11 
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days) and stained as described earlier [75]. All the viability assays were performed in triplicate or 
quadruplicate and reproduced at least twice in independent experimental sessions. 
 
5. Immuno-fluorescence, Proximity Ligation Assay (PLA) and 
confocal microscopy 
For immuno-fluorescence analyses cells grown on glass coverslips were fixed with 4% 
paraformaldehyde for 20 min and extracted for 5 min in PBS/Triton X-100 0.1% at room temperature. 
Cells were saturated with 10% fetal bovine serum in TBS supplemented with 0.1% Tween 20 and 
incubated over night with primary antibodies. A complete list of the antibodies used can be found in 
the Supplementary Table 2. Rhodamine Red-, DyLight
TM
549- or AlexaFluor
®
488-conjugated 
secondary antibodies (Jackson ImmunoResearch) were used for detection. Nuclei were counterstained 
with TO-PRO-3 (Invitrogen). 
To monitor the interaction between APE1 and NPM1 in living cells, I used the in situ 
Proximity Ligation Assay kit (Olink Bioscience). HeLa cells stably expressing a FLAG-tagged form 
of APE1 [124] were seeded on glass slides, treated with the selected compounds and 
fixed/permeabilized immediately after the treatment as indicated above. Cells were incubated with a 
FITC-conjugated mouse anti-FLAG antibody for 3h at 37°C and then with a rabbit anti-NPM1 
overnight at 4°C. PLA reactions were carried out following the manufacturer’s instructions. Technical 
controls, represented by the omission of either the anti-NPM1 or the anti-FLAG primary antibodies, 
resulted in the complete loss of the PLA signal. 
Fluorouridine (FUrd) incorporation to assess nucleolar transcription was monitored as 
described in [214, 215] with minor modifications. Briefly, cells were incubated with 2 mM FUrd 
(Sigma) in DMEM for 15 minutes at 37°C. Cells were then washed with ice-cold PBS and fixed with 
4% paraformaldehyde for 10 minutes at room temperature. FUrd was visualized after cell 
permeabilization with 0.5% Triton X-100 for 5 minutes at room temperature and incubation with a 
monoclonal anti-BrdU antibody (Sigma) for 1 hour; cells were washed twice with PBS, and then 
stained for 1 hour with an AlexaFluor
®
488-conjugated anti-mouse secondary antibody (Jackson 
ImmunoResearch). 
Cells were visualized through a Leica TCS SP laser-scanning confocal microscope (Leica 
Microsystems) equipped with a 488-nm argon laser, a 543-nm HeNe laser, and a 63X oil objective 
(HCX PL APO 63X Leica). Multi-color images were captured through sequential scanning. 
 Determination and scoring of PLA signals was performed by sectioning the whole cell height 
into six focal stacks, which were averaged and combined into a single image. This procedure allowed 
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me to detect the PLA signals present throughout the cell, regardless of their subcellular localization. 
At least 35 randomly selected cells per condition were analyzed following this procedure; PLA-spots 
present in each single cell were then scored using the BlobFinder software (Center for Image 
Analysis, Uppsala University, Uppsala, Sweden). The staining for FLAG-APE1 was used to identify 
cell nuclei, therefore allowing me to distinguish between nuclear and cytoplasmic interaction signals. 
 
6. In vivo assessment of the APE1 redox activity 
The APE1 redox activity was assessed as already described [204]. In brief, 1.1 x 10
4
 JHH6 
cells were seeded in 96-well plates, 24 hours later cells were co-transfected with 78.4 ng of pIL-8 
(human IL-8 promoter – driven firefly luciferase reporter), 1.6 ng of pRL-CMV (Renilla reporter, as a 
reference for transfection efficiency) and 120 ng of pUC9 carrier plasmid, using the 
Lipofectamine
®2000 Reagent (Invitrogen) as per manufacturer’s instructions. One day after 
transfection cells were pre-treated with the selected APE1/NPM1 inhibitor (10 M, 5 hours) or with 
E3330 (Sigma) (100 M, 4 hours) in serum-free medium and subsequently challenged with 2000 
U/ml TNF- (Preprotech) for further 3 hours. The activity of luciferases was measured using the 
Dual-Glo
®
 Luciferase Assay System (Promega). 
 
7. Surface Plasmon Resonance (SPR) Experiments 
SPR analyses were performed in collaboration with Dr. Daniela Marasco, at University of 
Naples, Italy. Real time binding assays were performed on a Biacore T-100 SPR instrument (GE 
Healthcare). Full length recombinant APE1 and NPM1 were bound at similar immobilization levels 
(2600 and 2800 RU, respectively) on a CM5 Biacore sensor chip in 10 mM sodium acetate, pH 5.5, 
by using the EDC/NHS chemistry, with a flow rate of 5 μl/min and an injection time of 7 min, as 
previously described [91]. Binding assays were carried out by injecting 100 L of small molecule 
analyte, at 60 l/min, in a running buffer composed of HBS (10 mM HEPES, 150 mM NaCl, 3 mM 
EDTA, pH 7.4), 0.1 mM TCEP and 10% DMSO. The BIAevaluation analysis package (version 4.1, 
GE Healthcare), was used to subtract the signal from the reference channel. 
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8. Preparation of cell extracts, Western blotting and co-immuno-
precipitation 
Whole cell extracts (WCE) and Western blotting analyses were performed as already 
described [75]. A complete list of the antibodies used can be found in the Supplementary Table 2. 
Protein concentration was determined by using the Protein Assay reagent (Bio-Rad) and images were 
acquired and quantified using a Chemidoc XRS video-densitometer. 
Cell extracts for in vitro BER assays were prepared by resuspending cells in 50 mM Tris pH 
7.4, 1 mM EDTA, 0.5 mM DTT, Protease Inhibitors Cocktail (Sigma), 1 mM PMSF; cell suspension 
was freeze-thawed and KCl was added to a final concentration of 222 mM. After 30 minutes on ice 
the cell lysate was cleared by centrifugation and supplemented with glycerol (10% final 
concentration) and stored at -80°C. 
For co-immuno-precipitation assays cells were transfected with FLAG-tagged NPM1 and, 24 
hours later, lysed in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 
supplemented with protease inhibitor cocktail (Sigma), 0.5 mM PMSF, 1 mM NaF, and 1 mM 
Na3VO4 under gentle rocking for 20 minutes at 4°C. The cell extract was clarified by centrifugation 
and co-immuno-precipitation was carried out for 3 hours using the anti-FLAG M2 affinity gel 
(Sigma) as per manufacturer’s indications. Co-immuno-precipitated material was eluted by incubation 
with 0.15 mg/ml FLAG peptide in Tris-buffered saline (TBS) and analyzed through Western blotting. 
 
9. rRNA maturation kinetics 
rRNA processing was monitored essentially as described by Burger and colleagues [197] 
with minor modifications. Briefly, 5 x 10
5
 HeLa cells were incubated with the indicated inhibitors and 
metabolically labeled with [
32
P]-orthophosphate (Perkin Elmer). For metabolic labeling cells were 
harvested by trypsinization and phosphate-depleted under rocking at 37°C for 1 hour in presence of 
unchanged drug concentrations, by incubation in phosphate-free DMEM (Invitrogen) supplemented 
with 10% dialyzed FBS. Medium was replaced with phosphate-free DMEM supplemented with 10% 
dialyzed FBS containing 15 Ci/ml [32P]-orthophosphate and cells were labeled for 1 hour. Medium 
was again replaced with normal DMEM supplemented with 10% FBS in presence of unchanged drug 
concentrations and total RNA was isolated after 2 hours using the Trizol
®
 Reagent (Invitrogen). RNA 
was separated on an agarose-formaldehyde gel loading the same amount of radioactivity per lane. 
Gels were vacuum-dried and subjected to autoradiography. To assess the 47S transcription rate RNA 
was isolated immediately after the [
32
P]-orthophosphate pulse. Ethidium bromide staining of the 28S 
EXPERIMENTAL METHODS 
94 
 
TESI DI DOTTORATO DI POLETTO MATTIA DISCUSSA PRESSO L’UNIVERSITÁ DI UDINE 
specie was used as loading control. Actinomycin D (1 g/ml) was used as positive control and was 
introduced for 1 hour during phosphate depletion. 
 
10. DNA damage accumulation assays 
Genomic DNA for AP-sites accumulation analysis was isolated from 1 x 10
6
 HeLa cells by 
using the Get pureDNA Kit (Dojindo). AP-sites content was measured by using the DNA Damage 
Quantification Kit (Dojindo) as per manufacturer’s indications. Briefly, 1 g of genomic DNA was 
labeled with a biotinylated aldehyde reactive robe (ARP) at for 1 hour at 37°C and ARP-DNA was 
purified following the manufacturer’s instructions. The amount of labeled ARP-DNA was then 
detected through a colorimetric reaction and eventually measured using a calibration curve provided 
with the kit. 
Alkali comet assay was carried out essentially as described in [234]. Briefly, HeLa cells were 
exposed to the indicated concentrations of the APE1/NPM1 inhibitors and washed twice with ice-cold 
PBS. Approximately 3 x 10
3
 cells were embedded in 0.5% low melting point agarose (Cambrex) in 
PBS and spread on microscope slides. Slides were placed in cold lysis solution (2.5 M NaCl, 100 mM 
EDTA, 10 mM Tris pH 10.0, 1% Triton X-100) for 1 hour at 4°C, and washed in cold 0.4 M Tris (pH 
7.4). Next, the slides were incubated in alkali solution (300 mM NaOH, 1 mM EDTA, final pH 13.0) 
for 30 minutes at 4°C and then electrophoresed horizontally for 30 minutes at 25 V, 350 mA at 4°C. 
Slides were briefly neutralized with 0.4 M Tris (pH 7.4), stained with ethidium bromide (2 g/ml) 
and viewed on a Ziess Axiovert 200 M fluorescent microscope (Zeiss). The analysis of the comet tail 
was carried out using the Comet Assay IV software (Perceptive Instruments) to determine the Olive 
tail moment. At least 100 cells per experimental condition were scored. 
 
11. BER assays 
The AP-incision activity in HeLa whole cell extracts was monitored as described earlier [235] 
with modifications. Briefly, HeLa cell extracts were prepared through lysis in 50 mM Tris-HCl pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5 mM PMSF and protease inhibitor cocktail 
(Sigma), for 20 minutes at 4°C and subsequent clarification; the supernatant was collected as whole 
cell extract. Enzymatic reactions were carried out using 50 ng of whole cell extract in a buffer 
containing 50 mM HEPES pH 7.5, 50 mM KCl, 1 mM MgCl2, and 1 mM DTT; the extract was pre-
incubated for 15 minutes at 22°C with the selected inhibitor, reactions were started by adding 100 nM 
double stranded abasic DNA substrate (obtained by annealing of a 34F oligonucleotide 5’-
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CTGCAGCTGATGCGCFGTACGGATCCCCGGGTAC-3’, where F indicates a tetrahydrofuran 
residue, with a complementary 34G oligonucleotide 5’-
GTACCCGGGGATCCGTACGGCGCATCAGCTGCAG-3’) and incubated at 37°C for the indicated 
time. Reactions were halted by addition of formamide buffer (96% formamide, 10 mM EDTA with 
traces of bromophenol blue and xylene cyanol), separated onto a 20% denaturing polyacrylamide gel 
and stained with SYBR
®
 Gold (Invitrogen) as per manufacturer’s indications. The percentage of 
substrate converted to product was determined after background subtraction using standard 
phosphorimager analysis and the ImageQuant software. 
In vitro WCE-based BER assays were carried out by using standard [
32
P]-radiolabeled 
oligonucleotide substrates essentially as described in [235]. Briefly, all reactions were performed in 
the same reaction buffer (50 mM HEPES pH 7.5, 100 mM KCl, 10% glycerol, 1 mM DTT) at 37°C 
for the indicated time; oligonucleotide substrates were already described in [235, 236]. Flap-incision 
reactions were carried out using 1 g of WCE; gap-filling reactions were carried out using 3 g of 
WCE and nick-ligation assays were completed with 5 g of WCE. Gap-filling reactions were 
supplemented with 0.5 mM dCTP, nick-ligation reactions were instead supplemented with 1 mM 
ATP. Reactions were stopped with 1 volume of formamide buffer and analyzed by electrophoresis on 
15% denaturing polyacrylamide gels or 20% sequencing gels (for gap-filling reactions). The 
percentage of substrate converted to product was determined as above. 
For reporter-based in vivo BER assays a pCMV/Luc plasmid was in vitro depurinated by 
incubation at 65°C for 40 minutes in 0.1 M sodium citrate and 0.5 M NaCl. DNA was ethanol-
precipitated and resuspended in water for transfection. 1 x 10
4
 cells were seeded onto 96 wells plates 
and transfected with 200 ng of either damaged or undamaged pCMV/Luc along with 8 ng of intact 
pCMV/RL (encoding for the Renilla luciferase, as a reference for transfection efficiency) using the 
Lipofectamine2000
®
 Reagent (Invitrogen) as per manufacturer’s indications. Luciferase activity was 
measured 8 hours after transfection by using the Dual-Glo
®
 Luciferase Assay System (Promega); 
repair efficiency was expressed as percentage of luciferase signal normalized to the undamaged 
plasmid signal. 
 
12. DSB-repair assays 
In vitro NHEJ assays were performed using MEF whole cell extracts prepared as described in 
[237]. Briefly, cells were freeze-thawed and cell pellet was lysed for 10 minutes on ice in 45 mM 
HEPES-KOH pH 7.8, 0.4 M KCl, 1 mM EDTA, 0.2% Triton X-100, 0.1 mM DTT, 10% glycerol, 
protease inhibitors. After centrifugation at 20,000 x g for 10 minutes the supernatant was diluted four-
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fold with 45 mM HEPES-KOH pH 7.8, 0.25 mM EDTA, 2% glycerol, 0.3 mg/ml BSA, aliquoted and 
stored at -80°C. NHEJ enzymatic assays were performed in a total volume of 10 l in a reaction 
buffer containing 20 mM HEPES-KOH pH 7.5, 10 mM MgCl2, 80 mM KCl, 1 mM ATP, and 1 mM 
DTT. Each reaction was carried out at 25°C using 2 g of whole cell extract and 10 ng of plasmid 
DNA substrate. Reactions were halted by adding SDS (0.05%) and EDTA (50 mM), RNA and 
proteins were then removed by incubation with 0.5 mg/ml RNase A (10 minutes at 25°C) followed by 
30 minutes at 37°C in presence of proteinase K (0.2 mg/ml). Samples were then resolved onto a 0.7% 
agarose gel and DNA was detected with SYBR
®
 Gold staining. 
For the reporter-based in vivo NHEJ assays a linear DNA substrate was generate through 
restriction or a dual luciferase-containing pmirGLO plasmid; after digestion, the restricted vector was 
separated by undigested forms and gel-purified. The day before transfection cells (6 x 10
3
 MEFs or 
2.5 x 10
4
 HCT116) were plated onto 96-well plates and allowed to adhere for 24 hours; cells were 
then transfected with 150 ng of DNA substrate and luciferase activity was read 24 hours post-
transfection. The presence of two reporter genes allowed me to calculate the repair capacity as the 
ratio between the luciferase activity of the cleaved reporter and the activity of the intact reporter. The 
intact reporter was here used as reference signal to normalize for transfection efficiency. A reference 
sample (i.e. the undamaged substrate, corresponding to 100% repair activity) was obtained through 
linearization of the pmirGLO plasmid with the KpnI restriction endonuclease, which did not damage 
any reporter in the vector. 
Rad51 foci formation was assessed after cell treatment with etoposide (100 M, 30 minutes) 
or bleomycin (100 g/ml, 1 hour) and release for the indicated time points. Cells were stained with an 
-Rad51 antibody and scored by manually counting cells containing more than three foci. At least 
100 cells per condition were scored. 
 
13. Real-time PCR 
Real-time PCR analyses were performed as described [75], using a CFX96
TM
 Real-Time PCR 
Detection System (BioRad). Primers sequences are listed in the Supplementary Table 3. FEN1 and 
XRCC1 primers sequences were from [238] and [239], respectively. Gene expression analysis was 
carried out using the CFX Manager
TM
 Software (BioRad) and using ACTB and GAPDH as reference 
genes. 
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14. Statistical analyses 
Statistical analyses were carried out by using the Student’s t test available with the Microsoft 
Office Excel package. p<0.05 was considered as statistically significant. 
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Supplementary Table 1 – Characteristics of the top hit molecules screened for their ability to inhibit the 
APE1/NPM1 interaction. For every compound analyzed the commercial or common name is indicated, as well 
as the AC50 measured during the primary screening, the conditions tested for the immuno-fluorescence assays, 
and the observed APE1 relocalization phenotype, if present. NA: not available, “-”: no effect. 
Compound ID Common or commercial name AC50 [M] Treatment conditions Phenotype 
NCGC00016600-01 Clofazimine 2.26 4.5 M, 2 and 8h - 
NCGC00142391-04 Folic acid 2.67 100 and 500 M, 4 and 16h - 
NCGC00025170-01 SU 4312 2.99 1 M, 8 and 16h - 
NCGC00015447-04 FSCPX 3.16 10 M, 8 and 16h 
No nucleolar 
accumulation 
NCGC00238831-01 NA 4.50 100 M, 4 and 8h - 
NCGC00013628-01 Rolitetracycline 5.97 10 M, 8 and 16h - 
NCGC00091268-01 Oxytetracycline 8.91 100 M, 8 and 16h - 
NCGC00167776-01 NA 8.91 1 M, 8 and 16h - 
NCGC00015478-02 GW 5074 9.47 10 M, 2 and 8h - 
NCGC00165830-01 Myoseverin B 11.2 100 M, 4 and 8h 
No nucleolar 
accumulation 
NCGC00025330-01 SB 408124 11.2 10 M, 8 and 16h - 
NCGC00167819-01 NA 11.2 10 M, 2 and 8h - 
NCGC00024246-05 Daunorubicinum 11.9 1 M, 2h 
No nucleolar 
accumulation 
NCGC00025000-03 Ketoconazole 11.9 10 M, 8 and 16h 
No nucleolar 
accumulation 
NCGC00017358-05 Rotenone 12.6 1 and 10 M, 16h 
No nucleolar 
accumulation 
NCGC00240013-01 NA 12.6 10 M, 8 and 16h - 
NCGC00016069-04 UK 14304 13.4 10 and 100 M, 4-8-16h - 
NCGC00015747-06 Nicardipine 13.4 10 M, 8 and 16h - 
NCGC00015280-03 C 8863 14.1 1 M, 16h or 10M, 2h - 
NCGC00092382-02 GW405833 14.1 10 M, 8 and 16h - 
NCGC00240145-01 NA 14.1 10 M, 8 and 16h - 
NCGC00159457-02 Troglitazone 15.0 10 M, 2-8-16h 
No nucleolar 
accumulation 
NCGC00159344-02 Carubicin 15.0 1 M, 2h 
No nucleolar 
accumulation 
NCGC00167493-01 Manidipine 15.8 10 M, 8 and 16h - 
NCGC00159958-01 NA 15.9 10 M, 8 and 16h Cyt. re-localization 
NCGC00165892-01 NA 15.9 10 M, 8 h - 
NCGC00159542-01 CGP 71683 15.9 10 M, 2h 
No nucleolar 
accumulation 
NCGC00159584-01 NA 17.8 1 and 10 M, 8h - 
NCGC00162178-02 Fiduxosin 17.8 10 M, 8 and 16h Cyt. re-localization 
NCGC00090903-01 SASP 18.9 100 M, 8 and 16h - 
NCGC00015392-04 DMCM 18.9 10 and 100 M, 2h - 
NCGC00159758-01 NA 19.8 10 M, 8 and 16h - 
NCGC00165880-01 NA 20.0 10 M, 2 and 8h - 
NCGC00167835-01 NA 20.0 10 M, 2 and 8h - 
NCGC00014648-01 Spiclomazine 21.2 10 M, 2 and 4h Cyt. re-localization 
NCGC00024955-02 ZM 241385 21.2 10 M, 8 and 16h 
No nucleolar 
accumulation 
NCGC00163174-01 N-(4-bromobenzyl)-5-methoxytryptamine 21.2 10 M, 2 and 8h - 
NCGC00025014-01 (S)(+)-Niguldipine 21.2 10 M, 2 and 8h Cyt. re-localization 
NCGC00015193-05 CGS-15943 21.2 10 M, 8 and 16h - 
NCGC00161419-02 Trimetrexate glucuronate 22.4 100 M, 2 and 8h - 
NCGC00094031-02 Ro 90-7501 22.4 100 M, 8 and 16h 
No nucleolar 
accumulation 
NCGC00167826-01 NA 22.4 10 M, 2 and 8h - 
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NCGC00015823-13 Piroxicam 23.8 10 and 100 M, 8h - 
NCGC00024650-01 BP 554 maleate 23.8 10 and 100 M, 8h - 
NCGC00015917-02 SB 206553 23.8 10 M, 8h or 100M, 2h Cyt. re-localization 
NCGC00025307-01 DMAQ-B1 23.8 1 and 10 M, 8h - 
NCGC00025379-01 SR 33805 oxalate 23.8 10 M, 2 and 8h Cyt. re-localization 
NCGC00025179-08 RU-486 25.1 10 M, 8 and 16h - 
NCGC00093935-01 Flupirtine maleate 25.1 100 M, 8 and 16h - 
NCGC00161030-01 NA 26.7 100 M, 2h - 
NCGC00015155-03 Bepridil 26.7 10 M, 8 and 16h 
No nucleolar 
accumulation 
NCGC00164547-01 Zafirlukast 26.7 10 M, 2 and 4h - 
NCGC00015424-04 Fluspirilene  28.2 1 M, 8 and 16h - 
NCGC00015300-05 Vanoxerine 28.2 1 M, 8h - 
NCGC00024760-01 GF 109203X 29.9 10 M, 2 and 4h - 
NCGC00074717-01 NA 29.9 100 M, 2 and 8h - 
NCGC00166312-01 Closantel 31.6 1 M, 2 and 8h - 
NCGC00015889-05 Raloxifene 31.6 10 M, 2 and 8h - 
 
Supplementary Table 2 – List of the antibodies used in the Western blotting and immuno-fluorescence 
experiments. The LigI antibody was a kind gift from Prof. Alan Tomkinson (University of New Mexico). 
Epitope Clonality Company 
APE1 Polyclonal Novus (NB 100-101) 
NPM1 Monoclonal Invitrogen (32-5200) 
NPM1 Polyclonal Abcam (ab15440) 
LigIII Monoclonal SantaCruz (sc-135883) 
XRCC1 Monoclonal Thermo Scientific (MS-434-P0) 
FEN1 Polyclonal Abcam (ab17993) 
PCNA Monoclonal SantaCruz (sc-56) 
Polcs Monoclonal Abcam (ab10362) 
Pol Polyclonal Abcam (ab26343) 
p14Arf Polyclonal Novus (NB200-111) 
Mule Polyclonal Laboratories (A300-486A) 
FLAG Monoclonal Sigma (F3165) 
Fibrillarin Monoclonal SantaCruz (sc-166001) 
Rad51 Polyclonal Novus (H00005888-B01P) 
LigIV Polyclonal Abcam (ab26039) 
DNA-PKcs Polyclonal SantaCruz (sc-9051) 
Ku70 Monoclonal SantaCruz (sc-12729) 
Mre11 Polyclonal Novus (NB100-142) 
BRCA2 Polyclonal SantaCruz (sc-8326) 
 
Supplementary Table 3 – Sequences of the primers used for the Real-time PCR experiments. 
Transcript Primer sequence (5’ -> 3’) 
APE1 
For: CGTCACAGCGATGCCAAAGC 
Rev: ATCTGGAGGGTCCTCGTACAGG 
FEN1 
For: ATTCGCTCTGCTCCGAACATTCCT 
Rev: TCAGCAATTAGTTTGGCAAGGCCG 
Pol 
For: TGGACTCTGAGTACATTGCTA 
Rev: TGGCTGTTTGCTGGATTC 
Polcs 
For: CGGCTACAACATTCAGAA 
Rev: GATTGGAAGGAGGAGTCA 
LigIII 
For: TTGTCTGCTACGAGAGTTC 
Rev: AATCTGCTTATCATTCAAGTTGT 
XRCC1 
For: AATGGCGAGGACCCGTATGC 
Rev: CACGTAGCGGATGAGCCTCC 
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ABBREVIATIONS 
 
5’-dRP: 5’-deoxyribonucleotide-phosphate 
8-oxo-dG: 7,8-dihydro-8-oxoguanine 
AAG: N-alkyladenine DNA glycosylase 
AML: acute myeloid leukemia 
AP: apurinic/apyrimidinic (site) 
APE1: apurinic/apyrimidinic endonuclease 1 
APTX: aprataxin 
ATM: ataxia telangiectasia mutated 
ATR: ataxia telangiectasia and Rad3 related 
BER: base excision repair 
Compound #3: N-(3-(benzo[d]thiazol-2-yl)-6-
isopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-
yl)acetamide 
DDR: DNA damage response 
DNA-PKcs: DNA-dependent protein kinase 
catalytic subunit  
DSB: double-strand break 
E3330: (2E)-3-[5-(2,3-dimethoxy-6-methyl 1,4-
benzoquinoyl)] -2-nonyl-2-propenoic acid 
EJ: end-joining 
ExoIII: exonuclease III 
FEN1: flap endonuclease 1 
HR: homologous recombination 
ICLs: interstrand crosslinks 
IL-8: interleukin 8 
IR: ionizing radiation 
KO: knockout 
LigI: DNA ligase I 
LigIII: DNA ligase III 
LigIV: DNA ligase IV 
LP: long-patch 
Mdm2: mouse double minute homolog 2 
MEFs: mouse embryonic fibroblasts 
MMR: mismatch repair 
MMS: methyl methanesulfonate 
MTS: [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt 
Mule: Mcl-1 ubiquitin ligase E3 
MX: methoxyamine 
nCaRE: negative calcium response elements 
NF-B: nuclear factor-B 
NIR: nucleotide incision repair 
NER: nucleotide excision repair 
NHEJ: nonhomologous end joining 
NPM1: nucleophosmin 
OGG1: 8-oxoguanine DNA glycosylase 
p14
Arf
: p14 alternative reading frame 
PARP: poly(ADP-ribose) polymerase 
PCNA: proliferating cell nuclear antigen 
PNKP: polynucleotide kinase 3’-phosphatase 
Pol I: RNA polymerase I 
Pol: DNA polymerase  
Polcs: DNA polymerase  catalytic subunit 
PTMs: post-translational modifications 
ROS: reactive oxygen species 
rRNA: ribosomal RNA 
SMUG1: single-strand-selective monofunctional 
uracil-DNA glycosylase 1 
SP: short-patch 
SSBR: single-strand break repair 
SSBs: single-strand breaks 
TDP1: tyrosyl-DNA phosphodiesterase 1 
TNF-: tumor necrosis factor- 
WCE: Whole cell exctract 
XRCC1: X-ray repair cross-complementing 1 
UNG: uracil-DNA glycosylase 
zAPE1: zebrafish APE1
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Protein acetylation plays many roles within living cells, modulating metabolism, signaling and cell
response to environmental stimuli, as well as having an impact on pathological conditions, such as cancer
pathogenesis and progression. The Apurinic/apyrimidinic endonuclease APE1 is a vital protein that exerts
many functions in mammalian cells, acting as a pivotal enzyme in the base excision repair (BER) pathway
of DNA lesions, as transcriptional modulator and being also involved in RNA metabolism. As an eclectic
and abundant protein, APE1 is extensively modulated through post-translational modifications, including
acetylation. Many findings have linked APE1 to cancer development and onset of chemo- and radio-resis-
tance. Here, we focus on APE1 acetylation pattern in triple negative breast cancer (TNBC). We describe
the validation and characterization of a polyclonal antibody that is specific for the acetylation on lysine
35 of the protein. Finally, we use the new antibody to analyze the APE1 acetylation pattern on a cohort of
TNBC specimens, exploiting immunohistochemistry. Our findings reveal a profound deregulation of APE1
acetylation status in TNBC, opening new perspectives for future improvements on treatment and progno-
sis of this molecular subtype of breast carcinomas.
 2012 Elsevier Inc. All rights reserved.1. Introduction
The complexity of the proteome extends far beyond the mere
number of protein-coding genes: several mechanisms that act
downstream transcription and translation greatly expand the
plethora of functions that a single protein-coding sequence can
achieve. Among these, post-translational modifications (PTMs) of
proteins modulate nearly all processes within living cells. More
than 200 different PTMs have been reported: from the covalent
functionalization of proteins with relatively large modifiers (e.g.
ubiquitin), to the alteration of target polypeptides with tiny chem-
ical moieties (e.g. methylation or acetylation) [1]. Since its discov-
ery in histones 40 years ago, lysine acetylation has been
investigated as an essential PTM that act modulating histones-
DNA interactions and, ultimately, chromatin accessibility. In the
last decades, however, the significance of protein acetylation hasll rights reserved.
uclease1; PTM, post-transla-
elements; BER, base excision
oly(ADP-ribose) Polymerase;
dical and Biological Sciences,
Fax: +39 0432 494301.increasingly become broader, as many groups have pointed out
the importance of this PTM for several non-histone proteins [2].
Acetylation, in fact, has profound consequences on protein func-
tions and regulates many physiological processes such as cellular
metabolism, migration and signaling, as well as pathological condi-
tions, such as cancer occurrence and progression [2,3].
The Apurinic/apyrimidinic endonuclease/redox effector factor-1
(APE1/Ref-1, hereafter APE1) is an essential and multifunctional
protein, firstly discovered as central enzyme in the base excision re-
pair (BER) pathway of DNA lesions [4,5]. APE1 acts as the main aba-
sic endonuclease within mammalian cells, contributing to the
maintenance of genomic stability against alkylative and oxidative
DNA damage. As the acronym suggests, the protein has also been
separately identified as a transcriptionalmodulator, able to activate
a broad range of transcription factors through a redox-mediated
mechanism. In addition to these ‘‘classical’’ functions, APE1 is in-
volved in other cellular processes such as RNAmetabolismand tran-
scriptional repression through the binding of negative calcium
response elements (nCaRE) sequences within gene promoters
[6,7]. APE1 is an abundant protein (106–107 copies/cell) and is en-
dowed with a relatively long half-life (approximately 8 h in HeLa
cells), therefore, to cope with a rapidly changing environment, cells
must rely on a fast way tomodulate APE1 activities and localization.
M. Poletto et al. / Biochemical and Biophysical Research Communications 424 (2012) 34–39 35Hence, it is not unexpected that the protein undergoes several PTMs
including phosphorylation, ubiquitination, proteolysis, S-nitrosa-
tion and acetylation [4,8]. Several acetylation sites have been found
within the APE1 poorly structured N-terminal region. In particular,
acetylation/deacetylation on K6 and K7 has been linked to the mod-
ulation of several APE1 activities, including its affinity to the nCaRE
sequences, the YB-1-mediated MDR1 gene activation and also the
BER function of the protein, upon genotoxic insult [9–11]. Recent
evidences from our laboratory, moreover, highlight the role of the
lysine cluster between K27 and K35 in the modulation of APE1 func-
tions. The acetylation status of these residues, in fact, appears to be
modulated by genotoxic stress and likely influences the accessibil-
ity of K6 and K7 to lysine acetyl-transferases and deacetylases, sug-
gesting the existence of a cross-talk between different acetylation
hot-spots of the protein. Themodification of lysineswithin the basic
K27 to K35 cluster, has been also linked to a modulation of APE1
endonuclease activity, subcellular localization, nucleic acids bind-
ing affinity and protein–protein interaction [12] and (Lirussi et al.,
unpublished results). Moreover, acetylation of the K27 to K35 cluster
induced by alkylating treatment with methyl-methanesulphonate
(MMS), is associated with an increased DNA repair activity of
APE1 whichmay account for the reduced sensitivity of some cancer
cells to DNA damaging agents (Lirussi et al., unpublished results). As
a central enzyme in the BERpathway, APE1has in fact been linked to
tumorigenesis and onset of chemo- and radio-resistance in several
malignancies. In particular, aberrant APE1 localization and expres-
sion patterns, have been related to an increased tumor aggressive-
ness and recurrence, lymph node positivity and poor prognosis
[13–16]. However, there are no data linking the acetylation status
of APE1 and tumor progression.
In this paper, we investigated the status of APE1 acetylation, on
the K27 to K35 cluster, in triple negative breast cancer (TNBC). We
developed and characterized a polyclonal antibody specific for
acetylated APE1 that we exploited to analyze, through immunohis-
tochemistry, a cohort of TNBC specimens. Our data point to a pro-
found deregulation of APE1 acetylation status in specific subtype of
breast carcinoma and represent a descriptive starting point for fu-
ture translational studies devoted to improve treatment and prog-
nosis of this disease.
2. Materials and methods
2.1. Peptide synthesis and purification
Different APE1 peptide regions (Table 1) containing K27/K31/K32/
K35 were chemically synthesized in the acetylated and non-
acetylated form. Solid phase peptide synthesis was performed on
an automated synthesizer Syro I (MultiSynTech), following Fmoc
methodologies [17]. Peptides were purified by preparative RP-HPLC
on a Shimadzu LC-8A, and analyzed throughmass spectrometry. LC-
ESI-Ion Trap (IT)-MS analysis was carried out on a Surveyor HPLC
system connected to a LCQ DECA XP IT (Thermo Scientific).Table 1
Sequences of the peptides used in this study.
Peptide name Sequencea
25–38 25KSKTAAKKNDKEAA38
25–3827,31,32,35Ac 25KSK(Ac)TAAK(Ac)K(Ac)NDK(Ac)EAA38
24–39 24KKSKTAAKKNDKEAAG39
24–3927,31,32,35Ac 24KKSK(Ac)TAAK(Ac)K(Ac)NDK(Ac)EAAG39
14–38 14GDELRTEPEAKKSKTAAKKNDKEAA38
14–3827,31,32,35Ac 14GDELRTEPEAKKSK(Ac)TAAK(Ac)K(Ac)NDK(Ac)EAA38
14–3831,32,35Ac 14GDELRTEPEAKKSKTAAK(Ac)K(Ac)NDK(Ac)EAA38
14–3827,31,32Ac 14GDELRTEPEAKKSK(Ac)TAAK(Ac)K(Ac)NDKEAA38
14–3835Ac 14GDELRTEPEAKKSKTAAKKNDK(Ac)EAA38
a Numbers indicate the position of the peptide within APE1 amino acidic
sequence. ‘‘Ac’’ denotes acetylated residues. K27/K31/K32/K35 are bolded.2.2. Generation of polyclonal antibody specific for acetylated APE1
Based on the identified acetylation sites at K27/K31/K32/K35, we
synthesized a peptide bearing the APE1 25–38 sequence and acet-
ylated lysine residues, which was conjugated through the N-termi-
nal CG dipeptide with keyhole limpet hemocyanin (KLH), i.e. KLH-
CG25KSK(Ac)TAAK(Ac)K(Ac)NDK(Ac)EAA38. Polyclonal antibodies
against this peptide were raised in rabbits following standard
procedures (PRIMM).
2.3. In vitro acetylation of recombinant APE1
Recombinant full length APE1 mutants were previously de-
scribed (Lirussi et al., unpublished results). Both recombinant
proteins or APE1 peptides were non-enzymatically acetylated
by incubation with 5 mM acetyl-CoA [18] and (Lirussi et al.,
unpublished results), in HAT buffer (50 mM Tris–HCl pH 8.0,
0.1 mM EDTA, 5% glycerol, 1 mM DTT) for 2 h at 30 C. Reaction
was stopped by adding Laemmli sample buffer and subjected
to immunoblotting using the indicated antibodies. The acetyla-
tion of proteins and peptides was confirmed through MS
analysis.
2.4. Cell culture, transfection and immuno-precipitation
Cell culture, transfection and immuno-precipitation have been
performed by using already published methodologies [12].
2.5. Immuno-fluorescence and immunohistochemistry
Immuno-fluorescences with the anti-APE1K27–35Ac (PRIMM)
have been carried out following previously described procedures
[12]. Briefly, cells were paraformaldehyde-fixed for 20 min at RT
and permeabilized for 5 min using a PBS, 0.5% (v/v) Triton X-100
solution. After saturation with 10% (v/v) foetal bovine serum
(Euroclone) for 30 min, slides were incubated with the polyclonal
anti-APE1K27–35Ac antibody (1:100 for 3 h at 37 C), followed by a
secondary anti-rabbit Dyt-Light549 conjugated (Jackson Immuno-
Research). Microscope slides were visualized through a TCS SP
laser-scanning confocal microscope (Leica).
Core biopsies of triple negative breast tumors were examined
by immunohistochemistry. All tissues were formalin-fixed for
16–24 h. Five micrometers formalin-fixed paraffin-embedded tis-
sue sections, mounted on Superfrost slides (Surgipath) were
immunohistochemically stained by using the peroxidase/DAB Plus
Dako REAL™ EnVision™ Detection System (Dako A/S). Antigen re-
trieval was performed in a water bath at 98 C with 0.01 M citrate
buffer, at pH 6.0 for 40 min. Endogenous peroxidase activity was
blocked by incubation in the Peroxidase Block solution (Dako A/
S) for 10 min. Primary mouse monoclonal anti-APE1 antibody
[20] diluted 1:200 (optimum working dilution) and primary rabbit
polyclonal anti-APE1K27–35Ac (PRIMM) antiserum diluted 1:100
were applied to each slide and incubated, respectively, for
60 min at room temperature and overnight at 4 C. After washing,
slides were incubated with the peroxidase/DAB Plus Dako REAL™
EnVision™ Detection System (Dako A/S) according to manufac-
turer’s guidelines. For reaction visualization, 3-3 diaminobenzidine
tetrahydrochloride was used as chromogen. The sections were
counterstained with Mayer haematoxylin. Normal breast tissue
sections were used as positive control, whereas negative control
was performed by replacing the primary antibody with PBS. Con-
trols were included in each staining run. Nuclear immunostaining
was quantitatively evaluated by using light microscopy: the entire
section was scanned at high-power magnification (400) and the
percentage of positive cells was scored.
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Fig. 1. The anti-APE1K27–35Ac antibody is specific for APE1 acetylation at K27/K31/K32/K35. (Panel A) Schematic view of the position of the acetyl-lysine residues in the primary
sequence of APE1. Lysines residues targeted by the antibody are indicated by an arrowhead. (Panel B) Western blotting analyses on synthetic APE1 peptides. Left panel: 10 lg
of chemically synthesized 25–38 or tetra-acetylated 25-3827,31,32,35Ac were separated onto a discontinuous Tris-tricine SDS–PAGE and then subjected to immunoblotting.
Right panel: the indicated amounts of BSA-conjugated 24–39 APE1 peptide, or unconjugated 14–38 and 25–38 APE1 peptides (either in their non-acetylated or tetra-
acetylated forms) were slot-blotted on PVDF membrane and subjected to immunoblotting. (Panel C) Western blotting analysis on the in vitro acetylated 25–38 peptide;
increasing amounts of the non-acetylated 25–38 peptide were in vitro acetylated as described in Section 2 and separated onto a discontinuous Tris-tricine SDS–PAGE prior to
immunoblotting analysis. All Western blotting analyses were performed using the anti-APE1K27–35Ac antibody. (Panel D) The anti-APE1K27–35Ac antibody recognizes in vitro
acetylated full length APE1. 2.5 lg of recombinant APE1 and its lysine to alanine mutants were in vitro acetylated as described in Section 2 and probed with either a
commercial anti-Acetyl-lysine antibody (Millipore) or the anti-APE1K27–35Ac antibody. Ponceau-S staining was used as a loading control for normalization. (Panel E) The anti-
APE1K27–35Ac antibody detects changes in the APE1 acetylation pattern upon MMS treatment. FLAG-APE1 was immuno-precipitated from HeLa cells treated for 4 h with MMS,
as indicated, was probed using the anti-APE1K27–35Ac antibody. Anti-FLAG (Sigma) was used as loading control. (Panel F) Immuno-fluorescence on HeLa cells performed using
either the anti-APE1K27–35Ac alone, or in presence of a 50-fold molar excess of 25–3827,31,32,35Ac or 25–38 peptides. Images were captured maintaining fixed photomultiplier
and laser parameters.
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Protein and peptides were separated onto 12% sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) or onto a
discontinuous Tris-tricine SDS–PAGE [19] and transferred to nitro-cellulose or PVDF membranes (Perkin Elmer). Western blotting
was carried out as already described [20], using 5% (w/v) bovine
serum albumin (BSA) as blocking agent and revealed using ECL
chemiluminescence procedure (GE Healthcare). Images were
acquired through a ChemiDoc XRS video-densitometer (Bio-Rad).
M. Poletto et al. / Biochemical and Biophysical Research Communications 424 (2012) 34–39 372.7. Surface plasmon resonance (SPR)
The BIAcore 3000 SPR system for Real time binding assay and
related reagents were from GE Healthcare. The polyclonal anti-
APE1K27–35Ac antibody was immobilized at a concentration of
25 lg/mL in 10 mM acetate buffer pH 5.0 (flow rate 5 lL/min, time
injection 7 min) on a CM5 Biacore sensor chip, using EDC/NHS
chemistry following the manufacturer’s instructions [21]. Residual
reactive groups were deactivated by treatment with 1 M ethanol-
amine hydrochloride, pH 8.5. Reference channel was prepared by
activating with EDC/NHS and deactivating with ethanolamine.
Binding assays were carried out at 20 lL/min, with 4.5 min con-
tact-time, APE1 peptides were diluted in running-buffer, HBS
(10 mM HEPES, 150 mM NaCl, 3 mM EDTA, pH 7.4) 0.1 mM TCEP.
Analyte injections of 90 lL were performed at the indicated con-
centrations. The BIAevaluation analysis package (v4.1, GE Health-
care) implemented by instrument software was used to subtract
the signal of the reference channel and to evaluate kinetic and
thermodynamic parameters of complexes.A 
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Fig. 2. The anti-APE1K27–35Ac antibody displays a major specificity for the acetylated
lysine 35. (Panel A) Representative overlay sensorgrams relative to a typical SPR
experiment of immobilized anti-APE1K27–35Ac at a 2000RU level with either A the
APE1 14–3827,31,32,35Ac (5–800 nM) peptide or B the APE1 14-3827,31,32Ac (0.1–
1000 lM) peptide.3. Results and discussion
3.1. Specificity of anti-APE1K27–35Ac antibody
To gain new insights into the role of acetylation in the func-
tional modulation of APE1, we developed a polyclonal antibody
in rabbit. The antibody (hereafter referred to as anti-APE1K27–
35Ac) was developed to recognize the tetra-acetylated form of the
APE1 N-terminal 27 to 35 lysines stretch (Fig. 1A). The anti-
APE1K27–35Ac antibody specificity was tested both by Western blot-
ting and slot blotting, using a panel of chemically synthesized APE1
25–38 or 24–39 peptides (Table 1) that were either acetylated dur-
ing synthesis (Fig. 1B) or in vitro acetylated after synthesis (Fig. 1C).
Immunoblotting analyses confirmed the ability of the antibody to
discriminate the acetylated peptides from their non-acetylated
counterparts. The ability of the anti-APE1K27–35Ac antibody to rec-
ognise APE1 acetylation within a full-length protein background
was investigated using purified recombinant lysine to alanine
APE1 mutants expressed in Escherichia coli (i.e. APE1WT, the double
mutants APE127,35Ala and APE131,32Ala, the quadruple mutant
APE127,31,32,35Ala and the deletion mutant APE1ND33, that lacks the
entire 1 to 33 N-terminal domain) (Lirussi et al., unpublished re-
sults). Recombinant proteins were in vitro acetylated using acet-
yl-CoA and subjected to Western blotting (Fig. 1D). Analyses
revealed that the anti-APE1K27–35Ac is able to detect APE1 acetyla-
tion only in presence of an acetylatable (i.e. not mutated) lysine
residue at position 35 (Fig. 1D – upper panel). The specificity of
the anti-APE1K27–35Ac antibody was also compared to that of a
commercial anti-Acetyl-lysine antibody (Millipore); this antibody
is also able to discriminate between acetylated APE1 forms, though
with a different pattern. In particular, all APE1 mutants are de-
tected by the Acetyl-lysine antibody when in their acetylated form,
in accordance with the broad specificity of the antibody and with
the presence of other acetylatable residues within APE1 (e.g. K6
and K7) (Fig. 1D – lower panel). Altogether these data suggest that
the anti-APE1K27–35Ac specifically recognizes APE1 acetylation
within the 27 to 35 lysines stretch, with a particular affinity toward
the acetylated K35 residue. This latter point is further highlighted
by the strong signal obtained with the APE1ND33 deletion mutant,
which conserves only K35, that is possibly located in a more
accessible position. To further validate the specificity of the
anti-APE1K27–35Ac antibody, we used immuno-precipitated APE1
samples obtained from HeLa cells treated with MMS, to increase
the acetylation status of the K27 to K35 cluster (Lirussi et al., unpub-
lished results). Fig. 1E shows that the anti-APE1K27–35Ac efficientlydetects changes in the acetylation pattern of the protein. We finally
assessed the staining pattern of the antibody using immuno-fluo-
rescence on HeLa cells: the selectivity of the staining was verified
through competition studies using the acetylated 25–38 peptide
(Fig. 1F).
Surface Plasmon resonance (SPR) biosensors are ideally suited
for antibody characterization and quantitative immunoassay
detection. Here, we exploited SPR to measure the affinity of the
antibody for the acetyl-lysine residues within APE1 amino acids
27 to 35 (Fig. 2). To characterize the kinetic values for the anti-
APE1K27–35Ac we employed different APE1 peptides as ligands
(Table 1). SPR data confirmed what observed through Western
blotting, showing that acetylated K35 is the preferential target site
for immunorecognition, with a measured KD in the sub-micromo-
lar range (Table 2). Notably, the lack of acetylation on K35 only, re-
sults in a dramatic reduction in the antibody affinity for the
cognate peptide (Fig. 2B, Table 2 and data not shown). Therefore,
these analyses lead us to conclude that the developed antibody
has major specificity toward the acetylated K35 residue of APE1.
3.2. Analysis of APE1 acetylation in triple negative breast Cancer
The APE1K27–35Ac antibody was used to study APE1 acetylation
in a cohort of triple negative breast cancer (TNBC) specimens. This
type of breast cancer comprises tumors that lack expression of
estrogen receptor (ER), progesterone receptor (PR) and overexpres-
sion/gene amplification of epidermal growth factor receptor type 2
(HER2) [22]. TNBC account for approximately 15% of all invasive
breast cancers and often show aggressive phenotypical character-
istics, such as a high histologic grade [23,24]. To date, no specific
molecular targets have been identified in TNBC and, accordingly,
no specific targeted therapies have been developed [25]. Therefore,
the prognosis of patients with TNBC is usually poorer than that of
Table 2
Kinetic and thermodynamic parameters of anti-APE1K27–35Ac toward peptides
described in Table 1.
Peptide Ka  104 (Ms) Kd  103 (1/s) KD (M)
14–38 NDa ND 103
14–3835Ac 2.39 6.52 270 ± 8  109
14–3831,32,35Ac 4.70 7.71 164 ± 3  109
14–3827,31,32Ac ND ND 103
14–3827,31,32,35Ac 3.62 5.10 141 ± 3  109
a ND: Not Determined.
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ings, however, indicate that a substantial diversity in biology, prog-
nosis and treatment sensitivity can be observed among tumor
defined as TNBC [28,29]. A cohort of 103 TNBC was investigated
for levels of total APE1 and acetylated APE1 by using immunohis-
tochemistry. Fig. 3 shows representative immunostainings and
quantitation of positivity: overexpression of total APE1 was
detected in TNBC compared to normal breast tissue, with 90% of
tumor specimens showing an APE1 nuclear positivity higher than
80% (Fig. 3B). This result is in accordance with previous works that
report a correlation between APE1 overexpression and tumor
aggressiveness in a variety of cancers [4,6]. In contrast, immuno-
staining of acetylated APE1 was very heterogeneous among TNBC
specimens: samples showing either low or high nuclear positivity
were observed (T1 and T2, respectively, in Fig. 3A). The heteroge-
neity of APE1K27–35Ac immunostaining among TNBC is quantita-APE1
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Fig. 3. Immunostaining of TNBC specimens for total APE1 and acetylated APE1. (Panel A)
antibody against total (APE1) and acetylated (APE1K27–35Ac) APE1. Positivity is indicated
APE1 and acetylated APE1. In x and y axes are indicated different classes of positivity an
immunostaining is indicated below the respecting bars.tively captured in Fig. 3B. These data suggest that in TNBC,
concomitantly with total APE1 overexpression, a specific deregula-
tion of the acetylation status of this protein is occurring. APE1
deregulation in breast carcinoma (present data and [30]) may be
linked to an impairment in its redox activity, being instrumental
in altering estrogen-responsive gene expression in breast cancer
cell lines [31].
Member of the Poly(ADP-ribose) Polymerase (PARP) family are
central to specific DNA damage repair pathways, particularly the
BER. PARP inhibition has been shown to enhance the cytotoxicity
of agents that generate single-strand breaks in DNA, such as radi-
ation and certain chemotherapy drugs (i.e. alkylating agents)
[32]. In addition, PARP inhibitors may induce cell death through
‘‘synthetic lethality’’, if the DNA repair mechanisms that rescue
BER-deficient cells are themselves impaired, as in BRCA-deficient
breast cancers [32,33]. Because of the phenotypic similarities be-
tween some TNBC and most BRCA1-associated breast cancers,
some have hypothesized that TNBC might also be sensitive to PARP
inhibition [32]. Interestingly, it has been recently demonstrated
that BRCA1 may be involved in regulation of the expression levels
of DNA repair genes such as APE1, OGG1 and NTH1 [34]. Thus,
APE1 represents an ideal candidate target for developing new ther-
apeutic strategies for breast cancer treatment. In particular, dereg-
ulation of APE1 observed in breast cancer specimens might be
exploited in order to induce synthetic lethality in tumors with de-
fects in other DNA repair pathway, as recently pointed out [33].
Our observations, therefore, represent a descriptive starting point
for future investigations; it would be interesting to understandT1 T2
APE1K27-35Ac
Representative cases of normal breast tissue (N) and TNBC (T1 and T2) stained with
by the brown colour. (Panel B) Quantitative analysis of nuclear positivity for total
d percentage of TNBC present within each class, respectively. APE1 or APE1K27–35Ac
M. Poletto et al. / Biochemical and Biophysical Research Communications 424 (2012) 34–39 39whether the deregulation of APE1 acetylation status is paralleled
by an impairment of its functions, in order to design novel thera-
peutic approaches to breast carcinoma.
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Nucleolar accumulation of APE1 depends on 
charged lysine residues that undergo acetylation 
upon genotoxic stress and modulate its BER 
activity in cells
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ABSTRACT Apurinic/apyrimidinic endonuclease 1 (APE1) is the main abasic endonuclease in 
the base excision repair (BER) pathway of DNA lesions caused by oxidation/alkylation in 
mammalian cells; within nucleoli it interacts with nucleophosmin and rRNA through N-termi-
nal Lys residues, some of which (K27/K31/K32/K35) may undergo acetylation in vivo. Here we 
study the functional role of these modifications during genotoxic damage and their in vivo 
relevance. We demonstrate that cells expressing a specific K-to-A multiple mutant are APE1 
nucleolar deficient and are more resistant to genotoxic treatment than those expressing the 
wild type, although they show impaired proliferation. Of interest, we find that genotoxic 
treatment induces acetylation at these K residues. We also find that the charged status of 
K27/K31/K32/K35 modulates acetylation at K6/K7 residues that are known to be involved in the 
coordination of BER activity through a mechanism regulated by the sirtuin 1 deacetylase. Of 
note, structural studies show that acetylation at K27/K31/K32/K35 may account for local confor-
mational changes on APE1 protein structure. These results highlight the emerging role of 
acetylation of critical Lys residues in regulating APE1 functions. They also suggest the exis-
tence of cross-talk between different Lys residues of APE1 occurring upon genotoxic dam-
age, which may modulate APE1 subnuclear distribution and enzymatic activity in vivo.
INTRODUCTION
Apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1) 
plays a central role in the maintenance of genome stability and re-
dox signaling (Bapat et al., 2009, 2010; Tell et al., 2010a; Wilson and 
Simeonov, 2010). Through its C-terminal domain (residues 61–318), 
it acts as an essential enzyme in the base excision repair (BER) path-
way of DNA damages caused by both endogenous and exogenous 
oxidizing/alkylating agents, including many chemotherapeutic 
drugs. In combination with thioredoxin (Ueno et al., 1999; Seemann 
and Hainaut, 2005) and through its N-terminal domain (residues 
1–127), it also functions as a regulatory redox agent to maintain 
cancer-related transcription factors (Egr-1, NF-κB, p53, HIF-1α, AP-1, 
and Pax proteins) in an active reduced state (Hirota et al., 1997; 
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mutants are reintroduced into APE1-silenced cell clones to deter-
mine the role of these crucial amino acids during cell response to 
genotoxic treatment.
RESULTS
Positively charged K27/K31/K32/K35 residues are essential 
for APE1 nucleolar accumulation through stabilization 
of protein interaction with NPM1 and rRNA
We previously demonstrated that charged K residues, located within 
the unstructured APE1 N-terminal domain (i.e., K24/K25/K27/K31/K32), 
are crucial for APE1 interaction with rRNA and NPM1 and for modu-
lating its catalytic activity on abasic DNA through regulation of prod-
uct binding. Of interest, some of these critical amino acids (i.e., K27/
K31/K32 in addition to K35) may undergo in vivo acetylation under 
basal conditions (Fantini et al., 2010). We hypothesized that the de-
gree of positive charges, modified by acetylation at these residues, 
may modulate APE1’s different functions through its redirection to 
different substrates and/or stimulation of its DNA-repair enzymatic 
activity (Fantini et al., 2010). To address this issue, we inspected 
the role of the positively charged residues within the region 27–35 in 
modulating the interaction between APE1 and NPM1. Colocaliza-
tion experiments in HeLa cells transiently transfected with either 
FLAG-tagged, wild-type APE1 (APE1WT), a K-to-A mutant (APE1K4pleA) 
in which the positive charges have been removed as in the case of 
constitutive acetylation, or a nonacetylatable K-to-R APE1 mutant 
(APE1K4pleR) showed that APE1K4pleA mutant has a marked exclusion 
from the nucleoli apparent in all expressing cells (Figure 1A). Silenc-
ing of the endogenous APE1 protein did not alter either the ability 
of the APE1WT and APE1K4pleR proteins to accumulate within the nu-
cleolar compartment or the inability of the APE1K4pleA to accumulate 
within the nucleolus (unpublished data). These data thus demon-
strate that APE1WT and APE1K4pleR nucleolar accumulation is not the 
consequence of their overexpression.
To complement these observations and also to exclude a possi-
ble contribution of the FLAG tag used to generate recombinant ec-
topic proteins, we exploited a live-cell imaging system as suggested 
by Schnell et al. (2012). APE1 cDNA was cloned into a pDendra2 
vector to express APE1 in fusion with the green photoconvertible 
fluorophore Dendra (Chudakov et al., 2007). As reported in Figure 
1B, the fluorophore alone is present in both the cytoplasm and the 
nuclear compartment, but it is completely excluded from the nucle-
oli, as demonstrated by quantitative fluorescence signal analyses. In 
contrast, whereas the expression of Dendra in fusion with APE1WT 
and APE1K4pleR results in an efficient accumulation of the protein 
within the nucleolar compartment, the Dendra-APE1K4pleA mutant 
displays a homogeneous nuclear distribution. This approach con-
firms immunofluorescence-based data on the reduced accumula-
tion of FLAG-tagged APE1K4pleA within the nucleoli and supports the 
evidence that the nucleolar accumulation of APE1 protein does not 
depend on the protein abundance nor does it depend on the spe-
cific tag used to generate the ectopic recombinant proteins (see 
also Supplemental Figure S1).
We supported our immunofluorescence data with biochemical 
interaction experiments. Coimmunoprecipitation analysis showed 
that the APE1K4pleA mutant has a significantly reduced interaction 
with NPM1 (Figure 2A), in accordance with its impaired nucleolar 
accumulation. The altered electrophoretic mobility observed for the 
APE1K4pleA mutant (Figure 2A) was further confirmed by SDS–PAGE 
analysis of recombinant proteins expressed in Escherichia coli and 
purified by chromatography. The effect is likely due to alteration of 
its overall charge, since electrospray ionization mass spectrometry 
analysis confirmed the correctness of protein mass values, and the 
Wei et al., 2000; Ziel et al., 2004; Gray et al., 2005; Pines et al., 2005; 
Tell et al., 2005, 2010a). APE1 can also act as a transcriptional repres-
sor through indirect binding to negative Ca2+-response elements 
(nCaRE), which are regulated by K6/K7 acetylation (Bhakat et al., 
2003). Recently APE1 was demonstrated to bind/cleave abasic RNA 
(Vascotto et al., 2009b; Fantini et al., 2010; Tell et al., 2010b) and to 
control c-Myc expression by cleaving its mRNA (Barnes et al., 2009). 
These discoveries pointed to a new function of APE1 in regulating 
gene expression through posttranscriptional mechanisms and 
brought to light the fact that this protein is a possible target for anti-
cancer therapy.
In this context, we showed that the first 35 amino acids in the 
nonstructured N-terminal domain of APE1 are required for a stable 
interaction with rRNA, nucleophosmin 1 (NPM1), and other proteins 
involved in ribosome biogenesis/RNA processing (Vascotto et al., 
2009b; Tell et al., 2010b). In particular, K residues within the protein 
region spanning amino acids 24–35 are involved in the interaction of 
APE1 with both rRNA and NPM1 and also regulate its in vitro enzy-
matic activity (Fantini et al., 2010). Of interest, some of these critical 
K residues, namely K27/K31/K32/K35, undergo in vivo acetylation. 
These results suggest that protein–protein interactions and/or post-
translational modifications (PTMs) involving the APE1 N-terminal 
domain may play important roles in vivo in coordinating and fine-
tuning the protein’s BER activity and functions on rRNA metabolism. 
Recently it was also demonstrated that APE1 K6/K7 may undergo 
acetylation during cell response to genotoxic treatment (Fantini 
et al., 2008) and that the acetylation status of these K residues, con-
trolled by the sirtuin 1 (SIRT1) deacetylase activity, should be impor-
tant in modulating protein DNA-repair function by regulating the 
kinetics of its interaction with other enzymes involved in BER, for 
example, XRCC1 (Yamamori et al., 2010).
APE1 is mainly a nuclear protein and is critical for controlling cel-
lular proliferative rates (Fung and Demple, 2005; Izumi et al., 2005; 
Vascotto et al., 2009b). We also showed that a considerable amount 
of APE1 is accumulated within the nucleoli of different cell lines 
(Vascotto et al., 2009b; Fantini et al., 2010), but its role within this 
compartment is unknown. Cytoplasmic, mitochondrial, and endo-
plasmic reticulum localizations have also been ascertained (Tell 
et al., 2001; Szczesny and Mitra, 2005; Chattopadhyay et al., 2006; 
Grillo et al., 2006; Mitra et al., 2007). APE1 is an abundant and rela-
tively stable protein in mammalian cells (Tell et al., 2009, 2010a). 
Fine-tuning of the multiple APE1 functions may therefore depend 
on the modulation of its PTMs and, eventually, on its interactome. 
Although a functional role has been determined for some PTMs 
(K6/K7 acetylation and K24/K25/K27 ubiquitination; Bhakat et al., 2003; 
Fantini et al., 2008; Busso et al., 2009), the identity and importance 
of various interacting partners in modulating APE1 biological func-
tions are still under investigation (Parlanti et al., 2007; Busso et al., 
2009; Vascotto et al., 2009b). APE1 may affect cell growth by di-
rectly acting on rRNA quality control mechanisms; in particular, 
APE1 interaction with NPM1 may affect its activity over rRNA mole-
cules. However, many aspects of this new function are undefined 
(Vascotto et al., 2009b; Tell et al., 2010b).
In this study, we address the biological role of APE1 acetylation at 
K27/K31/K32/K35 and, in light of recent evidence showing the emerg-
ing function of the nucleolus as a central sensor of protein trafficking 
during DNA repair after genotoxic treatment (Nalabothula et al., 
2010), the role of the nucleolus itself on the APE1 protective function 
toward genotoxic damage. We used a reconstitution strategy with 
APE1 mutants in which the charged Lys residues were replaced by 
either Ala or Arg to mimic constitutive acetylated (APE1K4pleA) and 
nonacetylatable (APE1K4pleR) protein forms, respectively. These 
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difference in their apparent mobility ob-
served in SDS–PAGE was abolished when 
separating various mutants in urea-contain-
ing denaturing gels (Supplemental Figure 
S2 and unpublished data). It was also ob-
served for other K-to-A mutants of APE1 
(Fantini et al., 2010). We then evaluated 
the contribution of the single K residues to 
the extent of APE1 nucleolar localization 
(Supplemental Figure S3) and the ability to 
interact with NPM1 (Figure 2B). Double mu-
tants APE1K27/35A, APE1K31/32A, APE1K27/35R, 
and APE1K31/32R and a deletion mutant lack-
ing 33 amino acids at the protein N-terminus 
(APE1NΔ33) were compared with APE1WT. 
Whereas APE1WT, APE1K27/35R, and 
APE1K31/32R displayed a nucleolar and 
nucleoplasmic staining, APE1K27/35A and 
APE1K31/32A showed two alternative stain-
ings, exhibiting nucleolar/nucleoplasmic or 
only nucleoplasmic positivity, respectively 
(Supplemental Figure S3). Coimmunopre-
cipitation experiments (Figure 2B) were in 
accordance with immunofluorescence anal-
yses and showed a substantial reduction of 
the interaction in the case of APE1K4pleA and 
APE1NΔ33 mutants and a moderate impair-
ment for APE1K27/35A and APE1K31/32A mu-
tants. Glutathione S-transferase (GST) pull-
down assays with recombinant purified 
proteins confirmed that these results were 
due to effects on direct interaction between 
APE1 and NPM1 (Figure 2C). This confirmed 
previous hypotheses (Fantini et al., 2010). 
We also checked the effect of the K-to-A 
mutation on the ability of APE1 to bind nu-
cleolar rRNA (Vascotto et al., 2009b). As ex-
pected, rRNA–chromatin immunoprecipita-
tion (ChIP) analyses showed that K-to-A 
mutations significantly alter APE1 binding to 
FIGURE 1: Positively charged K27/K31/K32/K35 residues are required for APE1 nucleolar 
accumulation. (A) Confocal microscopy of HeLa cells transfected with APE1WT, APE1K4pleA, or 
APE1K4pleR FLAG-tagged proteins and stained with antibodies against NPM1 (red) and ectopic 
FLAG-APE1 (green). Overlap of staining (yellow) demonstrated colocalization of the two 
proteins. Of note, the APE1K4pleA mutant was completely excluded from nucleoli (white 
arrowheads), whereas both APE1WT and the APE1K4pleR were accumulated within. Images are 
representative of 100% of transfected cells. (B) HeLa cells transfected with pDendra2-N empty 
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vector or encoding APE1 (wild-type and 
mutants) in fusion with Dendra fluorophore 
were analyzed with a live confocal 
microscopy workstation. Cells transfected 
with empty vector (Dendra) showed diffuse 
green fluorescence within cytoplasm and 
nucleus, with exclusion of the nucleolar 
compartment. APE1WT and APE1K4pleR mutant 
mainly localized within the nuclear 
compartment and accumulated within 
nucleoli. In contrast, APE1K4pleA did not show 
any nucleolar accumulation. Images were 
captured by using the same settings (488-nm 
laser at 10% of intensity and PMT at 760 V). 
Fluorescence intensity analysis was carried 
out on a 25-μm-long line (white). Graphs 
represent the fluorescence intensity 
measured through a cross section of the 
nucleus and demonstrate an incremental 
fluorescence in corresponding nucleoli only 
in the case of APE1WT and APE1K4pleR-Dendra 
fusion protein–expressing cells.
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FIGURE 2: Positively charged K27/K31/K32/K35 
residues are required for NPM1 interaction. (A) The 
APE1K4pleA mutant shows impaired interaction with 
NPM1. Coimmunoprecipitation (CoIP) analysis on 
HeLa cells transfected with APE1WT, APE1K4pleA, or 
APE1K4pleR FLAG-tagged proteins with endogenous 
NPM1. Western blot analysis was used to quantify 
the interaction among the different APE1 forms 
and NPM1 by using specific antibodies. IB, 
immunoblot. (B) K27/K31/K32/K35 residues are 
responsible for proper interaction of APE1 with 
NPM1. CoIP analysis on HeLa cells transfected with 
FLAG-tagged APE1WT, APE1NΔ33, or the APE1 
double (APE1K27/35A, APE1K31/32A, APE1K27/35R, and 
APE1K31/32R) or quadruple (APE1K4pleA and 
APE1K4pleR) K-to-A or K-to-R mutants. Western blot 
analysis was performed on total cell extracts (left) 
and on immunoprecipitated material (right) with 
specific antibody for endogenous NPM1. 
Normalized coimmunoprecipitated amounts of 
NPM1 are indicated under each relative bar. 
Anti-FLAG staining was used as loading control. 
(C) Interaction of K-to-A APE1 mutants with NPM1 
and rRNA. A 150-pmol amount of each bait 
GST-APE1 recombinant purified protein (rAPE1) 
was incubated with an equimolar amount of 
recombinant NPM1, as described in Materials and 
Methods. After GST pull-down, samples underwent 
Western blot analysis by using the indicated 
antibodies (right). NPM1 band intensities were 
normalized vs. those of GST-APE1 proteins, and 
the resulting values, expressed as percentage of 
bound with respect to APE1WT, were plotted in the 
histogram (left). Each bar represents the mean of 
two independent experiments whose variation was 
<10%. (D) Interaction of K-to-A APE1 mutants with 
NPM1 and rRNA. After transfection of HeLa cells, 
total cell lysates were prepared as described in 
Materials and Methods, and an RNA-ChIP assay 
was performed to measure the rRNA-binding 
activity of the different APE1 mutants. 
Immunoprecipitated samples underwent either 
Western blot analysis (right) or RNA extraction and 
quantification by reverse transcription and 
quantitative PCR analysis, using 18S and 47S 
rRNA–specific primers. Data are presented as a 
fold percentage of the amount of total 18S or 
47S rRNA with respect to the amount of 
immunoprecipitated FLAG-tagged APE1 protein, 
respectively. The resulting values are plotted in 
the histograms (left), showing the average values 
with SD of three independent experiments. 
(E) Nucleoplasmic interaction between APE1 and 
NPM1 is affected by K-to-A mutation on APE1. 
PLA technology was used to evaluate in vivo the 
effect of positively charged K27/K31/K32/K35 
residues on APE1 interaction with NPM1 in the 
nuclear compartment. Stable HeLa clones 
expressing APE1WT, APE1K4pleA, or APE1K4pleR 
FLAG-tagged proteins were seeded on a glass 
coverslip, and PLA reaction was carried out 
using anti-FLAG and anti-NPM1 antibodies. 
4′,6-Diamidino-2-phenylindole staining is used as a 
reference for the nuclei. The histogram represents 
the average number of PLA blobs scored for at 
least 30 cells per slide. Asterisks represent a 
significant difference between APE1WT and 
mutants.
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rRNA molecules (Figure 2D) and that a partial removal of positive 
charges in the region 27–35 strongly affects the protein binding to 
rRNA molecules.
Interaction between APE1 and NPM1 may also occur in the nu-
cleoplasmic compartment of cells. We measured the effect of the 
K-to-A mutation on the nucleoplasmic interaction of APE1 with 
NPM1 through proximity ligation assay (PLA) analysis, which allows 
in situ detection of two proteins that are at interacting distance of 
<40 nm (Weibrecht et al., 2010). Data displayed in Figure 2E show 
that nucleoplasmic interaction between APE1 and NPM1 was sig-
nificantly affected by the K-to-A mutation. Taken together, these 
data demonstrate that charged lysines within the 27–35 region are 
essential for APE1 maintenance within the nucleoli and for a proper/
stable interaction of this protein with NPM1 or rRNA molecules. 
Moreover, our data suggest that APE1 must lose the positive charge 
at more than two K residues (among K27/K31/K32/K35) to get a signifi-
cant reduction of the APE1/NPM1 interaction in the nucleus and 
loss of APE1 nucleolar accumulation.
Loss of APE1 nucleolar accumulation causes impairment 
of cell proliferation
APE1 protects cells against genotoxic damaging agents (Tell and 
Wilson, 2010). To clarify the biological relevance of the APE1 nucle-
olar accumulation, we estimated the effect of the expression of the 
nucleolar-deficient form of APE1 (i.e., APE1K4pleA) on cell viability 
with respect to APE1WT and APE1K4pleR mutant. To test the effects of 
the mutant proteins and exclude the contribution of the endoge-
nous one, we used inducible APE1-silenced (through small interfer-
ing RNA [siRNA] technology) HeLa cells, which were reconstituted 
with siRNA-resistant APE1 ectopic proteins in place of the endog-
enous one (Figure 3A; Vascotto et al., 2009a). The levels of the ec-
topic proteins expressed by the different cell clones used for the 
following experiments were comparable to that of the wild-type 
endogenous one before silencing, as demonstrated by quantita-
tive Western blot analysis (Supplemental Figure S4); the extent of 
the residual endogenous protein was <10%. Quantification of the 
nuclear amount of ectopic proteins after doxycycline treatment, 
demonstrated by Western blot analysis with a calibration curve, 
gave the following results (expressed as nanograms of APE1 per 
microgram of nuclear extract): 23.22 ± 6.04 for APE1WT, 18.63 ± 
4.84 for APE1K4pleA, and 17.69 ±4.60 for APE1K4pleR (Supplemental 
Figure S4B). Therefore these cell lines represent a reliable system 
for testing our hypothesis. On the basis of previous data showing 
that nucleolar APE1 may act as a cleansing factor in rRNA quality 
control, possibly affecting cellular proliferation through an impair-
ment of the overall protein synthesis machinery (Vascotto et al., 
2009b; Tell et al., 2010b), we investigated the effect of the nucleo-
lar-deficient form APE1K4pleA on cell proliferation rate under basal 
conditions. Of interest, by cell counting assays performed on re-
constituted cell clones, we obtained proof that APE1K4pleA acts as a 
loss-of-function mutation in terms of cell proliferation, whereas 
APE1K4pleR behaves similarly to APE1WT (Figure 3B). These data, 
confirmed by using at least two different clones for each mutant 
cell line, suggest that nucleolar APE1 is required for appropriate 
control of cell proliferation, perhaps through its role in rRNA me-
tabolism (Tell et al., 2010b). Colony formation assays confirmed cell 
proliferation data (Figure 3C). However, although the cell number 
in each colony of APE1K4pleR-expressing cells was always similar to 
that expressing APE1WT, these cells grew in a more widespread 
manner, possibly due to an altered migrating phenotype and/or an 
intercellular adhesion pattern. These data were indicative that abo-
lition of the acetylatable residues of APE1 at K27/K31/K32/K35 may 
significantly affect cell biology, even though it is also possible that 
the lower expression level of the APE1K4pleR (∼76%) with respect to 
APE1WT may also have an effect on this phenotype.
Increased APE1 acetylation at K27/K31/K32/K35 residues upon 
genotoxic damage
APE1 acetylation at K6/K7 is known to be enhanced after genotoxic 
insult by methyl methanesulfonate (MMS) and it has been shown to 
play a role in modulating APE1 interaction with XRCC1, possibly 
coordinating different enzymatic steps in the BER pathway 
(Yamamori et al., 2010). We therefore tested whether MMS treat-
ment, which promotes generation of DNA damage specifically re-
paired through BER, may also induce APE1 acetylation at K27/K31/
K32/K35 residues. Immunopurified APE1 samples from control and 
MMS-treated cells were separated by SDS–PAGE and excised 
bands and then analyzed by peptide mapping experiments. Semi-
quantitative nano–electrospray linear ion trap tandem mass spec-
trometry (nanoLC-ESI-LIT-MS/MS) analysis was performed on iden-
tical quantities of immunopurified APE1WT-FLAG protein samples 
obtained from HeLa cells before and after MMS treatment (Supple-
mental Figure S5). In particular, we evaluated the amount of the 
peptides (15–33)Ac3 and (15–35)Ac4 in each APE1 endoprotease 
AspN digest and compared them to that of the nonmodified coun-
terparts. Analysis was performed by extracting and integrating the 
corresponding nanoLC-ESI-LIT-MS peak areas equivalent to the as-
signed m/z values for the acetylated and nonacetylated peptides in 
the same total ion chromatogram. After MMS treatment, the amount 
of the peptide (15–33)Ac3 was significantly increased, and the pep-
tide (15–35)Ac4 was almost doubled as compared with that of the 
nonmodified counterparts (Figure 4A). The MMS-induced acetyla-
tion on the aforementioned residues was further demonstrated by 
Western blotting using a commercial anti–Ac-Lys antibody on im-
munopurified proteins from HeLa cells transiently transfected with 
the FLAG-tagged APE1WT and the nonacetylatable APE1K4pleR 
forms. It is striking that a significant increase of APE1 acetylation 
was observed after MMS treatment but mainly for APE1WT rather 
than for APE1K4pleR (Supplemental Figure S6). These data show that, 
besides increasing the acetylation status of K6/K7 (see later discus-
sion and Yamamori et al., 2010), MMS treatment also promotes 
acetylation at K27/K31/K32/K35 residues. The mild increase of Lys 
acetylation level in the mutant APE1K4pleR may possibly be ascribed 
to K6/K7 acetylation (see later discussion).
We then investigated the cellular distribution pattern of acety-
lated APE1 at K27/K31/K32/K35 residues by using an ad hoc–devel-
oped antibody that specifically recognized the peptide 25–38 fully 
acetylated at K27/K31/K32/K35, hereafter referred to as anti-APE1K27-35Ac 
(Poletto et al., 2012). This antibody was particularly efficient in rec-
ognizing acetylation at K35 with a measured affinity in the nanomolar 
range (196 nM for the tetra-acetylated stretch vs. 26,800 nM for 
the nonacetylated one, as assessed by surface plasmon resonance 
(SPR; Poletto et al., 2012). Preincubation of the antibody with the 
acetylated and nonacetylated peptides confirmed the specificity of 
the antibody (Poletto et al., 2012). The distribution pattern of 
APE1WT, APE1K4pleA, and APE1K4pleR was compared by using anti-
FLAG and anti-APE1K27-35Ac antibodies. Of interest, staining with the 
anti-APE1K27-35Ac antibody gave a pattern quite similar (i.e., nucleo-
lar exclusion) to that of the anti-FLAG antibody but only in the case 
of the APE1K4pleA mutant (Figure 4B). PLA was also carried out to 
demonstrate the in vivo occurrence of acetylation on endogenous 
APE1 by using either the anti-APE1K27-35Ac antibody alone (as a 
control) or together with an anti-APE1 antibody (Figure 4C). This 
assay clearly highlighted the proximity between the target of both 
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FIGURE 3: Expression of the nucleolus-deficient APE1 mutant causes impaired cell proliferation. (A) Generation of 
reconstituted cell lines expressing APE1K4pleA and APE1K4pleR mutants. HeLa cells were stably transfected with the 
inducible siRNA vectors and siRNA resistant APE1WT, APE1K4pleA, and APE1K4pleR–expressing vectors, as previously 
described (Vascotto et al., 2009a; Fantini et al., 2010). Expression of ectopic APE1 forms without silencing and after the 
suppression of endogenous APE1 expression after 10 d of treatment with doxycycline (Doxy) was assayed by Western 
blotting on total cellular extracts with an anti-APE1 antibody. Normalized expression levels for each clone of ectopic 
and endogenous APE1 protein after the silencing are indicated under each relative band. β-Tubulin was used as loading 
control. (B) Cell proliferation assays for APE1-reconstituted cell lines. APE1-expressing cell clones were seeded in 
60-mm Petri dishes. Growth was followed by measuring cell numbers at various times upon doxycycline treatment, as 
indicated. Cells were harvested at the indicated times, stained with trypan blue, and counted in triplicate. Data, 
expressed as cell number, are the mean ± SD of three independent experiments. (C) Colony formation assays for 
APE1-reconstituted cell lines. After 8 d of doxycycline treatment, 200 cells of APE1WT and the indicated APE1 mutants 
were seeded in 60-mm Petri dishes and grown for 8 d in medium supplemented with doxycycline to promote 
endogenous APE1 silencing. Then cells were stained with crystal violet and images captured by using a Leica S8 
microscope with 80× magnification. Data, expressed as number of cells per colony, are the mean ± SD of 10 colonies for 
each clone.
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antibodies, further suggesting that, in vivo, 
APE1 is acetylated at K27/K31/K32/K35 resi-
dues and that these acetylated forms are 
excluded from the nucleoli. Taken together, 
these data suggest that acetylation at these 
charged amino acids may control the nucle-
olar/nucleoplasmic distribution of APE1 
within cells.
Removal of positively charged K27/K31/
K32/K35 residues increases APE1 
DNA-repair activity in vivo
We tested whether abolition of positive 
charges on acetylatable residues may affect 
the APE1 DNA repair function in cells, as 
previously demonstrated in vitro by using 
recombinant purified proteins bearing two 
different clusters of K-to-A mutation (i.e., on 
residues 24/25/27 and on residues 
24/25/27/31/32; Fantini et al., 2010). For 
this purpose we used nuclear extracts from 
reconstituted cell clones after precise nor-
malization for the APE1 ectopic nuclear con-
tent with a titration curve (as shown in Sup-
plemental Figure S4). This normalization for 
APE1 ectopic protein expression allowed 
comparison of the enzymatic activities of 
the different protein mutants in the nuclear 
fractions from each clone. Figure 5A shows 
that the AP-endonuclease activity of the 
APE1K4pleA mutant, measured through cleav-
age assays performed with nuclear extracts, 
was significantly increased with respect to 
APE1WT-and APE1K4pleR-expressing cells. 
Moreover, Figure 5B shows a lower amount 
of abasic DNA lesions accumulated after 
MMS treatment by the APE1K4pleA- as com-
pared with the APE1WT-expressing cells. 
These results suggest that removal of posi-
tive charges at Lys 27–35, as exerted by 
acetylation, may result in a more enzymati-
cally active protein.
FIGURE 4: Genotoxic treatment promotes APE1 acetylation at K27/K31/K32/K35 residues. 
(A) Relative quantitative changes of APE1 acetylation at K27/K31/K32/K35 after MMS treatment. 
Mass spectrometry analysis of acetylated peptides present in the endoprotease AspN digest of 
FLAG-tagged APE1 WT purified from HeLa cells (see Materials and Methods for details). 
Histograms indicate the relative amounts of the peptides (15–33)Ac3 and (15–35)Ac4 with respect 
to their nonmodified counterparts before and after MMS treatment. Identical ionization 
tendencies were assumed for each peptide pair. Each bar represents the mean of three 
independent experiments. (B) Acetylated APE1 at K27/K31/K32/K35 residues is present within cell 
nucleoplasm but is excluded from nucleoli. Confocal microscopy of HeLa cells transfected with 
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FIGURE 5: Abolition of positively charges K27/K31/K32/K35 residues increases APE1 DNA-repair activity. (A) Nuclear 
extracts from APE1K4pleA mutant present an increased AP endonuclease activity on abasic DNA. AP-site incision activity 
of the nuclear extracts from HeLa-reconstituted cell clones was tested using an AP endonuclease activity assay as 
described in Material and Methods. The nuclear APE1 content in each clone was precisely quantified through a titration 
curve obtained using purified recombinant APE1 (Supplemental Figure S4). Nuclear ectopic APE1 protein levels were 
then normalized between the different cell clones in order to compare their relative enzymatic activities. Top left, 
concentration-dependent conversion of an AP site–containing DNA substrate (S) to the incised product (P). A 
representative image of the denaturing polyacrylamide gel of the enzymatic reactions is shown. The amounts 
(femtomoles) of APE1 used in the reaction and the percentage of substrate converted into product, as determined by 
standard phosphorimager analysis, are indicated. NE, no cell extract control. Bottom left, time-dependent kinetics of 
APE1 (2.15 ng) endonuclease activity from nuclear extracts of the different reconstituted cell clones. The image of a 
representative gel analysis is shown (bottom). Right, graph depicting the time-course kinetics of APE1 from incision 
results shown on the left. Average values are plotted ± SD of three independent experiments. Asterisks represent a 
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amino acids during MMS treatment is unknown. We thus checked 
whether the charged status of K27/K31/K32/K35 residues might play 
a role in modulating the acetylation status of K6/K7 through the 
contribution of SIRT1. First, we evaluated the effect of the modifi-
cation at K27/K31/K32/K35 on the ability of SIRT1 to deacetylate K6/
K7 in APE1. We found that recombinant purified APE1 protein is 
nonenzymatically acetylated after incubation with acetyl-CoA, as 
demonstrated for other proteins (Garbutt and Abraham, 1981). 
Thus, to obtain a significant amount of acetylated recombinant 
APE1 protein on K6/K7 residues, we treated purified recombinant 
rAPE1 obtained from E. coli with acetyl-CoA, as described in the 
Supplemental Information. Then we treated in vitro–acetylated 
rAPE1WT, rAPE1K4pleA, rAPE1K27/35A, or rAPE1K31/32A with purified re-
combinant SIRT1 protein and measured the acetylation level on 
K6/K7 through a specific antibody that recognizes only acetylation 
at these residues (Fantini et al., 2008; Sengupta et al., 2011). Of 
interest, although APE1WT was efficiently deacetylated by SIRT1 at 
K6/K7 (Figure 6A), the APE1K4pleA mutant did not show any deacety-
lation in this region; concomitant K-to-A substitutions at positions 
27 and 35 (APE1K27/35A mutant) or at positions 31 and 32 (APE1K31/32A 
mutant) caused an intermediate effect.
We then verified the ability of SIRT1 to directly deacetylate APE1 
at K27/K31/K32/K35 residues through in vitro deacetylation assays car-
ried out on acetylated purified recombinant rAPE1WT or mutant pro-
teins as substrates (Supplemental Figure S7). Protein acetylation 
level was monitored by using the anti-APE1K27-35Ac (Figure 6B). Incu-
bation with recombinant-purified SIRT1 protein revealed a marked 
decrease in acetyl-APE1 signal but only when APE1WT was used. 
These data were corroborated by qualitative peptide mapping ex-
periments on in vitro–acetylated rAPE1WT before and after incuba-
tion with SIRT1. This analysis demonstrated that SIRT1 was indeed 
able to deacetylate in vitro–acetylated rAPE1WT at least at K25/K27/
K32 residues (Supplemental Table S1).
The ability of SIRT1 to deacetylate in vitro APE1 at K27/K31/K32/K35 
was also analyzed on APE1 (25–38) peptides (Figure 6C), which were 
chemically synthesized either in their nonacetylated or tetra-acety-
lated form at these K residues. These peptides were used in a com-
petitive fluorescence-based assay in which a fluorogenic p53 acety-
lated peptide was used as SIRT1 substrate (Marcotte et al., 2004). 
As expected, we observed a dose-dependent decrease in the 
Cell viability experiments, after MMS treatment, were carried out 
to verify the enzymatic data. Thus, the effect of K27/K31/K32/K35 mu-
tation on cell viability after MMS treatment was measured by 
3-(4-5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium salt (MTS) and clonogenic assays using the 
reconstituted cell clones. The MTS data (Figure 5C) showed that the 
APE1K4pleA-mutant–expressing cells were significantly more resistant 
to MMS treatment than those expressing the nonacetylatable 
APE1K4pleR mutant. Of note, clonogenic assay experiments (Figure 
5D) confirmed these results and highlighted the relevant acetylation 
occurring at the K residues, as demonstrated by the higher sensitiv-
ity of APE1K4pleR-expressing cells after MMS treatment. We extended 
our observations on the protective function of the APE1K4pleA mutant 
by using tert-butyl-hydroperoxide (TBHP) as a reactive oxygen spe-
cies (ROS) generator (Lazzé et al., 2003). We recently demonstrated 
that APE1 knockdown sensitizes HeLa cells to TBHP treatment (Li 
et al., 2012). Therefore we now measured the sensitivity of the differ-
ent reconstituted cell clones to TBHP in a dose–response experi-
ment (Figure 5E). As in the case of MMS treatment, expression of the 
APE1K4pleA mutant exerted a protective function with regard to TBHP 
treatment with respect to APE1WT-expressing cells. Similarly to MMS 
treatment, the APE1K4pleR-mutant–expressing clone evidenced even 
more sensitivity than the APE1WT-expressing one. Taken together, 
these data show that acetylation at residues K27/K31/K32/K35 is asso-
ciated with cell response to DNA damage and confers protection to 
genotoxic treatment. The increased activity of the APE1K4pleA mutant 
may explain its proficient protective effect in vivo against genotoxic 
treatment, even though further explanatory mechanisms, such as its 
altered protein association in the cell or its possible higher stability 
(Vascotto et al., 2011), could also be invoked.
K6/K7 deacetylation by SIRT1 is modulated by the charged 
status of K27/K31/K32/K35residues
It was recently demonstrated that APE1 K6/K7 may undergo acety-
lation during cell response to genotoxic treatment (Fantini et al., 
2008; Yamamori et al., 2010) and that modulation of the acetyla-
tion status of these residues through SIRT1 deacetylase activity is 
important for the regulation of APE1 DNA-repair function after 
MMS treatment (Yamamori et al., 2010). However, the molecular 
mechanism regulating the SIRT1-mediated modification at these 
significant difference between APE1WT and APE1K4pleA. (B) Accumulation of genomic abasic (AP) lesions after MMS 
treatment (0.5 mM, 4 h) of reconstituted cell clones with APE1WT and APE1K4pleA mutant as measured by an aldehyde-
reactive probe. APE1WT and APE1K4pleA-expressing HeLa cells were grown in medium supplemented with Doxy (10 d) to 
silence endogenous APE1 expression and were treated with 0.5 mM MMS for 4 h. Counting at the AP sites was 
performed by using the AP-site quantification kit, as described in Materials and Methods. In the histogram, data are 
expressed as number of AP sites per 105 base pairs and represent the mean ± SD of four independent experiments. 
Asterisks represent a significant difference between the two conditions (untreated and MMS-treated cells). (C) Effects of 
APE1 acetylation mutants on cell viability after MMS treatment in reconstituted cells. APE1WT, APE1K4pleA-, and 
APE1K4pleR-expressing cells were grown in medium supplemented with Doxy to silence APE1 endogenous protein and 
treated with increasing concentrations of MMS for 8 h; the cytotoxic effect of this compound was determined by the 
MTS assay (see Materials and Methods for details). Each point, shown as percentage viability with respect to untreated 
clones, represents the mean ± SD of four observations, repeated in at least two independent assays. Asterisks represent 
a significant difference between APE1K4pleA and APE1K4pleR mutants. (D) Cell growth as measured by colony survival 
assay. One thousand cells of APE1WT-, APE1K4pleA-, and APE1K4pleR-expressing clones treated with increasing 
concentrations of MMS for 8 h were seeded in Petri dishes and then treated with Doxy for 10 d to silence endogenous 
APE1. Data, expressed as the percentage of change with respect to untreated clones, are the mean ± SD of three 
independent experiments. (E) Effects of APE1 acetylation mutants on cell viability after TBHP treatment in APE1WT-, 
APE1K4pleA-, and APE1K4pleR-expressing cells grown in medium supplemented with Doxy to silence APE1 endogenous 
protein. Cells were treated with increasing concentrations of TBHP for 6 h, and the cytotoxic effects were determined 
by the MTS assay. Each point, shown as percentage viability with respect to untreated clones, represents the mean ± SD 
of four observations, repeated in at least two independent assays. Asterisks represent a significant difference between 
APE1K4pleA and APE1K4pleR mutants.
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FIGURE 6: SIRT1 deacetylase activity on K6/K7 depends on the charged status of K27/K31/K32/K35 residues. (A) K6/K7 
acetylation, modulated by SIRT1, depends on the charged status of K27/K31/K32/K35 residues. Western blot analysis on 
purified recombinant APE1 proteins in vitro acetylated with acetyl-CoA and then incubated in the presence/absence of 
recombinant GST-SIRT1, as indicated. The analysis was carried out using an antibody specific for acetylated K6/K7 APE1 
(top). The histogram reports data obtained from densitometric quantification of the bands for each APE1 protein after 
normalization on Ponceau S staining (bottom). Data shown are the mean of two independent experimental sets whose 
variation was <10%. (B) SIRT1 deacetylates rAPE1 at K27/K31/K32/K35. Left, Western blot analysis on the in vitro–
acetylated and deacetylated purified recombinant APE1, further subjected to MS analysis (Supplemental Table S1). 
rAPE1WT was incubated with 0.5 mM acetyl-CoA and then with recombinant SIRT1 protein, as shown. Samples were 
separated onto 10% SDS–PAGE, and Western blot analysis was performed by using the anti-APE1K27-35Ac antibody. 
Ponceau S staining was used as loading control. Right, the histogram shows the densitometric quantification of the 
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could be responsible for APE1 subnuclear trafficking. Thus, we 
examined the subnuclear distribution of SIRT1 on c-myc-SIRT1–
transfected cells through immunofluorescence analysis. We found 
that transiently transfected c-myc-SIRT1 mainly localized in the nu-
cleoplasmic compartment and was not found in the nucleoli (Figure 
8A, left); quantification of the endogenous SIRT1 protein in bio-
chemically purified nucleoli confirmed its absence from this subnu-
clear compartment (Figure 8A, right). Evaluation of the acetylation 
status of APE1 present in nucleolar or nucleoplasmic fractions under 
basal conditions showed that APE1 acetylated at K6/K7 is mainly 
present within the nucleoplasm but almost absent in the nucleolus 
(Figure 8B). Of note, these findings may have important implications 
for SIRT1-mediated deacetylation at K6/K7 and demonstrate the 
possibility that APE1 acetylation modulates the protein’s subnuclear 
distribution and enzymatic functions, corroborating our previous 
work (Fantini et al., 2010).
It is known that Lys acetylation may control local conformational 
stability of proteins, thus affecting their activity, subcellular distribu-
tion, and protein–protein interaction network. To examine the effect 
of acetylation on the local structure of the N-terminal APE1 region, 
we analyzed the conformational behavior of the protein portion of 
residues 14–38, which contain K27/K31/K32/K35 residues acetylatable 
in vivo. To this end, we chemically synthesized and purified four 
peptides bearing differential acetylation at positions 27, 31, 32, and 
35 (Supplemental Table S2). To evaluate the effect of acetylation on 
peptide conformation, we undertook structural analysis of these 
peptides in solution by far-ultraviolet (UV) circular dichroism (CD) 
and nuclear magnetic resonance (NMR) spectroscopy. Figure 8C 
shows the overlay of CD spectra of APE1(14–38) and APE1(14–
38)K27/31/32/35Ac in aqueous buffer, indicating a minimum at ∼200 nm 
and a shoulder at ∼220 nm. These features suggest the presence of 
mixed conformational states in which an unfolded state coexists 
with a certain helical content. The propensity of this domain to 
adopt helical conformation was also confirmed by trifluoroethanol 
(TFE) titration experiments (Supplemental Figure S8A). In particular, 
the CD spectrum of the tetra-acetylated peptide showed a mini-
mum at 220 nm that was deeper than that of the nonacetylated 
counterpart, suggesting a role for the acetyl groups in determining 
structural changes in this protein region. An intermediate behavior 
was observed for the monoacetylated and triacetylated peptides, 
confirming the role of this K modification in modulating the confor-
mation of the N-terminal APE1 region (unpublished data).
To further address this point, we carried out additional NMR ex-
periments. In aqueous buffer, the one-dimensional (1D) spectra pre-
sented poor signal dispersion (Figure 8D, left), confirming a rather 
disordered state for both the tetra-acetylated and nonacetylated 
peptides. This observation was further strengthened by the analysis 
of two-dimensional (2D) [1H, 1H] total correlation spectroscopy 
(TOCSY) spectra (Griesinger et al., 1988; Figure 8D, middle), and 2D 
[1H, 1H] rotating frame nuclear Overhauser effect spectroscopy 
(ROESY) spectra (Bax and Davis, 1985; Figure 8D, right). In the latter 
case, the presence of a restricted set of cross-peaks in the NH-aliphatic 
side-chain proton correlation region made unfeasible the process of 
sequential resonance assignments, as often occurs for small, flexible 
fluorescence signal by using different amounts of the tetra-acety-
lated peptide (25–38); the nonacetylated counterpart was used as 
a negative control substrate. Best data fitting was observed with a 
one-site competition equation, which provided an IC50 value of 
4.6 ± 0.3 μM. These data support the conclusion that the acety-
lated APE1 region spanning amino acids 27–35 is a substrate for 
SIRT1 deacetylase activity. Taken together, these results demon-
strate that SIRT1’s ability to efficiently deacetylate APE1 at K6/K7 
residues relies on the presence of positive charges at K27/K31/K32/
K35. Moreover, SIRT1 is also able to bind and possibly deacetylate 
in vitro–acetylated APE1 K27/K31/K32/K35 residues.
Cross-talk between the charged state of K27/K31/K32/K35 and 
the acetylation status of K6/K7 residues through SIRT1
To understand whether SIRT1 activity on acetylated K6/K7 residues 
might be modulated in vivo by MMS as a function of the charged 
status of K27/K31/K32/K35, we performed coimmunoprecipitation 
experiments on transiently transfected HeLa cells. As shown in 
Figure 7A, an intact N-terminal domain is required for stable APE1 
binding to SIRT1. The APE1/SIRT1 association was induced after 
MMS treatment and was abolished in the case of both APE1NΔ33 
and APE1K4pleA mutants. Substitution of K27/K31/K32/K35 residues 
with nonacetylatable R residues was ineffective, suggesting that 
SIRT1 binding depends on the presence of positively charged 
amino acids spanning the APE1 region 27–35. Measurements of 
K6/K7 acetylation status with the specific antibody (performed on 
the same samples) clearly showed that, in agreement with the 
binding data, K6/K7 residues resulted in more acetylation both un-
der basal and after MMS treatment but only in the case of the 
APE1K4pleA mutant. In addition, the acetylation status of APE1WT 
and APE1K4pleR, both under basal conditions and after MMS treat-
ment, was comparable (Figure 7B), supporting the existence of 
cross-talk between the charged status of K27/K31/K32/K35 and the 
acetylation level of K6/K7.
We then investigated the cross-talk between K6/K7 and K27/K31/
K32/K35 acetylation status through siRNA experiments. HeLa cell lines 
stably expressing both endogenous APE1 and APE1WT, APE1K4pleA, 
and APE1K4pleR ectopic forms were silenced for SIRT1 expression as 
described in Materials and Methods. The acetylation level of K6/K7 
was then measured through Western blotting. Data shown in Figure 
7C demonstrate that the K6/K7 acetylation level of the ectopic APE1 
forms was increased ∼30–40% upon SIRT1 silencing but only in the 
case of APE1WT- and APE1K4pleR-expressing cells, whereas acetylation 
of K6/K7 of APE1K4pleA was <10%. As a control, the acetylation level 
of endogenous APE1 always increased (∼60–70%) upon SIRT1 si-
lencing in all the cell lines tested (unpublished data). Taken together, 
these data demonstrate that the acetylation/charged status of K27/
K31/K32/K35 residues controls the stability of the SIRT1/APE1 com-
plex, thus playing a role in the acetylation level of K6/K7.
Possible relevance of acetylation for APE1 subnuclear 
distribution and protein local conformation
The data suggest that a coordinated acetylation/deacetylation dy-
namic modulated by SIRT1 may occur within the cell nucleus and 
band intensities, after normalization to the nonacetylated APE1 form, of the in vitro–acetylated and deacetylated 
purified APE1 mutants. Data are the mean ± SD of three independent replicates. Asterisks represent a significant 
difference. (C) The acetylated APE1 25–38 peptide is a substrate of SIRT1 activity. Purified APE1 peptides (25–38) either 
in fully acetylated form at K27/K31/K32/K35 residues or not acetylated were analyzed as competitors in an in vitro 
deacetylase SIRT1 assay based on a fluorogenic acetylated peptide derived from p53 (region 379–382). Dose–response 
signals allowed an estimated IC50 value of 4.6 ± 0.3 μM of the acetylated APE1 25–38 region with respect to the p53 
peptide.
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FIGURE 7: Cross-talk between the acetylation status of K27/K31/K32/K35 and K6/K7 residues through SIRT1. 
(A) Positive charges at K27/K31/K32/K35 residues strongly influence the stability of SIRT1 binding to APE1. Western 
blot analysis performed on total cell extracts (left) and on immunoprecipitated material (right) from HeLa cells 
cotransfected with c-myc–tagged SIRT1 and APE1WT, APE1NΔ33, APE1K4pleA, or APE1K4pleR FLAG-tagged proteins and 
treated with 0.5 mM MMS for 8 h. Coimmunoprecipitated amounts of SIRT1 normalized with respect to APE1WT or 
APE1K4pleR, respectively, are indicated under each relative bar. Ponceau S staining was used as loading control. 
(B) Acetylation level of K6/K7 in APE1K4pleA mutant is higher than that of APE1WT both under basal conditions and 
after MMS treatment. Western blot analysis on CoIP material after MMS treatment from HeLa cells transfected with 
APE1WT and FLAG-tagged mutants is shown. The histogram indicates the relative amount of acetylated APE1K6/K7 in 
the different clones obtained from the densitometric quantification of acetylated APE1 bands, normalized with 
respect to the amount of APE1 FLAG-tagged immunopurified protein. Data shown are the mean of two 
independent experimental sets whose variation was <10%. (C) SIRT1 siRNA knockdown increases APE1 K6/K7 
acetylation. HeLa stable clones expressing APE1WT, APE1K4pleA, and APE1K4pleR were transfected with siRNA against 
SIRT1 protein or control siRNA. Western blot analysis was performed to detect differential amount of the 
acetylated K6/K7 APE1 after SIRT1 silencing. Arrows highlight bands of ectopic APE1 protein form; β-tubulin was 
used as a loading control. The histogram shows densitometric quantification of acetylated K6/K7 APE1 form. Data 
are expressed as percentage of induction of the acetylated K6/K7 APE1 after SIRT1 silencing after normalization 
for the total APE1 protein levels. Data shown are the mean of two independent experimental sets whose variation 
was <10%.
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to our previous data obtained in vitro with recombinant purified pro-
teins (Fantini et al., 2010). In many cases, the presence of the unstruc-
tured N-terminal domain of APE1 seemed essential for interaction of 
APE1 with different substrates (i.e., nucleic acids or proteins). Interac-
tion also increased after histone deacetylase (HDAC) inhibition, 
which promotes APE1 acetylation at K6/K7 residues (Bhakat et al., 
2003; Yamamori et al., 2010). This evidence strongly support the no-
tion that this unstructured domain is responsible for the modulation 
of APE1’s different functions through the recruitment of APE1 in dif-
ferent protein complexes by means of various amino acid side-chain 
modification events. From an evolutionary perspective, it can be hy-
pothesized that mammalian APE1 activity was made adjustable 
(through PTMs and/or interaction with other proteins), or expanded 
toward other substrates, with the acquisition of a protein N-terminus 
containing positively charged residues, without major modifications 
on the enzyme catalytic site, which retained the “canonical” function 
toward abasic DNA. The existence of such an N-terminal extension 
in only mammals may suggest its evolutionary significance in the 
face of increased functional complexity. For the noncomplexed pro-
tein in solution, the intrinsic lack of a secondary structure associated 
with this domain can confer functional advantages to mammalian 
APE1, including the ability to bind to different protein targets (e.g., 
NPM1, XRCC1, CSB, RNA, etc.; Vidal et al., 2001; Wong et al., 2007; 
Vascotto et al., 2009a; Tell et al., 2010a), thus allowing efficient con-
trol over the thermodynamics in the binding process to different sub-
strates. Because the protein’s N-terminus is required for the stabiliza-
tion of APE1 interaction with NPM1 or rRNA and for the control of 
the overall endonuclease activity (possibly decreasing the rate of 
product release once in the positively charged state; Fantini et al., 
2010; Figure 5), this region-specific multitasking function can provide 
a “trigger” for molecular regulation with important biological signifi-
cance. This should be regarded, however, in light of BER coordina-
tion to prevent formation of harmful, unprotected DNA strand 
breaks. Therefore subcellular distribution of APE1 and its enzymatic 
activity seem to be finely tuned to demand and in a time-dependent 
manner through multiple interactions with various protein partners 
and the coordinated occurrence of different PTMs, such as acetyla-
tion and ubiquitination (Busso et al., 2009, 2011). The observation 
that acetylation at K27/K31/K32/K35 residues may favor a transition to-
ward a more organized conformation (Supplemental Figure S8) 
would support the notion that this modification may significantly 
modulate the interaction with several protein partners on a structural 
basis. In addition, acetylation at the mentioned K residues may pro-
foundly affect APE1 protein stability, based on a recent report show-
ing that the same K residues can be also polyubiquitinated by UBR3, 
targeting the protein for degradation by the proteasome (Meisenberg 
et al., 2011). Given that acetylation competes with ubiquitination for 
the same K residues, it may represent the switch for controlling pro-
tein turnover rate. In this context, the acetylation at these residues 
that we observed during cell response to genotoxicants may stabilize 
protein half-life, thus preventing its degradation.
Few studies have reported on the effect of acetylation on the 
structure of small, ordered (Hughes and Waters, 2006; Liu and Duan, 
2008) and disordered (Smet-Nocca et al., 2010) peptides. Molecular 
dynamic simulations carried out on a peptide from the histone H3 
N-terminal tail in the nonacetylated and doubly acetylated forms 
revealed that acetylation, although not appreciably disturbing the 
overall structure of the most-populated states, influenced peptide 
stability (Liu and Duan, 2008). The effect of acetylation at K residues 
on the conformational properties of small random-coil peptides 
from the histone H4 N-terminal tail and from nonhistone thymine 
DNA glycosylase indicated that acetylation had little effect on the 
peptides that tumble very rapidly in solution. On the other hand, a 
detailed comparison of the 1D NMR data for the nonacetylated and 
tetra-acetylated APE1 peptides (Figure 8D, left) indicated that acety-
lation causes a small but clear improvement of spectral dispersion, 
which can be particularly appreciated in the NH region (Figure 8D, 
top left). Moreover, the intensity of ROE cross-peaks is increased in 
the spectra of APE1(14-38)K27/31/32/35Ac peptide as compared with the 
nonmodified counterpart (Figure 8D, right). This evidence, together 
with small chemical shift changes, point toward the presence of more 
organized conformations for the tetra-acetylated peptide in aqueous 
solution, in agreement with CD data. Similar conclusions are drawn 
from the analysis of NMR data for APE1(14–38) and APE1(14–
38)K27/31/32/35Ac peptides in phosphate:TFE solution (Supplemental 
Figure S8B), which suggested again the higher propensity of this 
domain in its acetylated form to adopt a more ordered conformation 
in contrast to the nonmodified counterpart. Also in this case, 
monoacetylated and triacetylated peptides showed an intermediate 
behavior (unpublished data). These data suggest that acetylation 
may account for local conformational changes on APE1 structure that 
may modulate its binding ability to different substrates.
DISCUSSION
APE1 is an unusually abundant DNA-repair protein in mammalian 
cells, with a wide nuclear distribution and an essential role in the 
BER pathway of DNA lesions (Tell and Wilson, 2010). We calculated 
that HeLa cells express ∼4 × 107 molecules per cell (Supplemental 
Figure S4A), whereas other enzymes of the BER pathway, such as Pol 
β or XRCC1, are present at an extent of <1/10 (Demple and DeMott, 
2002; Parsons et al., 2008). Therefore APE1 involvement in pre-
formed DNA-repair complexes may only partially explain the energy 
cost used to maintain such high protein concentration within the 
cells. Recently we found that APE1 may interact with rRNA and with 
proteins involved in RNA metabolism and is associated with nucleo-
lar structures through its interaction with NPM1 (Vascotto et al., 
2009b; Tell et al., 2010b). Interaction with rRNA and NPM1 strictly 
depends on the positive charge of K residues within the APE1 region 
24–35 placed within the unstructured protein N-terminal domain, as 
demonstrated by the inability of the corresponding K-to-A mutants 
(resembling constitutive acetylation at these residues) to stably bind 
both rRNA and NPM1 (Fantini et al., 2010). Of interest, some of 
these amino acids (i.e., K27/K31/K32/K35), which have been acquired 
during evolution, may undergo in vivo acetylation (Fantini et al., 
2010). We conjectured that, under physiological conditions, non-
acetylated APE1 may be stored in the nucleolar compartment 
through its binding to NPM1 and rRNA, but the in vivo relevance of 
APE1 nucleolar accumulation was still unclear. This study was aimed 
at addressing this issue.
We also found that APE1K4pleA binds poorly to NPM1 and rRNA in 
vivo and as a result is unable to accumulate within the nucleoli, 
whereas it is present in the nucleoplasm. Moreover, reconstitution of 
HeLa cells with this mutant gave improved protection from geno-
toxic damage induced by alkylating agents, such as MMS, and oxida-
tive stress-generating compounds, such as TBHP, through increased 
DNA-repair activity. As expected for a regulated pheno menon such 
as the response to a genome insult, an in vivo–augmented acetyla-
tion at K27/K31/K32/K35 residues was observed during cell response to 
genotoxic damage. Furthermore, cross-talk involving the SIRT1 
deacetylase occurred within cells between acetylation at K27/K31/K32/
K35 and at K6/K7 residues. Therefore we hypothesized that genotoxic 
stress may shift the equilibrium between the nonacetylated and 
acetylated APE1 forms toward the latter, which would result in the 
most enzymatically active one on abasic DNA. This also corresponds 
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FIGURE 8: Nucleolar APE1 hypoacetylated on K6/K7 and conformational impact of acetylation at K27/K31/K32/K35 on 
APE1 local structure. (A) SIRT1 resides within the nucleoplasm of HeLa cells. Left, confocal microscopy of HeLa cells 
cotransfected with green fluorescent protein–fused APE1 (APE1GFP) and c-myc-SIRT1 after fixing and staining with 
antibodies against NPM1 (red) and c-myc-SIRT1 (top, green; bottom, red). SIRT1, clearly excluded from nucleoli, 
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This is also underway in our laboratory. Of note, data obtained in 
this work not only show that nucleoli may act as a storage site so that 
an appropriate amount of APE1 is readily available for maintenance 
of genome stability, but also emphasize that nucleolar accumulation 
of APE1 controls cell proliferation, possibly through its rRNA cleans-
ing function. Compatible with this, APE1K4pleA-expressing cells, un-
der basal conditions, showed impairment in proliferation rate with 
respect to APEWT-expressing ones (Figure 3). Therefore it can be 
speculated that nucleolar APE1 is responsible for functional activity 
of the nucleolus in ribosome biogenesis. APE1 release from the nu-
cleoli after genotoxic treatment may constitute a signal to block ac-
tive protein synthesis and allow activation of the proper DNA-repair 
mechanisms. Experiments are in progress along these lines to ad-
dress this in light of the possibility that acetylation may control the 
APE1 trafficking from nucleoli to nucleoplasm.
In conclusion, our data shed light on novel molecular aspects 
highlighting the multifunctional nature of APE1 in regulating differ-
ent biological outcomes and point to acetylation as an important 
mechanism for the fine-tuning of protein functions, subcellular dis-
tribution, and stability. They also emphasize the need for additional 
investigation of the APE1 N-terminal domain in order to understand 
the structural details of the regulatory mechanisms for this multi-
functional protein. In addition, recent evidence on APE1 acetylation 
pattern in triple-negative breast cancer reveals that, concomitantly 
with total APE1 overexpression, a profound deregulation of APE1 
acetylation status occurs under pathological conditions (Poletto 
et al., 2012). This underscores the biological relevance of our find-
ings and the need for future investigation.
MATERIALS AND METHODS
Inducible APE1 knockdown and generation of APE1 
knock-in cell lines
Inducible silencing of endogenous APE1 and reconstitution with 
mutant proteins in HeLa cell clones was performed as described 
(Vascotto et al., 2009a,b) and as reported in the Supplemental 
Information. For inducible shRNA experiments, doxycycline (1 μg/ml; 
Sigma-Aldrich, St. Louis, MO) was added to the cell culture medium, 
and cells were grown for 10 d. All biological data were reproduced 
in at least two different cell clones for each model.
Cell culture and transient transfection with plasmids 
or siRNA knockdown
HeLa cells were grown in DMEM (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (EuroClone, Milan, Italy), 
100 U/ml penicillin, and 100 μg/ml streptomycin sulfate. One day 
overall polypeptide structure, while inducing local conformational 
changes (Smet-Nocca et al., 2010). In agreement with these studies, 
APE1(14–38) and APE1(14–38)K27/31/32/35Ac became disordered, as 
shown by the lack of ROE (Bax and Davis, 1985) cross-peak patterns, 
which are characteristic of ordered secondary structure elements. 
However, small differences in the NMR spectra (Figure 8 and Sup-
plemental Figure S8), concerning both chemical shift values and 
signal intensities, seem to indicate that at least local conformational 
changes may occur following acetylation. We cannot ignore that 
these changes may be important for the interaction of APE1 with 
SIRT1 deacetylase and with NPM1; they highlight the role that the 
charged status of K residues within this region may play at the pro-
tein structural level. Based on our data, it can be speculated that full 
acetylation of K27–35 may reduce SIRT1 binding to APE1, thus delay-
ing its enzymatic activity on K6/K7. This mechanism could represent 
a way to coordinate the kinetics of the overall acetylation status of 
the protein. According to this hypothesis, SIRT1 should first deacety-
late K27–35Ac before deacetylating K6/K7Ac. Our ability to identify 
APE1 peptides with varying amounts of acetylation on K27–35 sup-
ports the existence of a dynamic equilibrium between multiple 
acetylated forms of the protein within cells and thus its functional 
regulatory role. Moreover, the presence of SIRT1, found exclusively 
in the nucleoplasm but not in the nucleoli (similar to the APE1 acety-
lated on K27–35 and the reduced nucleolar presence of APE1 acety-
lated on K6/K7; Figure 8, A and B), suggests that acetylation of APE1 
may force its exit from nucleoli to nucleoplasm, where it can be 
deacetylated by SIRT1. This model is further supported by the sig-
nificantly reduced interaction of AcAPE1K27-35 with NPM1 (Figure 2). 
Further studies to identify the acetyltransferase able to acetylate 
APE1 within the nucleoli are in progress. Furthermore, this work sup-
ports findings by Yu et al. (2010), who demonstrated that these K 
residue conformational adjustments were concomitant with DNA 
binding and catalysis or with interaction with Pol β.
The nucleolar role of APE1 storage and regulation, as described 
here, may have profound biological consequences during cell re-
sponse to stressor signals, especially in light of recent evidence 
pointing to the nucleolus as a central hub in DNA damage 
(Nalabothula et al., 2010). Accordingly, the nucleolus seems respon-
sible for actively transmitting signals to the molecular complex regu-
lating p53 activity mediated by ARF–NPM1 interaction (Colombo 
et al., 2002; Lee et al., 2005; Nalabothula et al., 2010), and thus it is 
involved in the maintenance of genome stability. A careful elucida-
tion of the NPM1-ARF-p53 signaling networks and their involve-
ment in the DNA-repair pathway coordinated by APE1 is an impor-
tant subject for molecular carcinogenesis and deserves further study. 
colocalizes with APE1 in the nucleoplasm. The inner part of nucleoli, marked in the granular zone by NPM1, is negative 
for SIRT1. Right, biochemical isolation of nucleoli confirms that SIRT1 localizes in the nucleoplasmic fraction and it is 
excluded from nucleoli, where nucleolin, NPM1, and APE1 reside (see Materials and Methods for details). Nucleolin was 
used as a positive control for nuclear and nucleolar compartment. (B) Acetylated K6/K7-containing APE1 is enriched 
within the nucleoplasmic compartment with respect to nucleoli. After normalization for total APE1 protein amount, the 
levels of acetylated APE1 in nucleolar and nucleoplasmic fractions were analyzed through Western blotting. APE1 
acetylated at K6/K7 residues is predominately present within the nucleoplasmic fraction, whereas it is reduced in the 
nucleolar fraction. The histogram indicates the relative percentage amount of acetylated APE1 obtained from the 
densitometric quantification of acetylated APE1 bands normalized with respect to the amount of total APE1 in each 
fraction. Each bar represents the mean of two independent experiments whose variation was <10%. (C) CD spectra of 
the APE1(14–38) and APE1(14–38)K27/31/32/35Ac peptides in 10 mM phosphate buffer, pH 7. (D) Comparison of 1D (left), 
2D [1H, 1H] TOCSY (middle), and 2D [1H, 1H] ROESY (right) spectra of APE1(14–38) and APE1(14–38)K27/31/32/35Ac peptides 
in 10 mM phosphate buffer, pH 7.0. Two different expansions of the proton 1D spectrum are shown; the region 
between 0.8 and 2.4 ppm, in the lower inset, contains signals from side-chain protons. Acetyl methyl groups originate a 
peak around 2 ppm, which can be clearly seen in the spectrum of the acetylated peptide; peaks of backbone and 
side-chain NH atoms appear between 7.0 and 8.8 ppm in the upper inset. For 2D [1H, 1H] TOCSY and 2D [1H, 1H] ROESY 
experiments the HN-aliphatic protons correlation region of the spectra are reported.
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ing the ECL enhanced chemiluminescence procedure (GE Health-
care Piscataway, NJ) or Western Lightning Ultra (PerkinElmer, 
Waltham, MA). Normalization was performed by using a monoclonal 
anti-tubulin antibody (Sigma-Aldrich). Blots were quantified by using 
a Chemidoc XRS video densitometer (Bio-Rad, Hercules, CA).
Plasmids and expression of recombinant proteins
Expression and purification of recombinant proteins from E. coli 
were performed as previously described (Vascotto et al., 2009b; 
Fantini et al., 2010). Where recombinant proteins were used for in 
vitro assays, the acronym rAPE1 is used.
GST pull-down assay
A 150-pmol amount of either GST-tagged rAPE1WT or mutant pro-
teins was added to 15 μl of glutathione–Sepharose 4B beads (GE 
Healthcare), together with equimolar amounts of recombinant 
NPM1. Binding was performed in PBS, supplemented with 1 mM 
dithiothreitol (DTT) and 0.5 mM phenylmethylsulfonyl fluoride 
(PMSF) for 2 h, under rotation, at 4°C. Beads were washed three 
times with PBS, supplemented with 0.1% (vol/vol) Igepal CA-630 
(Sigma-Aldrich), 1 mM DTT, and 0.5 mM PMSF and resuspended in 
Laemmli sample buffer for Western blot analysis.
DNA–RNA ChIP assays
DNA–RNA ChIP assays were carried out by using a modified version 
of a protocol described earlier (Gilbert et al., 2000) and as detailed 
in the Supplemental Information.
Enzymatic fluorescence assays
To examine in vitro deacetylase activity on the acetylated APE1 re-
gion 25–38, we used the SIRT Fluorescent Activity Assay Kit (Biomol, 
Plymouth, PA). Optimizing manufacturer’s instructions, we used 
white plates (OPTI PLATE; PerkinElmer) with 384 wells at reduced 
volume (total reaction volume, 20 μl). Purified peptides were incu-
bated in 25 mM Tris-HCl, pH 8.0, 2.7 mM KCl, 137 mM NaCl, 1 mM 
MgCl2, and 1 mg/ml bovine serum albumin containing the enzyme 
(0.04 U/μl) and 25 μM Fluor de Lys-p53 peptide substrate (Arg-His-Lys-
Lys [Ac], from region 379–382 of human p53) in the presence/
absence of 250 μM NAD+ for 30 min at 37°C. Deacetylase activity 
was measured in arbitrary fluorescence units at 460 nm. Dose–
response experiments were carried out by using a 0–500 μM range 
of peptide concentration. Data fitting was performed using the 
GraphPad Prism 4 software, version 4.02 (GraphPad, La Jolla, CA). 
Data were in triplicate/duplicate from three independent assays.
Immunofluorescence confocal and proximity ligation 
analyses
Immunofluorescence procedures and PLA were carried out as de-
scribed earlier (Vascotto et al., 2009b, 2011). To study the interaction 
between APE1 and NPM1 in vivo, we used the in situ Proximity 
Ligation Assay technology (Olink Bioscience, Uppsala, Sweden). 
After incubation with monoclonal anti-APE1 (1:50) or anti-FLAG anti-
body (1:200) for 3 h at 37°C, cells were incubated with polyclonal 
anti-NPM1 (1:200) overnight at 4°C. PLA was performed following 
manufacturer’s instructions. Technical controls, represented by the 
omission of anti-NPM1 primary antibody, resulted in the complete 
loss of PLA signal. Cells were visualized through a Leica TCS SP laser-
scanning confocal microscope (Leica Microsystems, Wetzlar, 
Germany). Determination of PLA signals was performed using 
BlobFinder software (Center for Image Analysis, Uppsala University, 
Uppsala, Sweden). PLA technology was also used to detect acety-
lated APE1 at K27/K31/K32/K35 residues. Cells were incubated with the 
before transfection, cells were seeded in 10-cm plates at a density 
of 3.0 × 106 cells/plate. Cells were then transiently transfected 
with the indicated plasmids using the Lipofectamine 2000 reagent 
(Invitrogen), according to the manufacturer’s instructions. Cells were 
harvested either 24 or 48 h after transfection, as indicated.
For SIRT1-knockdown experiments, HeLa clones were trans-
fected with 150 nM siRNA siGENOME SMART pool or negative 
control siRNA 5′-CCAUGAGGUCAUGGUCUGdTdT-3′ (Dharmacon, 
Lafayette, CO), using Oligofectamine (Invitrogen). After 72 h the 
cells were harvested.
Preparation of total cell extracts and anti-FLAG 
coimmunoprecipitation
Preparation of total cell lysates and coimmunoprecipitation analyses 
were performed as described (Vascotto et al., 2009a,b).
Determination of AP endonuclease activity 
and abasic site assay
Determination of APE1 AP endonuclease activity was performed 
using an oligonucleotide cleavage assay, as described previously 
(Vascotto et al., 2009b) and detailed in the Supplemental 
Information.
Mass spectrometric analysis of APE1 acetylation
Characterization of APE1 acetylation was performed on the immu-
nopurified protein obtained from APE1-FLAG–expressing HeLa 
cells (Vascotto et al., 2009b). APE1 was resolved by SDS–PAGE; 
corresponding protein bands were excised, S-alkylated, and di-
gested with endoprotease AspN (Fantini et al., 2010). Digest ali-
quots were directly analyzed by nanoLC-ESI-LIT-MS/MS using an 
LTQ XL mass spectrometer (ThermoFisher Scientific, Waltham, MA) 
equipped with a Proxeon nanospray source connected to an Easy-
nanoLC (ThermoFisher Scientific; Arena et al., 2010; Scippa et al., 
2010), and analysis of APE1 acetylation was performed as described 
(D’Ambrosio et al., 2006) and detailed in the Supplemental Infor-
mation. A semiquantitative measurement of the amino acid modifi-
cation was obtained by extracting and integrating nanoLC-ESI-LIT-
MS peak areas corresponding to m/z values of the modified and 
nonmodified peptides in the same total ion chromatogram (Salzano 
et al., 2011). Modification extent was then assayed by evaluating 
the peak area of the modified peptide with respect to that of the 
modified peptide plus that of the nonmodified peptide, assuming 
identical ionization properties for modified and nonmodified spe-
cies. All these analyses were performed in triplicate.
Antibodies for immunofluorescence and immunoblotting
Antibodies used were anti-NPM1 monoclonal, anti-nucleolin mono-
clonal (Zymed, Invitrogen), anti-FLAG peroxidase-conjugated, 
anti-GST peroxidase-conjugated, anti-SIRT1 polyclonal (Abcam, 
Cambridge, MA), anti–c-myc (Santa Cruz Biotechnology, Santa Cruz, 
CA), and anti–β-tubulin monoclonal (Sigma-Aldrich). Anti-APE1 
monoclonal (Vascotto et al., 2009a) and anti-APE1K6K7Ac (Bhakat et al., 
2003) were described previously. Anti-APE1K27-35Ac polyclonal anti-
body was generated by PRIMM (Milan, Italy; Poletto et al., 2012).
Western blot analyses
For Western blot analyses, the indicated amounts of cell extracts 
were resolved in 12% SDS–PAGE and transferred to nitrocellulose 
membranes (Schleicher & Schuell BioScience, Dassel, Germany). 
Membranes were blocked with 5% (wt/vol) nonfat dry milk in phos-
phate-buffered saline (PBS) containing 0.1% (vol/vol) Tween 20 and 
probed with the indicated antibodies; blots were developed by us-
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anti-APE1K27–35Ac rabbit-polyclonal antibody diluted 1:1500 and then 
with a mouse-monoclonal anti-APE1 antibody (1:27). PLA was sub-
sequently carried out following manufacturer’s instructions.
Confocal analyses of APE1-Dendra fusion protein through 
in vivo live imaging
For in vivo APE1-Dendra trafficking studies, HeLa cells were 
seated on glass-bottom Petri dishes (thickness #1.5; WillCo Wells, 
Amsterdam, Netherlands), transfected with APE1-Dendra con-
structs, and grown in the presence of DMEM without phenol red. 
A Leica TCS SP laser-scanning confocal microscope was equipped 
with a heating system (Incubator S) and a CO2 controller (CTI 
Controller 3700 digital) to maintain cells in optimal growing con-
ditions. Images were captured 24 h after transfection using a 63× 
oil fluorescence objective. For Dendra green fluorescence acqui-
sition a 488-nm argon laser was regulated at 10% of power with 
PTM 750 V.
Cell viability, cell growth, and clonogenic assays
Cell viability was measured by using the MTS assay (Celltiter 96 
Aqueous One solution cell proliferation assay; Promega, Madison, 
WI) on HeLa cells stably expressing APE1WT, APE1K4pleA, and 
APE1K4pleR proteins grown in 96-well plates. After MMS (Sigma-
Aldrich) treatment or TBHP (Sigma-Aldrich), the MTS solution was 
added to each well and the plates were incubated for 2 h. Absor-
bance was measured at 490 nm by using a multiwell plate reader. 
The values were standardized to wells containing media alone.
Cell growth assays were performed as described (Vascotto et al., 
2009a,b) and detailed in the Supplemental Information, and clono-
genic assays were performed according to Plumb (1999) and essen-
tially as described previously (Vascotto et al., 2009a,b).
Circular dichroism spectroscopy
CD spectra were recorded on a Jasco J-810 spectropolarimeter 
(Jasco, Tokyo, Japan) at 25°C in the far-UV region from 190 to 260 nm. 
Each spectrum was obtained by averaging three scans, subtracting 
contributions from the corresponding blanks, and converting the sig-
nal to mean residue ellipticity in units of deg-cm2 dmol−1 res−1. Other 
experimental settings were 20 nm/min scan speed, 2.0 nm band-
width, 0.2 nm resolution, 50 mdeg sensitivity, and 4 s response. Pep-
tide concentration was kept at 100 μM, and a 0.1 cm path-length 
quartz cuvette was used. Spectra were acquired in 10 mM phosphate 
buffer, pH 7.0, containing various percentages of TFE.
NMR spectroscopy
NMR samples were prepared by dissolving APE1 peptides (1.5– 
2 mg) either in 600 μl of a 10 mM phosphate buffer, pH 7, contain-
ing 10% (vol/vol) D2O or in a mixture of 10 mM phosphate buf-
fer:2-2-2 trifluorethanol-d3 (98% deuterium; Armar Chemicals, 
Döttingen, Switzerland) 70:30 (vol/vol). The 2D [1H, 1H] TOCSY 
spectra (1024 × 256 total data points, 32 scans per t1 increment, 
70 ms mixing time; Griesinger et al., 1988) were recorded at 298 K 
on a Varian UNITYINOVA 600 spectrometer (Palo Alto, CA) equipped 
with a cold-probe. The 1D proton (128 scans and a relaxation delay 
of 1.5 s) and 2D [1H, 1H] ROESY (2048 × 256 total data points, 
64 scans per t1 increment, 200 ms mixing time) spectra were ac-
quired at 298 K on a Varian UNITYINOVA 400 spectrometer provided 
with z-axis pulsed-field gradients and a triple-resonance probe. 
Water signal was suppressed by means of either double pulsed 
field gradient selective echo techniques (Dalvit, 1998) or continu-
ous wave irradiation. Varian software VNMRJ 1.1D was implemented 
for spectral processing. The programs MestRe-C2.3a (Universidade 
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Nucleophosmin (NPM1) is a key factor involved in fundamental biological processes. Mutations involving
the NPM1 gene are the most frequent molecular alterations in acute myeloid leukemia. Here we report a
biophysical characterization of NPM1 and of its domains in order to gain insights into the role that inter-
domain interactions plays in the protein stabilization. Thermal denaturation analyses show that the
N-terminal domain is endowed with an exceptional thermal stability, as it does not unfold in the inves-
tigated temperature range (20–105 C). This finding is corroborated by chemical denaturation experi-
ments showing that this domain is not significantly affected by the addition of 8 M urea. These results
are consistent with the chaperone function of NPM1. In line with literature data, the other folded domain
of the NPM1, a 3-helix bundle domain located at the C-terminus, shows a lower stability. Interestingly,
the chemical and thermal stability of this latter domain, which embeds natural mutations related to acute
myeloid leukemia, is influenced by the presence of other regions of the protein. Small but significant sta-
bilizations of the C-terminal 3-helix bundle are provided by the adjacent unfolded fragment as well as by
the rest of the protein.
 2012 Elsevier Inc. All rights reserved.1. Introduction
The large majority of proteins are multidomain proteins, as a re-
sult of complex gene duplication events [1]. In these proteins, each
domain may fulfill its own function independently, or may operate
in a concerted manner with its neighbors. For practical reason,
most of biochemical and structural studies are concentrated on
the analysis of individual domains. Therefore, the mutual influence
of individual domains in determining the functional properties of
multidomain proteins is an open question in many cases.
Nucleophosmin (NPM1), also known as nucleolar phosphopro-
tein B23 or numatrin, is a multidomain protein that is implicated
in many fundamental biological processes [2,3]. Physiologically,
NPM1, despite its nucleolar localization, shuttles constantly across
nucleolar, nucleoplasmic and cytoplasmic compartments. Thisll rights reserved.
1, Nucleophosmin; NPM1_fl,
117 of NPM1; NPM1C-Ter108,
3–294 of NPM1; NPM1C-Ter70,
243 of NPM1.
Marasco), luigi.vitagliano@shuttling activity of NPM1 is critical for most of its functions,
including regulation of ribosome biogenesis and control of
centrosome duplication. Deregulation of NPM1 is implicated in
the pathogenesis of several human malignancies. Indeed, NPM1
has been described both as an oncogene and as a tumor suppressor
depending on the cell type [4–6]. It is important to note that muta-
tions involving the NPM1 gene are the most frequent molecular
alteration in acute myeloid leukemia (AML) accounting for about
60% of cases (i.e. one-third of adult AML) [7].
From the molecular point of view, NPM1 has a modular struc-
ture (Fig. 1). The analysis of the protein sequence shows the pres-
ence of distinct domains [8]. The N-terminal domain (NPM1N-Ter
residues 1–117) is the oligomerization domain, that plays a crucial
role in the molecular chaperone activity of the protein [2]. The high
resolution three-dimensional structure of this domain shows that
the NPM1N-Ter pentamer is formed by monomers that fold into
an eight-stranded b-barrel with a jellyroll topology [9]. The analy-
sis of the crystal packing has also suggested that NPM1N-Ter has a
propensity to form decamers through the association of two
distinct pentamers [9]. These NPM1 oligomers are the structural
units that engage in interaction with several proteins including
protamines, protamine-like type proteins, APE1/Ref-1, etc. [10,11].
Fig. 1. Schematic organization of NPM1 domains. Models of the folded domains at the N- (residues 9–117) and the C-terminal (residues 243–294) of the protein are reported
in the insets. The DNA binding region recently identified by Federici et al. is shown in cyan [13].
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ments responsible for RNA/DNA recognition. NMR investigations
have shown that the last 53 C-terminal residues (NPM1C-Ter53) fold
in a 3-helix bundle [12]. Interestingly, mutagenesis studies, carried
out on the protein region containing last 70 C-terminal residues
(NPM1C-Ter70), have shown that the high affinity of NPM1 for
DNA is due to the region proceeding the 3-helix bundle (residues
225–243) [13], although it has been recently demonstrated that
no direct interaction is established by this fragment with the
DNA [14]. The central portion of NPM1 is characterized by the
presence of two acid domains (residues 119–133 and 161–188). Fi-
nally, the protein contains two nuclear export and two nuclear
localization signals.
It is important to note that the interest for this protein is not
only dictated by its multiple biological functions. In recent years,
this protein, and in particular its C-terminal region NPM1C-Ter53,
has been a valuable subject for understanding basic questions re-
lated to protein folding and stability [15,16]. In this scenario, we
here report an analysis of the thermal and chemical stability of
NPM1 full length and some of its domains. Present analyses dem-
onstrate that the N-terminal domain NPM1N-Ter is endowed with
an uncommon thermal stability. Moreover, the completely differ-
ent secondary structure content of the folded N- and C-terminal
domains and the presence of Trp residues exclusively in the
C-terminal region of the protein have provided the opportunity
to selectively analyze the folding state of different NPM1 domains,
and, specifically, to evaluate the stability of the 3-helix bundle in
different contexts. Our analysis suggests that the stability of this
motif, that embeds mutation sites related to AML, is affected by
the rest of the protein.
2. Materials and methods
2.1. Preparation of recombinant NPM1, NPM1N-Ter, and NPM1C-Ter108
NPM1 full-length (NPM1_fl residues 1–294), NPM1N-Ter (resi-
dues 1–117), and NPM1C-Ter108 (residues 188–294) constructs were
expressed and purified as HisTag-fusion proteins in Escherichia coli
BL21(DE3) following or adapting the procedure previously de-
scribed [11]. The quality of purification was checked by coomas-
sie-stained SDS–polyacrylamide gel electrophoresis (PAGE)
analysis. Extensive dialysis against PBS was performed to remove
any trace of imidazole from the purified proteins.
2.2. Chemical synthesis of the fragment 225–243 (Pep225–243)
The fragment 225–243 (QESFKKQEKTPKTPKGPSS) embedding
the K229–K230 motifs, that are essential for the high affinity
DNA binding by NPM1, was chemically synthesized. Reagents for
peptide synthesis (Fmoc-protected amino acids and resins,
activation and deprotection reagents) were from Novabiochem(Laufelfingen, Switzerland) and InBios (Napoli, Italy). Solvents for
peptide synthesis and HPLC analyses were from Romil (Dublin,
Ireland); reversed phase columns for peptide analysis and the LC–
MS systemwere from ThermoFisher (Milan, Italy). Solid phase pep-
tide syntheses were performed on a fully automated multichannel
peptide synthesizer Syro I (Multisynthech, Germany). Preparative
RP-HPLC were carried out on a Shimadzu LC-8A, equipped with a
SPD-M10 AV detector and with a Phenomenex C18 Jupiter column
(50  22 mm ID; 10 lm). LC–MS analyses were carried out on a LCQ
DECA XP Ion Trap mass spectrometer equipped with a OPTON ESI
source, operating at 4.2 kV needle voltage and 320 C with a com-
plete Surveyor HPLC system, comprised of MS pump, an autosam-
pler and a photo diode array (PDA). Narrow bore 50  2 mm C18
BioBasic LC–MS columns were used for these analyses.
The peptide was synthesized employing the solid phase method
on a 50 lmol scale following standard Fmoc strategies [17]. Crude
product was purified by RP-HPLC applying a linear gradient of 0.1%
TFA CH3CN in 0.1% TFA water from 5% to 65% over 12 min using a
semi-preparative 2.2  5 cm C18 column at a flow rate of 20 mL/
min. Peptide purity and identity were confirmed by LC–MS and
once purified it was lyophilized and stored at 20 C until use.
2.3. CD spectroscopy and thermal denaturation
Far-UV CD spectra were recorded on a Jasco J-810 spectropolar-
imeter (JASCO Corp) in the wavelength interval 195–260 nm. For
each spectrum the signal was converted to mean residue ellipticity
in units of deg cm2 dmol1 res1.
Experiments were performed employing protein concentrations
of 16 lM in 50 mM phosphate buffer at pH 7.0, 1 mM DTT using a
0.1 cm path-length quartz cuvette. Pep225–243 at 100 lM concen-
tration was tested using the same buffer and identical instrumen-
tal experimental conditions.
Thermal denaturation experiments were performed by follow-
ing the CD signal at 214 nm for NPM1N-Ter and at 222 nm for
NPM1_fl and NPM1C-Ter108.
Data were collected at 0.2 nm resolution, 20 nm/min scan
speed, 1.0 nm bandwidth and 4 s response. A Peltier temperature
controller was used to set up the temperature of the sample.
2.4. Chemically induced denaturation
A buffer solution containing 50 mM of sodium phosphate (pH
7.0) 1 mM DTT was used in chemical denaturation experiments.
Urea was purchased from Sigma and further purified by recrystal-
lization from ethanol/water (1:1) mixtures. Stock solutions of urea
were mixed with protein solutions to give a constant final value of
the protein concentration (8 lM). The final concentration of dena-
turant was in the range 0.0–8.0 M. Each sample was incubated
overnight. Longer incubation times led to identical spectroscopic
signals.
Table 1
Thermodinamic parameters of urea-induced denaturation of NPM1 and of its
truncated forms.
NPM1_fl NPM1C-Ter108 NPM1C-Ter70* NPM1C-Ter53*
m Value
(kcal mol1 M1)
0.66 ± 0.04 0.99 ± 0.03 0.93 ± 0.16 0.787 ± 0.07
DG (kcal mol1) 2.77 3.76 3.49 2.02
* Values are taken from Ref. [13].
Fig. 2. CD spectra registered at 20 C of the synthetic Pep225–243 (A) and NPM1_fl (B)
in 50 mM phosphate buffer 50 mM (pH = 7).
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tion were followed by fluorescence spectroscopy investigations
that were carried out at 25 C. In order to follow the signal of the
Trp residues located in the C-terminal domain, spectra for NPM1_fl
and NPM1C-Ter108 were recorded upon excitation at 295 nm. On the
other hand, for NPM1N-Ter, which does not contain Trp residues, an
excitation at 280 nm was employed. Spectra were recorded in the
300–400 nm wavelength range using a Varian Cary Eclipse spec-
trofluorimeter. The determination of the m values reported in
Table 1 was performed by using the linear extrapolation method
(LEM) as described by Pace [18]. DGwas calculated asmC1/2, where
C1/2 is the concentration of the denaturant at the denaturation
midpoint.
3. Results and discussion
3.1. NPM1 overall structure: insights from secondary structure
prediction and circular dichroism studies
Previous literature studies have highlighted the modular
domain organization of NPM1. Two structured domains at the
N- and the C-terminus have been identified. Interestingly these do-
mains are characterized by different types of secondary structure
elements (Fig. 1). Indeed, the N-terminal folded domain (residues
1–117) assumes essentially a b-structure [9], whereas the C-termi-
nal folded domain (residues 243–294) forms a well defined right
handed 3-helix bundle [12].
In order to check the presence of additional structured domains
within the protein, we performed a secondary structure prediction
session on NPM1 sequence by using the PSIPRED server (http://bio-
inf.cs.ucl.ac.uk/psipred/). As shown in Fig. S1, the program predicts
the occurrence of several b-strands in the 15–120 region of the
protein, in agreement with the structural data reported on the
N-terminal oligomerization domain. In line with previous observa-
tions [13], the server provides a convincing prediction of helical
regions that form the C-terminal bundle. These findings proved
the reliability of the prediction method employed in this analysis.
As shown in Fig. S1, PSIPRED also predicts that the central region of
the protein is essentially unfolded, as only minor and sporadic sec-
ondary structure elements with a low level of confidence are de-
tected. No secondary structure elements is detected in the region
225–243 (QESFKKQEKTPKTPKGPSS) preceding the three helix
bundle, which contains the motif responsible for the high affinity
DNA binding. The analysis of the circular dichroism spectrum of
Pep225–243 confirms that this fragments is intrinsically unfolded
since it presents a single minimum below 200 nm (Fig. 2A). This
observation is in line with the very recent finding that this region
is disordered in the NMR structure of NPM1C-Ter70 [14].
The circular dichroism spectrum of the full-length protein
NPM1_fl registered at 20 C in the far-UV exhibits a rather sharp
minimum centered at 205 nm and a broader one at 222 nm
(Fig. 2B). These features are indicative of the presence of both a
and b secondary structure elements. A quantitative estimation of
the secondary structure content, performed by using the software
distributed with the Jasco-810 spectropolarimeter, suggests that
the a-helix and the b-sheet contents are 14% and 34%, respectively.These values are in line with those derived from the crystallo-
graphic structures of the N- and C-terminal domains and by
assuming that the central region is unfolded. Under this hypothe-
sis, the number of residues in a-helix and in b-sheet is 45 and 75,
respectively. Taking into account the total number of the residues
in the protein (294) the a-helix and the b-sheet content is 15% and
26%.
Altogether these results corroborate the notion that the modu-
lar structure of NPM1 is characterized by regions endowed with
distinct structural properties. Indeed, an unfolded central region
separates two folded domains displaying different secondary
structure elements. This feature has been here exploited to follow
the behavior of a single domain in the context of the entire protein.
3.2. The N-terminal domain of NPM1 is endowed with a remarkable
structural stability
In line with literature crystallographic data, the CD spectrum of
NPM1 N-terminal domain (residues 1–117 and hereafter denoted
as NPM1N-Ter), characterized by the presence of a single minimum
at 214 nm, is suggestive of domain assuming a b structure (Fig. 3).
The analysis of NPM1N-Ter CD spectra as a function of temperature
clearly indicates that the protein is stable over a wide range of
temperatures. Indeed, no significant variations of the spectra are
detected in the interval 20–90 C (Fig. 3A). Moreover, the signal
at the minimum (214 nm) does not display any significant varia-
tion up to 105 C (Fig. 3A). The remarkable thermal stability of this
domain is in line with the chaperone function of NPM1. Indeed,
previous literature studies have unveiled the ability of this protein
to protect several proteins from aggregation and to preserve their
activity at high temperatures.
Fig. 3. Thermally induced denaturation of NPM1N-Ter, NPM1_fl, NPM1C-Ter108, in the presence of 50 mM sodium phosphate buffer (pH 7.0) and 1 mM DTT. Panels (A, C, and E)
report the evolution of the CD signal as function of temperature for NPM1N-Ter, NPM1_fl, NPM1C-Ter108, respectively. Panels (B, D, and F) report the overlay of CD spectra
recorded at different temperatures for NPM1N-Ter, NPM1_fl, NPM1C-Ter108, respectively.
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The dependence of NPM1_fl CD spectra with temperature is re-
ported in Fig. 3C. A clear transition is detected at 68.3 C. Interest-
ingly, the protein presents a significant level of residual secondary
structure upon heating (Fig. 3D). Taking into account the high ther-
mal stability of NPM1N-Ter, these data may be interpreted by
assuming that the observed transition corresponds to the unfold-
ing of the C-terminal domain of the protein. Literature data carried
out on the isolated C-terminal 3-helix bundle NPM1C-Ter53, under
the same experimental conditions here employed to characterize
the full-length protein, indicate an unfolding temperature below
60 C (see Fig. 2 of Ref. [16]). Altogether, these observations sug-
gest that the 3-helix bundle is stabilized in the protein context
by approximately 10 C. To identify the structural determinant of
this stabilization, we performed thermal denaturation analysis
on a domain containing the last 108 C-terminal residues
(NPM1C-Ter108) that follows the second acidic region of the protein.
Therefore, NPM1C-Ter108 includes, in addition to the 3-helix bundle,
residues 223–245 implicated in the high affinity binding of DNA as
well as the fragment 188–222. As shown in Fig. 3E, NPM1C-Ter108
presents a Tm of 64.3 C, a value that is intermediate between
those displayed by NPM1C-Ter53 and NPM1_fl. This finding indicates
that the presence of both the fragment 188–243 and the N-termi-
nal regions of the protein induce a stabilization of the C-terminal
3-helix bundle.
3.4. Chemical stability of NPM1N-Ter, NPM1_fl, and NPM1C-Ter108
The chemical stability of NPM1 domains was checked by using
urea as denaturant. For NPM1N-Ter, upon the addition of urea, spec-
tra were recorded after an excitation at 280 nm to measure the
fluorescence signal of the three Tyr residues located in this domain
(positions 17, 29, and 67). These denaturation experiments con-
firmed the uncommon stability of the NPM1N-Ter domain high-
lighted by the thermal analyses. Indeed, as shown in Fig. 4A and
B, no significant variation of the fluorescence signal was detected
after the addition of the denaturant. Moreover, the maximum of
the fluorescence signal, located at 310 nm, suggests that the
three Tyr residues are buried in the entire range of urea concentra-
tion tested (0–8 M).The particular distribution of Trp residues, that are exclusively
located in the C-terminal region of the protein (positions 288 and
290), allows the evaluation of the folding state of the C-terminal
domain in different contexts. Indeed, ad hoc excitation of Trp resi-
dues (using a radiation with a 295 nm wavelength) could provide
information about their local environments independently from
the presence of other protein domains. As shown in Fig. 4C, both
the intensity and the wavelength of the peak of the fluorescence
signal exhibited by NPM1_fl are strongly affected by the addition
of the denaturant. The comparison of the spectra of samples con-
taining the protein incubated with either 0 or 8 M urea shows a
clear increase of the peak intensity and a shift of its wavelength
to higher values. The shift of the wavelength of the maximum from
325 to 355 nm is indicative of a process in which the initially bur-
ied Trp residues are fully exposed after the addition of 8 M urea.
The analysis of the progression of the increase of the peak intensity
upon denaturant addition shows that denaturation midpoint (C1/2)
occurs at [urea] = 4.2 M (Fig. 4D).
In analogous experiments (Fig. 4E and F), the C1/2 exhibited by
NPM1C-Ter108 against urea denaturation is 3.8 M. This value is
virtually coincident with that found for NPM1C-Ter70 in experiments
carried out by following the CD signal at 222 nm [13]. On the other
hand, literature data show that NPM1C-Ter53 presents a much lower
value for [urea]1/2 2.6 M.
Taken together these findings show that the presence of the
fragment 225–243 and the N-terminal regions significantly
stabilizes the terminal 3-helix bundle also against chemical
denaturants. The similar stability exhibited by NPM1C-Ter70 and
NPM1C-Ter108 suggests that the fragment 188–225 does not provide
any further contribution to the 3-helix bundle stability.
The similarity of the denaturation process of NPM1C-Ter108 and
NPM1C-Ter70 is also confirmed by the analysis of the m values and
DG values reported in Table 1 Notably, NPM1_fl presents a lower
m value when compared to the truncated forms. Since the m value
is related to the change in solvent accessible surface area upon
denaturation, this observation suggests that the other regions of
the protein (the N-terminal domains and/or the central acidic re-
gion) influences the denaturated state of the C-terminal domain.
In conclusion, present investigations show that the individual
domains of NPM1 are endowed with different stabilities. Indeed,
the N-terminal domain is endowed with an extraordinary stability
Fig. 4. Effect of urea incubation for for NPM1N-Ter, NPM1_fl, NPM1C-Ter108, followed at pH 7.0 and 25 C in the presence of 50 mM sodium phosphate buffer (pH 7.0) and 1 mM
DTT. (A) Tyr fluorescence upon excitation at 280 nm after the treatment with urea in the concentration range 0–8 M for NPM1N-Ter. (B) Overlay of fluorescence spectra at of
NPM1N-Ter sample untreated (red) or incubated with 8 M urea (blue). Panels (C and E) Trp fluorescence upon excitation at 295 nm after the treatment with urea in the
concentration range for NPM1_fl and NPM1C-Ter108, respectively. (D and F) Overlay of the fluorescence spectra at of the protein sample untreated (red) or incubated with 8 M
urea (blue) for NPM1_fl, and NPM1C-Ter108, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
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with the chaperone role of this domain highlighted by literature
reports [3,19,20]. On the other hand, present and literature data
indicate that the C-terminal 3-helix bundle, which embeds natural
mutations causing severe human diseases, undergoes thermal
transitions in the temperature range 55–70 C, depending on the
presence of additional protein regions in the investigated con-
structs. Particularly significant is the increase of the thermal stabil-
ity of this domain likely due to the presence of the proximal
fragment 225–243. Although present data show that this latter re-
gion is intrinsically unfolded and that this fragment is disordered
in NPM1C-Ter70 [14], it confers an extra stability to the bundle of
about 8 C. The presence of the remaining regions of the protein
confers further stability to the C-terminal domain. Similar results
have been obtained by performing chemical denaturation experi-
ments. Present results suggest that the effects of natural mutations
linked to severe diseases located in NPM1 C-terminal domain
should be evaluated in vitro by considering the entire protein or
at least the C-terminal fragment 225–294. On more general basis,
the common practice of dissecting multi-domain proteins into
small fragments may, in some circumstances, be an oversimplifica-
tion that can lead to artifactual interpretations of the results.
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Role of the unstructured N-terminal domain of the hAPE1 (human
apurinic/apyrimidinic endonuclease 1) in the modulation of its interaction
with nucleic acids and NPM1 (nucleophosmin)
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The hAPE1 (human apurinic/apyrimidinic endonuclease 1) is an
essential enzyme, being the main abasic endonuclease in higher
eukaryotes. However, there is strong evidence to show that hAPE1
can directly bind specific gene promoters, thus modulating their
transcriptional activity, even in the absence of specific DNA
damage. Recent findings, moreover, suggest a role for hAPE1 in
RNA processing, which is modulated by the interaction with
NPM1 (nucleophosmin). Independent domains account for many
activities of hAPE1; however, whereas the endonuclease and the
redox-active portions of the protein are well characterized, a better
understanding of the role of the unstructured N-terminal region is
needed. In the present study, we characterized the requirements
for the interaction of hAPE1 with NPM1 and undamaged nucleic
acids. We show that DNA/RNA secondary structure has an impact
on hAPE1 binding in the absence of damage. Biochemical studies,
using the isolated N-terminal region of the protein, reveal that the
hAPE1 N-terminal domain represents an evolutionary gain of
function, since its composition affects the protein’s stability and
ability to interact with both nucleic acids and NPM1. Although
required, however, this region is not sufficient itself to stably
interact with DNA or NPM1.
Key words: apurinic/apyrimidinic endonuclease 1 (APE1), nuc-
leophosmin (NPM1), protein–DNA interaction, protein–protein
interaction, phylogenesis.
INTRODUCTION
The hAPE1 [human APE1 (apurinic/apyrimidinic endonuclease
1)] is an essential and multifaceted protein involved in the DNA
BER (base excision repair) pathway and in the regulation of
gene expression, acting both as a redox co-activator for several
transcription factors and as a transcriptional repressor on nCaRE
(negative calcium response elements)-containing promoters
[1–3]. These biological activities are located in two distinct, but
partially overlapping, regions. The conserved C-terminal portion
(residues 61–318) is responsible for the enzymatic activity
on abasic DNA, whereas the N-terminal domain (residues
1–127) is mainly devoted to the redox co-activating function
towards different transcription factors such as Egr1 (early growth
response 1), NF-κB (nuclear factor κB) and p53 [4,5]. The
mechanisms of hAPE1 binding and recognition of its canonical
substrate, the abasic site containing DNA, have been thoroughly
investigated by several laboratories [6–8]. However, the notion
that hAPE1 is constitutively bound to undamaged nucleic acids is
getting stronger. Examples include the interaction of the protein
with genomic regions, such as the nCaRE sequences [2] or
the MDR1 (multidrug resistance protein 1) gene promoter [9],
and the reported association of hAPE1 with undamaged RNA
[10]. Acquisition of particular secondary structures (i.e. bulges,
hairpins, cruciforms, quadruplex etc.) by nucleic acids and their
regulatory roles in vivo are a well-known paradigm in molecular
biology. A previous study has carefully explored the interaction
between hAPE1 and undamaged nucleic acids [11]; nonetheless,
potential impacts of the secondary structure of the nucleic acid
on the binding affinity of hAPE1 have never been investigated.
In the last few years, an unexpected involvement of hAPE1 in
RNA metabolism has been unveiled: the protein is accumulated
within nucleoli through interaction with NPM1 (nucleophosmin;
also known as nucleolar phosphoprotein B23) and rRNA and
affects cell growth by directly acting on the RNA quality
control mechanisms [10,12,13]. Notably, the N-terminal domain
of hAPE1 (the first 43 residues) plays a pivotal role in this non-
canonical function of the protein, serving as an adaptable device
for protein–protein interactions and modulating its enzymatic
activity on abasic DNA, as well as its binding to RNA
molecules. Although many studies have thoroughly characterized
the structure of the hAPE1 C-terminal globular domain, only a
few have addressed the role of its N-terminal extension, perhaps as
a consequence of its intrinsic disordered folding [14–16]. A basic
cluster of lysine residues located within this region (Lys25–Lys35)
controls the binding affinity of hAPE1 for both NPM1 and nucleic
acids. Furthermore, several strands of evidence suggest that the
different functions of hAPE1 might be rapidly modulated in vivo
by post-translational modifications on its N-terminal domain,
such as ubiquitination, acetylation and proteolysis [2,17–21].
Interestingly, whereas the C-terminal portion of the protein shares
extensive similarity with most of its orthologue counterparts,
from Escherichia coli to mammals, its N-terminal extension is
considerably less conserved. The importance of this protein region
in modulating the many activities of hAPE1 suggests that the N-
terminal domain may be a recent acquisition during evolution
Abbreviations used: APE1, apurinic/apyrimidinic endonuclease 1; BER, base excision repair; DSP, dithiobis(succinimidyl propionate); DTT, dithiothreitol;
FBS, fetal bovine serum; GST, glutathione transferase; hAPE1, human APE1; MAT, metal-affinity tag; nCaRE: negative calcium response elements; NPM1,
nucleophosmin; PLA, proximity ligation assay; RU, response unit; SPR, surface plasmon resonance; zAPE1, zebrafish APE1.
1 To whom correspondence should be addressed (email gianluca.tell@uniud.it).
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[17], as already suggested for other BER proteins [22]. Aberrant
hAPE1 expression and localization patterns have been linked
to neurodegeneration and cancer; therefore, many groups are
currently directing their efforts to develop specific small-molecule
modulators of the different activities of the protein [23].
In the present study, we systematically characterized the
functional properties of the hAPE1 N-terminal domain, exploring
its nucleic acid-binding properties and its role in hAPE1–NPM1
interaction. In an effort to better characterize the features guiding
the binding of hAPE1 to undamaged nucleic acids, we used a
combined approach based on SPR (surface plasmon resonance),
EMSA analyses and GST (glutathione transferase) pull-down
experiments. The results of the present study show that the affinity
of hAPE1 for nucleic acids is enhanced by certain structural
elements and that the nucleic acid-binding activity of hAPE1 is
promoted by the N-terminal extension of the protein. This region,
although necessary for both the stabilization of the hAPE1–
nucleic acids and hAPE1–NPM1 interactions, shows only a weak
affinity for DNA or NPM1 when isolated from the hAPE1 globular
domain. Finally, exploiting a ‘domain swapping’ approach, we
demonstrate that lysine residues located within the N-terminal
domain of hAPE1 represent a phylogenetic gain of function
for the protein, since the composition of this domain influences
the stability of the protein and its ability to interact with both
nucleic acids and NPM1. Altogether, these data highlight the
role for the hAPE1 N-terminal region in modulating the many
functions of this pleiotropic protein. Further structural analyses
on this overlooked extension of the protein would be therefore
worthwhile in order to fully understand the substrate specificity of
hAPE1 and to design new anti-cancer drugs targeting this protein.
EXPERIMENTAL
Cell culture and transient transfection experiments
HeLa cells were grown in DMEM (Dulbecco’s modified Eagle’s
medium) supplemented with 10% FBS (fetal bovine serum),
100 units/ml penicillin and 10 mg/ml streptomycin sulfate. At
1 day before transfection, cells were seeded in 10-cm plates
at a density of 3×106 cells/plate. Cells were then transiently
transfected with 6 μg of either pcDNA5.1 (empty vector) or
pcDNA5.1-hAPE1 (full-length or amino acids 1–49) plasmids
per dish using the LipofectamineTM 2000 Reagent (Invitrogen)
according to the manufacturer’s instructions. Cells were harvested
at 24 h after transfection.
Multiple sequence alignments
For the multiple sequence alignments full-length hAPE1
orthologous metazoan sequences (human, Pan troglodytes,
Macaca mulatta, Equus caballus, Mus musculus, Rattus
norvegicus, Canis lupus familiaris, Sus scrofa, Bos taurus,
Ornithorhyncus anatinus, Salmo salar, Gasterosteus aculeatus,
Danio rerio, Xenopus tropicalis and Xenopus laevis) were
retrieved from the RefSeq protein database using the
BLAST algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and
aligned using the ClustalW2 program with default parameters
(http://www.ebi.ac.uk/Tools/msa/clustalw2/ ).
Western blotting analyses
The protein samples were electrophoresed by SDS/PAGE (10–
18% gels) or discontinuous Tris/Tricine SDS/PAGE [24].
Proteins were then transferred on to nitrocellulose membranes
(PerkinElmer), developed as described previously [12] using an
ECL (enhanced chemiluminescence) procedure (GE Healthcare)
and then quantified by using a ChemiDoc XRS video-
densitometer (Bio-Rad Laboratories).
Plasmids and expression of recombinant proteins
The constructs pGEX-3X-hAPE1 and pGEX-3X-zAPE1, enco-
ding for the GST-fused hAPE1 and zAPE1 (zebrafish APE1)
full-length proteins respectively, were provided by Dr Mark
R. Kelley (Indiana University, Indianapolis, IN, U.S.A.). The
plasmid encoding for full-length GST–NPM1 was provided by
Dr P.G. Pelicci (European Institute of Oncology, Milan, Italy).
The pTAC-MAT/hAPE1 and the pETM-20/zAPE1 constructs,
encoding for C-terminal-tagged MAT (metal-affinity tag)–hAPE1
and His6–zAPE1 respectively, were generated by subcloning. All
proteins were expressed in E. coli BL21(DE3) cells, induced
with 1 mM IPTG (isopropyl β-D-thiogalactopyranoside) and then
purified on an ¨AKTA Purifier FPLC system (GE Healthcare)
by using a GSTrap HP column (GE Healthcare) for the GST-
tagged proteins, or a HisTrap HP column (GE Healthcare) for the
His6- and MAT-tagged proteins. The quality of purification was
checked by SDS/PAGE analysis. Extensive dialysis against PBS
was performed to remove any trace of imidazole from the HisTrap-
purified proteins. Accurate quantification of all recombinant
proteins was performed by colorimetric Bradford assays (Bio-Rad
Laboratories) and confirmed by SDS/PAGE and Western blotting
analysis. To remove the GST tag, GST–hAPE1 was further
hydrolysed with Factor Xa as described previously [17]. The
zAPE1 K27 ‘swapping mutant’ and the hAPE1 N43 and zAPE1
N36 deletion mutants, as well as the hAPE1 1–48 and 1–49
constructs, were generated using the QuikChange Mutagenesis kit
(Stratagene) and the respective full-length constructs as templates,
following the manufacturer’s instructions and using standard
subcloning procedures.
GST pull-down assays with RNA or NPM1 and
co-immunoprecipitation
The indicated amount of GST-tagged protein was mixed, together
with the prey protein or 10 μg of total RNA, with 10 μl of
glutathione–Sepharose 4B beads (GE Healthcare). RNA was
extracted using the TRIzol® Reagent (Invitrogen). Binding was
performed in PBS supplemented with 5 mM DTT (dithiothreitol)
and 0.5 mM PMSF for 2 h under rotation at 4 ◦C. The beads
were washed three times with washing buffer [PBS supplemented
with 0.1% Igepal CA-630 (Sigma), 5 mM DTT and 0.5 mM
PMSF]. Beads were then resuspended in Laemmli sample buffer
for Western blotting analyses or in TRIzol® Reagent for RNA
extraction and rRNA quantification. The levels of 28S and 18S
rRNA transcripts were determined as described previously [17]
by using the iScript cDNA synthesis kit (Bio-Rad Laboratories)
according to the manufacturer’s instructions. Quantitative PCR
was then performed in an iQ5 multicolour real-time PCR detection
system (Bio-Rad Laboratories) according to the manufacturer’s
protocol. GST-tagged proteins were detected with an HRP
(horseradish peroxidase)-conjugated anti-GST antibody (Sigma),
whereas the prey proteins were detected using the indicated
antibodies. Co-immunoprecipitation analyses were performed as
described previously [12].
DSP [dithiobis(succinimidyl propionate)] cross-linking
The indicated amounts of recombinant NPM1 and hAPE1 (either
full-length or the amino acids 1–48 peptide), were allowed to
c© The Authors Journal compilation c© 2013 Biochemical Society
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interact at 37 ◦C for 15 min in a total volume of 10 μl; DSP (2 μg
in DMSO) was added and cross-linking was carried out for 30 min
at room temperature (22 ◦C). The reactions were quenched by
adding 0.5 volumes of ice-cold 0.4 M ammonium acetate and
incubating on ice for 10 min. Non-reducing Laemmli sample
buffer was immediately added and the samples were separated
by SDS/PAGE (8% gel).
Immunofluorescence confocal analyses and PLA (proximity
ligation assay)
Immunofluorescence was carried out as described previously [12].
FLAG-tagged 1–49 hAPE1 was labelled using an anti-FLAG
antibody and stained with a secondary anti-mouse Alexa FluorTM
488-conjugated antibody (Jackson ImmunoResearch). Nuclei
were counterstained with DAPI (4′,6-diamidino-2-phenylindole).
For the PLA analyses we used the Duolink II® reagent kit (Olink
Bioscience); cells were fixed in 4% (w/v) paraformaldehyde,
permeabilized with 0.25% PBS-Triton (PBS with Triton X-100)
and saturated with 10% (v/v) FBS. Slides were incubated with
primary antibodies (mouse anti-FLAG, 1:100 dilution and rabbit
anti-NPM1, 1:200 dilution) and then reactions were carried out
following the manufacturer’s instructions. Microscope slides were
mounted and visualized through a Leica TCS SP laser-scanning
confocal microscope.
hAPE1–nucleic acid binding through EMSA
hAPE1 binding to nucleic acids was assessed as described
previously [1] with some modifications. Briefly, in order to reduce
unspecific binding and to obtain more defined bound complexes,
recombinant proteins or peptides were incubated at 37 ◦C with
250 pmol of unlabelled poly(dT) for 15 min and then 2.5 pmol of
32P-labelled probe was added. The reactions were then incubated
for further 15 min and separated by native PAGE (6–10% gel) at
150 V for 4 h.
Southwestern assays
Bait proteins were separated using a pre-cast SDS/PAGE (Bio-
Rad Laboratories), electrotransferred on to a nitrocellulose
membrane and subsequently denatured and renatured by washing
six times in 1:1 serial dilutions of 6 M guanidinium/HCl in EMSA
buffer [40 mM Hepes (pH 8.0), 50 mM KCl, 2 mM EDTA, 10%
(v/v) glycerol and 1 mM DTT]. The membrane was then saturated
in 5% (w/v) BSA in EMSA buffer and incubated with 50 pmol of
the indicated 32P-labelled DNA probe at 37 ◦C, washed in EMSA
buffer to remove unspecific bound probe and finally subjected to
autoradiography.
SPR
Real-time binding assays were performed on a Biacore T-100
SPR instrument (GE Healthcare). Streptavidin was immobilized
on to a research-grade CM5 sensor chip using amine-coupling
chemistry. The immobilization steps were carried out at a flow
rate of 10 μl/min in Hepes buffer {20 mM Hepes, 150 mM NaCl,
3.4 mM EDTA, 0.005% P20 surfactant and 0.1 mM TCEP [tris-
(2-carboxyethyl)phosphine]}. All surfaces were simultaneously
activated for 30 s with a mixture of NHS (N-hydroxysuccinimide;
0.05 M) and EDC [N-ethyl-N ′-(3-dimethylaminopropyl)carbodi-
imide; 0.2 M]. Streptavidin was injected at a concentration of
20 μg/ml in 10 mM sodium acetate (pH 4.5) for 1 min. Ethan-
olamine (1 M, pH 8.5) was injected for 7 min to saturate the re-
maining activated groups. An average of 5000 RU (response units)
of streptavidin was immobilized on each flow cell. Biotinylated
oligonucleotides were injected at a concentration of 500 nM until
the desired level of immobilization was achieved (average value of
300 RU). Proteins were serially diluted in running buffer (80 nM–
2.0 μM) and injected at 20 ◦C at a flow rate of 60 μl/min for 1 min.
Disruption of any complex that remained bound after a 5-min
dissociation was achieved using a 30 s injection of 1 M NaCl at
100 μl/min. When the experimental data met the quality criteria,
the kinetic parameters were estimated assuming a 1:1 binding
model and using version 4.1 Evaluation Software (GE Health-
care). Conversely, an affinity steady-state model was applied to
fit the RUmax data compared with the protein concentrations and
fitting was performed with GraphPad Prism v4.00 [17].
CD
Far-UV CD spectra were recorded on a Jasco J-810
spectropolarimeter (JASCO) in a 195–260 nm interval.
Experiments were performed employing a protein concentration
of 5 μM in 10 mM phosphate buffer (pH 7.0), supplemented with
1 mM DTT and using a 0.1 cm path-length cuvette. Thermal
denaturation profiles were obtained by measuring the temperature
dependence of the signal at 225 nm in the 20–100 ◦C range with a
resolution of 0.5 ◦C and 1.0-nm bandwidth. A Peltier temperature
controller was used to set up the temperature of the sample with
the heating rate set to 1 ◦C/min. Data were collected at a 0.2-nm
resolution, 20 nm/min scan speed and a 4 s response and were
reported as the unfolded fraction against the temperature.
Statistical analyses
Statistical analyses were performed by using the Microsoft Excel
data analysis software for Student’s t test analysis. P < 0.05 was
considered statistically significant.
RESULTS AND DISCUSSION
The binding affinity of hAPE1 for undamaged nucleic acids is
dependent on their secondary structure
Several studies have thoroughly characterized hAPE1 structure
and its enzymatic activities on abasic DNA, examining its
substrate specificity and recognition mechanisms [7,11,25–28].
However, when considering undamaged structured nucleic acids,
the knowledge of hAPE1 substrate selectivity is still scarce.
In the present study we sought to determine whether some partic-
ular structural features were favoured by hAPE1 when binding to
nucleic acids. Hence, we used a biophysical approach exploiting
the SPR technique to quantitatively measure the binding affinity
of hAPE1 for intact oligonucleotides [29,30]. We compared
the binding affinity of recombinant purified full-length hAPE1
toward different single-stranded DNA probes, either intrinsically
lacking secondary structure (i.e. 34dT), or having a stem and
loop-like folding (e.g. Stem10 and Stem20) as predicted by
bioinformatics analyses (Figure 1A and Table 1). The results of
the SPR experiments (representative sensorgrams in Figure 1B
and Supplementary Figure S1C at http://www.biochemj.org/
bj/452/bj4520545add.htm) are summarized in Table 2. As already
observed by Beloglazova et al. [11], an increased length in
the stem region of the oligonucleotides augmented the affinity
of hAPE1 for undamaged DNA (compare the Stem10 and the
Stem20 sequences). This observation was confirmed by direct
EMSA experiments (Figure 1C) and by competition EMSA
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Figure 1 The secondary structure of the substrate determines the binding selectivity of hAPE1
(A) The predicted structures for the oligonucleotides used in the present study. Calculations were performed using either the Mfold web server (http://mfold.rna.albany.edu/?q=mfold) or the DINAMelt
web server (http://mfold.rna.albany.edu/?q=DINAMelt). The calculated minimum free energy for folding (G) at 37◦C and 50 mM Na+ is also reported. The arrow indicates the absence of loop in
the Stem20 no loop probe. (B) Representative overlay sensorgrams relative to a typical SPR experiment for the binding of hAPE1 to immobilized Biot-Stem20. The kinetic parameters were measured
injecting purified recombinant hAPE1 solutions at increasing concentrations (i.e. 87.5, 175, 350, 700, 1050, 1400 and 1750 nM). The K d values were estimated for each concentration using the
BIAevaluation v.4.1 software. (C) Positive effect of the stem length on ability of hAPE1 to bind undamaged DNA as evaluated through EMSA using the Stem10 and Stem20 oligonucleotides (Table 1).
For each reaction the indicated amount of purified recombinant hAPE1 was used. The results confirm a different binding capacity of hAPE1 towards double-stranded oligonucleotides of different
lengths. The arrow indicates the hAPE1–DNA complexes, whereas F denotes the position of the free oligonucleotide probe. wt, wild-type.
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Table 1 Oligonucleotide sequences used in the present study
The underlined nucleotides denote the position of the predicted loops.
Name Sequence
34dT 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-3′
Stem10 5′-CGATCGACGGATCCCCGTCGATCG-3′
Stem10 3′ A 5′-CGATCGACGGATCCCCGTCGATCGAAAAAA-3′
Stem10 5′ A 5′-AAAAAACGATCGACGGATCCCCGTCGATCG-3′
Stem20 5′-ATCGATCGATCGATCGACGGATCCCCGTCGATCGATCGATCGAT-3′
Stem20 no loop Forward, 5′-ATCGATCGATCGATCGACGGAT-3′ and reverse,
5′-CCCCGTCGATCGATCGATCGAT-3′
Stem20_2 5′-CGATCGATCGATCGATCGACGGATCCCCGTCGATCGATCGATCGATGC-3′
Stem20 Loop8 5′-CGATCGATCGATCGATCGACGGATCCTAGTCGATCGATCGATCGATCG-3′
Bulge Forward, 5′-CATTACTCATATCCCCGTCCATTG-3′ and reverse,
5′-CAATGGACGGTACAATGAGTAATG-3′
nCaRE_B2 Forward, 5′-TTTTTGAGACGGAGTTTCGCTCTTG-3′ and reverse,
5′-CAAGAGCGAAACTCCGTCTCAAAAA-3′
Table 2 Dissociation constants and kinetic parameters for the interaction
of full-length hAPE1 with different undamaged oligonucleotides
Data reported were obtained through SPR analyses using hAPE1 as analyte on the indicated
biotinylated oligonucleotide ligands. The kinetic parameters highlight the importance of
secondary structure for the recognition of undamaged nucleic acids by hAPE1.
Ligand k on (M− 1 · s− 1×105) k off (s− 1) Kd (μM)
34dT 0.004 0.112 308 +− 3.00
Stem10 0.270 0.020 1.03 +− 0.02
Stem20 0.292 0.007 0.25 +− 0.01
Stem20 no loop 0.068 0.024 4.06 +− 0.01
Stem10 3′A 0.060 0.240 6.20 +− 0.01
Stem10 5′A 0.059 0.059 2.11 +− 0.03
Stem20_2 0.284 0.007 0.25 +− 0.01
Stem20 Loop8 0.061 0.004 0.74 +− 0.02
Bulge 0.834 0.019 0.23 +− 0.02
nCaRE_B2 0.270 0.105 3.90 +− 0.80
experiments demonstrating the poor competitive ability of the
Stem10 toward the Stem20 oligonucleotide (results not shown).
The effect of the presence of an intact loop structure on the stability
of the protein–DNA complex then was investigated by comparing
the affinities of the Stem20 and the Stem20 no loop sequences.
Notably, hAPE1 showed a reduced affinity toward the ligand
without a loop (approximately 16-fold, Table 2). Accordingly,
EMSA experiments confirmed these findings, showing a more
stable hAPE1–DNA complex in the presence of an intact loop
(Supplementary Figures S1A and S1B). Furthermore, competitive
EMSA assays demonstrated that the Stem20 probe was a more
efficient competitor if compared with the Stem20 no loop (results
not shown). Binding affinities were also negatively affected by the
presence of an unstructured nucleotide stretch either 3′ or 5′ to the
double-stranded stem region (compare Stem10 3′A and Stem10
5′A with the Stem10 sequence). Experimental data allowed us to
speculate that the steric hindrance of a free poly(A) tail on the
double-stranded region bound by hAPE1 might accelerate
the dissociation rate, if protruding from the 3′-side. When
using the same stem length the size of the loop region affected
the binding: the expansion from 4 to 8 nucleotides reduced the
affinity of hAPE1 approximately 3-fold (compare the Stem20_2
and the Stem20 Loop8 sequence). The difference in Kd value can
be accounted for by a reduction in the association rate, suggesting
that hAPE1 preferentially approaches the DNA molecules from
the loop side as the stem side remains invariant between the
two oligonucleotides. A lower stability of the stem region in the
Stem20 Loop8 sequence could also reflect the decreased binding
affinity; bioinformatic predictions, however, do not suggest any
major difference in the unfolding free energy of the two molecules
(Figure 1A). We finally investigated whether the position of
the unstructured region might affect the binding capacity of
hAPE1 (compare Bulge, Stem20 and Stem20_2). Despite the
differences in both the dissociation and the association rates,
the overall affinity of hAPE1 for the oligonucleotides remained
unchanged, suggesting that a local denaturation of the double
helix, rather than its location within the double-stranded region,
is a feature that enhances binding of hAPE1 to undamaged DNA.
To compare our measurements on synthetic oligonucleotides
with a physiologically relevant undamaged DNA substrate, we
investigated the binding properties of hAPE1 towards an nCaRE
duplex sequence, namely nCaRE_B2 (G. Antoniali, L. Lirussi, C.
D’Ambrosio, F. Dal Piaz, C. Vascotto, D. Marasco, A. Scaloni,
F. Fogolari and G. Tell, unpublished work). This sequence
displayed a Kd value akin to that of the unstructured Stem20
no loop sequence (Table 2). It is worth pointing out that our
in vitro assays, performed with the isolated purified recombinant
protein, might underestimate the real affinity of hAPE1 for this
sequence, since interactions with other protein partners [e.g.
Ku70/80 and hnRNPL (heterogeneous nuclear ribonucleoprotein
L)] significantly increase the protein–DNA complex stability, as
already demonstrated previously (G. Antoniali, L. Lirussi, C.
D’Ambrosio, F. Dal Piaz, C. Vascotto, D. Marasco, A. Scaloni, F.
Fogolari and G. Tell, unpublished work) [31].
EMSA analyses were also performed on RNA substrates to
test whether the nature of the sugar backbone might affect the
binding activity of hAPE1 toward structured nucleic acids. The
results obtained confirmed that the structural requirements for
hAPE1 binding to undamaged substrates are not influenced by
the composition of the sugar backbone (results not shown). These
observations suggest that hAPE1 shows no apparent preference
for DNA or RNA substrates, as long as the nucleic acid is
undamaged and is endowed with a secondary structure. The results
of the present study are in agreement with experimental data
from other laboratories that have estimated Kd values for the
interaction of hAPE1 with structured RNA that is similar to our
values for DNA (∼0.9 μM) [32]. It must be noted, however, that
these experiments do not allow the exclusion of the existence of a
differential affinity of hAPE1 for abasic site-containing DNA or
RNA molecules, as has been suggested by others [12,26].
In summary, hAPE1 binding to undamaged nucleic acids
appears to be strongly affected by the presence of secondary
structural elements. In particular, the presence of a double-
stranded region is a primary element required for hAPE1 binding.
The occurrence of a single-stranded local distortion, moreover,
greatly enhances the interaction with nucleic acids. These factors
are corroborated by studies reporting a significant reduction in
the APE activity of the protein on single-stranded unstructured
(or poorly structured) substrates (e.g. [7]). The requirement of a
double-stranded DNA region is conceivable, on the basis of the
observation that hAPE1 contacts both of the DNA strands [27,28].
The presence of a loop or a bulge within a double-stranded stem
could mimic a local denaturation region that resembles a baseless
spot, hence explaining the increased affinity for loop-containing
structures displayed in vitro by hAPE1.
The N-terminal domain contributes to nucleic acid-binding
by hAPE1
We have shown previously that the N-terminal 33 amino acids of
hAPE1 is able itself to bind RNA oligonucleotides in solution [17].
Sequence alignment analyses, performed on different metazoan
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Figure 2 The isolated N-terminal region of hAPE1 interacts weakly with nucleic acids
(A) Multiple sequence alignment between full-length APE1 protein sequences from 15 different metazoan species. Only the N-terminal region of the alignment is reported. The arrow indicates the
beginning of the high-similarity region within the C-terminal globular domain; whereas the N-terminal part of the sequences is significantly less conserved. (B) The isolated recombinant 1–48 hAPE1
N-terminal peptide is able to compete (comp.) with the full-length protein for RNA binding. The binding ability of the peptide was evaluated through competition RNA pull down using GST-tagged
full-length hAPE1 as the bait and whole HeLa RNA as the prey in the presence of the indicated competitor. To quantify the amount of residual hAPE1-bound rRNA the pulled-down RNA was then
retrotranscribed and 28S or 18S rRNAs were amplified by real-time PCR. The affinity for the 18S rRNA was similar to that shown for the 28S (results not shown). The competition activity of the
1–48 hAPE1 peptide was also confirmed using an untagged synthetic 1–33 hAPE1 peptide. The histogram shows the relative affinity to rRNA with respect to the GST–hAPE1 sample. The error bars
represent the S.D. (n = 3). *P < 0.05. (C) EMSA dose–response analysis showing that the 1–48 peptide binds undamaged DNA with a low affinity when compared with the full-length hAPE1 protein.
For each reaction the indicated amount of purified recombinant protein was used. F denotes the position of the free oligonucleotide probe. (D) Southwestern blot assay showing a dose–response
binding of the nCaRE_B2 duplex to the 1–48 peptide. The indicated amounts of protein or peptide were separated by SDS/PAGE, electrotransferred on to nitrocellulose membranes (left-hand panel)
and probed with 32P-labelled nCaRE_B2 (right-hand panel). Note the difference in binding affinity between the full-length hAPE1 protein and the isolated peptide. MT, Mat; wt, wild-type.
species, highlight that the phylogenetic conservation of the amino
acid sequence among APE1 proteins from different organisms
starts at position 48 in the human protein, and is significantly lower
in the region spanning amino acids 1–48 (Figure 2A). In order
to better clarify the relevance of the non-conserved N-terminal
domain in modulating the binding ability of hAPE1 to nucleic
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acids, we cloned and expressed in E. coli cells the 1–48 amino
acid region of hAPE1 in fusion with a C-terminal MAT (Sup-
plementary Figures S2A and S2B at http://www.biochemj.org/
bj/452/bj4520545add.htm) and evaluated the binding properties
of the recombinant purified peptide toward different substrates,
including DNA and RNA. We indirectly estimated the rRNA-
binding activity of the peptide exploiting a GST pull-down
competition strategy. In these experiments, the full-length GST–
hAPE1 was used as the bait and total HeLa RNA as the prey,
while either the recombinant purified 1–48 peptide or its synthetic
untagged 1–33 counterpart were used as soluble competitors. The
data obtained revealed that both soluble peptides were able to
compete with full-length hAPE1 for rRNA binding, independently
of the presence of a tag (Figure 2B).
In order to compare the nucleic acid-binding activity of
the 1–48 peptide and that of the full-length hAPE1 protein,
we used EMSA analyses. Under our experimental conditions we
observed a low-affinity binding activity for the hAPE1 N-terminal
peptide towards the nCaREB_2 duplex sequence (Figure 2C
and Supplementary Figure S2C). Although at a reduced affinity,
however, the interaction with DNA was specific, as demonstrated
by both Southwestern assays (Figure 2D and Supplementary
Figure S2D) and Western blotting performed after the EMSA
analysis (Supplementary Figure S2E). These results, along with
the notion that the N-terminal 1–33 amino acid portion of hAPE1
is absolutely required for the stable interaction of the protein
with nucleic acids [12,17], suggest that this lysine-rich region
might act by stabilizing the association of hAPE1 with nucleic
acids through electrostatic interactions, whereas the remaining C-
terminal domain accounts for the specific binding to DNA/RNA.
Our data support a two-step model to describe the mechanism
through which hAPE1 contacts nucleic acids. The unstructured
N-terminal domain would be required for the preliminary low-
affinity binding process in search of the proper lesion to be
repaired, as suggested for other DNA-binding proteins [33].
Recognition of a local distortion (or an abasic site) involves
and is stabilized by a higher-affinity binding event. The whole
hAPE1 molecule would, at this point, become necessary for the
recognition of the structured nucleic acid region. Intriguingly, this
model nicely fits previous hypothesis proposed by Masuda et al.
[34] more than a decade ago.
The N-terminal domain of hAPE1 is necessary, but not sufficient,
for a stable binding to NPM1
In our previous work, we demonstrated that the N-terminal 1–
33 amino acid domain of hAPE1, besides being essential for
stabilizing its binding to nucleic acids, is also required for a stable
interaction with NPM1 [12] and that lysine residues spanning
the region 27–35 of hAPE1 are directly involved in stabilizing
this interaction [17]. However, we did not check whether the N-
terminal domain of hAPE1 was able to directly bind to NPM1
itself. In an effort to better characterize the protein–protein
interaction features of the hAPE1 N-terminal domain and its
relative contribution to the overall binding, we analysed the ability
of the 1–48 peptide to directly interact with NPM1. We expressed
both the full-length hAPE1 and the 1–48 peptide in fusion with a
MAT. The recombinant proteins were affinity purified and tested
for their binding ability toward GST-tagged NPM1 through GST
pull-down assays (Figure 3A). Although the full-length hAPE1
protein was able to directly interact with NPM1 (Figure 3A,
left-hand panel), we failed to detect any stable peptide–NPM1
association in vitro (Figure 3A, right-hand panel), even under less
stringent binding conditions (results not shown). This negative
result prompted us to hypothesize that, if present, any peptide–
NPM1 association could be too weak to be detected through a
direct pull-down assay. We confirmed this hypothesis through a
competition GST pull-down assay, in which the 1–48 peptide
was used to squelch the binding occurring between the full-
length hAPE1 and GST–NPM1 (Figure 3B). The peptide, as
well as an untagged full-length hAPE1, was able to displace the
association between the MAT-tagged hAPE1 and GST–NPM1.
However, whereas the competitor untagged hAPE1 was also
efficiently recovered in the pulled-down fraction, the competitor
1–48 peptide was not. This indicates that the peptide was able
to mask the hAPE1-binding site on NPM1, thus competing with
the hAPE1–NPM1 association, although its interaction with the
protein was too weak to be maintained during the washing steps.
The observed competition effect could also be interpreted by
assuming a masking effect of the peptide on the full-length hAPE1
N-terminal region, however, to the best of our knowledge, no
oligomerization ability has ever been described for hAPE1.
To definitely prove the ability of the N-terminal peptide
to directly associate with NPM1, we performed an in vitro
stabilization of the complex exploiting the bifunctional cross-
linker DSP (Figure 3C). As expected, treatment of NPM1 alone
with DSP resulted in the stabilization of slow migrating oligomers,
as documented previously [35]. Moreover, the full-length hAPE1
protein and its N-terminal peptide were detected as slow migrating
signals only in the presence of both NPM1 and DSP, indicating a
direct association for both with NPM1. The lower affinity of the
1–48 peptide toward NPM1, in comparison with that of the full-
length protein, indicates that the C-terminal domain of hAPE1
contributes to the stabilization of the protein–protein interaction.
To evaluate whether the interaction between the hAPE1 N-
terminal extension and NPM1 also occurs in vivo, we created a
HeLa cell line expressing a FLAG-tagged 1–49 hAPE1 peptide
upon treatment with doxycycline, as already described previously
[36]. As assessed using Western blotting, the peptide expression
increased after the addition of doxycycline to the culture medium
(Figure 4A, upper panel). Interestingly, the ectopically expressed
peptide showed a peculiar localization pattern, being cytoplasmic
and nuclear, but excluded from nucleoli (Figure 4A, lower panel),
in contrast with the nuclear/nucleolar accumulation observed
for the wild-type protein both under basal conditions [12,21]
and when ectopically expressed (Figure 4A, lower panel). This
result confirms that the C-terminal domain of hAPE1 contributes
to the nucleolar accumulation of the protein within cells,
despite the fact that the N-terminal domain retains the nuclear
localization signal of the protein [37]. This phenomenon may
be explained by the relevance that the C-terminal domain has
in stabilizing both rRNA and NPM1 binding. By exploiting this
cell model, we performed co-immunoprecipitation experiments
and demonstrated the occurrence of a molecular interaction
between NPM1 and the isolated hAPE1 N-terminal peptide.
However, the FLAG-tagged 1–49 peptide was only able to co-
precipitate NPM1 poorly when compared with the full-length
protein (Figure 4B). This result parallels our in vitro results with
recombinant purified proteins and confirms that the unstructured
N-terminal region of hAPE1 does indeed interact with NPM1,
albeit with a lower affinity in the absence of the remaining
C-terminal domain. We further confirmed the presence of an
interaction occurring between the FLAG-tagged 1–49 hAPE1
peptide and endogenous NPM1 using a PLA [21], which allows
the quantification of physical proximity between molecules
at a distance lower than 40 nm (Supplementary Figure S3A
at http://www.biochemj.org/bj/452/bj4520545add.htm) [38]. The
PLA signal was present in the nucleoplasmic compartment only in
the presence of both the anti-FLAG and the anti-NPM1 antibodies,
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Figure 3 The unstructured N-terminal domain of hAPE1 is required, but not sufficient, for stable binding to NPM1 in vitro
(A) A representative GST pull-down experiment showing the absence of a stable interaction, in vitro, between recombinant GST-tagged NPM1 (bait) and the MAT-tagged 1–48 hAPE1 N-terminal
peptide (prey) (right-hand panel). The same assay using full-length MAT-tagged hAPE1 is reported as a positive control (left-hand panel). The assay was performed as described in the Experimental
section using the indicated amounts of recombinant proteins. (B) The recombinant 1–48 hAPE1 peptide is able to compete, in vitro, with the full-length hAPE1 protein for the binding to NPM1.
Competition GST pull down using GST–NPM1 as the bait and MAT-tagged full-length hAPE1 as the prey. The hAPE1–NPM1 interaction was evaluated in the presence of a 10-fold excess competitor
(comp.; i.e. untagged full-length hAPE1 as a positive control or MAT-tagged 1–48 peptide). The extent of interaction was assessed using an anti-MAT antibody to recognize the pulled down hAPE1
prey. The competing untagged hAPE1 was visualized using an anti-APE1 antibody. The histogram shows the average of three independent experiments with the error bars representing the S.D.
*P < 0.05. ¥, Residual GST contaminant in the untagged hAPE1 preparation. (C) The low-affinity binding between the N-terminal recombinant hAPE1 peptide and NPM1 is stabilized by in vitro
cross-linking. Recombinant purified NPM1 was incubated alone or together with either the 1–48 peptide or full-length hAPE1 as indicated. The bifunctional cross-linker DSP was also added where
indicated. The presence of high-molecular-mass complexes was assessed by Western blotting using an anti-NPM1, an anti-APE1 or an anti-MAT antibody. The formation of high-molecular-mass
complexes in the presence of DSP denotes the ability of the 1–48 peptide to interact weakly with NPM1. MT, Mat; WB, Western blot; wt, wild-type.
being absent when using either the anti-FLAG or the anti-NPM1
alone. This demonstrates the existence of an interaction between
the isolated hAPE1 N-terminal domain and endogenous NPM1
only in the nucleoplasmic compartment. We also measured, using
PLA, the extent of endogenous hAPE1–NPM1 interaction in the
presence or absence of expression of the 1–49 peptide. In this
case, the expression of the N-terminal region resulted in a poor,
but statistically significant, competing effect (about 10% loss in
interaction, Figure 4C). Altogether, these results confirm that the
unstructured hAPE1 N-terminal domain alone is required, but not
sufficient, for a stable binding of hAPE1 to NPM1 both in vitro and
in vivo. Notably, several studies have demonstrated that hAPE1,
targeted by granzymes A and K, undergoes proteolysis in living
cells and its truncation products (hAPE1 N31 or 35) have
been proposed to take part in the apoptotic process [18,39,40].
In light of the results of the present paper, it may be tempting
to speculate that the N-terminal proteolytic products (the 1–31
or 1–35 peptides) might also exert an active regulatory function
within cell, for example by competing with the full-length protein
for binding to nucleic acids or protein partners, such as NPM1,
XRCC1 (X-ray repair complementing defective repair in Chinese
hamster cells) [41], DNA polymerase β [42] or CSB (Cockayne
syndrome B) [43] and thus possibly acting as decoy peptide.
The evolutionarily acquired N-terminal domain of hAPE1 influences
the stability and the binding properties of the protein
Given the importance of the unstructured N-terminal region
of hAPE1 in tuning many of the protein’s functions, the poor
evolutionary conservation of this domain appears remarkable.
hAPE1 belongs to the exonuclease III family of endonucleases,
being 27% identical with the archetype E. coli ExoIII (xth)
[14]. Although the C-terminal domain of the human protein is
conserved from prokaryotes to mammals, the N-terminal portion
of hAPE1, comprising the redox domain, is not [17,44]. Metazoan
hAPE1 orthologues, in fact, share a unique basic N-terminal
extension that heavily affects the isoelectric point of the whole
protein. Interestingly, the overall positive charges number within
this basic region increased during evolution (from nine in fishes
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Figure 4 The hAPE1 N-terminal peptide interacts weakly with endogenous NPM1 in HeLa cells
(A) Upper panels, Western blotting analysis of the expression kinetics of the FLAG-tagged 1–49 hAPE1 peptide following the doxycycline treatment of HeLa. The peptide expression is induced after
2 days of treatment. Lower panel, immunofluorescence confocal analysis on HeLa cells after 5 days of doxycycline treatment shows the lack of nucleolar accumulation of the 1–49 peptide (white
arrowheads), in contrast with the nucleolar positivity shown by the full-length hAPE1. (B) The recombinant 1–49 peptide binds poorly to endogenous NPM1 in vivo. NPM1 co-immunoprecipitation
carried out using HeLa cells transfected either with an empty vector (mock) or a FLAG–full-length hAPE1- or a FLAG–1–49-expressing vector as shown. The amount of immunoprecipitated NPM1
was evaluated using Western blotting with an anti-NPM1 antibody. (C) The competition effect of the 1–49 hAPE1 peptide on endogenous hAPE1–NPM1 interaction. The extent of endogenous
hAPE1–NPM1 interaction was measured by PLA of HeLa cells either expressing the 1–49 hAPE1 peptide or mock transfected. The hAPE1–NPM1 association was estimated by scoring the interaction
signals in transfected cells. Peptide expression resulted in a significant competing effect, leading to a 10 % reduction in hAPE1–NPM1 interaction. The boxplot shows the relative amount of
hAPE1–NPM1 interaction in 1–49-expressing cells with respect to the mock-transfected cells +− S.D. (n = 70). *P < 0.05. IP, immuoprecipitation; WB, Western blot; wt, wild-type.
to 11 in mammals; Figure 2A; [17]), this event has possibly
been paralleled by an improved ability of APE1 to cope with
a progressively complex cellular environment.
Our recent work showed that the DNA-binding activity of
hAPE1 is substantially higher than that of the orthologous
protein from a phylogenetically distant organism, such as
zebrafish (zAPE1) [17]. In the present study, we hypothesized
that evolutionarily acquired amino acids within the N-terminal
domain of the protein could account for the increased binding
properties of hAPE1 towards both nucleic acids and NPM1.
As a proof of concept, we performed interaction experiments
with recombinant purified hAPE1 and zAPE1 enzymes. Initially,
through GST pull-down experiments, we confirmed that zAPE1
has a lower binding activity towards both NPM1 (Figure 5A)
and rRNA (Figure 5B). We then used insertional mutagenesis to
generate a mutant recombinant zAPE1 protein (namely, zAPE1
K27) bearing, after Glu26, a lysine residue followed by a TAA
(threonine–alanine–alanine) spacer spanning amino acids 28–30,
in order to mimic the local charge density and distribution present
within the wild-type hAPE1 N-terminal 24–35 region (Figure 5C).
Interestingly, the theoretical isoelectric point, calculated for the
whole unstructured N-terminal domain, is identical in both
the wild-type human protein and the zAPE1 K27 mutant (Table 3).
The NPM1-binding activity of the purified recombinant
proteins was then analysed using GST pull down with equimolar
amounts of each protein (Figure 5D and Supplementary Figure
S4A at http://www.biochemj.org/bj/452/bj4520545add.htm). The
data obtained indicate that, whereas the wild-type zAPE1 is less
able to interact with NPM1 than hAPE1, the full NPM1-binding
activity of the ‘swapping mutant’ is clearly restored. Notably, both
the hAPE1 N43 and the zAPE1 N36 deletion mutants, lacking
the entire N-terminal extension, showed neglectable interaction
ability. Although recognizing the limitations of this approach
when evaluating the binding of zAPE1 to a human NPM1 protein
(even though both human and zebrafish NPM1 share extensive
similarity and have a nearly identical pI value), our ‘domain
swapping’ approach supports the notion that the reduction
in binding affinity might be a consequence of a decreased
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Figure 5 The amino acidic composition of the N-terminal region enhances the affinity of the human APE1 protein for nucleic acids and NPM1
(A) zAPE1 has a lower affinity than hAPE1 for NPM1. GST pull-down assay using equimolar amounts of recombinant GST-tagged hAPE1 or zAPE1 as baits and His-tagged NPM1 as the prey. The
amount of pulled-down NPM1 was quantified through densitometric analysis (right-hand panel). The histogram show the results from three independent experiments with the error bars representing
the S.D. (n = 3), *P < 0.05. ¥, Residual GST contaminant in the GST–hAPE1 preparation. (B) zAPE1 has lower affinity than hAPE1 for rRNA. The APE1–RNA-binding capacity was evaluated through
RNA pull down using GST-tagged full-length hAPE1 or zAPE1 as the bait and whole HeLa RNA as the prey. To quantify the amount of residual hAPE1-bound rRNA the pulled-down RNA was then
retrotranscribed and 28S or 18S rRNAs were amplified by real-time PCR. The affinity for the 18S rRNA was similar to what shown for the 28S (results not shown). The histogram reports the relative
affinity to rRNA with respect to the GST–hAPE1 sample. Error bars represent the S.D. (n = 3). *P < 0.001. (C) Multiple sequence alignment of the N-terminal region of wild-type hAPE1, zAPE1 and
the mutant zAPE1 K27. The four-amino-acid insertion mutation in zAPE1 K27 is boxed. (D) The NPM1-binding affinity of the ‘domain swapping’ mutant measured using GST pull down. GST-tagged
NPM1 was used as the bait, whereas wild-type or mutant APE1 proteins were used as preys. The amount of pulled-down preys was assessed by Western blotting using an anti-APE1 antibody and
is shown as the percentage of input prey. Whereas wild-type zAPE1 and the deletion mutants N43 hAPE1 and N36 zAPE1 show a loss of function phenotype, the NPM1-binding capacity of
the zAPE1 K27 mutant is restored. (E) Binding affinity of the ‘domain swapping’ mutant for the nCaRE_B2 (left-hand panel) or the Stem20 (right-hand panel) oligonucleotides as measured using
EMSA. The nucleic acid-binding activity of the proteins reflects what was observed using SPR (Table 4): the wild-type zAPE1 protein and the deletion mutants N43 hAPE1 and N36 zAPE1 show
a reduced binding ability, whereas the zAPE1 K27 mutant displays a gain of function. F, the position of the free oligonucleotide probe. Arrows indicate the bound complex. (F) Overlay of thermal
melting profiles for recombinant hAPE1, zAPE1 and zAPE1 K27 in the 25–65◦C range shown as the unfolded fraction against temperature, measured by CD at 222 nm. The difference in thermal
stability observed between the wild-type hAPE1 and zAPE1 is clearly restored by the N-terminal insertions in the zAPE1 K27 mutant. WB, Western blot; wt, wild-type.
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Table 3 Predicted biophysical characteristics of the recombinant proteins
used in the present study
The table reports the theoretical molecular masses and isoelectric points calculated using the
Expasy pI/Mw tool (http://web.expasy.org/compute_pi/). The pI value of the N-terminal region
was calculated restricting the analysis to the human Ala43 or the homologue Ile36 in fish. Note the
identical pI values between the wild-type (wt) hAPE1 and the zAPE1 K27 N-terminal extensions.
N/A, not available.
Molecular Isoelectric point Isoelectric point
Protein mass (whole protein) (N-terminal)
hAPE1 wt 35564 8.33 9.10
zAPE1 wt 34881 5.77 8.04
hAPE1 N43 31217 7.59 N/A
zAPE1 N36 31207 5.54 N/A
zAPE1 K27 35252 5.96 9.10
number of positive charges within the N-terminal region of
zAPE1.
A similar functional rescue for the zAPE1 K27 mutant was
also observed when analysing the DNA-binding activity of the
proteins (Figure 5E). EMSA experiments carried out with either
a nCaRE_B2 duplex (Figure 5E, left-hand panel) or the Stem20
sequence (Figure 5E, right-hand panel) revealed a reduced binding
activity for wild-type zAPE1 and both the hAPE1 N43 and
the zAPE1 N36 deletion mutants, with a restored functionality
in the case of the zAPE1 K27 protein. EMSA analyses showed
clear differences in the electrophoretic mobility of the hAPE1 and
zAPE1 in complex with the nucleic acid substrates, suggesting
the existence of possible conformational differences between
the two recombinant proteins when bound to the cognate DNA.
The formation of a DNA–protein complex between the hAPE1
N43 mutant and the Stem20 substrate (Figure 5E, right-hand
panel), but not with the nCaRE_B2 DNA, is probably owing
to the presence of a highly stable stem-loop structure within
the Stem20 sequence, absent in the case of the nCaRE_B2
duplex (also see the SPR data below). This observation again
supports the concept that the C-terminal domain of hAPE1
may account for the high-affinity binding to structured nucleic
acid substrates. Moreover, the complete lack of nucleic acid-
binding activity observed for the hAPE1 N33 mutant [12,17]
suggests that the acidic residues in the 33–42 region might have a
negative effect on the overall nucleic acid-binding capacity of the
protein.
In order to corroborate these findings, we carried out SPR
experiments on zAPE1 and its mutants (Table 4) using both
the Stem20 and nCaRE_B2 sequences, which showed different
affinities for hAPE1 (Table 2). Interestingly, both the association
and dissociation rate constants could be determined when the
Stem20 was used as ligand; whereas, they were too high to
be determined with the nCaRE_B2 (in this case affinities were
determined through Langmuir isotherm fitting; Supplementary
Figure S4B). These results further point to the relevance of
the presence of a stable stem-loop secondary structure within
the oligonucleotide for a robust APE1–nucleic acid interaction.
This result is corroborated by the presence of a detectable
binding activity of the N-terminal truncated proteins (hAPE1
N43 and zAPE1 N36) only for the stem-loop substrate
(i.e. Stem20). Similarly to what was observed in the EMSA
experiments (Figure 5E) with both DNA substrates, the measured
Kd values were higher for zAPE1 than for hAPE1 (for the
kinetic parameters with the human protein see Table 2). The
zAPE1 K27 mutant, in turn, displayed an intermediate behaviour,
Table 4 Dissociation constants and kinetic parameters for the interaction of
the mutated APE1 proteins with the Stem20 and nCaRE_B2 oligonucleotides
Results were obtained using SPR analyses using different APE1 mutants as analytes on the
indicated biotinylated oligonucleotide ligands. The affinity values for the nCaRE_B2 sequence
were determined through Langmuir isotherm fitting (see the text for details). wt, wild-type.
Stem20 nCaRE_B2
Protein k on (M− 1 · s− 1×105) k off (s− 1) K d (μM) K d (μM)
zAPE1 wt 0.174 0.053 3.28 +− 0.07 5.7 +− 0.2
zAPE1 N36 0.232 0.530 23.0 +− 0.5 No binding
hAPE1 N43 0.841 0.733 10.3 +− 0.3 No binding
zAPE1 K27 0.419 0.067 1.60 +− 0.02 2.4 +− 0.9
confirming the restored binding activity of the ‘swapping mutant’
(Table 4).
In order to correlate the solution stability with binding ability,
we performed CD analyses on wild-type, mutant and truncated
APE1 proteins. The crystal structures of two vertebrate redox-
inactive enzymes C65A hAPE1 and zAPE1, in their N-terminally
truncated variants (C65A 40–318 hAPE1 and 33–310 zAPE1),
revealed no substantial differences in the structural organization
of the globular region of APE1 [44]. This was confirmed by
our analyses as the CD spectra of all our proteins exhibited
minima at 225 and 208 nm, typical of α-helices and β-strands
(results not shown). This indicates that, as expected, the C-
terminal globular region of the protein predominantly accounts
for the folded portion of the APE1 proteins. Thermal denaturation
experiments were carried out to investigate protein stability:
the sigmoidal profile of folded fraction against temperature
(Figure 5F) shows that the unfolding process was fully co-
operative for all of the proteins tested. By comparing the Tm
values, however, an influence of the N-terminal extension on
protein stability could be highlighted. Indeed, whereas hAPE1
has a Tm value of 41.5 ◦C, the Tm value measured for zAPE1 was
46.5 ◦C. Interestingly, the mutations and insertions in the zAPE1
K27 mutant effectively reduced the stability of the protein, since
the measured Tm value (39.5 ◦C) was closer to that of hAPE1
(Figure 5F). These results suggest a direct correlation between
the ability to recognize different oligonucleotides or protein
substrates and the flexibility of the N-terminal region of APE1.
Moreover, these data also support the hypothesis that the altered
mobility observed in the EMSA experiments between hAPE1
and zAPE1 bound to the cognate DNA sequences (Figure 5E)
might be ascribed to substantial conformational differences in
the two protein–DNA complexes. Similar CD analyses carried
out on both the hAPE1 N43 and the zAPE1 N36 deletion
mutants indicated that the differences in thermal stability between
human and zebrafish proteins are already present in their globular
portions (the Tm values were 44 ◦C and 50.5 ◦C respectively),
despite the similar structural organization (Supplementary
Figure S4C).
Taken together, these results indicate that the amino acid
composition and the local charge distribution within the N-
terminal domain of hAPE1 are responsible for its evolutionarily
acquired binding properties towards both nucleic acids and NPM1
and have an impact on the flexibility of the N-terminal region
of APE1. Therefore the results of the present study point to
the insertion of human Lys27, as well as the proper charge
distribution, as central steps in the phylogenesis of this protein.
From a phylogenic perspective, the acquisition of additional lysine
residues could have provided the human protein with novel ways
to fine-tune its different activities by the means of new ‘hot spots’
c© The Authors Journal compilation c© 2013 Biochemical Society
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that can undergo acetylation or ubiquitination [17,19–21] and
regulate substrate accessibility, on the basis of protein plasticity
in solution. In conclusion, in light of the results of the present study
and others [17,21,42,45], we suggest that the hAPE1 unstructured
N-terminal domain might represent a flexible device that has been
selected during evolution to specifically modulate the nucleic
acid- and NPM1-binding functions of the protein. It would be
interesting to explore novel pharmacological strategies aiming at
the functional modulation of the protein using small molecules
and/or peptides that target its N-terminal region.
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ORIGINAL ARTICLE
Functional regulation of the apurinic/apyrimidinic endonuclease 1
by nucleophosmin: impact on tumor biology
C Vascotto1, L Lirussi1, M Poletto1, M Tiribelli2, D Damiani2, D Fabbro1, G Damante1, B Demple3, E Colombo4 and G Tell1
Nucleophosmin 1 (NPM1) is a nucleolar protein involved in ribosome biogenesis, stress responses and maintaining genome
stability. One-third of acute myeloid leukemias (AMLs) are associated with aberrant localization of NPM1 to the cytoplasm
(NPM1cþ ). This mutation is critical during leukemogenesis and constitutes a good prognostic factor for chemotherapy. At present,
there is no clear molecular basis for the role of NPM1 in DNA repair and the tumorigenic process. We found that the nuclear
apurinic/apyrimidinic endonuclease 1 (APE1), a core enzyme in base excision DNA repair (BER) of DNA lesions, specifically interacts
with NPM1 within nucleoli and the nucleoplasm. Cytoplasmic accumulation of APE1 is associated with cancers including, as we
show, NPM1cþ AML. Here we show that NPM1 stimulates APE1 BER activity in cells. We provide evidence that expression of the
NPM1cþ variant causes cytoplasmic accumulation of APE1 in: (i) a heterologous cell system (HeLa cells); (ii) the myeloid cell line
OCI/AML3 stably expressing NPM1cþ ; and (iii) primary lymphoblasts of NPM1cþ AML patients. Consistent with impaired APE1
localization, OCI/AML3 cells and blasts of AML patients have impaired BER activity. Cytoplasmic APE1 in NPM1cþ myeloid cells is
truncated due to proteolysis. Thus, the good prognostic response of NPM1cþ AML to chemotherapy may result from the
cytoplasmic relocalization of APE1 and the consequent BER deficiency. NPM1 thus has an indirect but significant role in BER in vivo
that may also be important for NPM1cþ tumorigenesis.
Oncogene (2013) 0, 000–000. doi:10.1038/onc.2013.251
Keywords: APE1/Ref-1; NPM1; acute myeloid leukemia; base excision repair
INTRODUCTION
The nucleolar protein nucleophosmin 1 (NPM1) is implicated in a
variety of cellular processes including ribosome biogenesis and
centrosome duplication, and NPM1 is frequently altered in some
cancers.1 NPM1 physically interacts with p53 and is believed
to regulate this tumor-suppressor protein, thus contributing
to maintenance of genome integrity.2,3 However, a direct
involvement of NPM1 in DNA repair has not been demonstrated.
NPM1 mutations are the most frequently known gene altera-
tions in cytogenetically normal acute myeloid leukemia (AML)
patients and are considered as positive prognostic factors.4
The NPM1 mutations identified so far in cytogenetically normal
AML patients generate a new nuclear export signal while also
disrupting the nucleolar localization signal (Supplementary
Figure S1), which relocalizes mutated NPM1 to the cytoplasm
(NPM1cþ ).5,6 A formal in vivo demonstration that mutant
NPM1cþ is endowed with oncogenic potential has been
recently presented.7 A plausible hypothesis is that NPM1cþ
causes abnormal cytoplasmic localization of important NPM1-
interacting proteins that impairs their functions.1,8–15 All NPM1cþ
AMLs are characterized by haploinsufficient expression, with only
one NPM1 allele affected by the mutation. NPM1cþ is dominant
by forming mixed oligomers with wild-type (WT) NPM1 and
moving it to the cytoplasm. The presence of the NPM1cþ
mutation is a favorable marker for relapse-free and overall survival
in AML with a normal karyotype, and for complete remission
after chemotherapy using DNA-damaging compounds (that is,
daunorubicin, cytarabine and so on).
Interestingly, overexpression of WT NPM1 has been
described in a number of solid malignancies such as hepatic,
gastric, ovarian and prostate cancers.1,16 In those cases, it has been
suggested that increased amounts of NPM1 could limit
the DNA-damage response to help effect cellular transfor-
mation. However, molecular support for this hypothesis is
still lacking.
We recently demonstrated that NPM1 physically interacts
with apurinic/apyrimidinic endonuclease 1/redox effector
factor 1 (APE1/Ref-1) within nucleoli and in the nucleoplasm
of tumor cells.17 APE1 has a crucial role in the maintenance of
genome stability, in redox signaling and other processes,18 and it
is a promising target for augmenting chemotherapy.18,19 APE1 is
the main apurinic/apyrimidinic (AP) endonuclease in mammalian
cells and a multifunctional protein. APE1 is an essential enzyme in
the base excision DNA repair (BER) pathway for DNA damage
caused by both endogenous and exogenous oxidizing or
alkylating agents, including chemotherapeutic drugs.20–23 APE1
can also act as a redox-regulatory protein, maintaining cancer-
related transcription factors (Egr-1, NF-kB, p53, HIF-1a, AP-1 and
Pax proteins) in an active reduced state,18,24–28 and it may act as a
transcriptional repressor.29 APE1 binds and cleaves abasic sites
in RNA17,30,31 and can control c-Myc expression by nicking its
mRNA.32 In this context, we have shown that the first 35 amino
acids of APE1 are required for a stable interaction with NPM1 and
other proteins involved in ribosome biogenesis/RNA processing,17
and for APE1 stable binding to RNA.30,33 The direct interaction
with NPM1 stimulates the enzymatic activity of APE1 on abasic
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DNA in vitro,17,30 although the in vivo effects were not known. This
work presented here is aimed at filling this gap.
RESULTS
NPM1 / cells are more sensitive than control cells to DNA
damages repaired through the BER pathway
We earlier demonstrated that NPM1 stimulates the APE1
endonuclease activity in vitro by means of protein–protein
interaction.17,30 Our data clearly showed that, although the Km
of APE1 for the abasic substrate is not significantly affected by
the presence of NPM1, its catalytic activity is increased almost
10-fold in the presence of a two-fold excess of NPM1 recombinant
protein. As product release by APE1 appears to be rate-
limiting,34,35 these observations suggest that interaction
with NPM1 increases the speed of this reaction step. To evaluate
the role of the APE1/NPM1 interaction in vivo, we tested
the effect of NPM1 absence on the BER capacity exploiting a
NPM1 / cell model developed on the p53 / background for
immortalization.36
First, we checked whether NPM1 expression affected the
amount of APE1 protein and its subcellular localization. APE1
and NPM1 protein levels were evaluated by immunoblot analysis
of nuclear and cytoplasmic fractions of p53 / mouse embryonic
fibroblasts (MEFs) with NPM1þ /þ or NPM1 / alleles36 (Figure 1a
left and Supplementary Figure S2). Quantification of the
immunoblots (Figure 1a right and Supplementary Figure S3)
showed that NPM1 / cells had about 40% more nuclear APE1
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than cells expressing WT NPM1 protein. This increased content
was associated with a slightly increased APE1 transcription, as
measured by quantitative PCR analysis (not shown). Immuno-
fluorescence (IF) analysis (Figure 1b) showed that, in NPM1þ /þ
cells, APE1 localization was nuclear with a strong accumulation in
nucleolar structures, as previously shown for some tumor cell
lines.17 In contrast, in NPM1 / cells, APE1 did not accumulate
within nucleoli, although nucleolar structures are still intact
in these cells (data not shown).36 Reexpression of NPM1 in
MEF-NPM1 / cells promoted APE1 nucleolar accumulation
(Figure 1c and Supplementary Figure S4), demonstrating that
interaction with NPM1 is essential for APE1 nucleolar distribution.
Moreover, recent data from our laboratory also showed that
expression of an APE1 mutant not able to interact with NPM1 was
unable to accumulate within nucleoli, demonstrating that a
functional interaction with NPM1 is required for physical
accumulation of APE1 within nucleoli.37
To test the functional relevance of NPM1 in BER, we next
assayed the sensitivity of the NPM1 / cells to different
genotoxic treatments known to cause DNA lesions that are
repaired through the BER pathway.38 First, we used methyl
methanesulfonate (MMS), which is a monofunctional methylating
agent causing lesions repaired predominantly by BER pathway.39
Cell viability experiments showed that NPM1 / cells were
significantly more sensitive than NPM1þ /þ cells to MMS
(Figure 1d). We then evaluated the ability of the MEFs to
efficiently remove AP sites from the DNA of MMS-treated cells.
As shown in Figure 1e, NPM1 / cells retained a significantly
higher level of AP sites following MMS treatment than did
NPM1þ /þ cells. Notably, this difference was also apparent under
basal conditions, further pointing to an impairment in the AP-site
incision step within the BER pathway in NPM1 / cells.
BER removes also damages caused by reactive oxygen species,
such as oxidized bases (for example, 8-oxoG). Thus, we performed
cell viability experiments with acute doses of H2O2 as genotoxic
agent, combined with treatment of the cells with methoxyamine,
an inhibitor of APE1-dependent repair.40 Data reported in
Supplementary Figure S5A clearly showed that NPM1 / cells
were significantly more sensitive to this treatment than NPM1þ /þ
cells. To confirm this result with an alternative oxidizing agent, we
used KBrO3, a carcinogenic agent known to induce predominantly
8-oxoG lesions on DNA after reduction of the bromate by cellular
thiols, such as glutathione, or reduced cysteines.41 As displayed in
Figure 1f, treatment with KBrO3, NPM1
 / cells were significantly
less viable than control cells at all the release time points.
We also determined the sensitivity of NPM1 / cells to the
radiomimetic bleomycin (BLM), as still another DNA-damaging
agent that requires BER intervention.42 BLM, which targets both
single-stranded DNA and double-stranded DNA, as well as
RNA molecules, causes formation of 4-oxidized AP sites or
30-phosphoglycolate products that account for the majority of
the BLM-induced DNA lesions.42,43 Cell viability was measured on
MEFs after a 1-h treatment with increasing doses of BLM, followed
by 48 h of recovery. Data reported in Figure 1g and
Supplementary Figure S5B clearly confirmed the protective
function exerted by NPM1 against BLM treatment. Notably, the
differential sensitivity of the two isogenic cell lines was not
apparent when using the poly (ADP-ribose) polymerase-inhibitor
PJ34 (Supplementary Figure S6A) or upon ultraviolet-C irradiation,
which promotes DNA damages repaired through NER
(Supplementary Figure S6B). Comet assay analysis performed
under basal condition (data not shown) did not reveal any
significant difference between the steady-state level of DNA
damage of the two isogenic cell lines. The latter observations
suggest that, if any, only a marginal involvement of the other
pathways, besides BER, may account for the observed effects on
cell viability exerted by the genotoxicants used in this study,
which, besides AP sites, may cause DNA-strand breaks.
Collectively, these data indicate that NPM1 is essential for cell
protection from different genotoxic treatments that elicit a BER
response.
The lower APE1 BER activity of NPM1 / cells is rescued by NPM1
reconstitution
To define the BER defect accompanying NPM1 deficiency, we
measured the APE1 enzymatic activity in nuclear extracts from the
two MEF cell lines. Endonuclease assays showed that despite the
higher expression levels of APE1 protein in NPM1 / cells, their
AP endonuclease activity did not significantly differ from that of
the control cells (Figure 2a). Treatment of the two cell lines with
two different APE1 inhibitors (that is, methoxyamine39 and
compound 344) alone demonstrated that NPM1 / cells were
significantly more sensitive to AP endonuclease activity inhibition,
confirming the hypothesis that APE1 functional activity, under
genotoxic conditions, strictly depends on NPM1 expression
Figure 1. Absence of NPM1 is associated to a higher sensitivity of cells to genotoxic treatments causing DNA lesions repaired through BER.
(a) Left: representative western blotting analysis of MEF-NPM1þ /þ and NPM1 / nuclear extracts of three independent subfractionation
experiments. Nuclear cell extracts of 5 mg of the two cell lines were analyzed through western blotting for the expression of APE1 and NPM1
content. Lysine demethylase (LSD1) was used as nuclear marker and loading control, whereas tubulin was used to evaluate cytoplasmic
contaminations. Right: relative percentages of chemiluminescence intensity of APE1 signals are reported in the histogram showing a
significant increase of APE1 nuclear expression in NPM1 / clone (40±9%) with respect to NPM1þ /þ cells. Histograms, showing the amount
of APE1 nuclear protein, represent the mean±s.d. values of three independent experiments. (b) APE1 subcellular localization was detected
through confocal analysis on MEF-NPM1þ /þ and NPM1 / cells using a specific monoclonal a-APE1 antibody and a secondary antibody a-
mouse conjugated with Rhodamine-Red. Yellow arrows indicate APE1 accumulation within nucleoli. A diffused nuclear staining without
nucleolar accumulation could be observed in the NPM1 / cells. (c) Confocal analysis of APE1/NPM1 colocalization in MEF-NPM1 / after
reexpression of NPM1. NPM1 / cells transfected with the empty vector (Empty) showed a uniform nuclear staining for APE1 (red). On the
contrary, NPM1 / cells transfected with pCMV5.1 vector expressing NPM1 in fusion with a C-term FLAG (NPM1 rec.) show APE1
accumulation within nucleolar structure and colocalization with NPM1 (yellow arrows). (d) MTS assay was used to evaluate cell viability of
MEF-NPM1þ /þ and NPM1 / cells after treatment with increasing amounts of MMS for 8 h. Absence of NPM1 negatively affects cell viability
making NPM1 / cells more sensitive to genotoxic damages. Mean±s.d. values are the result of three independent experiments. (e) The
amount of abasic (AP) sites was measured in MEF-NPM1þ /þ and NPM1 / cells under basal conditions and after treatment with 0.5mM of
MMS for 4 h. NPM1 / cells display a significantly higher amount of AP sites if compared with NPM1þ /þ cells. Treatment with an alkylating
agent leads to the accumulation of AP sites in NPM1 / cells (5.14±0.25/105 bp) if compared with NPM1þ /þ cells (3.58±0.20/105 bp).
Mean±s.d. values are the result of three independent experiments. (f ) MTS assay was used to evaluate cell viability of MEF-NPM1þ /þ and
NPM1 / cells. After Potassium bromate (40mM for 30min) treatment, cells were allowed to recover for the indicated periods of time.
Absence of NPM1 negatively affects cell viability, making NPM1 / cells more sensitive to genotoxic damages. Mean±s.d. values are the
result of three independent experiments. (g) Trypan blue cell counting was used to measure cytotoxicity of BLM in MEF cells. Mean±s.d.
values are the result of three independent experiments.
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(Figures 2b and c). We circumstantiated these findings by
measuring the endonuclease activity of APE1, using nuclear
extracts of MEF cells after normalization for APE1 content.
Consistent with our previous in vitro findings,17 APE1
endonuclease activity in NPM1 / extracts was significantly
lower than that from NPM1þ /þ cells (Figure 2d). Thus, the
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increased APE1 nuclear content observed in NPM1 / cells could
reflect a compensatory mechanism to maintain overall BER activity
that still remains insufficient to efficiently correct genotoxic damage.
To confirm that the APE1 defect observed in NPM1 / cells
was due to NPM1 loss, rather than some other effect of the
knockout gene, we restored NPM1 in the NPM1 / cell lines by
ectopic expression of the WT protein from a plasmid vector and
measured the AP endonuclease activity in these cells (Figure 2e).
The results showed that NPM1 reexpression in NPM1 / cells
increased their AP endonuclease activity when compared with
control cells transfected with the empty expression vector. We
biologically circumstantiated these biochemical data, by performing
cell viability experiments in stable cell lines reexpressing the WT
NPM1 protein in the NPM1 / background. Data reported in
Figure 2f confirmed the hypothesis made, clearly showing that
reexpression of NPM1 significantly reduced the sensitivity of
NPM1 / cells to genotoxic treatment.
Collectively, our data demonstrate that NPM1 is a novel indirect
effector of BER by regulating APE1 localization and activity in vivo.
Ectopic expression of the NPM1cþ AML protein causes increased
cytoplasmic APE1 localization in HeLa cells
We examined the oncological relevance of our findings by testing
the effect of the NPM1cþ mutation on BER, and by studying the
effect of NPM1cþ on the APE1–NPM1 interaction. To address the
latter, we assessed the extent of APE1–NPM1 interaction using the
proximity ligation assay (PLA).45 HeLa cells expressing the
NPM1cþmutant protein showed relocalization of NPM1 to the
cytoplasmic compartment of the protein. As expected, the control
WT protein presented its typical nucleolar staining (Figure 3a). The
specificity of the PLA analysis was tested by comparing the ability
of NPM1 to interact with APE1WT, or with an APE1ND33-deletion
mutant that has lower affinity for NPM1.17 Specificity was clearly
demonstrated (Supplementary Figure S7 and Supplementary
Movies) by the presence of nuclear and nucleolar PLA spots only
when APE1WT was expressed. When the APE1ND33 protein was
instead expressed, the PLA signals were reduced in number and
relocalized to the cytoplasmic compartment in accordance with
APE1ND33 pancellular localization. We then tested the ability of the
NPM1cþ 46 mutant protein to interact with Flag-tagged APE1
protein. In control cells (NPM1WT), the APE1–NPM1 interaction
occurred primarily in the nucleolar and nucleoplasmic compart-
ments, whereas the interaction with NPM1cþ protein was mostly
apparent in the cytoplasmic compartment (Figure 3b). Quantifica-
tion of these results, through scoring of the PLA signals, showed
that the NPM1cþ mutation significantly reduced the APE1–NPM1
association within the nuclei of transfected cells, leading to a
significant increase of the APE1–NPM1 interaction within the
cytoplasmic compartment. Accordingly, only in the case of cells
expressing the NPM1cþmutant protein, the APE1 staining was
extranuclear, consistent with the PLA signal distribution (Figures
3b and c). These observations indicate the existence of a direct
correlation between expression of the NPM1cþ protein and the
presence of APE1 in the cytoplasm.
NPM1cþ expression is associated with altered APE1 protein
stability in both AML cell lines and blasts from AML patients
We assessed the biochemical relevance of the APE1 cytoplasmic
relocalization due to NPM1cþ expression in the myeloid cell line
OCI/AML3, which stably expresses a NPM1cþmutant protein.47
We analyzed the distribution of APE1 using IF and by
quantification of the nuclear and cytoplasmic levels of APE1 in
subcellular fractions of OCI/AML3 and control OCI/AML2 cell lines
through western blot analysis. The mRNA expression levels of
APE1 were similar between the two cell lines, as demonstrated by
quantitative PCR analyses (data not shown). IF analysis showed
that NPM1cþ expression was associated with APE1 accumulation
in the cytoplasmic compartment of OCI/AML3 cells (Figure 4a).
Immunoblot analysis indicated that a significant amount of
truncated APE1 protein could be detected in the whole and in
the cytoplasmic extracts of OCI/AML3 cell line (Figure 4b).
Strikingly, accumulation of this truncated protein form was also
apparent in blasts from AML patients (Figure 4c), confirming the
biological relevance of this observation. Several groups have
demonstrated that APE1 is targeted by granzymes A and K, to
generate truncation products (APE1ND31-35) that functionally
inactivate APE1 in DNA repair and to take part in apoptosis.48–50
We have also recently shown that expression of non-cleavable
proficient form of APE1 protein protects cells from genotoxic
stresses,51 thus confirming that the N-terminal deletion of the
protein causes its functional impairment in vivo. This truncated
protein corresponded to the APE1ND33 truncation derivative
already described,48–50 but was due to a specific proteolytic
activity, independent of granzyme A protein, which is not
expressed in these cell lines (Lirussi et al., in preparation).
Figure 2. Absence of NPM1 negatively affects APE1 endonuclease activity. (a) The same amount of whole-cell extracts (600 ng) from MEF-
NPM1þ /þ and NPM1 / was used to evaluate APE1’s endonuclease activity in the two cell lines. A representative image shows the
conversion of the substrate (S) to product (P) operated by APE1. In the diagram on the right, the mean±s.d. values of the densitometric
analyses of three independent experiments are reported. (b) MTS assay was used to evaluate cell viability of MEF-NPM1þ /þ and NPM1 /
cells after treatment with increasing amount of methoxyamine (MX) for 24 h. Absence of NPM1 negatively affects cell viability, making
NPM1 / cells more sensitive to the damage. Mean±s.d. values are the result of three independent experiments. (c) WST-8 assay was used to
evaluate the sensitization of MEF-NPM1þ /þ and NPM1 / cells to the inhibition of the APE1 endonuclease activity. Cells were incubated
with the indicated amounts of the APE1-inhibitor compound 3, and viability was measured 24 h later. Mean±s.d. values are the result of three
independent experiments. (d) Left: on the basis of western blotting analysis of MEF-NPM1þ /þ and NPM1 / cells reported in Figure 1a,
normalized amount of nuclear cell extract (NCE) was loaded onto SDS–PAGE to obtain equal amounts of APE1. Immunoblot analysis
confirmed the presence of the same amount of APE1 protein in the nuclear extracts of the two cell lines. LSD1 was used as nuclear marker,
whereas tubulin was used to evaluate cytoplasmic contaminations. Right: normalized amount of NCE from both cell lines was used to evaluate
APE1 endonuclease activity. A representative image shows the conversion of the substrate (S) to product (P) operated by APE1. In the diagram
below are reported the mean±s.d. values of the densitometric analysis of three independent experiments. (e) Left: MEF-NPM1 / cells were
transiently transfected with pCMV5.1 vector expressing NPM1 in fusion with a C-term FLAG (NPM1 rec.) or the empty vector (Empty) as
control. Total cell extracts of 7.5 mg from Empty and NPM1-transfected cells were separated onto SDS–PAGE, and western blotting analysis was
performed using a-NPM1 and a-APE1 antibodies. Right: cell extracts of 50 ng from Empty and NPM1-reconstituted MEF-NPM1 / cells were
used to evaluate APE1 endonuclease activity. The representative image reported shows the conversion of the substrate (S) to product
(P) by the endonuclease activity of APE1. In the diagram below are reported the mean±s.d. values of the densitometric analyses of three
independent experiments. (f ) Left: MEF-NPM1 / cells were stably transfected with p3X-FLAG-CMV vector expressing NPM1 in fusion with a
C-term FLAG (NPM1) or the empty vector (Empty) as control. Total cell extracts of 7.5 mg of each clone were separated onto SDS–PAGE, and
western blotting analysis was performed using a-NPM1 and a-tubulin antibodies. Right: MTS assay was used to evaluate cell viability of MEF-
NPM1 / cells reconstituted with NPM1 after treatment with increasing amounts of MMS for 8 h. Reexpression of NPM1 rescues cell viability,
making NPM1 / reconstituted cells less sensitive to genotoxic damages. Mean±s.d. values are the result of three independent experiments.
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Though total APE1 protein levels were comparable between
OCI/AML3 and OCI/AML2 control cells, NPM1cþ expressing cells,
having almost 50% less WT NPM1 protein, have lower APE1
nuclear content (Figure 4b). AP endonuclease assays performed
with nuclear extracts of the two cell lines confirmed that
OCI/AML3 cells have a significantly reduced APE1 DNA incision
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activity (Figure 4d). We then evaluated the ability of the AML cells
to efficiently remove AP sites from the DNA of MMS-treated cells.
As shown in Figure 4e, OCI/AML3 cells retained a significantly
higher level of AP sites both under basal conditions and following
MMS treatment than did OCI/AML2 cells. Cell-viability experiments
were in agreement with these observations showing that OCI/
AML3 cells were significantly more sensitive to MMS treatment
than OCI/AML2 cells (Figure 4f).
To provide additional mechanistic insights into the role of APE1
delocalization in NPM1cþ cells and to prove which of the APE1
known functions (that is, DNA repair or redox) are affected by
NPM1cþ expression accounting for the higher sensitivity of OCI/
AML3 cells to genotoxicants, we performed sensitization experi-
ments to MMS treatment with specific APE1 inhibitors. Methoxy-
amine, as an APE1 DNA-repair inhibitor, and the well-known E3330
redox inhibitor52 were used for this purpose. Data obtained
(Supplementary Fig S8) show that treatment with the DNA-repair
inhibitor, but not with the E3330 redox inhibitor, sensitizes OCI/
AML2 cells to MMS treatment and phenocopies the response of
the NMP1cþ expressing cells. Moreover, this experiment demon-
strates that the functional impairment of the APE1 DNA repair
in NPM1cþ cells does not further increase the sensitivity of
NPM1cþ cells to genotoxic damage.
Altogether, these data allow to conclude that APE1 functional
suppression by NPM1cþ induced relocalization is important for
regulating cellular sensitivity to DNA damage in NPM1cþ cells.
Blasts from AML patients, expressing the NPM1cþmutant protein,
have increased cytoplasmic APE1–NPM1 interaction and show
impaired BER activity
We tested whether the altered interaction between APE1 and
NPM1cþ observed upon ectopic expression of the mutant
protein in cell lines also occurs in blasts from AML patients
constitutively expressing the NPM1cþ protein. IF and PLA
analyses (Figures 5a and b) clearly showed that the NPM1cþ
mutations leads to a reduction of the APE1/NPM1 interaction in
nuclei, coupled to a strong increase of the APE1/NPM1 association
in the cytoplasms of AML blasts. This phenotype is associated with
the relocalization of APE1 protein to the cytoplasm, as previously
observed in a heterologous cell system (Figure 3b).
To evaluate the physiological relevance of the altered interac-
tion between APE1 and NPM1cþ , we compared the sensitivity of
blasts from AML patients expressing either the WT or the cþ form
of NPM1 with that of healthy donors to DNA-alkylation damage
induced by MMS. Cell-viability experiments demonstrated that
blasts from AML patients expressing the NPM1cþ form were
significantly more sensitive to MMS than healthy control cells and
AML-WT NPM1 blasts (Figure 5c). These data support the
conclusion that alteration of APE1 distribution due to the
NPM1cþ mutation has a significant impact on the BER activity
in vivo and has a functional relevance in AML pathogenesis.
DISCUSSION
Here we demonstrated that NPM1 has an indirect but significant
role in BER through functional regulation of the APE1 endonu-
clease activity. This observation is the first evidence highlighting a
clear function of NPM1 in DNA repair, and these new results
provide a possible alternative explanation for a role of NPM1 in
the maintenance of genomic stability in addition to its known
effect on p53 stability.2,3 It has been recently shown that
homologous recombination-impaired BRCA-deficient cells are
hypersensitive to poly (ADP-ribose) polymerase inhibitors that
block repair of single-strand breaks, a subpathway of BER.
Interestingly, NPM1 functionally interacts with BRCA2 having a
role in centrosome duplication.53 Therefore, it could be speculated
that the differential sensitivity of NPM1 / cells to genotoxicants
used in this study could be ascribed to an impaired ability of these
cells to repair DNA-strand breaks. However, our data showing no
differential sensitivity to poly (ADP-ribose) polymerase inhibitors,
together with a similar efficiency of repair of strand breaks (as
measured through comet assays) by the two isogenic cell lines,
would exclude this hypothesis, leaving BER impairment as the
main process affected by the loss of NPM1 expression. Moreover,
our findings may illuminate the prompt response to
chemotherapy of AML expressing the NPM1cþ mutation. Our
data support the hypothesis that some biological effects of
NPM1cþ may be exerted through impaired functions of
important NPM1-interacting proteins caused by their abnormal
cytoplasmic localization.1,8–13
APE1 subcellular distribution within different cell types is mainly
nuclear and critically controls the cellular proliferation rate,54–56
however, in some tumors APE1 can be cytoplasmic or nuclear/
cytoplasmic.18,28 Increased expression of APE1 is associated with
different tumorigenic processes.28 In particular, a higher
expression of APE1, with consequently increased BER activity,
has been described in several cancer types,28 where it correlates
with a higher tumor aggressiveness and is associated with
chemoresistance.18 Extranuclear APE1 has a role within
mitochondria in repairing mitochondrial DNA damage57–59 and
in controlling the intracellular reactive oxygen species production
through inhibition of Rac1.60,61 However, a possible causal role of
an increased APE1 expression in tumorigenesis, as well as the
mechanisms responsible for the unusual APE1 accumulation in the
cytoplasmic compartment, has never been investigated in detail.
The observations reported herein provide a molecular explana-
tion for the delocalization of APE1 to the cytoplasm observed in
AML tumors associated with NPM1cþ . Because APE1 interacts
with many different partners involved in RNA metabolism,17,31,37
the occurrence of extranuclear APE1 localization may be explained
on the basis of altered expression levels of its protein partners that
may undergo delocalization, as is the case of NPM1cþ itself.
Alternatively, increased expression of APE1 cytoplasmic partners,
rather than mutations occurring in APE1 itself, may directly affect
the distribution of the protein. Notably, no polymorphisms
Figure 3. NPM1 mutation alters APE1 localization in HeLa cells. (a) Representative confocal microscopy images of HeLa cells transiently
transfected with pcDNA-HA vectors expressing WT NPM1 or the NPM1cþ mutant. Twenty-four hours after transfection cells were fixed and
stained with a primary antibody a-HA-Tag and a secondary antibody a-rabbit conjugated with Rhodamine Red. In cells expressing WT NPM1,
the ectopic HA-tagged protein localizes, as expected, only within the granular component of nucleoli. On the contrary, cells expressing
NPM1cþ mutant show also strong cytoplasm positivity. (b) PLA technology was used on HeLa cells to quantify the occurrence of in vivo
interaction between APE1 and NPM1. Cells were transiently transfected with APE1-FLAG and NPM1-HA-WT or the NPM1cþ mutant. Confocal
microscopy analysis highlights the presence of distinct fluorescent red dots (PLA signals), indicating the occurrence of in vivo interaction
between APE1-FLAG and NPM1-HA, whereas green fluorescence shows APE1-FLAG-tagged protein localization. PLA control is represented by
cells incubated only with a-FLAG antibody. In cells transfected with WT NPM1, APE1 accumulates within the nucleus where also PLA signals
are mostly present. In NPM1cþ expressing cells, a diffused cytoplasmic APE1 staining could be observed along with the relocalization of PLA
signal. (c) Blob Finder software was used to quantify the relative distribution of PLA signals between nucleus and cytoplasm of cells transfected
with WT NPM1 or NPM1cþmutant. In NPM1cþ expressing cells, most of the interaction between APE1 and NPM1 occurs within the
cytoplasm (nuclear: 26±7%), whereas in WT NPM1 cells, PLA signal is predominantly nuclear (nuclear: 79±8%). Reported results are the mean
of 30 cells for each condition.
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Figure 4. NPM1cþ mutation alters APE1 subcellular localization and affects its endonuclease activity in OCI/AML3 cell line. (a) Representative
images of fluorescence microscopy analysis of APE1 on OCI/AML2 (WT NPM1) and OCI/AML3 (NPM1cþ ) cell lines. A total of 2 104 cells were
centrifuged onto glass slides using a cytospin, and IF was performed as reported in Materials and Methods section. A secondary a-mouse
Rhodamine Red-conjugated antibody was used to visualize APE1. Nuclei are stained with 4’,6-diamidino-2-phenylindole. A predominant cytoplasmic
positivity of APE1 could be observed in OCI/AML3 cells only, linking NPM1cþ mutation with APE1 cytoplasmic relocalization. (b) In all, 10mg of total
cell extract (WCE), 10mg of cytoplasmic cell extract (CCE) and 5mg of nuclear cell extract (NCE) of OCI/AML2 and 3 were separated onto SDS–PAGE,
immunoblotted and analyzed for their content of APE1 and NPM1 (WT and cþ ). NPM1cþ protein was detected with a specific antibody
recognizing only the NPM1cþmutant form.47 Western blotting analysis showed the presence of truncated APE1 protein (*) only in the whole and
cytoplasmic extracts from OCI/AML3 cell line. Actin was used as loading control, whereas tubulin and LSD1 were used as markers of cytoplasmic and
nuclear fraction enrichment, respectively. (c) Total cell extracts of 10mg from OCI/AML2 and 3 and of blast from AML patients expressing WT NPM
and NPM1cþ mutant were separated onto SDS–PAGE, immunoblotted and analyzed for their APE1 content. The expression of NPM1cþmutant
form is associated with the presence of truncated APE1 protein (*) in extracts from both the OCI/AML3 cell line and blasts from a patient carrying this
mutation. Actin was used as loading control. (d) OCI/AML2 and OCI/AML3 nuclear cell extracts of 50ng were used to evaluate the APE1
endonuclease activity. A representative image shows the conversion of the substrate (S) to product (P) operated by APE1. OCI/AML3 cells show
lower AP-incision activity, in accordance with the decreased nuclear APE1 content. The diagram below reports the mean±s.d. values obtained from
the densitometric analysis of three independent experiments. (e) The amount of abasic (AP) sites was measured in OCI/AML2 and OCI/AML3 cells
under basal conditions and after treatment with 0.5 and 1mM MMS for 4h. OCI/AML3 cells display a significantly higher amount of AP sites if
compared with OCI/AML2 cells. Mean±s.d. values are the result of three independent experiments. (f ) CellTiter-Glo Luminescent Cell Viability assay
was used to evaluate the sensitization of OCI/AML2 and OCI/AML3 cells to MMS. Cells were incubated with the indicated amounts of MMS for 8h.
Expression of NPM1cþ negatively affects cell viability. Mean±s.d. values are the result of three independent experiments.
NPM1cþ protein impairs APE1 function in AML
C Vascotto et al
8
Oncogene (2013), 1 – 12 & 2013 Macmillan Publishers Limited
APE1 MergedDAPI NPM1
CT
RL
A
M
L
10m 10m
CT
RL
APE1 PLA-Cy3 Merged
A
M
L
*
*
*p<0.05
0%
20%
40%
60%
80%
100%
120%
0 200 500
Ce
ll 
vi
ab
ili
ty
CTRL
NPM1-WT
NPM1-c+
10m 10m
10m10m10m10m
5m 5m 5m
5m5m5m
MMS (M)
Figure 5. NPM1 mutation alters APE1 localization, reducing cell resistance to genotoxic damage in blasts from AML patients. (a) Representative
images of fluorescence microscopy analysis of APE1 and NPM1 on blasts from AML patients (AML) carrying NPM1cþ mutation and healthy
donors (CTRL). A total of 2 104 cells were centrifuged onto glass slides using a cytospin, and IF analyses were performed as reported in Materials
and Methods section. A secondary a-mouse-Alexa Fluor 488-conjugated antibody was used to visualize APE1 (green), and a secondary a-rabbit-
Rhodamine-conjugated antibody was used to visualize NPM1 (red). Nuclei are stained with 4’,6-diamidino-2-phenylindole. In merged images,
yellow arrows indicate the occurrence of colocalization between APE1 and NPM1. In control cells, NPM1 accumulates within nucleoli while being
mainly excluded from this subcellular compartment in blasts from AML patients, which show a predominant cytoplasmic positivity. Accordingly,
APE1 delocalizes from nucleus to cytoplasm in blasts from AML patients. (b) Representative images of PLA analysis to evaluate the interaction
between APE1 and NPM1 on blasts from AML patients (AML) carrying NPM1cþ mutation and healthy donors (CTRL). A total of 2.5 104 cells
were centrifuged onto glass slides using a cytospin, and PLA was performed as reported in Materials and Methods section. APE1 (green)
accumulates within the nucleus in control cells while being mainly excluded from this subcellular compartment in blasts from AML patients. In
accordance, also PLA signal delocalizes from nucleus to cytoplasm in blasts from AML patients. (c) Cell viability of blasts from healthy donors
(CTRL, n¼ 3), AML patients expressing WT NPM1 (NPM1-WT, n¼ 3) or the NPM1cþmutant form (NPM1cþ , n¼ 4) after 4h of treatment with the
indicated doses of MMS was measured through the MTS assay. AML cells expressing the NPM1-cþ are more sensitive to the alkylating agent than
blasts from healthy donors and AML patients expressing the NPM1-WT form. Mean±s.d. values are the result of three independent experiments.
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occurring on the known bipartite NLS of APE1 have been
described so far, nor alternative splicing forms have been
found that could explain the cytoplasmic accumulation of APE1
in tumors. As the majority of the polymorphisms described in
literature involve residues not responsible for either the DNA
repair or the redox functions of the protein, but rather changes that
often fall within the N domain involved in protein–protein
interactions and protein stability,33,62 a reasonable explanation for
the delocalization of the protein observed in tumors may be
ascribed to alterations of a complex network of interactions
affecting, in turn, APE1 functional status. Here, we showed that in
OCI/AML3 cells expressing the NPM1cþ allele, as well as in blasts
from AML patients, APE1 protein is destabilized (Figures 4b and c). It
can be inferred that, similarly to the case of p19Arf, the physiological
function of NPM1 is to ensure the proper localization of APE1 and
to protect it from degradation, being possible that NPM1 protein
may function as a chaperone for APE1, allowing its correct folding.
Our model (Figure 6a) is in accordance and further extends a
previous one1 trying to explain the relative contribution (direct or
indirect) of NPM1 expression to cellular transformation. Our model
takes into account the evidence that tumors of hematopoietic
origin, such as AML, are associated with WT NPM1 deficiency,
whereas a number of solid tumors (that is, gastric, hepatic and
ovarian) show increased expression of WT NPM1. In the first case,
the contribution of a NPM1 mutation is causally linked to the
transformation process. Indeed, reduced nuclear NPM1 levels, as a
consequence of the mutation of one WT allele, may lead to genomic
instability due to BER impairment, and thus to an increased cellular
burden of DNA damage. Therefore, the impaired DNA-damage
response may block cell proliferation inefficiently, such that some
cells would escape the checkpoint and establish an immortalized
clone prone to further oncogenic transformation. Alternatively
(Figure 6b), elevated WT NPM1 expression levels would contribute
to the generation of permissive condition for oncogenic transforma-
tion. In that case, the presence of high NPM1 levels may limit DNA
damage and promote the DNA-damage response (due to increased
BER), associated with oncogenic stress signals in a normal cell, and
therefore may support cell survival and eventually transformation.
This model could also involve the APE1 protein in two ways: through
an impaired BER response and the resulting genetic instability; and
through the establishment of conditions permissive for transforma-
tion. Our evidence suggests that defects in the APE1–NPM1
interaction can be associated with the genomic instability observed
in tumors, which supports the concept that interfering with this
interaction may sensitize cancer cells to chemotherapy and
radiotherapy.
MATERIALS AND METHODS
Cell lines and materials
HeLa, MEF p53 / /NPM1þ /þ (NPM1þ /þ )36 and MEF p53 / /NPM1 /
(NPM1 / )36 cell lines were grown in Dulbecco’s modified Eagle’s medium
(Euroclone, Milan, Italy) supplemented with 10% fetal bovine serum
(Euroclone), 100U/ml penicillin and 10mg/ml streptomycin sulfate. OCI/
AML2 and 3 cells were grown in alpha-MEM (Euroclone) supplemented with
20% fetal bovine serum, 100U/ml penicillin and 10mg/ml streptomycin
sulfate. Leukemic cells were obtained from the bone marrow of patients with
acute leukemia during diagnostic procedures. Mononuclear cells were
separated on a Ficoll–Hystopaque 1077 (Sigma Aldrich, Milan, Italy) density
gradient, then were washed twice in phosphate-buffered saline, checked for
viability by using the trypan blue exclusion test and suspended in phosphate-
buffered saline. Presence of mutations in the NPM1 gene was detected as
previously described.63 Blast from patients were grown in RPMI (Invitrogen,
Monza, Italy) supplemented with 20% fetal bovine serum. Stable cell lines
reexpressing WT NPM1 in the NPM1 / background were obtained as
previously described.17 All chemical reagents were supplied from Sigma
Aldrich unless otherwise specified.
Cell-viability analyses
Cell viability was measured by using the MTS assay (Promega, Milan, Italy) on
MEF cells (5 103 cells) and blasts from patients (60 103 cells) grown in 96-
well plates. Cells were plated, and after MMS, KBrO3 or acute H2O2 treatment,
20ml of MTS solution was added to each well and plates were incubated for
2h at 37 1C. Absorbance (at 490nm) was measured by using a multiwell plate
reader. The values were standardized to wells containing media alone.
Cytotoxicity induced by BLM was evaluated using a trypan blue exclusion
assay. A total of 4 104 cells per well were plated in six-well plates, treated
for 60min with reported amounts of BLM and then grown for 2 additional
days in fresh media. Cell viability for OCI/AML cell lines (2.5 104 cells) was
measured by CellTiter-Glo Luminescent Cell Viability Assay (Promega)
according to the manufacturer’s protocol. Cells were incubated with the
indicated doses of MMS for 8h at 37 1C in agitation. Luminescent signals
were measured using the Turner BioSystems Luminometer (Promega). Cell
survival upon inhibition of APE1 AP endonuclease activity was measured with
the WST-8 assay. MEF cells were seeded onto 96-well plates (6 103 cells)
and allowed to adhere for 24h. MEFs were then incubated with the
indicated amounts of compound 3 (N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl
-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide),44 and viability was
measured 24 h later using the CCK-8 Kit (Dojindo, Munich, Germany) as
per the manufacturer’s instructions.
Plasmid preparation
The construct pcDNA3-HA-NPM1cþ was generated by using the
Quickchange II XL Mutagenesis kit (Stratagene, Milan, Italy) and the
pcDNA3-HA-NPM1-WT as template following the manufacturer’s instruc-
tions. Direct sequencing was performed in order to verify the sequence
accuracy. WT NPM1 and NPM1cþ cDNA were also subcloned in
pCMV5.1-FLAG and p3X-FLAG-CMV vectors for reconstitution experiments
on MEF-NPM1 / cells.
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Figure 6. Relative contribution of NPM1/APE1 expression to cellular
transformation: a model for APE1 role in tumorigenesis? (a) Reduced
NPM1 levels due to loss of one WT allele leads to genomic instability
through impairment of BER and increased DNA damage. As a
consequence, the DNA-damage response blocks cellular prolifera-
tion. Few cells may escape the block and establish an immortalized
clone prone to be transformed by oncogene activation. (b)
Oncogene activation in a normal cell leads to unscheduled DNA
replication and DNA damage. Cellular checkpoints are activated
favoring apoptosis or senescence as response to uncontrolled
proliferative signals. The presence of high NPM1/APE1 levels may
limit DNA damage and DNA-damage response, and therefore
support cell survival and eventually transformation. This model also
includes APE1 protein both in the first case as having a causative
role in the transformation process itself and in the second case, in
which NPM1 and APE1 expression levels are simultaneously
elevated, generating a permissive condition for transformation.
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AP-sites measurements
Genomic DNA was isolated from 2 106 cells by using the DNAzol Reagent
(Invitrogen), and then concentration and purity were determined spectro-
photometrically. Samples of 0.1mg/ml of genomic DNA were analyzed to
quantify abasic damage in chromosomal DNA using the DNA Damage
Quantification Kit (Dojindo) according to the manufacturer’s instructions.
IF and PLA analysis
For IF analysis on HeLa and MEFs, cells were grown on glass coverslips,
whereas blasts and OCI/AML 2 and 3 cells were centrifuged onto glass
slides using a cytospin. Then, cells were fixed with 4% (wt/vol)
paraformaldehyde for 20min at room temperature and permeabilized
for 5min with phosphate-buffered saline–0.25% (vol/vol) Triton X-100.
Cells were incubated for 30min with 10% fetal bovine serum in TBS–0.1%
(vol/vol) Tween 20 (blocking solution) to block unspecific binding of the
antibodies. Cells were then incubated with primary antibodies diluted in
blocking solutions: monoclonal-a-APE1 (diluted 1:50, 3 h, 37 1C), polyclonal
a-NPM1 (diluted 1:200, overnight, 4 1C), monoclonal a-FLAG-FITC-
conjugated (diluted 1:100, 3 h, 37 1C) and polyclonal a-HA (diluted 1:500,
overnight, 4 1C). Then cells were washed three times for 5min each with
TBS–0.1% (vol/vol) Tween 20 (Washing Solution) and incubated with
secondary antibody: a-mouse or a-rabbit Rhodamine Red-conjugated or
Alexa Fluor 488-conjugated (diluted 1:200, 2 h, 25 1C) (Jackson Immuno,
West Grove, PA, USA). After washing three times, coverslips were mounted
on microscope slides with a mounting media containing 4’,6-diamidino-2-
phenylindole and an anti-fade reagent. For PLA analysis on blasts from
patient’s primary antibody a-APE1 was previously labeled with the Zenon
a-Mouse IgG Labeling Kit (Invitrogen) using the Alexa Fluor 488 according
to the manufacturer’s instructions.
To study the interaction of APE1 with NPM1 in vivo, we used the in situ
PLA technology (Olink Bioscience, Uppsala, Sweden). After incubation with
monoclonal a-APE1 (1:50) or a-FLAG antibody (1:100) for 3 h at 37 1C, cells
were incubated with polyclonal a-NPM1 (1:200) or polyclonal a-HA
antibody (Sigma-Aldrich) (1:500) overnight at 4 1C. PLA was performed
following the manufacturer’s instructions and as previously reported.36
Technical controls, represented by the omission of a-NPM1/a-HA primary
antibody, resulted in the complete loss of PLA signal. Images were
captured through a confocal microscope, and quantification of PLA signal
was performed using the Blob Finder software (Center for Image Analysis,
Uppsala University).
Cells were visualized through a Leica TCS SP laser-scanning
confocal microscope (Leica Microsystems, Milan, Italy) or a DMB6000B
inverted microscope equipped with a DFC300FX digital camera
(Leica Microsystems).
Preparation of cell extracts and protein quantification
Cell extracts were prepared as already described in Vascotto et al.17 and as
reported in Supplementary Information.
Cell transfection and western blotting analyses
Plasmids were prepared and used for transfection and western blotting
analysis, as already described in Fantini et al.30 and as reported in
Supplementary Information.
Incision assays on abasic double-stranded DNA
APE1 endonuclease activity was evaluated as already described17 and as
reported in Supplementary Information.
Statistical analysis
Statistical analysis on biological data was performed using the Microsoft
Excel data analysis program for Student’s t-test analysis.
ABBREVIATIONS
AML, acute myeloid leukemia; APE1/Ref-1, apurinic/apyrimidinic
endonuclease 1/redox effector factor 1; BER, base excision DNA
repair; NPM1, nucleophosmin 1.
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ABSTRACT
Objectives: To correlate the expression profile of human 
apurinic endonuclease/redox factor 1 (APE1/Ref-1) with that 
of nucleolar/nucleoplasmic protein nucleophosmin 1 (NPM1) 
in association with the aggressiveness and progression of 
high-grade ovarian serous cancer.
Methods: Retrospective study analyzing a tissue microarray 
of 73 women affected by high-grade ovarian serous cancer. 
Protein expression was assessed by immunohistochemistry 
on primary tumor masses and synchronous peritoneal 
metastases if present.
Results: APE1/Ref-1 and NPM1 showed a significant 
correlation in ovarian serous cancer. Patients with a 
poorer outcome showed a significant overexpression 
of nuclear NPM1 protein. A Cox proportional hazards 
multivariate regression model revealed NPM1 expression 
to be independently significant for overall survival in high-
grade ovarian serous cancers after correcting for stage, age, 
cytoreduction completeness, and platinum resistance.
Conclusions: APE1/Ref-1 interacts with NPM1 to control 
the DNA damage repair system, and it is likely that this 
interaction plays a defining role in high-grade ovarian 
serous carcinoma. A high NPM1 immunohistochemical 
expression was independently correlated with a shorter 
survival period and thus appears to be an important 
prognostic factor.
Ovarian cancer occurs relatively rarely (accounting for 
3.1% of female cancers in our region of Italy), but it is a 
leading cause of death among gynecologic malignancies as a 
result of three key tensions: the advanced stage of the tumor 
at diagnosis, the high frequency of recurrences, and its highly 
chemoresistant nature. Despite an improvement in survival 
in the past years—due to a more effective combination of 
surgery and empirically optimized cytotoxic drugs—the over-
all cure rate remains low.1 A hallmark of high-grade serous 
carcinoma is defective homologous DNA repair. The new-
est breakthrough in treatment is poly adenosine diphosphate 
ribose polymerase inhibitors,2 which suppress the ability 
of cells to repair single-strand DNA breaks, leading to cell 
death (for tumor cells that lack homologous repair capability). 
The use of alternative DNA repair inhibitors as a therapeutic 
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strategy presents an interesting avenue for exploration, and 
the study of the DNA repair system in ovarian cancer is the 
first step in this direction.
DNA repair mechanisms appear to play out both in the 
development and chemoresistance of ovarian cancer.1,3 In 
this article, we focus on the immunohistochemical expression 
of two proteins involved in DNA repair mechanisms: human 
apurinic endonuclease/redox factor 1 (APE1/Ref-1) and 
nucleolar/nucleoplasmic protein nucleophosmin 1 (NPM1).
The DNA base excision repair (BER) pathway repairs 
DNA damage caused by various agents, including chemo-
therapeutics such as bleomycins, cisplatin, alkylating agents, 
and ionizing radiations, generating abasic (AP) sites.4-8 APE1/
Ref-1 is the main apurinic/apyrimidinic endonuclease in 
mammalian cells and catalyzes the removal of the abasic site, 
a rate-limiting step in BER.9 It does this by hydrolyzing the 5′ 
phosphodiester bond of the AP site to generate a DNA inter-
mediate that contains a single-strand break with 3′-hydroxyl 
and deoxy-ribose-5′-phosphate (5′-dRp) termini. However, 
APE1/Ref-1 can generate a 3′-hydroxyl terminus in other 
ways: through its 3′-5′ exonuclease activity, APE1/Ref-1 can 
remove a 3′-phospho-a,b-unsaturated aldehyde, formed by 
complex glycosylases and by radiation.4 APE1/Ref-1 can also 
remove a 3′ terminal phosphate (through its 3′ phosphatase 
activity), produced by glycosylases NEIL1 and NEIL2.9 As 
such, the APE1/Ref-1 enzyme has a key responsibility for the 
incision of AP sites and the generation of a 3′-OH, a primer 
for Pol-b.4 Upregulation of this ubiquitous and essential pro-
tein is at the core of chemoresistance in several tumors, such 
as hepatic, prostate, and ovarian cancers; accordingly, the 
protein is attracting attention since it offers a promising target 
for combination cancer therapy.4,10
While APE1/Ref-1 essentiality is attributed to its spe-
cific role in BER,11 it has a secondary independent cellular 
function as a redox factor, coactivating several transcription 
factors involved in cancer promotion and progression, such 
as nuclear factor (NF)–kB. It thus plays a causative role in a 
range of inflammatory processes.11,12 Several recent advances 
have centered on the development of new APE1/Ref-1 
inhibitors that interfere with either the DNA repair function 
or the redox activity of the protein.4,10 However, since it is 
hard to separate the roles played by each different APE1/
Ref-1 function in tumor chemoresistance and identify how a 
specific inhibitor would discriminate between untransformed 
and neoplastic cells, these methods potentially present some 
functional limitations.
NPM1 is an abundant protein that resides specifically 
within the granular region of the nucleolus. It is involved 
in a variety of cellular processes, including centrosome 
duplication, maintenance of the genome integrity, and ribo-
some biogenesis.13 It also has a chaperone activity regulated 
by phosphorylation14 and an endoribonuclease activity at a 
specific site of the spacer region between the 5.8S and the 
28S ribosomal RNAs (rRNAs).15 Notably, it has recently been 
demonstrated that the role of NPM1 in centrosome duplica-
tion is triggered by its interaction with BRCA2, a gene with 
germline mutations that are known to be linked to a predispo-
sition to ovarian cancer.16
Recent studies have discovered and characterized the 
molecular interaction between NPM1 and APE1/Ref-1, which 
modulates a new function of APE1/Ref-1 in rRNA metabo-
lism.17,18 This interaction involves Lys27/31/32/35 residues 
of APE1/Ref-1 and the oligomerization domain of NPM1. 
Observations prove that NPM1 has a significant stimulatory 
effect on APE1/Ref-1 DNA repair activity in BER and that 
without this interaction, the proliferation of tumor cell lines is 
affected, thus providing a new means through which APE1/
Ref-1 can affect cell growth and gene expression in cancer 
cells. Accordingly, NPM1–/– cells impair BER and react more 
sensitively to alkylating agents.19 These findings suggest that 
an aberrant APE1/Ref-1–NPM1 functional interaction can be 
linked with the genomic instability of cancers and imply that 
interfering with the APE1/Ref-1–NPM1 dynamic might allow 
for improved sensitization of patients to chemotherapy.
Ovarian cancer, as well as hepatocellular carcinoma, is 
characterized by altered expression and subcellular distribu-
tion of APE1/Ref-1 in relation to normal tissue,20,21 with 
hepatocellular carcinoma also showing increased NPM1 
expression levels.22 Data are not, however, currently avail-
able concerning either the expression of NPM1 in ovarian 
cancer or a possible association between APE1/Ref-1 and 
NPM1 expression levels and cancer progression. This study 
was aimed at filling in this gap. APE1/Ref-1 localization 
is eminently nuclear, while in these tumors, it can be cyto-
plasmic and nuclear/cytoplasmic. Elevated levels of APE1/
Ref-1 have been linked to chemotherapy resistance, poor 
prognosis, and survival11,20 and are related to a higher repair 
activity, suggesting that BER may account for the onset of 
chemoresistance.23-25
In this study, by assessing a cohort comprising 73 
patients affected by high-grade ovarian serous carcinoma, we 
correlated the expression profile of APE1/Ref-1 with that of 
NPM1 in association with the aggressiveness and progression 
of the tumor.
Materials and Methods
Patients and Specimens
From the registry of the Pathology Department of the 
University Hospital of Udine, Udine, Italy, a total of 105 
patients who had a pathologic diagnosis of ovarian serous car-
cinoma between January 2003 and July 2008 were identified. 
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We focused solely on cases involving primary interventions 
with a diagnosis of high-grade ovarian serous carcinoma and 
excluded patients who underwent chemotherapy before sur-
gery. This retrospective study was conducted in accord with 
the code of ethics of the 1975 Declaration of Helsinki. The 
histopathologic grading of these cases was evaluated using 
the Malpica system26 (low and high grade), and we decided 
to include in this study only high-grade ovarian serous carci-
noma, in accordance with literature that considers low- and 
high-grade serous carcinomas as two different types of car-
cinoma.27 This resulted in a total population of 73 patients. 
Excluded cases consisted of 20 patients with intraperitoneal 
recurrences, three who underwent neoadjuvant therapy after 
laparoscopic staging but before primary surgery, and nine 
affected by low-grade ovarian serous cancer. All cases were 
classified into stages according to the International Federa-
tion of Gynecology and Obstetrics (FIGO) staging system28 
(stages I, II, III, and IV) and the TNM classification of 
malignant tumors for ovarian cancer.29 Other information, 
such as clinical history and treatment of each patient, was 
gathered from clinical files. Data collected included age at 
intervention, date and radicality of intervention, contingent 
assumption of any hormonal or nonhormonal therapy, par-
ity, gravidity, last menses before intervention, and informa-
tion on clinical follow-up activities up to January 2011. In 
archived clinical records, follow-up information consisted 
of data collected during medical examination (unexplained 
weight loss, presence of ascites), diagnostic imaging (ultra-
sound, computed tomography [CT], or positron emission 
tomography–fludeoxyglucose/CT), blood tests (increase of 
serum CA125), and second-look surgery. We also made 
detailed notes about any first-line chemotherapy. During the 
study period, patients were treated with either single-agent 
chemotherapy (carboplatin) or platinum-based combina-
tion chemotherapy (carboplatin and paclitaxel) ❚Table 1❚. 
Patients with FIGO stage IA or IB with low-grade tumors 
were not treated with adjuvant chemotherapy (National Com-
prehensive Cancer Network guidelines, http://www.nccn.
org/professionals/physician_gls/f_guidelines.asp). Platinum 
resistance was defined as disease progression during first-line 
chemotherapy or relapse within 6 months after treatment.30
Preparation of Tissue Microarray Slides
The tissue microarray (TMA) technique allows us to 
simultaneously analyze multiple formalin-fixed, paraf-
fin-embedded tissues. H&E-stained sections were care-
fully examined to select representative regions from each 
selected donor block. TMAs were created using a Beecher 
(Sun Prairie, WI) tissue microarrayer, and a cylindrical, 
thin-walled needle (inner diameter of 1.5 mm) was used 
for coring tissues and transferring cored samples into array 
cavities in the recipient block. A total of 73 blocks were 
available, and for each block, we performed two core biop-
sies representing the primary carcinoma (which involved 
one or both ovaries) and the metastasis, where a speci-
men was available. From the recipient block, we obtained 
4-µm-thick transverse sections.
For antigen retrieval and deparaffinization, slides were 
heated for 20 minutes at 98°C in Target Retrieval Solution 
(low pH, K8005; DAKO, Glostrup, Denmark) with PT-link 
(DAKO). The slides were then incubated at room tempera-
ture in hydrogen peroxide (H2O2) for 10 minutes to block 
endogenous peroxidase activity. The sections were rinsed in 
phosphate-buffered saline and then incubated in a wet cham-
ber at room temperature for 1 hour with the following primary 
antibodies: monoclonal APE1/Ref-1 (diluted 1:300; Novus 
Biologicals, Cambridge, England)18 and NPM1 (diluted 
1:200; Invitrogen Life Technologies, Milan, Italy). A DAKO 
REAL EnVision Rabbit/Mouse (K5007) was used as a second 
antibody. Horseradish peroxidase activity was detected using 
DAKO REAL 3,3′-diaminobenzidine + chromogen (K5007) 
as substrate for three minutes in accordance with the manufac-
turer’s instructions. Sections were counterstained with hema-
toxylin with a cover slip. Sections incubated with nonimmune 
rabbit serum instead of the primary antibody were used as 
negative controls.
❚Table 1❚
Population Descriptiona
Characteristic Value
Age at intervention, mean (SD), y 63.6 (12.2)
Menopausal status (n = 73) 56 (77)
Family history of cancer (n = 73) 11 (15)
Adjuvant chemotherapy (n = 73) 70 (96)
Survival after intervention, median (IQR), mo 39 (22-57)
Death from cancer (n = 73) 43 (59)
FIGO staging (n = 73) 
   IA 7 (9)
   IB 0
   IC 4 (6)
   IIA 3 (4)
   IIB 4 (6)
   IIC 6 (8)
   IIIA 7 (9)
   IIIB 14 (19)
   IIIC 26 (36)
   IV 2 (3)
Cytoreduction among stage FIGO III (n = 47) 
   Complete 39 (83)
   Incomplete 8 (17)
First-line chemotherapy (n = 73) 
   Carboplatin monotherapy 9 (12)
   Carboplatin combination therapy 61 (84)
   No chemotherapy 3 (4)
Five-year overall survival, % (95% CI) 
   FIGO I-II 42 (24-75)
   FIGO III-IV 31 (20-49)
CI, confidence interval; FIGO, International Federation of Gynecology and 
Obstetrics; IQR, interquartile range.
a Data are presented as number (%) unless otherwise indicated.
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Semiquantitative analysis of the immunohistochemical 
staining was performed independently by two pathologists 
(M.O. and L.M.), and the staining was semiquantitatively 
evaluated to produce an H-score (the product of the actual 
percentage of positive-stained cells and intensity score—
evaluated as 3 = strong, 2 = moderate, and 1 = weak—giv-
ing a possible range of 0-300). In case of discrepancies, the 
pathologists together reviewed the specimen and gave a final 
shared score. In case of disagreement, they reviewed the case 
with a third pathologist.
Statistical Analysis
Data were analyzed using R (version 2.14.1, R Founda-
tion for Statistical Computing, Vienna, Austria), and P < .05 
was considered significant. For all proteins analyzed, the 
staining was investigated in terms of percentage of positive 
cells and H-score. Normality of variables was tested with 
the Kolmogorov-Smirnov test. Nonparametric data were 
presented with the median value and the interquartile range 
(IQR), whereas parametric data were described with the mean 
value and its standard deviation. The Kruskal-Wallis test and 
the one-way analysis of variance for continuous variables 
were used for the variance analysis where appropriate. For 
comparison of multiple categorical variables, the c2 test was 
used. For bivariate analysis, the following statistical tests were 
applied: the Wilcoxon test, t test, Spearman r, and Kendall t 
for continuous variables and the c2 and Fisher exact tests for 
categorical variables. In this work except where otherwise 
specified, the H-score of the primary ovarian tumor was 
used for survival analysis. Overall survival was analyzed 
using Kaplan-Meier curves and with a log-rank test being 
performed to test for trends. In the Kaplan-Meier survival 
analysis, we divided our population into two sets: one where 
the studied proteins were expressed at a level higher than the 
median value of the distribution and the other in which the 
expression was lower. Last, we performed Cox proportional 
hazards univariate and multivariate regression analysis. All 
potentially influencing factors and their interactions were 
accommodated in a single statistical model, except when the 
interaction term was nonsignificant (in which case, we ana-
lyzed the no-interaction model). All P values presented also 
have been adjusted for multiple comparisons using the Holm-
Bonferroni correction.
Results
Description of the Population
In Table 1, we present the characteristics of our popu-
lation. Twelve percent received single-agent carboplatin 
chemotherapy as their first-line treatment; 84% underwent 
carboplatin combination chemotherapy. The remaining 4% 
received no chemotherapy (FIGO IA or IB). On the basis of 
our retrospective analysis, we found that nine patients were 
platinum resistant at first-line chemotherapy. We also noted 
that all patients who had platinum resistance were classed as 
FIGO stage III or higher. We therefore experienced a 12% 
prevalence of platinum resistance among the total population 
and an 18% prevalence for the subpopulation of patients at 
FIGO stage III and higher.
APE1/Ref-1, NPM1 Protein Expression, and Overall 
Survival
We found APE1/Ref-1 and NPM1 proteins to be 
expressed in the nucleus of high-grade ovarian serous can-
cer cells with median (IQR) H-scores, respectively, of 100 
(20-133) and 10 (0-77) ❚Image 1A❚, ❚Image 1B❚, ❚Image 1C❚, 
and ❚Image 1D❚. Both primary ovarian mass and peritoneal 
metastasis expressed these two proteins in a comparable man-
ner. We recorded median (IQR) APE1/Ref-1 H-scores of 100 
(20-133) in the primary ovarian cancer and 80 (40-130) in 
peritoneal locations (P = .442). Similarly, the median (IQR) 
NPM1 H-score was 10 (0-77) in the primary ovarian location 
and 8 (0-80) in the peritoneal metastasis (again, the difference 
was not significant; P = .765). Furthermore, APE1/Ref-1 and 
NPM1 H-scores in our specimens displayed a significant 
positive correlation, with a r of 0.39 (95% confidence inter-
val [CI], 0.19-0.56; P < .05) ❚Image 1E❚. All nine patients 
with platinum resistance presented a significantly higher 
nuclear APE1/Ref-1 H-score (190; IQR, 190-195) than did 
platinum-sensitive patients (120; IQR, 74-142) (P < .05). 
Moreover, the NPM1 H-score was nonsignificantly higher in 
platinum-resistant patients (median [IQR], 90 [80-100]) than 
in platinum-sensitive patients (52 [20-100]) (P = .300).
We then focused specifically on the set of patients who 
expressed NPM1 or APE1/Ref-1 at levels higher than the 
median value of the distribution (data not shown), and we 
noted differences in overall survival, which we detail below 
❚Figure 1A❚ and ❚Figure 1B❚ (P < .05).
A significantly decreased overall survival rate in the 
group of women expressing NPM1 at levels higher than 
the median value of the distribution in the ovarian primary 
tumor (P < .05) was found (as shown in Figure 1B). We also 
observed a significant decreased survival rate among women 
with a nuclear expression of APE1/Ref-1 higher than the 
median value of the distribution (see Figure 1A). However, 
this significant difference was not confirmed in the multi-
variate model, as shown below ❚Table 2❚. Furthermore, the 
five-year overall survival rate was 51% (95% CI, 36%-71%) 
for patients with an NPM1 H-score lower than the median 
value of the distribution, while for patients expressing 
NPM1 at levels higher than the median, the same rate was 
17% (95% CI, 7%-40%) (P < .05). In ❚Image 2❚, we present 
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❚Image 1❚ Human apurinic endonuclease/redox factor 
1 (APE1/Ref-1) and nucleolar/nucleoplasmic protein 
nucleophosmin 1 (NPM1) expression in ovarian serous 
cancer and correlation between APE1/Ref-1 and NPM1 
expression. We show one case with a high APE1/Ref-1 
and NPM1 H-score (case 1, A and C) and one case with a 
low APE1/Ref-1 and NPM1 H-score (case 2, B and D). A, 
APE1/Ref-1 expression shown by immunohistochemistry 
in high-grade ovarian serous cancer (high H-score = above 
the 50th percentile of the distribution). APE1/Ref-1 staining 
was observed in the tumor cell nucleus (×200; inset, ×400). 
B, APE1/Ref-1 expression shown by immunohistochemistry in high-grade ovarian serous cancer (low H-score = under 
the 50th percentile of the distribution) (×200; inset, ×400). C, NPM1 expression shown by immunohistochemistry in high-
grade ovarian serous cancer (high H-score = above the 50th percentile of the distribution). NPM1 staining was observed 
in the tumor cell nucleus and nucleoli (×200; inset, ×400). D, NPM1 expression shown by immunohistochemistry in high-
grade ovarian serous cancer (low H-score = under the 50th percentile of the distribution) (×200; inset, ×400). E, Correlation 
between human APE1/Ref-1 and NPM1 H-score values (least squares line and Pearson test).
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more details about H-score distribution and show that with 
increasing NPM1 H-score, it will decrease the chance of 
survival (Image 2A).
We performed Cox proportional hazards univariate and 
multivariate regression analysis for our population of high-
grade ovarian serous cancers, analyzing the two studied 
proteins in context with the main variables known to affect 
survival (Table 2). Our results demonstrated that high NPM1 
H-score values were associated with a higher probability of 
death than were low H-score values (P < .05) in both uni-
variate and multivariate analysis when we corrected for FIGO 
staging, age at intervention, complete surgical cytoreduction 
at first intervention, and platinum resistance at first-line che-
motherapy (Table 2).
We then looked in detail at FIGO stages in high-grade 
serous carcinomas and the significant impact that high nuclear 
NPM1 H-scores had on survival ❚Figure 2A❚ and ❚Figure 2B❚. 
There was no significant difference in NPM1 H-score values 
between the FIGO stages (Figure 2B). In addition, there was 
a clear division among high-grade ovarian serous cancers for 
patients at FIGO stages III to IV: those with low NPM1 nucle-
ar expression had a significantly longer overall survival period 
than those with a high NPM1 expression (P < .05) (Figure 
2A). Only in 66% of cases with peritoneal metastases was 
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❚Figure 1❚ Kaplan-Meier curves of overall survival and human apurinic endonuclease/redox factor 1 (APE1/Ref-1) or nucleolar/
nucleoplasmic protein nucleophosmin 1 (NPM1) expression in high-grade ovarian serous cancer (P values refer to log-rank 
test). A, Nuclear H-score of APE1/Ref1 above the 50th percentile of the distribution (H-score >100, dashed line) showed a 
significantly lower survival than the subgroup with H-scores under the 50th percentile of the distribution (solid line). APE1/Ref-1 
nuclear staining, P = .042. B, Women with a nuclear NPM1 H-score above the 50th percentile of the distribution (H-score >10, 
dashed line) showed a significantly lower survival than the subgroup with H-scores under the 50th percentile of the distribution 
(solid line). NPM1 nuclear staining, P = .001.
❚Table 2❚
Cox Proportional Hazards Regression Models in High-Grade Cancers
 Univariate Multivariate
Characteristic HR (95% CI) P Value HR (95% CI) P Value P Valuea
APE1/Ref-1 H-score >100b 1.86 (1.01-3.40) <.05 1.74 (0.88-3.41) .110 .148
NPM1 H-score >10b 2.65 (1.42-4.95) <.05 2.98 (1.46-6.08) <.05 <.05
Age at intervention 1.01 (0.98-1.03) .584 1.03 (1.0-1.06) .074 .148
FIGO III-IV 1.6 (1.06-2.42) <.05 1.65 (1.02-2.67) <.05 .127
Complete cytoreduction 0.43 (0.21-0.85) <.05 0.41 (0.20-0.83) <.05 .055
Platinum resistance 4.87 (2.19-10.83) <.05 9.07 (3.61-22.76) <.05 <.05
APE1/Ref-1, human apurinic endonuclease/redox factor 1; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; NPM1, 
nucleophosmin 1.
a Holm-Bonferroni correction.
b H-score value higher than the median of the distribution.
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❚Image 2❚ Nucleolar/nucleoplasmic protein nucleophosmin 1 (NPM1) and human apurinic endonuclease/redox factor 1 (APE1/
Ref-1) expression in ovarian serous cancer. A, NPM1 H-score distribution and Cox proportional hazards analysis. We found 
an increased hazard ratio (HR) in cases with an H-score in the third or fourth quartile of the distribution, with a greater risk 
of reduced survival in the fourth quartile of the distribution compared with the third quartile. B-D, Some examples of NPM1 
H-score distribution. B, NPM1 expression shown by immunohistochemistry in high-grade ovarian serous cancer (fourth quartile 
of the distribution H-score >77). NPM1 staining was observed in the tumor cell nucleus and nucleoli (×200; inset, ×400). C, 
NPM1 expression shown by immunohistochemistry in high-grade ovarian serous cancer (third quartile of the distribution 
H-score >10-77) (×200; inset, ×400). D, NPM1 expression shown by immunohistochemistry in high-grade ovarian serous cancer 
(first to second quartiles of the distribution H-score 0-10) (×200; inset, ×400). 
a tissue sample of peritoneal spread present in our archives. 
Anyway, we also found the NPM1 H-score of peritoneal 
metastases to be correlated with survival. In fact, an NPM1 
H-score higher than the median value of the distribution had 
a hazard ratio (HR) of 1.88 (95% CI, 0.85-4.15; P = .117) 
and the NPM1 H-score higher than the third quartile value of 
the distribution had an HR of 3.73 (95% CI, 1.37-10.15; P < 
.05). Delving deeper, we found that among women at FIGO 
stages III to IV, those who expressed low nuclear NPM1 had 
a five-year overall survival rate of 48% (95% CI, 31%-76%), 
while those in the subgroup with high levels experienced a 
five-year overall survival rate of just 15% (5%-41%) (P < 
.05). We observed the same general pattern in overall survival 
again for patients at FIGO stages I to II in high-grade ovarian 
serous cancers, but in these cases, our findings were without 
statistical significance.
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permissive condition for further oncogenic transformation, 
with its indirect stimulatory effect on APE1/Ref-1 being 
a key dynamic.19,31,32 High NPM1 levels may both limit 
damage to DNA and promote DNA repair (due to increased 
BER), associated with oncogenic stressor signals activation 
in a normal cell, so that it may support, in association with 
an increased APE1/Ref-1 expression level, cell survival 
as the cancer develops. Our evidence suggests that APE1/
Ref-1–NPM1 proteins are linked to cancer aggressiveness, 
which supports the concept that interfering with the APE1/
Discussion
Our study revealed a link between an overexpression 
of nuclear NPM1 protein and poor outcomes for women 
diagnosed with high-grade ovarian serous cancer. Interest-
ingly, we found a significant positive correlation between 
APE1/Ref-1 and NPM1 H-scores, possibly lending support 
to the emerging hypothesis that the DNA repair function of 
these two proteins may contribute to a patient’s chemore-
sistance. The relative contribution of NPM1 overexpression 
to cancer progression may be due to its role in generating a 
❚Image 2❚ (cont) E, APE1/Ref-1 H-score distribution and Cox proportional hazards analysis. We found an increased HR in cases 
with an H-score in the fourth quartile of the distribution. F-H, Some examples of APE1/Ref-1 H-score distribution. F, APE1/Ref-1 
expression shown by immunohistochemistry in high-grade ovarian serous cancer (fourth quartile of the distribution H-score 
>133). APE1/Ref-1 staining was observed in the tumor cell nucleus (×200; inset, ×400). G, APE1/Ref-1 expression shown by 
immunohistochemistry in high-grade ovarian serous cancer (third quartile of the distribution H-score >100-133) (×200; inset, 
×400). H, APE1/Ref-1 expression shown by immunohistochemistry in high-grade ovarian serous cancer (first to second quartiles 
of the distribution H-score 0-100) (×200; inset, ×400).
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NPM1 H-scores and shortened survival periods, which to our 
knowledge has been evidenced in ovarian cancer for the first 
time, is a key strength of our study. Data presented herein 
could influence the clinical management (prognosis determi-
nation) and planning of future therapies with respect to drug 
development and testing on ovarian cancer by presenting 
new avenues for exploration. Our study also benefitted from 
a relatively long follow-up period (from a minimum of three 
years to a maximum of eight years) and from the statistical 
power gained by analyzing a large number of affected women 
in the TMA model.
To conclude, we have presented the first study linking 
NPM1 expression and its prognostic role in overall survival 
for high-grade ovarian serous carcinoma. Our preliminary 
data demonstrate that the level of NPM1 expression in the 
primary tumor and peritoneal metastases influences survival 
and strongly suggests that its interaction with APE1/Ref-1 
plays an important role in ovarian cancer. In particular, the 
NPM1 immunohistochemical assay would allow specialists 
to more accurately define a prognosis for patients with high-
grade ovarian serous carcinoma.
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Ref-1–NPM1 interaction might enable improved sensiti-
zation of cancer cells to chemotherapy and radiotherapy. 
Corroborating this hypothesis, we found a higher nuclear 
expression of APE1/Ref-1 in platinum-resistant cancers than 
in platinum-sensitive ones.
In this article, we have not inspected which of the known 
APE1/Ref-1 functions are associated with NPM1 overexpres-
sion. It is plausible that both BER and rRNA activities may 
be involved, thus affecting cell proliferation and cell survival. 
Work along these lines is currently ongoing.
The APE1/Ref-1 interactome network is gaining signifi-
cance in the research field for understanding ovarian cancer 
development. This has recently been underlined by the dis-
covery that another known protein binding partner (ERp57)33 
plays an important role in chemoresistance mechanisms in 
ovarian cancer by modulating the attachment of microtubules 
to chromosomes following paclitaxel treatment. An interac-
tion with the NPM1 protein is also involved.34,35
The main limitation of this study is its retrospective 
design. This prevented us from accurately assessing cases of 
disease-free survival and from building a true picture of che-
motherapy effectiveness that accounted for the emergence of 
tumor chemoresistance during the follow-up period. Another 
limitation was the retrospective application of platinum resis-
tance definitions at first-line chemotherapy. The definition we 
used likely underestimates the real prevalence in our popula-
tion—to illustrate, platinum resistance rates in the existing 
literature for FIGO stage III or higher sit at about 30%.36 
Conversely, the strong correlation between high nuclear 
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❚Figure 2❚ Kaplan-Meier curves of overall survival, International Federation of Gynecology and Obstetrics (FIGO) staging in high-
grade ovarian serous cancer, and nucleolar/nucleoplasmic protein nucleophosmin 1 (NPM1) expression in high-grade ovarian 
serous cancer. A, Stage III to IV and NPM1 expression in high-grade ovarian serous cancer: looking at NPM1 expression among 
the stage III to IV cases (dot-dash line), we identified two subgroups. The subgroup of women with a nuclear NPM1 H-score 
above the 50th percentile of the distribution (H-score >10, dashed line) showed a significantly lower survival than the subgroup 
with H-scores under the 50th percentile of the distribution (solid line) (P < .05, log-rank test). B, NPM1 H-score in stages I to II 
and III to IV in high-grade ovarian serous cancer (P = .151, Wilcoxon test).
PROOF
10     Am J Clin Pathol  2014;141:000
10     DOI: 10.1309/AJCPIDKDLSGE26CX    
© American Society for Clinical Pathology
Londero et al / APE1/Ref-1 and NPM1 in Ovarian Serous Cancer
 14. Szebeni A, Hingorani K, Negi S, et al. Role of protein kinase 
CK2 phosphorylation in the molecular chaperone activity of 
nucleolar protein b23. J Biol Chem. 2003;278:9107-9115.
 15. Savkur RS, Olson MO. Preferential cleavage in pre-ribosomal 
RNA byprotein B23 endoribonuclease. Nucleic Acids Res. 
1998;26:4508-4515.
 16. Wang HF, Takenaka K, Nakanishi A, et al. BRCA2 and 
nucleophosmin coregulate centrosome amplification and 
form a complex with the Rho effector kinase ROCK2. Cancer 
Res. 2011;71:68-77.
 17. Tell G, Wilson DM III, Lee CH. Intrusion of a DNA repair 
protein in the RNome world: is this the beginning of a new 
era? Mol Cell Biol. 2010;30:366-371.
 18. Vascotto C, Fantini D, Romanello M, et al. APE1/Ref-1 
interacts with NPM1 within nucleoli and plays a role in the 
rRNA quality control process. Mol Cell Biol. 2009;29:1834-1854.
 19. Vascotto C, Lirussi L, Poletto M, et al. Functional 
regulation of the apurinic/apyrimidinic endonuclease 1 by 
nucleophosmin: impact on tumor biology. Oncogene. 2013. 
doi:10.1038/onc.2013.251.
 20. Di Maso V, Avellini C, Crocè LS, et al. Subcellular 
localization of APE1/Ref-1 in human hepatocellular 
carcinoma: possible prognostic significance. Mol Med. 
2007;13:89-96.
 21. Kakolyris S, Kaklamanis L, Giatromanolaki A, et al. 
Expression and subcellular localization of human AP 
endonuclease 1 (HAP1/Ref-1) protein: a basis for its role in 
human disease. Histopathology. 1998;33:561-569.
 22. Yun JP, Miao J, Chen GG, et al. Increased expression 
of nucleophosmin/B23 in hepatocellular carcinoma and 
correlation with clinicopathological parameters. Br J Cancer. 
2007;96:477-484.
 23. Bobola MS, Blank A, Berger MS, et al. Apurinic/apyrimidinic 
endonuclease activity is elevated in human adult gliomas. 
Clin Cancer Res. 2001;7:3510-3518.
 24. Robertson KA, Bullock HA, Xu Y, et al. Altered expression 
of Ape1/Ref-1 in germ cell tumors and overexpression in 
NT2 cells confers resistance to bleomycin and radiation. 
Cancer Res. 2001;61:2220-2225.
 25. Rossi O, Carrozzino F, Cappelli E, et al. Analysis of repair of 
abasic sites in early onset breast cancer patients. Int J Cancer. 
2000;85:21-26.
 26. Malpica A, Deavers MT, Lu K, et al. Grading ovarian 
serous carcinoma using a two-tier system. Am J Surg Pathol. 
2004;28:496-504.
 27. Vang R, Shih IM, Kurman RJ. Ovarian low-grade and high-
grade serous carcinoma: pathogenesis, clinicopathologic and 
molecular biologic features, and diagnostic problems. Adv 
Anat Pathol. 2009;16:267-282.
 28. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma 
of the ovary: FIGO 26th Annual Report on the Results of 
Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 
2006;95(suppl 1):S161-S192.
 29. Gospodarowicz M, Wittekind C, Sobin L, et al. TNM 
Classification of Malignant Tumours. 7th ed. New York, NY: 
Wiley-Blackwell; 2009.
 30. Al-Attar A, Gossage L, Fareed KR, et al. Human apurinic/
apyrimidinic endonuclease (APE1) is a prognostic factor in 
ovarian, gastro-oesophageal and pancreatico-biliary cancers. 
Br J Cancer. 2010;102:704-709.
 31. Fantini D, Vascotto C, Marasco D, et al. Critical lysine 
residues within the overlooked N-terminal domain of human 
APE1 regulate its biological functions. Nucleic Acids Res. 
2010;38:8239-8256.
PRIN2008_CCPKRP_003) to G.T. This study had also financial 
support from the University of Udine. 
  This study was presented at Società Italiana di Anatomia 
Patologica e Citopatologia Diagnostica—Divisione Italiana 
della International Academy of Pathology; October 25-27, 2012; 
Florence, Italy. 
  Acknowledgments: We are grateful to Eilidh P. J. McIntosh 
for her suggestions on the style and grammatical correctness of 
our English. We are grateful to Matteo De Luca and Federico 
Todaro for the technical assistance. We are also grateful to Diego 
Marchesoni, MD, Carlo Alberto Beltrami, MD, Giuliano Fabiani, 
MD, and Monica Della Martina, MD, for their help  
and suggestions.
References
 1. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian 
cancer: new opportunities for translation. Nat Rev Cancer. 
2009;9:415-428.
 2. Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) 
polymerase inhibitors: on the horizon of tailored and 
personalized therapies for epithelial ovarian cancer. Curr 
Opin Oncol. 2012;24:564-571.
 3. Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of 
human ovarian cancer stem cells unravels the mechanisms for 
repair and chemoresistance. Cell Cycle. 2009;8:158-166.
 4. Wilson DM III, Simeonov A. Small molecule inhibitors of 
DNA repair nuclease activities of APE1. Cell Mol Life Sci. 
2010;67:3621-3631.
 5. Kothandapani A, Dangeti VSMN, Brown AR, et al. 
Novel role of base excision repair in mediating cisplatin 
cytotoxicity. J Biol Chem. 2011;286:14564-14574.
 6. Sengupta S, Mantha AK, Mitra S, et al. Human AP 
endonuclease (APE1/Ref-1) and its acetylation regulate 
YB-1-p300 recruitment and RNA polymerase II loading in 
the drug-induced activation of multidrug resistance gene 
MDR1. Oncogene. 2011;30:482-493.
 7. Arora S, Kothandapani A, Tillison K, et al. Downregulation 
of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. 
DNA Repair (Amst). 2010;9:745-753.
 8. Wu HH, Cheng YW, Chang JT, et al. Subcellular 
localization of apurinic endonuclease 1 promotes lung 
tumor aggressiveness via NF-kappaB activation. Oncogene. 
2010;29:4330-4340.
 9. Tell G, Fantini D, Quadrifoglio F. Understanding different 
functions of mammalian AP endonuclease (APE1) as a 
promising tool for cancer treatment. Cell Mol Life Sci. 
2010;67:3589-3608.
 10. Kelley MR, Georgiadis MM, Fishel ML. APE1/Ref-1 role in 
redox signaling: translational applications of targeting the 
redox function of the DNA repair/redox protein APE1/Ref-1. 
Curr Mol Pharmacol. 2012;5:36-53.
 11. Tell G, Damante G, Caldwell D, et al. The intracellular 
localization of APE1/Ref-1: more than a passive 
phenomenon? Antioxid Redox Signal. 2005;7:367-384.
 12. Xanthoudakis S, Miao GG, Curran T. The redox 
and DNA-repair activities of Ref-1 are encoded by 
nonoverlapping domains. Proc Natl Acad Sci U S A. 
1994;91:23-27.
 13. Frehlick LJ, Eirín-López JM, Ausió J. New insights into the 
nucleophosmin/nucleoplasmin family of nuclear chaperones. 
Bioessays. 2007;29:49-59.
PROOF
Am J Clin Pathol  2014;141:000     11
11     DOI: 10.1309/AJCPIDKDLSGE26CX     11
© American Society for Clinical Pathology
AJCP / Original Article
 35. Cicchillitti L, Della Corte A, Di Michele M, et al. 
Characterisation of a multimeric protein complex associated 
with ERp57 within the nucleus in paclitaxel-sensitive and 
-resistant epithelial ovarian cancer cells: the involvement 
of specific conformational states of beta-actin. Int J Oncol. 
2010;37:445-454.
 36. McGuire WP, Hoskins WJ, Brady MF, et al. 
Cyclophosphamide and cisplatin compared with paclitaxel 
and cisplatin in patients with stage III and stage IV ovarian 
cancer. N Engl J Med. 1996;334:1-6.
 32. Vascotto C, Cesaratto L, Zeef LAH, et al. Genome-
wide analysis and proteomic studies reveal APE1/Ref-1 
multifunctional role in mammalian cells. Proteomics. 
2009;9:1058-1074.
 33. Vascotto C, Bisetto E, Li M, et al. Knock-in reconstitution 
studies reveal an unexpected role of Cys-65 in regulating 
APE1/Ref-1 subcellular trafficking and function. Mol Biol 
Cell. 2011;22:3887-3901.
 34. Cicchillitti L, Di Michele M, Urbani A, et al. Comparative 
proteomic analysis of paclitaxel sensitive A2780 epithelial 
ovarian cancer cell line and its resistant counterpart 
A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res. 
2009;8:1902-1912.
PROOF
FORUM REVIEW ARTICLE
Emerging Roles of the Nucleolus in Regulating
the DNA Damage Response:
The Noncanonical DNA Repair Enzyme APE1/Ref-1
as a Paradigmatical Example
Giulia Antoniali,* Lisa Lirussi,* Mattia Poletto,* and Gianluca Tell
Abstract
Significance: An emerging concept in DNA repair mechanisms is the evidence that some key enzymes, besides
their role in the maintenance of genome stability, display also unexpected noncanonical functions associated
with RNA metabolism in specific subcellular districts (e.g., nucleoli). During the evolution of these key enzymes,
the acquisition of unfolded domains significantly amplified the possibility to interact with different partners and
substrates, possibly explaining their phylogenetic gain of functions. Recent Advances: After nucleolar stress or
DNA damage, many DNA repair proteins can freely relocalize from nucleoli to the nucleoplasm. This process
may represent a surveillance mechanism to monitor the synthesis and correct assembly of ribosomal units
affecting cell cycle progression or inducing p53-mediated apoptosis or senescence. Critical Issues: A paradigm
for this kind of regulation is represented by some enzymes of the DNA base excision repair (BER) pathway, such
as apurinic/apyrimidinic endonuclease 1 (APE1). In this review, the role of the nucleolus and the noncanonical
functions of the APE1 protein are discussed in light of their possible implications in human pathologies. Future
Directions: A productive cross-talk between DNA repair enzymes and proteins involved in RNA metabolism
seems reasonable as the nucleolus is emerging as a dynamic functional hub that coordinates cell growth arrest
and DNA repair mechanisms. These findings will drive further analyses on other BER proteins and might imply
that nucleic acid processing enzymes are more versatile than originally thought having evolved DNA-targeted
functions after a previous life in the early RNA world. Antioxid. Redox Signal. 20, 621–639.
Overview on RNA Oxidative Damages, a Glimpse
on Human Pathologies
An emerging body of evidence links DNA repair pro-teins to specific aspects of RNA metabolism associated
with quality control processes toward damaged RNA mole-
cules (e.g., oxidized or abasic RNA) (Fig. 1). Due to its intrinsic
nature (i.e., mostly single-stranded and with bases not pro-
tected by hydrogen bonding or binding to specific proteins)
and to its relatively higher amount, RNA may be more sus-
ceptible to oxidative insults than DNA (107). Not only 8-
hydroxyguanosine (8-OHG) but also 5-hydroxycytidine,
5-hydroxyuridine, and 8-hydroxyadenosine have been iden-
tified in oxidized RNA (160).While oxidative damage toDNA
is essentially repaired through the base excision repair (BER)
pathway, no evidences of similar repair processes have been
described for RNA molecules, even though some BER pro-
teins recently entered the arena of the RNome world (138). If
not repaired, damage to RNA molecules may lead to ribo-
somal dysfunctions and erroneous translation; thus, signifi-
cantly affecting the overall protein synthesis mechanism (38,
135). Moreover, RNA damage has been shown to cause cell
cycle arrest and cell death with or without the contribution of
p53 and inhibition of protein synthesis (11). Oxidative RNA
modifications can occur not only in protein-coding RNAs, but
also in noncoding RNAs that recently have been revealed to
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contribute to the complexity of the mammalian brain (109). It
has been hypothesized that RNA oxidation, causing aberrant
expression of microRNAs and proteins, may initiate inap-
propriate cell fate pathways. Such sublethal damage to cells,
while less toxic than genomic mutations and not inheritable,
might be associated with underlying mechanisms of degen-
eration, such as age-associated neurodegeneration.
Currently, little is known about how cells may cope with
damaged RNA, either modified or oxidized, but it is clear that
such RNA can impair protein synthesis; thus, affecting cell
function and viability. Therefore, specific surveillance mech-
anisms are needed to remove damaged molecules from the
RNA pool to guarantee the biological integrity of cells. The
idea that quality control mechanisms might exist to repair
RNA was put forward after the identification of the bio-
chemical activities of the mammalian AlkB homologs. In
particular, it was discovered that AlkB (from Escherichia coli)
and the human homolog hABH3, besides being able to di-
rectly reverse alkylation damage on DNA bases, were able to
demethylate damaged bases on RNA; thus, playing a key role
in the repair of specific RNA lesions (1, 111). While repair
mechanisms have been demonstrated for alkylated RNA, the
existence of such cleansing activities has not yet been identi-
fied for oxidatively damaged RNA. However, their existence
appears unlikely, in the absence of direct reversal strategies,
due to the lack of a template for accurate repair, as happens in
the case of double-stranded DNA. The observation that under
oxidative stress RNA modifications can occur up to a 10–20-
fold higher extent than DNA (88), raises the question of how
oxidized RNA may be specifically removed or repaired. The
recent findings by Berquist et al. (12), Barnes et al. (7), and
Vascotto et al. (149) highlight a novel ‘‘moonlighting’’ role for
the repair apurinic/apyrimidinic (AP) endonuclease 1 (APE1)
in RNA metabolism, both as a possible ‘‘cleansing’’ factor for
damaged abasic RNA and as a regulator of c-myc gene ex-
pression through mRNA decay. In agreement with this hy-
pothesis, a significant reduction in the protein synthesis rate
occurs upon silencing of APE1 expression (149). Enzymatic
(e.g., by specific N-ribohydrolases, including the toxin ricin)
(126), besides spontaneous (91), generation of abasic sites
occurs upon ribosomal RNA (rRNA) oxidation. A role for the
Y box binding protein 1 (YB-1) in recognizing 8-OHG sites has
also been hypothesized (56), but no specific enzymatic
mechanisms that can remove the oxidized base have been
described yet. The accumulation of the 8-OHG substrates,
which occurs upon silencing of APE1 expression (149), may
thus, be explained under the assumption that enzymatic re-
moval of oxidized RNA bases represents the limiting step in
the process. According to this model, as already hypothesized
for DNA substrates, APE1 could act through stimulation of a
yet unknown glycosylase activity, by allowing a faster turn-
over (152). The APE1 interaction with RNA and with proteins
FIG. 1. Potential consequences of unrepaired RNA damage. RNA intrinsic nature renders it more susceptible to damage,
such as oxidation. The molecular and surveillance mechanisms that cope with RNA damage are still poorly understood. If
unrepaired, aberrant RNA may give rise to translation of defective and toxic protein aggregates that eventually leads to cell
cycle arrest and consequently to cell death. These molecular processes have been associated with cancer onset, aging, and
neurodegeneration.
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involved in ribosome assembly (i.e., RSSA, RLA0) and RNA
maturation (i.e., PRP19) within the cytoplasm (149), could also
represent a molecular proof of concept for the ‘‘extranuclear’’
functions of this noncanonical DNA repair enzyme. The RNA-
mediated association with some of the APE1 protein partners
would reinforce the view of APE1 as an essential factor in the
RNA quality control process and may also explain the cyto-
plasmic accumulation of APE1 observed in a number of tu-
moral cell types (136, 137). An age-associated increase in
oxidative nucleic acids damage, predominantly to RNA, has
been recently highlighted in neurons from human and rodent
brains; this phenomenon may play a fundamental role in the
development of age-associated neurodegeneration (109). Oxi-
dative damage to RNA molecules, both coding for proteins
(mRNA) or performing translation (rRNA and tRNA), has
been recently associated with the occurrence of neurodegen-
erative diseases, such as Alzheimer’s disease (AD), Parkinson
disease (PD), dementia with Lewy bodies, and amyotrophic
lateral sclerosis (107) and its impact in cancer development
cannot be excluded, at present (11). Remarkably, studies per-
formed on either human samples or experimental models,
show that RNA oxidation is a characteristic of aging neurons.
Its prominent occurrence in vulnerable neurons at early stage
of age-associated neurodegenerative disorders indicates that
RNA oxidation actively contributes to the development of the
degeneration. Therefore, all the hypotheses concerning the in-
volvement of APE1 in the development of such pathologies
should be re-interpreted in light of these findings. The role
played by APE1 in RNA-related processes needs further in-
vestigations, since its ability to recognize and cleave the RNA
abasic sites (12, 42, 89, 138, 149) is compatible with a leading
role in the early stages of the RNA quality control process.
Additional studies aiming at the understanding the mecha-
nisms related to oxidative RNA damage processing and their
consequences may provide significant insights into the patho-
genesis of neurodegenerative disorders, leading to improve-
ments in the current therapeutic strategies.
The vast majority of cellular RNA is transcribed, assem-
bled, and processed within nucleoli. These subcellular com-
partments appear to be perfect sensors for cellular stress, as
they integrate RNA damage and growth control with signals
to the DNA repair machineries. The following paragraphs
will describe the emerging dynamics roles of this organelle in
regulating the trafficking of DNA repair proteins during
genotoxic damage.
Structure, Composition, and Classical Functions
of the Nucleolus
The nucleolus is considered the ribosome factory of eu-
karyotic cells (18, 62) in which synthesis, maturation, and
processing of rRNA, as well as assembly of rRNA with ribo-
somal proteins (RPs) take place (62) (Fig. 2). This membrane-
less organelle is considered a dynamic structure (4, 84), where
protein complexes are continuously exchanged with the nu-
cleoplasm. Its classical tripartite organization has been dis-
sected using electron microscopy and reflects the different
steps of ribosomal biogenesis (130): (i) the fibrillar center,where
the RNA polymerase I (Pol I) transcription starts; (ii) the dense
fibrillar component, where the initial stages of pre-rRNA pro-
cessing occur and (iii) the granular component involved in the
late processing steps (62). Transcription of the ribosomal DNA
(rDNA) repeats generates a 47S pre-rRNA precursor that is
further cleaved and processed into 28S, 18S, and 5.8S rRNAs
and concomitantly assembled into large and small ribosomal
subunits together with the 5S rRNA molecules (18, 32a). These
complex series of events is controlled, in yeast, by roughly 150
small nucleolar RNAs (snoRNAs) and two large ribonucleo-
protein complexes, named small subunit processosome (for the
40S ribosomal subunit) and large subunit processosome (for
the 60S ribosomal subunit) (130). Two types of nucleotide
modifications (2¢-O-methylation and pseudouridylation) are
introduced during the maturation process by snoRNAs be-
longing to the box C/D or box H/ACA families and mediate
endonucleolytic cleavages of pre-RNAs (130, 32a). In addition,
ribosomal gene transcription is regulated through the modu-
lation of the transcriptional apparatus and epigenetic silencing
(131). Large and small mature ribosome particles are inde-
pendently exported to the cytoplasm through an exportin 1
(CRM1) and Ran-GTP-dependent mechanism: export of 60S
subunit requires the exchange of complexes Noc1-Noc2 by
Noc3-Noc2 (102) and the associationwith the adaptor shuttling
protein NMD3 (142), whereas the 40S needs the heterodimer
Noc4p/Nop14p (103). The work by Hinsby et al. exploited a
machine learning-based predictor of nuclear export signals to
analyze the late stage pre-40S complex, suggesting a role also
for the human homolog of yeast DIM2p in the targeting and
translocation of the late 40S to the cytoplasm (63).
The organization, the number, and the size of nucleoli in
each cell is directly linked to the nucleolar activity (i.e., Pol I
transcription rate), which, in turn, depends on cell growth and
metabolism (20). Generally, highly proliferating cells present
many small nucleoli (62, 130). Ribosomal biosynthesis is a
highly energy- and resources-consuming process (134); this
explains why this process is tightly regulated by changes in cell
proliferation, growth rates, and metabolic activities. Nucleoli
constantly integrate different signaling events, maintaining the
ribosomal subunit pool required to properly support protein
synthesis during cell growth and division (18).
Biosynthesis of ribosomes is a very efficient process, since it
has been estimated that 14,000 new ribosomal subunits can be
synthesized every minute in an exponentially growing cell
(125). The process has to be fine-tuned and several evidences
indicate that ubiquitin and ubiquitin-like proteins-based
regulatory circuits may control different stages of ribosome
formation (129). Lam et al. (83) demonstrated that the levels of
unassembled RPs within nucleoli exceed the required
RP:rRNA ratio and identified an ubiquitin-proteasome-
mediated mechanism, that monitors and degrades this excess
(115). Ribosomal structural proteins are imported from the
cytoplasm in supra-stoichiometric complexes and exported in
the form of assembled ribosomal subunits; this ensures that
RPs are never rate-limiting for the ribosomal assembly (83).
The excess of protein undergoes ubiquitylation and degra-
dation in the nucleoplasm through the proteasome system
(114, 129), indicating that mammalian cells produce large
amount of these proteins and degrade those that are not as-
sembled with rRNA.
‘‘Dynamic Trafficking:’’
Keywords of the Nucleolar Physiology
The nucleolus appears as a very dynamic organelle and
different types of rearrangements involve this subnuclear
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district. First, the ribosome assembly is a vectorial process, in
which the ribosomal particles move away from their biogen-
esis sites. The second dynamic aspect is represented by the
constant flux of proteins from the nucleoli to the nucleoplasm.
Lastly, nucleolar components present scheduled reorganiza-
tion every cell cycle, with assembly and disassembly steps
required for the redistribution of nucleolar components be-
tween the two daughter cells (110).
The cyclic reorganization observed during cell cycle in-
volves the nucleolus as a whole, as this organelle assembles at
the end of each mitosis to remain functionally active until the
beginning of the next one (4, 62). The nucleolar disassembly
observed during mitosis is linked to rDNA transcriptional
repression induced by CDK1-cyclin B-directed phosphoryla-
tion of components of the rDNA transcription machinery
(130). Conversely, the formation of functional nucleoli at the
exit of mitosis is not uniquely controlled by the resumption of
rDNA transcription, but by a two-steps process regulated by
cyclin-dependent kinases that connects the resumption of
rDNA transcription and the restoration of rRNA processing
(130). During late telophase, nucleoli form around the nucle-
olar organization regions, which are chromosomal domains
where rDNAs, clustered in head-to-tail arrays (62, 84), are
transcribed. This sub-nuclear compartmentalization allows
the cells to locally concentrate all the factors required for the
ribosomal biogenesis (18, 20).
The Way to Move: Visitors Versus Resident
Nucleolar Proteins
Differently from nuclear localization signals (NLSs), nu-
cleolar localization sequences (NoLSs) are not well charac-
terized and no clear consensus sequences have been described
yet (115, 130). NoLSs identified so far are rich in basic residues
(e.g., Arg and Lys) (40), but also Trp residues were described
to play a functional role for the nucleolar localization of nu-
cleophosmin 1 (NPM1) (108a). Since the mass per unit nu-
cleolar volume is only twofold higher compared with the
nucleoplasm, all diffusing macromolecules should theoreti-
cally be able to enter nucleoli: it is now clear that the residence
time of nucleolar proteins depends on their relative affinity for
preanchored complexes present within the nucleolus itself
FIG. 2. The nucleolus, a multifunctional domain. The unveiling of the ‘‘nucleolome’’ allowed the understanding of the
complexity of the nucleolus, firstly described only as a ribosome factory. The multifunctionality of the nucleolus includes
different noncanonical functions as the control of cell proliferation and cell growth, regulation of protein stability, stress and
DDR, telomere metabolism, maturation of small RNAs, and control of viral life-cycle. An illustrative mechanism for each
function is summarized. MDM2, mouse double minute 2 homolog; ARF, p14 alternative reading frame; ADAR2, double-
stranded RNA-specific adenosine deaminase 2; NS, nucleostemin; VHL, von Hippel-Lindau protein; HIF, hypoxia-inducible
factor; ING1, inhibitor of growth family protein, member 1; PML, promyelocytic leukemia protein; DNA Topo I, DNA
topoisomerase I; TERC, telomerase RNA component; TERT, telomerase reverse transcriptase; GNL3L, guanine nucleotide
binding protein-like 3 (nucleolar)-like; TRF, telomeric repeat-binding factor 2; REV, regulator of expression of virion protein;
Tat, trans-activator of transcription; Ub, ubiquitin; DDR, DNA damage response. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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(114, 115). The ability of different proteins to localize within
the nucleolus has been linked to the stable interaction with
anchored resident proteins, such asNPM1 or nucleolin (NCL),
that may act as carriers, or as a retention scaffolds, supporting
the idea that the residence time of proteins within the nucle-
olar compartment is strongly related to their specific interac-
tions in a process known as ‘‘nucleolar sequestration’’ (40, 115,
130). Though all the molecules resident in the nucleoplasm
may, in principle, enter into nucleoli, only those with an af-
finity for nucleolar resident proteins, are retained for longer
times (110). For this reason some authors suggested the con-
cept of ‘‘retention signal’’ in place of ‘‘targeting signal’’ for the
nucleoli (121). Since the residence time is quite short andmost
of the nucleolar proteins shuttle from nucleoli to nucleoplasm
and vice versa, the interaction of visitor proteins with an-
chored nucleolar residents has to be reversible (110, 115).
Current models show that proteins and RNAs continuously
flow and freely diffuse through the nuclear space (131): the
average residence time for most nucleolar proteins within
nucleoli is estimated to be only a few tens of seconds. Thus,
nucleolus appears as a steady state structure with its com-
ponent in a dynamic equilibrium with the surrounding nu-
cleoplasm (121). However, in spite of this continual exchange
of molecules between these two compartments, nucleolar
domains are maintained because the number of retained
proteins is higher than the amount of molecules that are re-
leased from the same domain (32a). Resident factors, able to
connect and bind multiple protein partners, are considered as
‘‘hub proteins’’ and might be responsible for the nucleolar
localization of the vast majority of visitor proteins in the ab-
sence of RNA–protein interactions. Each hub protein may
have different recognition requirements; thus, possibly ex-
plaining the occurrence of different NoLSs. Two typical ex-
amples of hub proteins are NCL and NPM1, which contain
disordered regions involved in protein–RNA interactions
(40).
Recently, an additional protein retention mechanism based
on GTP-driven cycles has been identified for nucleostemin
(121). The GTP-GDP exchange mechanism is not the only
intracellular signal able to move nucleolar proteins: stimuli as
the hydrogen ion were already described by Mekhail et al.
(98), who demonstrated how the nucleolar sequestration of
the von Hippel-Lindau protein after a pH change promotes
the stabilization of the hypoxia-inducible factor, triggering a
general cell response to hypoxic conditions (115).
New Concepts in the Nucleolus Physiology:
Beyond the Ribosome Factory
In the 60s, after the identification of the localization of ri-
bosomal genes, the main function of the nucleolus was nicely
summarized as ‘‘an organelle formed by the act of building a
ribosome’’ (63). In the last decades, thanks to the development
of technologies, such as protocols for the isolation of large
amounts of nucleoli and the improvement of high-throughput
mass-spectrometry-based proteomic approaches, several
proteomic analyses were undertaken, unveiling the ‘‘nucleo-
lome’’ (4, 5, 18, 32a, 125). Over 4500 proteins were described to
localize within nucleoli and both bibliographic and bioinfor-
matics analyses allowed to classify eight major functional
groups (RPs, ribosome biogenesis, chromatin structure,
mRNAmetabolism, translation, chaperones, fibrous proteins,
and others [see Fig. 3 for further details]) (3, 18, 32a, 108).
Characterization of the nucleolar proteome under different
stress conditions (e.g., actinomycin D) further underlined the
complexity of the nucleolome dynamics (5).
FIG. 3. Classification of functional groups
and subgroups for the ‘‘nucleolome.’’
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The nucleolome includes proteins related to cell cycle reg-
ulation, DNA damage and pre-mRNA processing (84), sug-
gesting that this organelle may act as a multitasking district,
beingmore than a simple ribosome factory (18, 62, 63, 84, 125).
These particular multifunctional features are possibly related
to the presence of many different nucleolar proteins endowed
with multiple roles (e.g., NCL and Nopp140) (90a). Nucleolar
proteins unrelated to ribosome assembly mostly contain an
RNA-bindingmotif or have a chaperone function and are able
to shuttle between the nucleolus and the nucleoplasm (90a). It
is currently known that nucleoli carry outmany nonribosomal
activities, such as: control of cell cycle and proliferation (62,
63, 130), stress sensing (18, 21, 64, 96, 108, 124, 139), tumor
surveillance, DNA damage repair (18, 41, 84), regulation of
protein stability and apoptosis, telomere metabolism (18),
maturation of small RNAs, including tRNAs and small nu-
clear RNAs, maturation of the spliceosome and of the signal
recognition particle (63, 115, 121), and also control of viral life-
cycle (62, 71), acting in several ways as a sequestration core
facility (Fig. 2) (21, 40, 63).
The assumption that a protein acts and executes its func-
tions where it is more abundant is invalid for some nucleolar
components: a high protein concentration in a given cellular
compartment might not correspond to a quantitative signal
for its activity (114). A clear example is represented by the
many DNA repair proteins that reside within nucleoli (see
Table 1 for more details), which in this instance, appear to act
as storage sites (see below). After nucleolar stress or DNA
damage, these proteins can relocalize to the nucleoplasm. The
nucleolar stress responsemay therefore, act as amechanism of
surveillance monitoring the synthesis and the correct assem-
bly of ribosomal units: it may halt the cell cycle progression
until enough functional ribosomes are built or it may induce
p53-mediated apoptosis or senescence (134). This represents
an elegant and efficient way to coordinate arrest of cell growth
and induction of DNA repair by controlling only the subcel-
lular distribution of proteins.
Linking Nucleolar Physiology to Human Diseases
Several reports highlighted the presence of a layer of het-
erochromatin, called perinucleolar compartment (PNC), at
the nucleolar periphery. The PNC is associated with specific
DNA loci and it is enriched in RNA-binding proteins and
RNA polymerase III transcripts (62, 114). These discoid-
shaped caps are usually found in mammalian transformed
cells, tumor-derived cell lines, and tumor biopsies, accounting
for a possible connection between PNC and tumor initiation
and progression (114). Despite the apparent link between
cancer and PNC, the exact role of these nucleolar subdomains
has not been identified yet.
Nucleoli are closely linked to cellular homeostasis and
human health (62): rapidly proliferating cells, such as cancer
cells, usually present a strong upregulation of genes involved
in the ribosomal biogenesis. This phenomenon accounts for
the presence of several prominent nucleoli that are a typical
cytological feature of neoplastic cells (129). Morphological
and functional changes associated with cancer usually corre-
late with quantitative and qualitative differences in the ribo-
some biosynthesis rate (62) and are a consequence of the
increasedmetabolic needs of the cell (105). This could indicate
that the nucleolus undergoes an adaptive response upon
cellular transformation; on the other hand, the increased rate
of ribosome biogenesis might be actively involved in, and
contribute to, tumorigenesis (105). More recently, the accu-
mulation of chemically modified ribosomes upon oxidative
stress (e.g., bearing 8-OHG modifications, or cross-linked
rRNA-RPs complexes) is emerging as a contributing factor in
the progression of neurodegenerative diseases, such as AD
and PD (62). In addition, a novel link between nucleolar
damage and neurodegeneration has recently been established
through the association of PD with nucleolar integrity. These
interesting findings also establish the existence of a direct
signaling axis connecting the ribosomal synthesis rate and
oxidative stress (122). Under this perspective, the deep un-
derstanding of changes related to tumor progression and the
composition and dynamics of the nucleolome might be im-
portant to clarify the mechanisms of tumorigenesis and for
designing new therapeutic strategies.
Dynamics of DNA Repair Proteins During Genotoxic
Damage: Nucleolus and RNA Binding
Cellular life is continuously threatened by stressful condi-
tions, such as viral infections, oncogenic activations, temper-
ature shocks, and genotoxic damage, which must be
immediately dealt with by the cell tomaintain its homeostasis.
DNA damage typically involves the storage sites of the
genetic material, such as nucleus and mitochondria. De-
pending on the origin of the genotoxin (exogenous vs.
endogenous), its nature (physical vs. chemical) or its uptake
mechanisms, differential burden of damage can be accu-
mulated both in nuclear and in mitochondrial DNA. Upon
genotoxic insults a dynamic redistribution of DNA repair
proteins to the site of damage is frequently observed; this
phenomenon leads to the accumulation of DNA repair fac-
tors, often into spatially restricted foci. Relocalization events
usually occur through cytoplasmic-mitochondrial, cyto-
plasmic-nucleoplasmic, and nucleolar-nucleoplasmic shut-
tling regulated by post-translational modifications (PTMs)
and triggered by the damage itself (51).
Why nature selected such a time-consuming process in-
volving reorganization of cell proteome upon DNA damage,
instead of constitutively accumulating eachDNA repair factor
within the proper target compartment? Is there any functional
relationship between RNAmetabolism and the DNA damage
response (DDR), which may involve an active site of RNA
production, such as the nucleolus? These legitimate questions
are still a matter of debate; however, based on existing data at
least four possible explanations, not mutually exclusive, ap-
pear reliable: (i) the concentration, under physiological levels
of DNA damage, of high amounts of DNA repair proteins in
specific subcellular regions might be deleterious for nucleic
acids integrity. Many repair proteins, in fact, are endowed
with DNA trimming or modifying activities. Examples in-
clude APE1 or the DNA polymerase b (Polb); overexpression
of these proteins has already been shown to promote genomic
instability, possibly due to the lack of coordination of their
enzymatic activities (26); (ii) repair factors may exert more
than one specific function that cannot be directly linked to
their DNA repair activity. This situation is nicely exemplified
by the APE1 protein, which nucleolar localization is necessary
for cellular proliferation (see below), or by proteins, such
as the Werner syndrome helicase (WRN), or the flap
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endonuclease 1 (FEN1) (54), that are required for the active
transcription of ribosomal genes in the nucleolus. All these
factors promptly relocalize to the nucleoplasm to exert their
DNA repair function upon UV irradiation; (iii) while a lower
steady-state amount of DNA repair enzymes is sufficient to
grant a basal level of genome stability maintenance, it is likely
that genotoxin-induced protein accumulation mechanisms
have evolved, to cope with sustained DNA damage. Thus,
increasing the local concentration of DNA repair factors may
be a simple and fast way to amplify the local DNA repair
capacity; (iv) disruption of the nucleolar structure, often ob-
served occurring upon DNA damage, may halt rRNA pro-
duction; thus, leading to a block of the protein synthesis
machinery and allowing proper DNA repair. This may rep-
resent an efficient coupling mechanism involving nucleolus
dynamics, RNA-binding, and DNA repair, which allows
synchronization of DDR and arrest of cellular growth.
While many examples of proteome dynamics have been
reported to occur during DDR, this review will focus on the
relocalization of nucleolar proteins; for detailed information
concerning general subcellular reorganization, please refer to
Tembe and Henderson (139) and references therein.
The Nucleolus as DNA Damage Sensor and Storage
Facility for DNA Repair Proteins
As already mentioned, recent proteomic analyses have
pointed at the nucleolus as a mediator of the cell cycle regu-
lation, tumor suppressing or protumorigenic activities, and
DDR (5, 17, 63, 108). The presence of rRNA and hub proteins,
such as NCL and NPM1 is likely the critical factor for the
nucleolar accumulation ofmany proteins not uniquely related
to ribosome biogenesis (27, 40). Among these, many DNA
repair factors have been shown to localize within the nucle-
olus (Table 1), which acts as a stress response organelle and
responds, in a unique damage-specific manner, to different
cellular stresses (5, 17, 30, 106). During a stress response a
broad reorganization of the nucleolar proteome occurs; in-
terestingly, the vast majority of nucleolar proteins migrate
toward the nucleoplasm and not vice versa, indicating that
the nucleolus may act as a reservoir able to release critical
factors upon DNA damage (108, 139). Very few proteins have
been reported to migrate to the nucleolus during the stress
response. Among these ING1 and PML, which are thought to
participate in triggering of apoptosis and in cell cycle arrest,
respectively (139). Intriguingly, chaperones, such asHsc70 are
targeted to the nucleolus after the stress response, possibly to
restore the nucleolar function during the cellular recovery
from stress. Typically, during the response to DNAdamage or
transcriptional inhibition, one of the first events is represented
by the interruption of the ribosomal synthesis (108). This
mechanism likely represents a cellular strategy to maintain
homeostasis, indeed, as already pointed out, the ribosomal
biogenesis is a rather expensive energy-consuming process
(20). The impairment of rRNA transcription and processing is
often, but not always, associatedwith nucleolar disintegration
and condensation phenomena that lead to the formation of
caps and necklace-like structures (20, 106). An extensive
analysis of the effects of chemotherapeutic drugs on ribosome
biogenesis and nucleolar integrity has recently been carried
out by Burger et al. (23). For a broader list of responses to
different stress stimuli, please refer to Boulon et al. (20). Along
with the inhibition of ribosomal biogenesis, massive reorga-
nization occurs, with a rapid outflow of ‘‘nucleolar effectors’’,
such as p14Arf, NCL, and NPM1, which slow down or arrest
the cell-cycle in both p53-dependent and independent man-
ners (20, 31, 34, 49, 86). Concurrently, also DNA repair factors
stored within nucleoli and frequently bound to NCL and
NPM1 are released into the nucleoplasm; the transient arrest
of the cell-cycle progression possibly facilitates the DNA re-
pair process. Only after resolution of DNA damage, rRNA
synthesis is restored, as suggested by the inverse correlation
existing between the rDNA transcription rate and c-H2AX
foci number (80). Notably, many nucleolar effectors also play
a role within the nucleoplasm: beside the contribution to the
modulation of the cell-cycle, several reports have pointed out
that NCL or NPM1 may directly participate in the DDR. For
instance, NCL has been shown to tune proliferating cell nu-
clear antigen (PCNA) activity in the nucleotide excision repair
(NER) pathway (161), while NPM1 has been involved in the
BER modulation (see below). Interestingly, both these pro-
teins display strand annealing activity in vitro (19, 55) and
have been identified as stress-responsive RNA-binding pro-
teins, suggesting that upon genotoxic damage these factors
maymodulate DNA, as well as RNA repair or cleansing (162).
More importantly, emerging evidences further highlight the
importance of nucleolar hub proteins in human pathology.
The link between NPM1 and oncogenesis, for example, is a
well-established paradigm (31, 52, 151) and we recently
demonstrated that in acute myeloid leukemia bearing NPM1
mutations, the cytoplasmic de-localization of the mutant
NPM1c + leads to extensive BER impairment due to APE1
nuclear deprivation (150). This evidence denotes how the
deregulation of an important nucleolar factormight impact on
the overall cellular dynamics and not only on the ribosome
biogenesis, supporting the view of the nucleolus as a multi-
functional and versatile organelle. Recent evidences from
Lewinska et al. showed that, in yeast, the nucleolus acts as
stress sensor also for oxidative stress. Their work linked the
nucleolar exit of the Pol I-specific transcription factor Rrn3p,
to the response to oxidation, suggesting that oxidative dam-
age is indeed a cellular stress that is sensed from the nucleolus
leading to arrest of the ribosome transcription (87). Interest-
ingly, diethyl maleate-induced oxidative stress has been
demonstrated to modulate also the whole nuclear export
system through impairment of the CRM1-mediated nuclear
export, coupled to relocalization of the nuclear pore compo-
nent Nup98 to the nucleolus (33). Altogether, these observa-
tions underline the role of the nucleolus as stress sensor,
further confirming the validity of the aforementioned model
involving arrest of ribosome biogenesis, followed by nucleo-
plasmic and nucleolar proteome rewiring.
The damage-specificity of the nucleolar response is clearly
depicted by the differential response to diverse DNA dam-
aging stimuli: DNA repair factors undergo selective mobili-
zation upon specific genotoxic conditions (Table 1). UV and
ionizing radiation (IR), for instance, elicit markedly differen-
tial responses in terms of nucleolar proteome reorganization.
Whereas UV stress is characterized by fast and persistent
(hours), fluctuations of nucleolar nonhomologous end joining
(NHEJ) proteins, IR lead to quicker (minutes), but less per-
sistent responses, which are more limited, in terms of mag-
nitude (106). The dynamic reorganization of nucleolar
proteins upon DNA damage has been nicely described by
628 ANTONIALI ET AL.
Adelmant et al., who showed that microinjection of sheared
DNA, to mimic the presence of strand breaks, leads to
the rearrangement of Ku complexes. Intriguingly, in the ab-
sence of DNA damage, Ku associates with rRNA- and RP-
containing complexes; a DDR onset elicits the exit of Ku from
nucleoli and the modification of its interactome (2). This
process likely represents a general response mechanism,
where the nucleolus acts as a sensitive ‘‘antenna’’ for stress
and DNA damage and as central hub for the coordination of
the cellular response to stress conditions. The ability to un-
dergo highly dynamic and selective reorganization allow for
prompt release of DNA repair factors that are stored within
this organelle. An essential question still remains to be an-
swered: which is the triggering event that begins the signaling
cascade linking DNAdamage to the early nucleolar response?
PTMs are usually a quick way to rewire the cellular proteome.
APE1 and WRN translocation from the nucleolus is for in-
stance triggered by acetylation (16, 89); on the contrary, FEN1
has been shown to migrate to the nucleoplasm upon UV ir-
radiation in a phosphorylation-dependent manner. Re-
markably, mutations that mimic or impair the UV-induced
FEN1 phosphorylation, cause UV sensitivity (54), suggesting
thatDNAdamage-inducedprotein translocation is essential for
a correct DDR. Griffiths et al. pointed to SUMOylation as the
major PTM targeting DNA glycosylases in yeast (51); this PTM
has also been implicated in the modulation of rDNA repair
through export of the rDNAdouble-strandbreaks (DSBs) to the
nucleoplasm by the homologous recombination (HR) machin-
ery (39). In addition, the nucleolus has been reported to contain
several DNA damage sensors (e.g., the ataxia telangiectasia
mutated [ATM], the ataxia telangiectasia and Rad3-related
[ATR], and p53) (5, 123) and it has been demonstrated that,
upon DNA damage induction, Pol I-mediated transcription is
blocked in an ATM-dependent manner, and not by the DNA
damage itself. Interestingly, through microirradiation studies,
Kruhlak et al. showed that transcription of rDNA is transiently
arrested only in damaged nucleoli, whereas the neighboring
ones maintain normal transcriptional activity (80). Moreover,
Rubbi and Milner, have elegantly shown that nucleolar dis-
ruption, rather than DNA damage, may lead to p53 stabiliza-
tion, suggesting that the nucleolus may constitutively promote
p53 degradation, unlessDNAdamage occurs (124). Itwould be
interesting to understand if and how the extra-nucleolar DNA
damage is ultimately signaled to the nucleolus andwhich is the
event that triggers the nucleolar segregation.
The Paradigmatic Example of the APE1/NPM1
Interaction
APE1 is a typical example of DNA repair protein activated
during the nucleolar stress response. APE1 is a multifunctional
and essential factor in mammals that was identified about 20
years ago as the major AP-endonuclease in the BER pathway,
as well as a redox coactivator of transcription factors (37, 157).
The recent observation that APE1 is able to bind and cleave
RNA highlighted previously unsuspected roles for the protein
(77, 138). We found indeed that this protein associates with
NPM1 in the nucleolus, where it may have a functional role as
RNA cleansing factor. This hypothesis is corroborated by
studies performedwith inducible HeLa APE1 knock down cell
lines, which showed how APE1 depletion leads to a wide-
spread accumulation of unrepaired oxidized RNA species (i.e.,
8-OHG) upon oxidative stress. Notably, under unstressed
conditions, APE1 knock down cells display impaired transla-
tion ability, lower protein content and overall cell growth im-
pairment (149). These evidences point to a major contribution
for APE1 as cellular scavenger of damaged RNA species. The
nucleolar storage of APE1 is mediated by the interaction of the
flexible and evolutionarily acquired N-terminal extension of
the protein with both rRNA andNPM1 (42, 89, 116). However,
the protein does not constitutively accumulate in the nucleoli;
in fact, upon Pol I inhibitionwith actinomycinD,APE1 shuttles
to the nucleoplasm (149). The evidence that treatment with the
E3330 redox inhibitor (45) causes APE1 nucleolar exit and its
accumulation to the nucleoplasm (147) suggests that the redox
status of APE1 may play a significant role in controlling its
subcellular trafficking. Interestingly, the APE1/NPM1 associ-
ation is also impaired during oxidative stress (149), suggesting
that the protein may be released from the nucleolus during
stress conditions, possibly to operate within the BER pathway.
In accordance with this observation, we delineated a complex
regulatory pattern of NPM1 on APE1 endonuclease activities:
NPM1 acts as an inhibitor of the APE1 ribonuclease function,
but as an activator of the AP-endonuclease function on DNA
(149, 150). This model suggests that when APE1 resides within
the nucleolus, its activity is mainly focused on the rRNA
quality control machinery, possibly modulated by NPM1.
Whereas, during the DDR, the simultaneous outflow of APE1
and NPM1 to the nucleoplasm, leads to the activation of the
APE1 AP-endonuclease function (Fig. 4). In agreement with
this view, many reports point to the involvement of NPM1 in
different aspects of the DDR, yet, the exact contribution(s) of
this protein to the stress response is currently elusive (31, 79,
127). It is worth pointing out that the lack of NPM1 has been
proved to sensitize cells to genotoxins that elicit a BER response
and that APE1 catalytic activity is impaired inNPM1knock out
cells (150). These elements suggest that NPM1 plays a direct
role in the BER modulation, which is still poorly understood.
As discussed in the previous section of this review, the key
event that triggers the APE1 release from nucleoli upon geno-
toxic stress is still amatter of debate. It is known that theAPE1/
NPM1 interaction is modulated by acetylation on the N-
terminal domain of APE1 (42, 89). Acetylation of this protein
region is induced upon genotoxic stress (89, 128); it is therefore,
likely that, once again, stress-induced PTMs drive APE1 shut-
tling to the nucleoplasm in response to DNA damage. In an
effort to characterize the response of APE1 to genotoxic stress,
we generated a quadruple lysine to alanine substitution that
mimics constitutive APE1 acetylation. As anticipated, the in-
ability of this mutant to interact with NPM1 leads to nucleolar
exclusion of the APE1 mutant. Interestingly, the lack of APE1
nucleolar accumulation causes a severe impairment of cellular
proliferation, indicating that the presence of APE1 within nu-
cleoli is required to ensure a proper cellular growth rate (89).
These aspects of the APE1 biology still deserve thorough in-
vestigation and fascinatingly open novel perspectives for an-
titumor therapy, as targeting theAPE1/NPM1 interactionmay
prove effective in counteracting cellular proliferation.
The APE1 protein is commonly renowned as DNA repair
protein and only recently it has been identified as an enzyme
active on abasic RNA molecules, unveiling its noncanonical
function. Perhaps earlier examples of this versatility of func-
tion in dealing with genotoxic damage were described for the
RP S3, both in Drosophila and humans. Specifically, S3 has
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been found to protect cells from genotoxic stress through: (i)
its DNase activity on abasic sites in Drosophila (155); (ii) its
ability to stimulate, the activity of the uracil-DNA glycosylase
hUNG in human cells (78); (iii) its ability to bind with high
affinity the oxidative lesion 8-OHG in humans (60) and (iv) its
functional interaction, always in human cells, with other
well-known DNA repair proteins, such as the 8-OHG DNA
glycosylase (OGG1) and APE1 (61). Recent findings are in-
creasingly pointing to the involvement of noncanonical pro-
teins (57) and even of noncoding RNA molecules (46) in the
DDR, addingmore layers of complexity to this mechanism. An
intriguing emerging evidence is that the association of DNA
repair proteins to noncanonical binding partners (i.e.,RNA and
RNA-binding proteins) is mainly driven by the presence of
unfolded protein domains acquired during phylogenesis,
which may be responsible for novel gain of function activities.
Relevance of the Unfolded Domains in BER Proteins:
The Missing Link for a Phylogenetic Gain of Function?
Until recently, BER was considered the simplest among the
DNA repair pathways since an in vitro reconstituted nuclear
BER required only four or five core enzymes. However, recent
studies have revealed that BER is much more complex, in-
volving a network of distinct and integrated cell cycle- and
genome-specific sub-pathways in which numerous non-
canonical proteins take part (58, 59). Notably, many of these
proteins are involved in RNA-metabolism processes. Actu-
ally, several noncanonical factors have been demonstrated to
participate BER, even though their in vivo functions are yet to
be fully unraveled. The list of non-BER proteins includes for
instance: YB-1 [which has been shown to interact with the
endonuclease VIII-like 2 (NEIL2) glycosylase (35), the endo-
nuclease III-like glycosylase (NTH1) and APE1 (29)], NEIL2
[which was also found to interact with the RNA-binding
protein hnRNP-U (6)], HMGB1 [which has been implicated in
single-strand break (SSB) repair involving Polb (90)] and the
tumor suppressor p53, which was also shown to play a role in
DNAdamage repair through direct binding to APE1 and Polb
(168). The list of these non-BER proteins is still growing,
supporting the notion that BER in vivo is far more complex
than the simple model that we can reconstitute in vitro. In
particular, the characterization of the BER interactome iden-
tified multiprotein complexes; thus, suggesting that complete
FIG. 4. Dynamic turnover of the APE1/NPM1 complex in response to cellular stress. Under basal conditions (left) the
cellular APE1 pool is dynamically distributed throughout the cell, with prevalent accumulation in the nucleus and nucleoli.
This accounts for the maintenance of a basal DNA repair capacity (both nuclear and mitochondrial), redox-mediated tran-
scriptional modulation, cell proliferation, and RNA cleansing activity. Upon genotoxic stress and/or arrest of Pol I tran-
scription (right) the dynamic equilibrium of APE1 localization is tipped towards a nucleoplasmic accumulation of the protein
(149). The APE1 relocalization is likely mediated by simultaneous migration of NPM1 outside the nucleolus and hyper-
acetylation of the N-terminal region of APE1 itself (90). This situation ensures a potentiated DNA repair response, as both the
nucleoplasmic APE1/NPM1 association and its acetylation have been linked to increased catalytic activity of the protein. The
absence of APE1 from nucleoli, moreover, might favor a temporary arrest of cellular proliferation, useful to allow for more
efficient DNA repair. If the DNA damage is sustained, it is likely a redistribution of a pool of APE1 to the cytoplasm. This
phenomenon should boost the mitochondrial BER and possibly contribute to the cellular RNA cleansing capacity. APE1,
apurinic/apyrimidinic endonuclease 1; BER, base excision repair; NPM1, nucleophosmin 1; Pol I, RNA polymerase I. To see
this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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repair occurs through the action of BER complexes formed by
core proteins and noncanonical factors (BERosomes) (59). The
previous and simplistic view of the BERmechanism, based on
the analysis of cocrystal structures of substrate-bound pro-
teins, proposed a pathway consisting of sequential steps in
which individual repair enzymes carry out reactions inde-
pendently. In contrast with this original concept, recent dis-
coveries showed that early BER enzymes stably interact with
most of the downstream repair components. The initial view
of BER as a ‘‘hand-off’’ or ‘‘passing the baton’’ process has
been revisited by Hegde et al. who introduced, rather, a new
paradigm in which the dynamic interplay of highly coordi-
nated interactions between different BER proteins would in-
crease the efficiency and the versatility of the process.
It has been observed that frequently those machines whose
operations must be tuned rapidly in response to specific and
diverse cellular needs, present components that are not fully
structured. Such ‘‘malleable machines’’ (47), conversely to rigid
entities, might presumably better respond to different condi-
tions, for instance by promoting conformational rearrange-
ments and facilitating multiple targets recognition. Structural
analyses exploiting both experimental and modeling ap-
proaches have indeed evidenced the presence of disordered
segments preferentially localized at the N- or C-terminus of
different mammalian DNA repair proteins, a peculiar feature
which is absent in their bacterial prototypes. These observa-
tions thus, suggest that, during evolution, higher organisms
have acquired these binding domains to regulate multiprotein
interactions and to improve pathways (e.g., BER) efficiency, in
an increasingly oxidizing environment. Long disordered seg-
ments are a common feature observed in a large percentage of
proteins; being prevalent especially among proteins involved
in vital processes, such as transcription, translation, signal
transduction, and protein phosphorylation (47, 145). Such un-
structured regions may provide versatility in recognizing
multiple targets, promoting communication with many pro-
teins in response to environmental changes; thus, expanding
the capacities of ordered complexes and representing a pow-
erful strategy selected by nature to quickly explore a vast in-
teraction space with unique thermodynamic advantages (132).
Disordered regions were shown to be prevalent in DNA
binding proteins, particularly in those involved in targeted
sequence binding (e.g., repair proteins and transcription fac-
tors) (143, 153). Disordered prediction tools (PONDR and
PrDOS) have been used to compare the secondary structure of
human and bacterial early BER proteins (59). These analyses
showed that mammalian DNA glycosylases are endowedwith
unique nonconserved extensions at their N- or C-termini,
which are absent in their homologs in lower organisms (58).
The human NEIL1 glycosylase, for instance, contains an ex-
tended disordered region spanning about 100 residues at the
C-terminus, absent in the E. coli Nei-like protein. Similar com-
parisons between the human DNA glycosylases hNTH1, the
MutY homolog (hMYH), and their E. coli prototypes (i.e., en-
donuclease III and MutY, respectively), indicate that both
hNTH1 and hMYH have extended disordered tails at the N-
terminus that are absent in the E. coli enzymes (66, 140). Like-
wise, the N-terminal disordered region present in the human
APE1 is absent in exonuclease III (Xth), its E. coli ortholog. The
size range of the unstructured extensions is about 50–100 res-
idues. In the case of human APE1 it consists of*65 residues,
being mostly disordered (59).
These disordered regions, due to their structural flexibility
and plasticity have been shown to provide BER proteins with
functional advantages and appear to be essential for their
biological functions, including damage sensing (153), protein–
protein interactions, repair regulation via PTMs and contain-
ing NLSs (118). Furthermore, the presence of disordered
segments only in eukaryotic proteins, with the highest degree
of disorder in mammals, suggests their evolutionary acqui-
sition and well correlates with the increase in regulatory
complexity observed in higher organisms.
FIG. 5. Schematic representation
of multiple regulatory functions of
the APE1 disordered N-terminal
region. APE1 crystal structure
(yellow) bound to abasic DNA
(grey) is from the pdb (1DEW) and
displayed using the PDBV soft-
ware. The deposited APE1 crystal
structure was obtained using a
truncated APE1 form (residues 40–
318); missing residues have been
manually added. The unstructured
N-terminal portion of APE1 (resi-
dues 1–42) is essential for APE1 bi-
ological functions being site of
PTMs, target of many interactions
and, including the NLS. NLS, nu-
clear localization signal; PTMs,
post-translational modifications. To
see this illustration in color, the
reader is referred to the web ver-
sion of this article at www
.liebertpub.com/ars
NONCANONICAL FUNCTIONS OF DNA REPAIR PROTEINS AND RNA METABOLISM 631
Among the BER enzymes, APE1 offers a paradigmatic ex-
ample of how a disordered tail can endow a protein with
unique activities. The first crystallographic structure of the
human APE1 in complex with DNA was obtained using a
truncated protein lacking the first 35 amino acids and reveled
that this protein consists of two symmetric alpha/beta fold
with a significant structural similarity to both bovine DNase I
and its E. coli homologue Xth (50). A crystal structure of the
full-length protein has also been reported, but again, the N-
terminal region was unresolved (10). Three functionally in-
dependent domains can be distinguished within the APE1
protein (Fig. 5): (i) the first 33–35 amino acid region consists of
a structurally disordered segment (133) essential for the in-
teraction with other proteins (148, 149) and harboring sites for
PTMs (14, 24, 70, 89, 159, 165, 166) and RNA interaction (89);
(ii) the redox domain is located in a region between amino
acids 35 and 127; and (iii) the DNA repair domain, which
spans the C-terminal domain of the protein from about resi-
due 61 onwards (42, 68). Whereas the APE1 C-terminal do-
main involved in AP endonuclease activity is conserved from
bacteria to humans, the N-terminal region is unique to
mammals suggesting a recent acquisition during evolution.
Remarkably, this peculiar region also accounts for non-
canonical activities that have been ascribed to APE1, includ-
ing its role in RNA metabolism (42, 89, 116, 138, 148, 149).
Over the past two decades, knowledge of the biological
functions, mechanisms of action, interactions, and regulation
of the APE1 protein has increased exponentially. In particular,
it has become apparent that APE1 participates in multiple
cellular processes not only confined to the maintenance of
genome stability, in accordance with the current general view
that many DNA repair enzymes may exert miscellaneous
activities, being implicated, for example, in different steps of
gene regulation (74, 113). As already mentioned, RNA decay
and processing events require a wide spectrum of proteins,
including RNA helicases, polymerases and, above all, exori-
bonucleases and endoribonucleases. For many years, it has
been assumed that eukaryotes RNA cleavage relies mostly on
the action of exoribonucleases, in contrast with prokaryotes,
where RNA decay is mainlymediated by endoribonucleolytic
processes (82, 101). In recent years, the unexpected implica-
tion of numerous endoribonucleases in the RNA turnover in
eukaryotes significantly contributed to a change of perspec-
tive on the eukaryotic RNAmetabolism (141). APE1 is among
the several examples of recently identified enzymes whose
endoribonucleolytic activity has been found to associate with
the regulation of RNA stability. Evidence of its RNase H-like
activity was first suggested by Barzilay et al. who demon-
strated that APE1 is able to bind with relatively low affinity
undamaged single- and double-stranded RNA molecules,
albeit not exhibiting unspecific nuclease activity (9). Later on,
it has been discovered that APE1 possesses the ability to
cleave AP sites within single-stranded RNA molecules and
that the nucleic acid secondary structure significantly influ-
ences the APE1 incision activity (12). Despite these first in vitro
suggestions of APE1 biological relevance in the removal of
AP-site-containing RNA, the unequivocal demonstration of
APE1 involvement in RNA processing was brought only few
years later. Very recently, in fact, Barnes et al. identified APE1
as the major endonuclease associated with polysomes and
capable of cleaving the coding region determinant of the c-myc
mRNA; thus, influencing c-myc half-life in cells (7). Surpris-
ingly, recent biochemical studies performed using recombi-
nant APE1 demonstrated that the APE1 endoribonuclease
function is not limited to c-mycmRNA, but it may potentially
influence the biogenesis and hence, the stability of other
transcripts, including also miRNAs (77). These works dem-
onstrated that APE1-mediated RNA cleavage occurred,
in vitro, at single-stranded or weakly paired regions, prefer-
entially 3¢ of pyrimidines at UA, UG, and CA sites. This latter
finding, in particular, led to hypothesize the possible in-
volvement of APE1 in mRNA splicing events, since CA re-
peats are renowned as potent splicing modulators (15).
Furthermore, the in vivo involvement of APE1 in RNA meta-
bolic pathways was further corroborated by the observation
of the APE1 association, through its N-terminal domain, with
rRNA and the ribosome processing protein NPM1 within
nucleoli (149). Furthermore, APE1 has been shown to interact
with factors involved in the splicing process, such as the
heterogeneous nuclear ribonucleoprotein L (81) [which is a
key regulator of splicing that binds CA repeats with high
affinity (65)], YB-1 (29, 119), as well as with proteins involved
in the ribosome assembly and RNA maturation within cyto-
plasm (149).
So far, many studies have characterized the involvement of
the APE1 C-terminal domain in RNA metabolism, demon-
strating that the APE1 endoribonuclease activity and its nu-
clease function on DNA share the same active site (76).
However, few groups have investigated the role of the un-
structured N-terminal extension, possibly as a consequence of
its disordered nature. A recent work published form our
group systematically characterized the binding properties of
the APE1 N-terminal disordered region towards nucleic acids
and NPM1. We demonstrated that the N-terminus, in partic-
ular acquired Lys residues therein located, appear to be es-
sential for the stabilization of both protein–protein and
nucleic acids–protein interactions, as well as influencing the
thermal stability of the protein. These evidences clearly sup-
port the notion that this unstructured domainmight represent
an evolutionary gain function necessary for mammals to cope
with a progressively complex cellular environment (116).
In light of these recent findings and taking into account also
previous reports on the pivotal role of APE1 disordered N-
terminal region, we speculate that the targeting of this un-
folded protein domain could be a valuable tool to interfere
with the different APE1 functions in vivo.
Relevance of the Unstructured Domain of BER
Proteins for Designing Novel Anticancer Strategies
BER proteins have been broadly explored as targets for
cancer therapy (67); in particular, current approaches to can-
cer treatment report more effective results when specific DNA
repair inhibitors are used in combination with DNA damag-
ing drugs. The foremost rationale of the combined therapy is
that impairment of BER enzymes is likely to sensitize cancer
cells to chemotherapeutic agents. Druggable BER targets for
cancer treatment include: FEN1, Polb, APE1, and the poly
[ADP-ribose] polymerase 1 (PARP1); while targeting of DNA
glycosylases results inefficacious because of the functional
redundancy of this class of enzymes (58).
In the last decade, remarkable attention has been posed on
the development of PARP1 and APE1 inhibitors. The APE1
relevance for cell survival is demonstrated by the fact that
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knocking out the APE1 gene induces either apoptosis in dif-
ferentiated cells (69) or developmental failure during em-
bryogenesis (158). Accumulating evidences have indicated
that deregulation of APE1 in both expression and subcellular
localization is indeed associated with different tumorigenic
processes: APE1 upregulation or dysregulated expression has
been described in a variety of cancers, including prostate,
pancreatic, ovarian, cervical, germ cell, rhabdomyosarcoma,
and colon (43, 92). Furthermore, it has been reported that el-
evated APE1 levels and anomalous intracellular localization
are also typically correlated with aggressive proliferation and
increased resistance to chemotherapeutic drugs and IR, im-
plying that APE1 enhances repair and survival of tumor cells
(92). Therefore, considering that APE1 expression appears to
be linked to chemoresistance and taking into account that
several studies have shown that decreasing APE1 levels may
lead to cell growth arrest and to an increased cellular sensi-
tivity to DNA damaging agents (44, 45, 85, 154), APE1 rep-
resents a promising target for pharmacological treatment. A
description of all the APE1-targeting molecules currently
under investigation is beyond the focus of this review, for an
exhaustive review on APE1 inhibitors, the reader is redirected
to (146). All the APE1 small-molecule inhibitors developed so
far were designed to target specific APE1 functions, namely
the DNA repair or the redox activity of the protein. It is
however, still a matter of debate whether the enhanced sen-
sitivity to cytotoxic agents observed upon APE1 inhibition is
solely related to the loss of DNA repair activity, or is also
linked to the loss of its transcriptional regulatory function, or
both. Despite the efforts aimed at determining the relative
importance of the attenuation of the APE1’s repair or tran-
scriptional functions, all currently available APE1 inhibitors
display limited specificity for cancer cells. Therefore, explo-
ration of novel opportunities for APE1 targeting is obviously a
path that deserves further consideration. Based on several
observations attesting the critical role of disordered segments
in many BER enzyme functions, we propose that the N-
terminal unstructured portion of the APE1 protein could be
considered as a new potential target for cancer therapy.
Classical pharmacological strategies usually target structured
regions of proteins; however, considering the biological rele-
vance of intrinsically disordered proteins, the ability to in-
terfere with their interactions opens enormous potentials for
drug discovery. Actually, there is a continuous progress in
the development of small molecules directed against disor-
dered protein regions; several low molecular weight com-
pounds are effective in the specific inhibition of molecular
interactions based on intrinsically disordered domains. For
example, small molecules binding the disordered regions of c-
myc, Ab, EWS-Fli1 have recently been discovered (100, 144).
Although the binding of a small molecule to a disordered
region/protein may appear counterintuitive due to the in-
trinsic poor selectivity, this may also be considered a major
advantage because it would facilitate the screening of initial
compounds, which affinity and specificity could be succes-
sively improved through standard molecular optimization
procedures.
In conclusion, we suggest that it would be interesting to
investigate novel pharmacological approaches aimed at in-
terfering with the APE1 N-terminal region in light of its im-
portant role in the coordination of many different functions of
the protein, both in DNA repair and RNA metabolism.
Conclusions and Speculations
Different independent studies provided in vitro and in vivo
evidence that many DNA repair proteins, particularly in the
BER pathway (e.g., APE1), are involved in RNA metabolism.
Interestingly, many of these proteins are also part of the nu-
cleolar proteome where they bind specific carrier proteins
(e.g., NPM1, NCL) and rRNA. Upon genotoxic stress, many
DNA repair proteins exit from nucleoli and switch their in-
teractome network from proteins involved in RNA metabo-
lism to DNA repair complexes. Although still in the early
phases, these findings have raised many questions and spec-
ulations concerning the role of these proteins, including APE1
as a paradigmatic example, in RNAmetabolism. For instance:
1. Why should a protein involved in DNA repair play a
role in RNA metabolism? One possible explanation is
that this duality would preserve genetic stability not
only through the DNA repair activity, but also through
the ability to cleanse damaged RNA that may otherwise
be inaccurately translated, or degrade unwanted for-
eign RNA (e.g., viral RNA).
2. Do the redox function of APE1 and its role in RNA
metabolism represent two sides of the same coin devoted
to modulate gene expression through transcriptional and
post-transcriptional mechanisms? Modulation of APE1
subcellular distribution through its redox status may
represent an elegant, specific, and energetically economic
mechanism to tune gene expression upon genotoxic
stress conditions.
3. IsAPE1 an ancient proteinwith a newly identified andyet
unappreciated role? The current information regarding
the primary amino acid sequence of APE1 across species
seems to suggest a phylogenetic ‘‘gain-of-function’’ and
hence, support this hypothesis. However, further experi-
mental and bioinformatics studies ofAPE1 orthologsmay
reveal additional insights into this question.
4. Suppressing the amount of APE1 has proven effective
in sensitizing cancer cells to chemotherapeutic agents.
This finding has led to the proposal that selective in-
hibition of the APE1 DNA repair activity is an attractive
avenue for the development of novel anticancer thera-
pies. Similarly, one can envision targeting the non-DNA
repair functions of APE1, namely its RNA-repair and/
or RNA-cleavage activities, as novel approaches for the
treatment of cancer or neurological disorders. None-
theless, such therapeutic aims still need further studies
to increase our understanding of the role of APE1 in its
noncanonical functions.
In closing, a productive cross-talk between DNA repair
enzymes and proteins involved in RNA metabolism seems
reasonable and nucleolus is emerging as a dynamic functional
hub that coordinates cell growth arrest and DNA repair
mechanisms. These findings will drive further analysis of
other BER proteins, such as FEN1, and might imply that nu-
cleic acid processing enzymes are more versatile than origi-
nally thought andmay have evolved DNA-targeted functions
after a prior life in the early RNA world. The observation of
cytoplasmic localization for canonical DNA repair proteins,
such as APE1, simply beyond their mitochondrial targeting,
may therefore, suggest much more than just an ‘‘abnormal’’
distribution pattern.
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Background:Nucleophosmin (NPM1, B23) is a multifunctional protein that is involved in a variety of fundamen-
tal biological processes. NPM1/B23 deregulation is implicated in the pathogenesis of several human malignan-
cies. This protein exerts its functions through the interaction with a multiplicity of biological partners. Very
recently it is has been shown that NPM1/B23 specifically recognizes DNA G-quadruplexes through its C-
terminal region.
Methods: Through a rational dissection approach of protein here we show that the intrinsically unfolded regions
of NPM1/B23 significantly contribute to the binding of c-MYC G-quadruplex motif. Interestingly, the analysis of
the ability of distinct NPM1/B23 fragments to bind this quadruplex led to the identifications of distinct NPM1/
B23-based peptides that individually present a high affinity for this motif.E
CResults: These results suggest that the tight binding of NPM1/B23 to the G-quadruplex is achieved through thecooperation of both folded and unfolded regions that are individually able to bind it. The dissection of NPM1/B23 also unveils that its H1 helix is intrinsically endowed with an unusual thermal stability.
Conclusions: These findings have implications for the unfolding mechanism of NPM1/B23, for the G-quadruplex
affinity of the different NPM1/B23 isoforms and for the design of peptide-based molecules able to interact with
this DNA motif.© 2014 Published by Elsevier B.V.R
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R1. Introduction
Nucleophosmin (NPM1, also known as B23, No38 and numatrin)
is an abundantmultifunctional protein, initially identified as a phospho-
protein, which is present in high quantities in the granular region of nu-
cleoli [1,2]. NPM1/B23 is, however, capable of shuttling between
nucleus and cytoplasm [3]. NPM1/B23 plays a plethora of functions in-
cluding the regulation of ribosome biogenesis, chromatin remodeling,
DNA replication, recombination, transcription, repair and the control
of centrosome duplication [4,5]. This protein has been found over-
expressed in tumors of different histological origins, including gastric,
ovarian, bladder and prostate carcinomas and in various hematologicaletic acid; DMF, Dimethylformamide;
triazole; DIEA, Di-isopropylethylami
omatography–Mass Spectrometry;
pectroscopy; RMSD, Root Mean Squa
niversity “Federico II”, Via Mezzocan
).
, et al., G-quadruplex DNA re
.org/10.1016/j.bbagen.2014.0malignancies [6–9]. Notably, NPM1/B23 has been identified as themost
frequentlymutated gene in acutemyeloid leukemia (AML) patients, ac-
counting for approximately 30% of cases [10–14].
NPM1/B23 belongs to the nucleophosmin/nucleoplasmin family of
proteins [15]. Three distinct isoforms of the protein have been reported
to be expressed in human cells. B23.1, the longest and the most abun-
dant, is also the best characterized isoform. B23.2 and B23.3 are splicing
variants that lack the C-terminal 35 amino-acids and a 29 amino-acid
stretch (residues 195–223) in the basic region, respectively [16].
Structural characterizations of B23.1 have shown that the protein is
endowed with a modular structure (Fig. 1). The N-terminal domain ex-
tends for approximately 100 residues and displays an eight-strandedDCM, Dichloromethane; HBTU, 1-H-Benzotriazolium, 1-[bis(dimethylamino)methylene]-
ne; Fmoc, Fluorenylmethoxycarbonyl; TCEP, Tris(2-Carboxyethyl) phosphine; HPLC, High
EDC, 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride; NHS, N-hydroxy-
re Deviation; TOCSY, Total Correlation Spectroscopy; C_53 NPM1, NPM1 242–294; C_70
none, 16, 80134 Naples, Italy. Tel.: +39 081 2532043; fax: +39 081 2534574.
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242-259 B23.2 SSVEDIKAKMQASIEKAH
259-277 B23.1 GSLPKVEAKFINYVKNCFR 
A
B
NES
94-102 AD
NLS
152-157 AD
NLS
190-197 BD
NoLS
288-290
Oligomerization                               
Molecular Chaperone Histone Binding DNA/RNA Binding
1 110 111 189 190 294
188EKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGS260
C_107 NPM1
C_70 NPM1 
C_53 NPM1 
225
188
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Fig. 1. Schematic representation of NPM1 protein.Q2 (A) Themodular structure of NPM1, functional, structural domains andprimary structure of C_107NPM1are pointed out and (B) primary
sequences of C_107NPM1-based peptides were analyzed in this study.
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Ebeta-barrel fold. Five N-terminal domains oligomerize to form a crown-
shaped pentamer [17]. Two or more of these pentamers may associate
to form decamers or higher oligomeric species [18]. The central portion
of NPM1 is characterized by the presence of two acid domains (residues
119–133 and 161–188) and a basic region (residues 198–239). The C-
terminal domain (CTD) of B23.1 forms a globular structure consisting
of a three helix bundle. The destabilization of this structural unit abol-
ishes the nucleolar localization of the protein [19]. The C-terminal re-
gion of the protein has also been the subject of a number of intriguing
investigations aimed at unveiling its folding mechanism [20–23]. De-
spite the structural heterogeneity of the different regions of the protein,
recent biophysical studies have highlighted their mutual stabilization
upon treatments with temperature or chemical denaturants [21,24].
The analysis of the NPM1/B23 sequence also shows that the protein
shuttling abilities between intracellular compartments rely on several
signaling sequences: i) a NES (nuclear export) motif with two leucines
in the N-terminal domain, ii) NLSs (nuclear localization) between
the two acidic stretches and, iii) a NoLS (nucleolar localization) with
aromatic-rich residues at the C-terminal domain [20]. NPM1/B23
exerts its functions essentially through interactions with a variety of bi-
ological partners. NPM1 interactions with other proteins (e.g. p53,
p14arf, Fbw7γ, APE-1) [25–29], ribosomal proteins RPL5, RPS9, RPL23,
HIV proteins REV TAT) [30] are generally mediated by the N-terminal
domain, whereas the C-terminal moiety regulates the binding of DNA/
RNA.
NPM1was shown to bind both DNA and RNA oligonucleotides, with
a preference for single stranded structureswith respect to those double-
stranded, independently of the sequence [31,32].Please cite this article as: P.L. Scognamiglio, et al., G-quadruplex DNA re
Biochim. Biophys. Acta (2014), http://dx.doi.org/10.1016/j.bbagen.2014.0Recently, it is has been shown that the C-terminus of NPM1 is able to
specifically recognize G-quadruplex DNA motifs [33,34]. This finding is
of great interest since thesemotifs are attractive targets for tumor treat-
ment for their selective localization on promoters of several oncogenes
and on telomeric regions [34,35]. In particular, it has been demonstrat-
ed that the NPM1 C-terminal domain recognizes in vitro a well-
characterized G-quadruplex forming sequence present at the NHEIII re-
gion of the c-MYC oncogene promoter [33]. This promoter region
adopts a G-quadruplex structure both in vitro and in vivo, regulating
up to 90% of the total c-MYC transcriptional rate [36]. NMR studies
have shown that this G-quadruplex is recognized by NPM1 primarily
by residues belonging to the helices H1 and H2 of the three-helix bun-
dle. Nevertheless, mutagenesis analyses have shown that a fundamen-
tal contribution to the G-quadruplex binding is provided by the
residues Lys 229 and Lys 230 [34]. Intriguingly, the region embedding
these residues is disordered in the NMR structure of the complex.
Attempts to explain these puzzling findings were based on the observa-
tion that the presence of an unstructured segment adjacent to the
interacting domain could provide a larger platform for long-range elec-
trostatic interactions or transient physical contacts [34].
In order to gain further insights into this intricate recognitionmech-
anism, here we evaluated the ability of individual fragments of NPM1 to
bind this G-quadruplex. Interestingly, the dissection of NPM1 led to the
identification of distinct protein segments that present high affinity for
this motif. The structural characterization of these fragments provides
new clues about the folding/unfolding process of the triple helix bundle
motif. Moreover, present findings delineate strategies for the develop-
ment of peptide-based entities for targeting the c-MYC G-quadruplex.cognition by nucleophosmin: New insights from protein dissection,
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2. Material and methods
2.1. Preparation of recombinant C_107 NPM1
C_107 NPM1 (residues 188–294) constructs were expressed and
purified as HisTag-fusion proteins in Escherichia coli BL21 (DE3) follow-
ing or adapting the procedure previously described [37]. The quality of
purification was checked by Coomassie-stained SDS-polyacrylamide
gel electrophoresis (PAGE) analysis. Extensive dialysis against PBS was
performed to remove any trace of imidazole from the purified proteins.
2.2. G-quadruplex
Oligonucleotide TGGGGAGGGTGGGGAGGGTGGGGAAGG biotinylat-
ed at the 5′-end used in this study was purchased from PRIMM s.r.l
(Milan, Italy) and purified by HPLC. For annealing, as already reported,
in 20 mM Hepes, pH 7.0, with 100 mM NaCl, oligo was heated to 95 °C
for 15 min and slowly cooled down at RT, overnight.
2.3. Surface Plasmon Resonance
The interactions between biotinylated c-MYC G-quadruplex with
purified C_107 NPM1, and peptides NPM1 188–225, 225–243, 242–
259 and 242–259_B23.2, were all measured using the SPR technique
and BIAcore T-100, 3000 (GE Healthcare Milano, Italy). Biotinylated c-
MYC G-quadruplex was immobilized on a sensor chip SA, pre-coated
with streptavidin (GE Healthcare Milano, Italy). The capturing proce-
dure on the biosensor surface was performed as reported in [38]. Run-
ning buffer was Hepes-buffered saline-EP, which contains 10 mM
Hepes, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% (v/v) surfactant P20.
Analytes were dissolved in running buffer, and binding experiments
were performed at 25 °C with a flow rate of 20 μL/min. The association
phase (kon)was followed for 180 s,whereas the dissociation phase (koff)
was followed for 300 s. The complete dissociation of active complex
formed was achieved by addition of 1 M NaCl, for 60 s before each
new cycle start. The reference chip sensorgrams were opportunely
subtracted to sample sensorgrams. When experimental data met quali-
ty criteria, kinetic parameters were estimated assuming a 1:1 binding
model and using version 4.1 Evaluation Software (GE Healthcare), and
it was so only for C_107 NPM1. Conversely, for C_107 NPM1 derived
peptides the fit of the equilibrium values for the SPR response vs. the li-
gand concentrationwas employed andperformedwithGraphPad Prism
v4.00 [39] using the one-site binding equation.
2.4. Peptide synthesis
Reagents for peptide synthesis (Fmoc-protected amino acids and
resins, activation and deprotection reagents) were from Novabiochem
(Läufelfingen, Switzerland) and InBios (Napoli, Italy). Solvents for pep-
tide synthesis and HPLC analyseswere fromRomil (Dublin, Ireland); re-
versed phase columns for peptide analysis and the LC–MS system were
from ThermoFisher (Milan, Italy). Solid phase peptide syntheses were
performed on a fully automated multichannel peptide synthesizer
Syro I (Multisynthech, Germany). Preparative RP-HPLC was carried
out on a Shimadzu LC-8A, equipped with a SPD-M10 AV detector and
with a Phenomenex C18 Jupiter column (50 × 22 mm ID; 10 μm). LC–
MS analyses were carried out on a LCQ DECA XP Ion Trap mass spec-
trometer equipped with a OPTON ESI source, operating at 4.2 kV needle
voltage and 320 °C with a complete Surveyor HPLC system, comprised
of MS pump, an autosampler and a photo diode array (PDA). Narrow
bore 50 × 2 mm C18 BioBasic LC–MS columns were used for these
analyses.
The peptides 188–225, 225–243, 242–259, 242–259_B23.2, and
259–277 were synthesized employing the solid phase method on a
50 μmol scale following standard Fmoc strategies [40]. Rink-amide
resin (substitution 0.5 mmol/g) was used as solid support. ActivationPlease cite this article as: P.L. Scognamiglio, et al., G-quadruplex DNA re
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of amino acids was achieved using HBTU/HOBt/DIEA (1:1:2), whereas
Fmoc deprotectionwas carried out using a 20% (v/v) piperidine solution
in DMF. All couplings were performed for 15 min and deprotections
for 10min and at the end of peptide chain assembly peptideswere acet-
ylated at their N-termini. Peptides were removed from the resin by
treatment with a TFA:TIS:H2O (90:5:5, v/v/v) mixture for 90 min
at room temperature; then crude peptides were precipitated in
cold ether, dissolved in a water/acetonitrile (1:1, v/v) mixture and
lyophilized.
Productswere purified byRP-HPLC applying a linear gradient of 0.1%
TFA CH3CN in 0.1% TFA water from 5% to 65% over 12 min using a semi-
preparative 2.2 × 5 cm C18 column at a flow rate of 20 mL/min.
Peptides and purity and identity were confirmed by LC–MS. Purified
peptides were lyophilized and stored at−20 °C until use.
2.5. Circular dichroism (CD) spectroscopy
CD spectra were recorded on a Jasco J-810 spectropolarimeter
(JASCO Corp, Milan, Italy). CD spectra were registered at 25 °C in
the far UV region from 190 to 260 nm. Each spectrumwas obtained av-
eraging three scans, subtracting contributions from corresponding
blanks and converting the signal to mean residue ellipticity in units
of deg∗cm2∗dmol−1∗res−1. Other experimental settings were:
20 nm/min scan speed, 2.0 nm band width, 0.2 nm resolution,
50 mdeg sensitivity, and 4 s response. The concentration of peptides
was kept at 10 × 10−5 M and a 0.1 cm path-length quartz cuvette was
used. Spectra were acquired in 10 mM phosphate buffer at pH 7.0.
Thermal denaturation profiles were obtained bymeasuring the tem-
perature dependence of the ellipticity at 220 nm in the 293–363K range
with a resolution of 0.5 °C and 1.0 nm bandwidth. The heating rate was
1 K/min and the response at 16 s with a Peltier temperature controller.
A buffer solution containing 10 mM of sodium phosphate was used
in chemical denaturation experiments. Urea was purchased from
Sigma and further purified by recrystallization from ethanol/water
(1:1) mixtures. Stock solutions of urea were mixed with peptide solu-
tions to give a constant final value of the peptide concentration
(100 μM). The final concentration of denaturant was in the range
0.0–8.0 M. Each sample was incubated overnight. Longer incubation
times led to identical spectroscopic signals.
2.6. NMR experiment
NMR analysiswas performed for 242–259 and 242–259_B23.2. NMR
samples consisted of peptides (242–259: 1 mg; 242–259_B23.2:
0.8 mg) dissolved in 600 μL of 10 mM sodium phosphate buffer pH =
7.2; samples contain 5% (v/v) D2O (99.8% d, Armar Scientific,
Switzerland). Most NMR spectra were recorded at 298 K on a Varian
Unity INOVA 600 MHz spectrometer provided with a cold probe. The
process of proton resonance assignment was conducted by following a
standard protocol which relies on comparison of 2D[1H, 1H] TOCSY
(Total Correlation Spectroscopy) [41] (70 ms mixing time) and NOESY
(Nuclear Overhauser Enhancement Spectroscopy) [42] (200 and
300msmixing times) spectra. Chemical shifts were referencedwith re-
spect to internal TSP (trimethylsilyl-3-propionic acid sodium salt-d4,
99% d, Armar Scientific, Switzerland) (see Appendix Tables A1, A2 for
242–259_B23.1, 242–259_B23.2, respectively).
1D spectra were recorded with a relaxation delay of 1 s and 32–64
scans. 2D experiments were generally acquired with 32–64 scans,
128–256 FIDs in t1, 1024 or 2048 data points in t2.
Water suppression was achieved with the DPFGSE (Double Pulsed
Field Gradient Selective Echo) [43] sequence. Spectra were processed
with VNMRJ 1.1D (Varian by Agilent Technologies, Italy) and analyzed
with the NEASY [44] program that is included in the CARA (Computer
Aided Resonance Assignment) software package (http://www.nmr.ch/).
Analysis of Hα chemical shifts and deviations from random coil valuescognition by nucleophosmin: New insights from protein dissection,
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t1:2Dissociation constants for the interaction of NPM1 regions with c-
t1:3MYC G-quadruplex.
Ligand KD (μM) t1:4
C_70 NPM1 1.9 ± 0.1⁎ t1:5
C_53 NPM1 82 ± 15⁎ t1:6
C_107 NPM1 0.328 ± 0.003 t1:7
188–225 NPM1 18 ± 5 t1:8
225–243 NPM1 54 ± 15 t1:9
242–259 NPM1 275 ± 43 t1:10
t1:11⁎ [33].
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were estimated with NmrView [45,46] by using the database byWishart
et al. for peptide random coil chemical shift values [47].
For the 242–259 peptide additional NMR spectra (1D [1H] and 2D
[1H, 1H] TOCSY (70 ms)) were recorded on a Varian Unity INOVA
400 MHz spectrometer at the following temperatures: 298, 303, 308,
313, 318, 323, and 333 K.
Peptide structure calculations were performed with CYANA [48]
(version 2.1). Distance constraints for structure calculations were
gained from NOESY experiments (300 ms mixing time). Angular
constraints were generated with the GRIDSEARCH module of CYANA.
Calculations generally started from 100 random conformers; the 20
structures with the best CYANA target functions (i.e. the lowest values)
were inspected with MOLMOL [49].
3. Results
3.1. C_107 NPM1/B23.1 binds c-MYC G-quadruplex with high affinity
Previous investigations have shown that the binding affinity of
NPM1 toward the c-MYC G-quadruplex depends on the length of the
C-terminal region considered. Indeed, the C_53 NPM1 fragment of the
protein (residues 242–294), which exclusively includes the three-
helix bundlemotif, binds thequadruplexwith a KD of 82 μM. The affinity
increases (KD = 1.9 μM) if an 18-residue stretch of the basic region is
added to C_53 to generate C_70 NPM1 (residues 225–294) [33]. Since
we have recently shown that the region 188–225 has stabilizing effects
on C_70 NPM1, we evaluated the effect of this extension of the C-
terminal region on G-quadruplex recognition. In particular, the affinity
of C_107 NPM1 (residues 188–294) toward c-MYC G-quadruplex se-
quence was measured by SPR. A biotinylated oligonucleotide sequence
was efficiently immobilized on SA-chip (averaged immobilization
level 300RU) andC_107NPM1was employed as analyte (concentration
range 0.1–10 μM). Dose–response sensorgrams (Fig. 2) revealed that
C_107NPM1 avidly binds c-MYCG-quadruplex; the association rate ap-
peared to be rapid (ka= 8.09 ∗ 104 M−1 s−1) whereas the dissociation
was slow (kd = 0.0266 s−1), thus providing a KD value of 0.328 μM
(Table 1). This finding clearly indicates that C_107 NPM1 presents a
higher affinity for the G-quadruplex compared to C_70 and C_53
NPM1. Therefore, in addition to the region 225–241 [33], the region
188–224 also contributes to the complex formation.
3.2. Dissecting the C-terminal region of B23.1 and B23.2
The progressive increase of the affinity for the G-quadruplex upon
the addition of extra-fragments on the N-terminal side of the three
helix bundle motif, prompted us to dissect the C-terminal region ofU
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Fig. 2. Binding of C_107 NPM1 with c-MYC G-quadruplex through SPR. Overlay of
sensorgrams for the interaction between biotinylated at 5′ c-MYC G-quadruplex sequence
immobilized on a SA (streptavidin) sensor chip and C_107NPM1 (as analyte). Experimen-
tal curves (colored lines) related to different concentrations of analyte (0.1, 0.5, 0,8 1, 2, 5,
7, 10 μM)were fitted according to a single exponential bindingmodel with 1:1 stoichiom-
etry (gray lines).
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previous findings, the following fragments of NPM1/B23.1 were consid-
ered: 188–225, 225–243 (both belonging to the basic region), 242–259
(Helix 1), and 259–277 (Helix 2). For the region 242–259, a variant cor-
responding to the C-terminal end of B23.2 (242–259_B23.2) was also
investigated (Fig. 1).
3.2.1. Intrinsic structural preferences of fragments of B23.1 and B23.2
C-terminal region
All peptides reported in Fig. 1 were chemically synthesized with
good yields by SPPS, using Fmoc methodologies as N-terminal acetylat-
ed and C-terminal amidated derivatives and purified by RP-HPLC (see
Materials and methods for further details). Their identity and purity
(averaged purity N 97%) were assessed by LC–MS (data not shown).
To evaluate the impact of structural preferences of these fragments
on their ability to bind c-MYC G-quadruplex, all peptides were charac-
terized by far-UV circular dichroism (CD) and NMR spectroscopies. It
is worth mentioning that the intrinsic tendency to aggregate and
precipitate of the peptide 259–277 (corresponding to H2) prevented
accurate structure and binding analyses.
The CD analysis shows a different structural behavior of the peptides
used.
NPM1 188–225 (Fig. 3A) and 225–243 [21] CD spectra show typical
random coil profiles presenting only one minimum at around 200 nm,
as expected. On the other hand the two variants corresponding to
the region 242–259 (242–259_B23.1 and 242–259_B23.2) showed
spectra with bands at 190, 205, and 222 nm suggestive of the presence
of α-helical conformation (Figs. 3B and A1). This conformation ap-
peared stable within 4 h. Indeed the overlay of CD spectra registered
within this time-lapse did not show any variation in the position and
intensity of the bands.
In this framework, to gain deeper insights into the structure of the
H1 region once separated from protein context, we performed NMR
studies on both 242–259 variants.
For 242–259 in phosphate buffer, proton resonance assignments
were obtained by comparison of 2D [1H,1H] TOCSY [41] and NOESY ex-
periments [42] (Fig. 4A). Chemical shift deviations from random coil
values [47] (Fig. 5a) were then evaluated and indicated a propensity
for the peptide to form a helix in the region between Glu245 and
Met251 (estimated helical content: 38.9%). The tendency of the
peptide to adopt a helical conformationwas further verifiedbyNOEpat-
tern [50] (Fig. 4B). Here, several contacts indicative of helices, mainly
HNi–HN(i + 1); Hαi–HN(i + 2); Hαi–HN(i + 3); and Hαi–Hβ(i + 3),
were observed in the segment encompassing residues Val244–Lys250.
However, these NOEs coexist with rather strong sequential contacts of
the type Hαi–HN(i + 1) that are, instead, hallmarks of extended and/
or random coil conformations and suggest a certain degree of disorder
for the peptide in solution.
To get additional informations, we carried out complete structural
calculations. The analysis of the NMR ensemble of structures (Fig. 5B),
carried out with the software MOLMOL [49], revealed the presence, incognition by nucleophosmin: New insights from protein dissection,
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Fig. 3. Circular dichroism studies of C_107NPM1-based peptides. CD spectra of NPM1 (A) 188–225 and (B) 242–259, for the latter the overlay of spectra recorded at different times (0–4 h)
is reported, and they were registered at 293 K in 10 mM phosphate buffer, pH 7.2.
5P.L. Scognamiglio et al. / Biochimica et Biophysica Acta xxx (2014) xxx–xxxmost of the conformers, of a disordered pseudo-helical segment
in between Val244 and Met251, composed of a turn of 3.10 helix
(Val244–Ile247), and of a bend from Ile247 to Met251. This analysis
clearly indicates that the C-terminal end is flexible.
NMR conformational analyses were carried out for 242–259_B23.2
in similar experimental conditions. Recorded 2D [1H, 1H] TOCSY and
NOESY spectra (Fig. A2) allowed to assign proton resonances also for
this peptide. The NMR parameters, i.e. chemical shift deviations from
random coil values (Fig. 5g) andNOE pattern (Fig. A3), indicate a similar
helix propensity and conformational behavior as 242–259 in the region
between Val244 and Ala249. Despite the two amino-acid substitutions
occurring at the very end of the two peptides (Fig. 1), the C-terminus
of both 242–259 and 242–259_B23.2 is disordered.U
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Fig. 4.NMR analysis of NPM1 242–259 B23.1 peptide. (A) 2D [1H, 1H] TOCSY (70msmixing tim
proton correlation region is shown. (B) NOE intensity diagrams for NPM1 242–259 B23.1. The a
nectivity between the Hx and Hy protons in the i and i + z residue respectively is indicated w
software CYANA [48] was used to generate the NOE diagram.
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R3.2.2. The helical fragments 242–259 of B23.1 and B23.2 are endowed with
a remarkable stability
The analysis of the thermal and chemical stabilities of 242–259 and
242–259_B23.2 unveils some unexpected features. Spectra collected
over the temperature range 293 to 371 K indicate a marginal decrease
of the CD signal (Fig. 6A). This experiment indicates that this sequence re-
tains a significant amount of the helical structure at a very high tempera-
ture, even if a slight variation of ellipticity at 222 nm in the range 333–371
K (inset of Fig. 6A) suggests that a decrease of total helical content occurs.
This thermal stability is very unusual for short peptides and has been
occasionally reported for peptides with unnatural constrains [51].
These observations prompted us to perform additional NMR studies
to better characterize the influence of higher temperatures on 242–259S S V E D I  K A KM Q A S I  E K G G
dNN(i,i+1)
d N(i,i+1)
d N(i,i+1)
dNN(i,i+2)
d N(i,i+2)
d N(i,i+3)
d (i,i+3)
B
α
α
β
α
αβ
e) (left panel) and 2D [1H, 1H] NOESY (300msmixing time) (right panel), theHN-aliphatic
mino acid sequence is reported on the top of diagramwith the one letter code. A NOE con-
ith “dxy(i, i + z)”. The thickness of the bars reflects the corresponding NOE intensity. The
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Oconformation (Fig. 6B). Proton Hα chemical shift changes were moni-tored as a function of the temperature (298–333 K) and chemical shift
deviations from random coil values were estimated to indicate possible
changes in the overall helical content. NMRsignals that aremainly influ-
enced by temperature are those belonging to HN protons that become
progressively broad and totally disappear at 333 K (Fig. 6B), minor
changes are evident and affect the side chain aliphatic protons as well
(Fig. A4a, b).
The broadening of HN lines (Fig. 6B) indicates that by raising the
temperature, HN amide protons become gradually more exposed to
the solvent, possibly because a partial unfolding of the pseudo-helical
structure takes place. In details, for 242–259 when increasing the tem-
perature the helical content drops from 38.9% to 22.2% (according to
CD results) and a residual helical structure is likely to persist between
Glu245 and Lys248, as estimated from chemical shift deviations of Hα
protons from random coil values (Fig. 5f).
The analysis of the chemical stability of 242–259 was checked by
using urea as chaotropic reagent. As shown in Fig. 6C–D, the intensity
of the CD signal measured at 222 nm was significantly affected by the
addition of even low amounts of the denaturant. Nevertheless, the anal-
ysis of the progression of the decrease of the CD signal intensity showsPlease cite this article as: P.L. Scognamiglio, et al., G-quadruplex DNA re
Biochim. Biophys. Acta (2014), http://dx.doi.org/10.1016/j.bbagen.2014.0that a significant degree of secondary structure is retained even upon
the addition of urea, 8 M. Similar trends were observed for the urea-
induced chemical denaturation of 242–259_B23.2 (data not shown).
3.2.3. Fragments of B23.1 and B23.2 C-terminal region are individually able
to bind the c-MYC G-quadruplex
The ability of C_107 NPM1-based peptides to bind G-quadruplex
was checked by using SPR direct binding assays. These experiments
were carried out in the same way of those involving the C_107 NPM1
by using biotinylated c-MYC G-quadruplex as a ligand and the peptides
as analytes.
All the C_107 NPM1 regions showed detectable binding to c-MYCG-
quadruplex (Table 1). The overlay of the sensorgrams corresponding to
the peptide NPM1 188–225 (Fig. 7A–B) showed a clear dose–response
binding, in the concentration range of 5–450 μM, and the estimation
of KD value was 18 ± 5 μM, while the affinity of NPM1 225–243 was
three-fold lower, since experiments performed in a larger concentration
range (10–1000 μM)provided a KD value of 54±15 μM(Fig. 7C–D). The
sequence corresponding to H1 was analyzed in a similar concentration
range (50–1200 μM) and data fitting provided a further fifteen-fold
higher KD value of 275 ± 43 μM (Fig. 7E–F). Other variants of NPM1cognition by nucleophosmin: New insights from protein dissection,
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(Fig. A5). The presence of different residues in the C-terminal region
did not substantially affect the binding capacities of H1 variants.
4. Discussion
The involvement of NPM1/B23 in a variety of distinct biological pro-
cesses is a direct consequence of its ability to establish intermolecular
partnerships. The promiscuity of the protein is favored by its modular
structure, in which structured domains alternate with disordered re-
gions. Despite the importance of the NPM1/B23 interactions in physio-
logical and pathological conditions, their biophysical and structural
characterization is still incomplete. Very recently, it has been shown
that the binding of G-quadruplex DNA by NPM1/B23 is important for
the nucleolar localization of the protein [52]. The inability of leukemic
NPM1/B23 variant to establish this interaction leads to the aberrant cy-
toplasmic localization of the protein.
Present findings demonstrate that the C-terminal region of the pro-
tein is able to bind the c-MYC G-quadruplex with a sub-micromolar af-
finity. The comparison of these results with previous literature data
indicates that the progressive inclusion of portions of the basic region
increases the binding affinity of NPM1/B23 for the G-quadruplex se-
quence. Intriguingly, the inclusion of these regions had also stabilizingPlease cite this article as: P.L. Scognamiglio, et al., G-quadruplex DNA re
Biochim. Biophys. Acta (2014), http://dx.doi.org/10.1016/j.bbagen.2014.0effects on the thermal and chemical stabilities of the terminal three
helix bundle motif [21,24].
The dissection of NPM1/B23 demonstrates that several fragments of
the protein are intrinsically able to bind the G-quadruplex with high
affinity. Present data also indicate that, in addition to the unfolded
region 225–242, another intrinsically disordered fragment of the
protein (residues 188–225) significantly contributes to the binding
of the G-quadruplex. Therefore, the tight binding of NPM1/B23 to the
G-quadruplex is achieved through the cooperation of both folded and
unfolded regions that are individually able to bind it. As mentioned in
the Introduction, in the NMR structure of the complex between NPM1
C_70 and the c-MYC G-quadruplex direct interactions with the DNA
were established only by the three helix bundle motif [34]. Indeed, the
region 225–242 remains flexible without forming any permanent con-
tact with the G-quadruplex. On the other hand, here we show that
both regions 188–225 and 225–243 of NPM1/B23 are indeed able to di-
rectly bind the G-quadruplex. These apparently contrasting results may
be reconciled by assuming that the three helix bundlemotif and the dis-
ordered basic regions recognize the same regions of the G-quadruplex.
In this scenario, the intrinsically disordered regions may play a dual
role in the G-quadruplex binding. Taking advantage of the great flexibil-
ity, they could efficiently anchor the DNA in the initial stage of the rec-
ognition process. Subsequently, after the binding of theG-quadruplex tocognition by nucleophosmin: New insights from protein dissection,
2.017
E
C
TE
D
 P
R
O
O
F
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470Q12
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
0 250 500 750 1000 1250
0
25
50
75
NPM1 188-225 (  M)
0 100 200 300 400 500
0
50
100
150
0
50
100
150
0 100 200 300 400 500 600
0
50
100
150
0 100 200 300 400 500 600
0 250 500 750 1250
0
200
300
40
R
Um
ax
R
Um
ax
R
Um
ax
100
10000 100 200 300 400 500
Time (s)
Time (s)
Time (s)
600
200
300
40
10
0R
es
po
ns
e 
(R
U)
 
R
es
po
ns
e 
(R
U)
 
R
es
po
ns
e 
(R
U)
 
NPM1 225-243 (  M)
NPM1 242-259 (  M)
A B
C D
E F
Fig. 7. Binding of C_107NPM1 derived peptides to c-MYCG-quadruplex through SPR. Overlay of sensorgrams for the interaction between biotinylated at 5′ c-MYCG-quadruplex sequence
immobilized on a SA (streptavidin) sensor chip and C_107 NPM1 derived peptides. NPM1 (A) 188–225 (C) 225–243, and (E) 242–259 experimental curves that represent different con-
centrations of analyte and were fitted according to a single exponential binding model with 1:1 stoichiometry, (B), (D), and (F), respectively.
8 P.L. Scognamiglio et al. / Biochimica et Biophysica Acta xxx (2014) xxx–xxxU
N
C
O
R
Rthe three helix binding motif, the positively charges of these basic re-
gions may generate a long-range favorable electrostatic environment,
as previously suggested [34]. The ability of analyzed peptides to bind
c-MYC G-quadruplex represents a solid ground for designing newmol-
ecules able to interact with this DNA motif.
The present findings also suggest a reduced G-quadruplex affinity
for the two splicing variants B23.2 and B23.3. In particular, a reduced af-
finity of B23.3 is likely due to the lack of the basic region 195–223 in this
isoform. Moreover, the truncation of the C-terminus of the three helix
bundle motif to the helix H1 in B23.2 is also expected to strongly de-
crease the affinity for the G-quadruplex, since we show here that this
helix exhibits a significantly reduced affinity, when compared to the
whole domain. These suggestions are in line with the results indepen-
dently obtained by Okuwaki and coworkers, who very recently ana-
lyzed the binding of the different NPM1/B23 isoforms and truncated
forms to RNA [53]. However, very recently, it has been demonstrated,
through ITC analysis, that the affinity of the full-length NPM1 for the
same G-quadruplex is 3.8 μM [54] that is a value closer to that one ob-
tained for the C_70 NPM1 than that for the C_107 NPM1. In the case of
full-length NPM1 the electrostatic interactions established between
the basic domain and the preceding acidic unstructured domains
could influence G-quadruplex recognition.
The dissection of NPM1/B23 and the biophysical characterization of
the resulting fragments also unveil that the H1 helix of both B23.1 and
B23.2 is intrinsically endowed with an unusual thermal stability. APlease cite this article as: P.L. Scognamiglio, et al., G-quadruplex DNA re
Biochim. Biophys. Acta (2014), http://dx.doi.org/10.1016/j.bbagen.2014.0combined CD and NMR analyses show that the N-terminal region of
H1 assumes a helical conformation, despite the intrinsic flexibility of
the peptides. Indeed, the NMR analysis shows that the segment from
Glu245 to Met251 clearly exhibits a tendency to adopt an ordered
helical structure. CD and NMR data both indicate that this short helical
segment is rather stable upon temperature increase. Evidence of
this structure is detected in the entire temperature range (293–371 K
for CD and 298–333 K for NMR) explored by using the two techniques.
This thermal stability is very unusual for a short peptide that has
been derived from a protein sequence. Similar high stabilities have
rather been reported, only in few cases, for peptides whose sequences
have been ad-hoc designed [51,55]. These unexpected results hold in-
teresting implications for NPM1/B23 folding/unfolding process. In the
last years, the folding pathway of several constructs of the NPM1 C-
terminal region has been characterized in detail [21–24]. These studies
have highlighted the presence of residual structure in the denatured
state of the protein [56]. In particular, biophysical characterizations
have detected a “native-like” structure that is retained in the denatured
state of the wild-type protein, involving the helices H2–H3 of the three
helix bundle motif. It has been shown that the presence of these native-
like features in the NPM1/B23 denatured state accelerates the folding
process. Moreover, it has been suggested that the identification and
the characterization of these native-like featuresmay be away to design
new molecules that could restore the native fold in pathological mu-
tants. The intrinsic stability of the H1 helix provides support to thecognition by nucleophosmin: New insights from protein dissection,
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erties, although in previous analyses this helix was considered to be
unfolded. Of particular interest, in this context, is the observation
that Trp290 interacts in the native fold with the intrinsically folded N-
terminal region of H1. In line with the previous suggestions, this obser-
vation may be exploited in future studies for designing molecules able
to stabilize the fold of the domain and to restore the protein function
in NPM1/B23 mutants.
5. Conclusions
In conclusion this study unveils structural and functional determi-
nants of the interaction between G-quadruplex DNA and NPM1, by an-
alyzing the contribution of single protein regions in DNA recognition
mechanism. Through a rational fragmentation approach results clearly
indicate a crucial and direct role exerted by IDRs in DNA recognition,
speculating a synergic action of IDRs along with H1 region in formation
of the complexwith G-quadruplex inwhich the flexible basic fragments
primarily allow to accommodate DNA structures. This study shed new
light for the design of small molecules and/or peptides able to stabilize
G-quadruplex/NPM1complex which could help the research in the
field of AML disease.
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